0001043961-16-000034.txt : 20160815 0001043961-16-000034.hdr.sgml : 20160815 20160812180037 ACCESSION NUMBER: 0001043961-16-000034 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 62 CONFORMED PERIOD OF REPORT: 20160630 FILED AS OF DATE: 20160815 DATE AS OF CHANGE: 20160812 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TRANSGENOMIC INC CENTRAL INDEX KEY: 0001043961 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 911789357 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36439 FILM NUMBER: 161829409 BUSINESS ADDRESS: STREET 1: 12325 EMMET ST CITY: OMAHA STATE: NE ZIP: 68164 BUSINESS PHONE: 4027385480 MAIL ADDRESS: STREET 1: 12325 EMMET STREET CITY: OMAHA STATE: NE ZIP: 68164 10-Q 1 tbio-20160630x10q.htm 10-Q Document

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 _______________________________
 FORM 10-Q
 _______________________________

(Mark One)
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended June 30, 2016
OR 
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from _____ to _____
Commission File Number: 000-30975
 _______________________________
TRANSGENOMIC, INC.
(Exact name of registrant as specified in its charter)
 _______________________________

Delaware
 
91-1789357
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)
 
 
 
12325 Emmet Street, Omaha, Nebraska
 
68164
(Address of principal executive offices)
 
(Zip Code)
(402) 452-5400
(Registrant’s telephone number, including area code)
 _______________________________
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes   x No   o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).   Yes   x No   o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
 
o
Accelerated filer
 
o
Non-accelerated filer
 
o  (Do not check if a smaller reporting company)
Smaller reporting company
 
x
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes   o    No   x
As of July 31, 2016, the number of shares of common stock outstanding was 23,547,946.


TRANSGENOMIC, INC.
INDEX
 
 
 
 
 
 
 
 
Page No.    
 
 
 
 
PART I.
 
 
 
 
 
Item 1.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8
 
 
 
 
Item 2.
 
 
 
 
 
Item 3.
 
Quantitative and Qualitative Disclosures About Market Risk
 
 
 
 
Item 4.
 
 
 
 
 
PART II.
 
 
 
 
 
Item 1.
 
 
 
 
 
Item 1A.
 
 
 
 
 
Item 6.
 
 
 
 
 

2

PART I. FINANCIAL INFORMATION 
Item 1.
Financial Statements
TRANSGENOMIC, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED BALANCE SHEETS
(Dollars in thousands, except per share data)
 
June 30,
 
 
 
2016
 
December 31,
 
(unaudited)
 
2015
ASSETS
 
 
 
CURRENT ASSETS:
 
 
 
Cash and cash equivalents
$
421

 
$
444

Accounts receivable, net
328

 
264

Inventories, net
39

 
50

Other current assets
325

 
537

Assets held for sale
690

 
1,987

Total current assets
1,803

 
3,282

PROPERTY AND EQUIPMENT:
 
 
 
Equipment
5,592

 
5,593

Furniture, fixtures & leasehold improvements
1,565

 
1,565

 
7,157

 
7,158

Less: accumulated depreciation
(6,953
)
 
(6,899
)
 
204

 
259

OTHER ASSETS:
 
 
 
Intangibles, net
1,029

 
1,170

Other assets
58

 
105

 
$
3,094

 
$
4,816

LIABILITIES AND STOCKHOLDERS’ DEFICIT
 
 
 
CURRENT LIABILITIES:
 
 
 
Current maturities of long-term debt
$
7,814

 
$
7,596

Accounts payable
5,620

 
3,781

Accrued compensation
259

 
321

Accrued expenses
2,847

 
3,734

Deferred revenue
111

 
217

Other liabilities
1,068

 
1,068

Liabilities held for sale
—

 
264

Total current liabilities
17,719

 
16,981

LONG TERM LIABILITIES:
 
 
 
Common stock warrant liability
1,442

 
350

Other long-term liabilities
223

 
305

Total liabilities
19,384

 
17,636

STOCKHOLDERS’ DEFICIT:
 
 
 
Convertible preferred stock, $0.01 par value, 15,000,000 shares authorized, 214,705 and 4,029,502 shares issued and outstanding, respectively
2

 
40

Common stock, $0.01 par value, 150,000,000 shares authorized, 23,103,875 and 13,915,691 shares issued and outstanding, respectively
231

 
139

Additional paid-in capital
201,140

 
200,403

Accumulated other comprehensive income
—

 
10

Accumulated deficit
(217,663
)
 
(213,412
)
Total stockholders’ deficit
(16,290
)
 
(12,820
)
 
$
3,094

 
$
4,816


See notes to unaudited condensed consolidated financial statements.

3

TRANSGENOMIC, INC. AND SUBSIDIARY
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Dollars in thousands, except per share data)
 
 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2016
 
2015
 
2016
 
2015
NET SALES
$
505

 
$
442

 
$
741

 
$
1,192

COST OF GOODS SOLD
542

 
465

 
1,047

 
930

Gross profit
(37
)
 
(23
)
 
(306
)
 
262

OPERATING EXPENSES:
 
 
 
 
 
 
 
Selling, general and administrative
1,436

 
1,908

 
3,140

 
3,712

Research and development
402

 
468

 
672

 
919

 
1,838

 
2,376

 
3,812

 
4,631

OPERATING LOSS FROM CONTINUING OPERATIONS
(1,875
)
 
(2,399
)
 
(4,118
)
 
(4,369
)
OTHER INCOME (EXPENSE):
 
 
 
 
 
 
 
Interest expense, net
(328
)
 
(186
)
 
(497
)
 
(376
)
Warrant revaluation
24

 
(270
)
 
345

 
(415
)
Other, net
—

 
—

 
—

 
(13
)
 
(304
)
 
(456
)
 
(152
)
 
(804
)
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
(2,179
)
 
(2,855
)
 
(4,270
)
 
(5,173
)
INCOME TAX BENEFIT
—

 
(1
)
 
—

 
(1
)
LOSS FROM CONTINUING OPERATIONS
(2,179
)
 
(2,854
)
 
(4,270
)
 
(5,172
)
INCOME (LOSS) FROM DISCONTINUED OPERATIONS, NET OF TAXES
1,182

 
(421
)
 
9

 
(1,144
)
NET LOSS
(997
)
 
(3,275
)
 
(4,261
)
 
(6,316
)
 
 
 
 
 
 
 
 
PREFERRED STOCK DIVIDENDS
—

 
(331
)
 
(21
)
 
(662
)
 
 
 
 
 
 
 
 
NET LOSS FROM CONTINUING OPERATIONS AVAILABLE TO COMMON STOCKHOLDERS
(2,179
)
 
(3,185
)
 
(4,291
)
 
(5,834
)
NET INCOME (LOSS) FROM DISCONTINUED OPERATIONS AVAILABLE TO COMMON STOCKHOLDERS
1,182

 
(421
)
 
9

 
(1,144
)
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS
$
(997
)
 
$
(3,606
)
 
$
(4,282
)
 
$
(6,978
)
 
 
 
 
 
 
 
 
BASIC AND DILUTED LOSS PER COMMON SHARE FROM CONTINUING OPERATIONS
$
(0.10
)
 
$
(0.26
)
 
$
(0.20
)
 
$
(0.54
)
BASIC AND DILUTED INCOME (LOSS) PER COMMON SHARE FROM DISCONTINUED OPERATIONS
$
0.05

 
$
(0.03
)
 
$
—

 
$
(0.11
)
BASIC AND DILUTED LOSS PER COMMON SHARE
$
(0.05
)
 
$
(0.30
)
 
$
(0.20
)
 
$
(0.65
)
BASIC AND DILUTED WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING
21,797,442

 
12,149,632

 
21,060,387

 
10,778,857


See notes to unaudited condensed consolidated financial statements.

4

TRANSGENOMIC, INC. AND SUBSIDIARY
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Dollars in thousands)

 
Three Months Ended  
 June 30,
 
Six Months Ended 
 June 30,
 
2016
 
2015
 
2016
 
2015
Net Loss
$
(997
)
 
$
(3,275
)
 
$
(4,261
)
 
$
(6,316
)
Other comprehensive loss - foreign currency translation adjustment
—

 
42

 
—

 
8

Comprehensive Loss
$
(997
)
 
$
(3,233
)
 
$
(4,261
)
 
$
(6,308
)
 
 
 
 
 
 
 
 

 See notes to unaudited condensed consolidated financial statements.



5

TRANSGENOMIC, INC. AND SUBSIDIARY
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT
Six Months Ended 
 June 30, 2016
(Dollars in thousands, except share data)
 


 
Preferred Stock

Common Stock

 

 

 

 
 
Outstanding
Shares

Par
Value

Outstanding
Shares

Par
Value

Additional
Paid-in
Capital

Accumulated
Deficit

Accumulated
Other
Comprehensive
Income

Total
Balance, December 31, 2015
4,029,502

 
$
40

 
13,915,691


$
139


$
200,403


$
(213,412
)

$
10


$
(12,820
)
Net loss
—


—


—


—


—


(4,261
)

—


(4,261
)
Foreign currency translation adjustment
—


—


—


—


—


10


(10
)

—

Stock-based compensation
—


—


—


—


141


—


—


141

Issuance of common shares
—

 
—

 
257,467

 
2

 
105

 
—

 
—

 
107

Private placement, net
2,365,243

 
24


—


—


519


—


—


543

Dividends on preferred stock
—


—


—


—


(4,475
)

—


—


(4,475
)
Conversion of preferred stock and preferred stock dividends
(6,180,040
)
 
(62
)
 
8,930,717

 
90

 
4,447

 
—

 
—

 
4,475

Balance, June 30, 2016
214,705


$
2


23,103,875


$
231


$
201,140


$
(217,663
)

$
—


$
(16,290
)

See notes to unaudited condensed consolidated financial statements.


6

TRANSGENOMIC, INC. AND SUBSIDIARY
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Dollars in thousands) 
 
Six Months Ended 
 June 30,
 
2016
 
2015
CASH FLOWS USED IN OPERATING ACTIVITIES:
 
 
 
Net loss
$
(4,261
)
 
$
(6,316
)
Less income from discontinued operations, net of tax
9

 
(1,144
)
Loss from continuing operations
(4,270
)
 
(5,172
)
 
 
 
 
Adjustments to reconcile net loss to net cash flows used in operating activities:
 
 
 
Depreciation and amortization
189

 
156

Stock-based compensation
119

 
322

Provision for losses on doubtful accounts
70

 
—

Warrant revaluation
(345
)
 
415

Loss on sale of fixed assets
—

 
14

Deferred interest
47

 
61

Deferred tax provision
—

 
81

Changes in operating assets and liabilities:
 
 
 
Accounts receivable
(134
)
 
301

Inventories
11

 
—

Other current assets
253

 
(243
)
Accounts payable
1,839

 
367

Accrued expenses and other liabilities
(613
)
 
(240
)
Net cash used in continuing operations
(2,834
)
 
(3,938
)
Net cash provided by (used in) discontinued operations
79

 
(2,074
)
Net cash used in operating activities
(2,755
)
 
(6,012
)
CASH FLOWS PROVIDED BY (USED IN) INVESTING ACTIVITIES:
 
 
 
Purchases of property and equipment
(19
)
 
(194
)
Other assets
(7
)
 
(46
)
Net cash used in continuing operations
(26
)
 
(240
)
Net cash provided by discontinued operations
962

 
—

Net cash provided by (used in) investing activities
936

 
(240
)
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES:
 
 
 
Principal payments on capital lease obligations
(1
)
 
(34
)
Issuance of preferred stock, net
1,779

 
—

Issuance of common stock, net
68

 
6,209

Proceeds from borrowings
500

 
923

Principal payment on note payable
(550
)
 
(148
)
Net cash flows provided by financing activities
1,796

 
6,950

EFFECT OF FOREIGN CURRENCY EXCHANGE RATE CHANGES ON CASH
—

 
2

NET CHANGE IN CASH AND CASH EQUIVALENTS
(23
)
 
700

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD
444

 
1,609

CASH AND CASH EQUIVALENTS AT END OF PERIOD
$
421

 
$
2,309

SUPPLEMENTAL CASH FLOW INFORMATION
 
 
 
Cash paid during the period for:
 
 
 
Interest
$
—

 
$
222

See notes to unaudited condensed consolidated financial statements.

7


TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Three and Six Months Ended June 30, 2016 and 2015

1. BUSINESS DESCRIPTION
Business Description.

Transgenomic, Inc. (“we”, “us”, “our”, the “Company” or “Transgenomic”) is a biotechnology company advancing personalized medicine for the detection and treatment of cancer and inherited diseases through our proprietary molecular technologies and clinical and research services. A key goal is to bring our Multiplexed ICE COLD-PCR (“MX-ICP”) product to the clinical market through strategic partnerships and licensing agreements, enabling the use of blood and other bodily fluids for more effective and patient-friendly diagnosis, monitoring and treatment of cancer.

MX-ICP is technology proprietary to Transgenomic. It is a reagent that improves the ability to detect genetic mutations. This technology has been validated internally on all currently available sequencing platforms, including Sanger, Next Gen Sequencing and Digital PCR. By enhancing the level of detection of genetic mutations and suppressing the normal or wild-type DNA, several benefits are provided.

Historically, our operations were organized and reviewed by management along our major product lines and presented in two business segments: Laboratory Services and Genetic Assays and Platforms. Beginning with the quarter ended September 30, 2015, our operations are now organized as one business segment, our Laboratory Services segment, and during the second half of 2015, we began presenting our Genetic Assays and Platforms segment and a portion of our Laboratory Services segment in discontinued operations.

Our current Laboratory Services business consists of our laboratory in Omaha, Nebraska, which is focused on providing genetic analytical services related to Oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical and biotechnology companies. Our laboratory employs a variety of genomic testing service technologies, including our proprietary MX-ICP technology. Our laboratory in Omaha is certified under the Clinical Laboratory Improvement Amendments (“CLIA”) as a high complexity laboratory and is accredited by the College of American Pathologists.

Our condensed consolidated balance sheets, statements of operations and statements of cash flows for all periods presented reflect our former Genetic Assays and Platforms activities and Patient Testing business as discontinued operations (See Note 3 - “Discontinued Operations”).

Going Concern.

The condensed consolidated financial statements have been prepared using accounting principles generally accepted in the United States of America (“GAAP”) applicable for a going concern, which assume that we will realize our assets and discharge our liabilities in the ordinary course of business. We have incurred substantial operating losses and have used cash in our operating activities for the past few years. As of June 30, 2016, we had negative working capital of $15.9 million. Our ability to continue as a going concern is dependent upon a combination of generating additional revenue, improving cash collections, potentially selling underutilized assets and, if necessary, raising additional financing to meet our obligations and pay our liabilities arising from normal business operations when they come due. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that we will be able to continue as a going concern. These condensed consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern. We cannot be certain that additional financing will be available on acceptable terms, or at all, and our failure to raise capital when needed could limit our ability to continue our operations.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation.
The accompanying condensed consolidated financial statements are presented in conformity with GAAP. All amounts are presented in U.S. Dollars (“$”). Supplemental cash flows from discontinued operations are presented in Note 3 - “Discontinued Operations”. We have evaluated events occurring subsequent to June 30, 2016 for potential recognition or disclosure in the consolidated financial statements and concluded there were no subsequent events that required recognition or disclosure.

8
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three and Six Months Ended June 30, 2016 and 2015


The condensed consolidated balance sheet as of December 31, 2015 was derived from our audited balance sheet as of that date. There has been no change in the balance sheet from December 31, 2015. The accompanying condensed consolidated financial statements as of and for the three and six months ended June 30, 2016 and 2015 are unaudited and reflect all adjustments (consisting of only normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the interim periods. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2015 contained in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on April 14, 2016. The results of operations for the interim periods presented are not necessarily indicative of the results for fiscal year 2016.
Certain prior year amounts have been reclassified to conform to the current year presentation in our condensed consolidated financial statements, which consists of the effects of reclassifications from the presentation of our discontinued operations.
Principles of Consolidation.
The condensed consolidated financial statements include the accounts of Transgenomic, Inc. and our wholly owned subsidiary. All inter-company balances and transactions have been eliminated in consolidation.
Risks and Uncertainties.
Certain risks and uncertainties are inherent in our day-to-day operations and in the process of preparing our financial statements. The more significant of those risks are presented below and throughout the notes to the unaudited condensed consolidated financial statements.
Use of Estimates.
The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of net sales and expenses during the reporting period. In addition, estimates and assumptions associated with the determination of the fair value of certain assets and related impairments require considerable judgment by management. Actual results could differ from the estimates and assumptions used in preparing these condensed consolidated financial statements.
Fair Value.
Unless otherwise specified, book value approximates fair market value. The common stock warrant liability is recorded at fair value. See Note 9 - “Fair Value” for additional information.
Cash and Cash Equivalents and Other Current Assets.
Cash and cash equivalents include cash and investments with original maturities at the date of acquisition of three months or less. Other current assets as of June 30, 2016 of $0.3 million include prepaid assets of $0.1 million and other receivables of $0.2 million.
Concentrations of Cash.
From time to time, we may maintain a cash position with financial institutions in amounts that exceed federally insured limits. We have not experienced any losses on such accounts as of June 30, 2016.
Accounts Receivable.
The following is a summary of activity for the allowance for doubtful accounts from continuing operations during the three and six months ended June 30, 2016 and 2015: 

9
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three and Six Months Ended June 30, 2016 and 2015


 
Dollars in Thousands
 
Beginning
Balance
 
Additions
 
Deductions
 
Ending
Balance
Three Months Ended June 30, 2016
$
108

 
$
49

 
$
—

 
$
157

Three Months Ended June 30, 2015
$
20

 
$
—

 
$
—

 
$
20

Six Months Ended June 30, 2016
$
87

 
$
70

 
$
—

 
$
157

Six Months Ended June 30, 2015
$
20

 
$
—

 
$
—

 
$
20

While payment terms are generally 30 days, we have also provided extended payment terms in certain cases. Accounts receivable are carried at original invoice amount and shown net of allowance for doubtful accounts. The estimate made for doubtful accounts is based on a review of all outstanding amounts on a quarterly basis. We determine the allowance for doubtful accounts by regularly evaluating individual payor receivables and considering a payor’s financial condition, credit history, reimbursement rates and current economic conditions. Accounts receivable are written off when deemed uncollectible and after all collection efforts have been exhausted. Recoveries of accounts receivable previously written off are recorded as a reduction in bad debt expense when received.
Inventories.
Inventories are stated at the lower of cost or market net of allowance for obsolete inventory. Cost is computed using standard costs for finished goods and average or latest actual cost for raw materials and work in process, which approximates the first-in, first-out (FIFO) method. At June 30, 2016, our net inventories were less than $0.1 million and were comprised predominantly of raw materials.
 
The following is a summary of activity for the allowance for obsolete inventory during the three and six months ended June 30, 2016 and 2015: 
 
Dollars in Thousands
 
Beginning
Balance
 
Additions
 
Deductions
 
Ending
Balance
Three Months Ended June 30, 2016
$
63

 
$
—

 
$
—

 
$
63

Three Months Ended June 30, 2015
$
—

 
$
—

 
$
—

 
$
—

Six Months Ended June 30, 2016
$
63

 
$
—

 
$
—

 
$
63

Six Months Ended June 30, 2015
$
—

 
$
—

 
$
—

 
$
—

We determine the allowance for obsolescence by evaluating inventory quarterly for items deemed to be slow moving or obsolete.
Property and Equipment.
Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets as follows:
 
Leasehold improvements
1 to 10 years
Furniture and fixtures
3 to 7 years
Production equipment
3 to 7 years
Computer equipment
3 to 7 years
Research and development equipment
2 to 7 years
Depreciation expense in continuing operations related to property and equipment was less than $0.1 million for each of the three month periods ended June 30, 2016 and 2015. Depreciation expense was $0.1 million for each of the six month periods ended June 30, 2016 and 2015. Depreciation expense during each period includes depreciation related to equipment acquired under capital leases.
Intangible Assets.
Intangible assets include intellectual property and patents.

10
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three and Six Months Ended June 30, 2016 and 2015


1. Intellectual Property.    Initial costs paid to license intellectual property from independent third parties are capitalized and amortized using the straight-line method over the license period. Ongoing royalties related to such licenses are expensed as incurred.
2. Patents.    We capitalize legal costs, filing fees and other expenses associated with obtaining patents on new discoveries and amortize these costs using the straight-line method over the shorter of the legal life of the patent or its economic life beginning on the date the patent is issued.
Stock-Based Compensation.
All stock-based awards to date have exercise prices equal to the market value of the shares at the date of grant and have 10-year contractual terms. Unvested awards as of June 30, 2016 had vesting periods of up to three years from the date of grant. None of the awards outstanding at June 30, 2016 are subject to performance or market-based vesting conditions.
We measure and recognize compensation expense for all stock-based awards made to employees and directors. Compensation expense, net of estimated forfeitures, is based on the calculated fair value of the awards as measured at the grant date and is expensed over the service period of the awards.
During the three and six months ended June 30, 2016, we recorded compensation expense for all stock awards of less than $0.1 million and $0.1 million, respectively, within selling, general and administrative expense. During the three and six months ended June 30, 2015, we recorded compensation expense for all stock awards of $0.2 million and $0.3 million, respectively. As of June 30, 2016, the unrecognized compensation expense related to unvested stock awards was $0.2 million, which is expected to be recognized over a weighted-average period of 1.2 years.
We granted stock options to purchase an aggregate of zero and 14,000 shares of our common stock during the three and six months ended June 30, 2016, respectively. The fair value of the stock options granted was estimated on the grant date using the Black-Scholes option pricing model with the following assumptions: risk-free interest rates of 1.91% based on the U.S. Treasury yield in effect at the time of grant; dividend yields of zero percent; expected lives of 6.00 years, based on expected exercise activity behavior; and volatility of 85% based on the historical volatility of our common stock over a time that is consistent with the expected life of the options.
Included in our stock awards outstanding as of June 30, 2016 were stock appreciation rights (“SARs”) to purchase 98,333 shares of our common stock. The SARs were issued solely to our executive officers and will vest over three years from the date of grant.
Net Sales Recognition.
Revenue is realized and earned when all of the following criteria are met:
•
Persuasive evidence of an arrangement exists;
•
Delivery has occurred or services have been rendered;
•
The seller’s price to the buyer is fixed or determinable; and
•
Collectability is reasonably assured.

In our Biomarker Identification laboratory, we perform services on a project by project basis. When we receive payment in advance, we initially defer the revenue and recognize it when we deliver the service. These projects typically do not extend beyond one year. At each of June 30, 2016 and December 31, 2015, deferred net sales associated with pharmacogenomics research projects included in the balance sheet in deferred revenue was $0.1 million.

Net sales from Patient Testing laboratories, reported as part of discontinued operations, are recognized on an individual test basis and take place when the test report is completed, reviewed and sent to the client less the reserve for insurance, Medicare and Medicaid contractual adjustments. There are no deferred net sales associated with our Patient Testing services. Adjustments to the allowances, based on actual receipts from third party payers, are reflected in the estimated contractual allowance applied prospectively. In the fourth quarter of 2015, we adjusted our contractual allowance rates to better reflect the reimbursement level we expect to achieve on Patient Testing billings. The adjustment negatively impacted our Patient Testing revenues for all periods after the third quarter of 2015. (See Note 3 - “Discontinued Operations”).

Net sales of Genetic Assays and Platforms products, reported as discontinued operations (See Note 3 - “Discontinued Operations”) are recognized in accordance with the terms of the sales arrangement. Such recognition is based on receipt of an

11
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three and Six Months Ended June 30, 2016 and 2015


unconditional customer order and transfer of title and risk of ownership to the customer, typically upon shipment of the product under a purchase order. Our sales terms do not provide for the right of return unless the product is damaged or defective. Net sales from certain services associated with the analytical instruments, to be performed subsequent to shipment of the products, is deferred and recognized when the services are provided. Such services, mainly limited to installation and training services that are not essential to the functionality of the instruments, typically are performed in a timely manner subsequent to shipment of the instrument. We also enter into various service contracts that cover installed instruments. These contracts cover specific time periods and net sales associated with these contracts are deferred and recognized ratably over the service period.
Common Stock Warrants.
Certain of our issued and outstanding warrants to purchase common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability (“Common Stock Warrant Liability”). We are required to present these instruments at fair value at each reporting date and any changes in fair values are recorded as an adjustment to earnings. The Common Stock Warrant Liabilities are considered Level Three financial instruments for purposes of fair value measurement. See Note 9 - “Fair Value” for additional information.
Loss Per Share.
Basic loss per share is calculated based on the weighted-average number of common shares outstanding during each period. Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock. Options, warrants and conversion rights pertaining to 10,721,464 and 8,286,963 shares of our common stock have been excluded from the computation of diluted loss per share at June 30, 2016 and 2015, respectively, because the effect is anti-dilutive due to the net loss.
Recent Accounting Pronouncements.
In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (“ASU No. 2014-09”). This guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to a customer. ASU No. 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. In July 2015, the FASB decided to defer the effective date of this new accounting guidance by one year. As a result, ASU No. 2014-09 will be effective for us for all annual and interim reporting periods beginning after December 15, 2017 and early adoption would be permitted as of the original effective date. The new standard permits the use of either the retrospective or cumulative effect transition method. We do not expect to early adopt this guidance and we have not selected a transition method. We are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows.

In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40)(“ASU No. 2014-15”). This guidance addresses management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2016. Early adoption is permitted. We do not expect to early adopt this guidance and do not believe that the adoption of this guidance will have a material impact on our consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard amends the recognition of lease assets and lease liabilities by lessees for those leases currently classified as operating leases and amends disclosure requirements associated with leasing arrangements. The new standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently assessing the impact that the adoption of this ASU will have on our consolidated financial statements.
In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard simplifies several aspects related to the accounting for share-based payment transactions, including the accounting for income taxes, statutory tax withholding requirements, forfeitures and classification on the statement of cash flows. This guidance is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2016; however, early adoption is permitted. We do not expect to early adopt this guidance and are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows.

12
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three and Six Months Ended June 30, 2016 and 2015



3. DISCONTINUED OPERATIONS

On September 8, 2015, we entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Edge BioSystems, Inc. (“Edge Bio”), pursuant to which we sold our manufacturing, marketing and selling of high quality polymer and silica based beads and resin and chromatography columns business (collectively, the “Columns Business”). The Columns Business was part of our former segment, Genetic Assays and Platforms. Pursuant to the Asset Purchase Agreement, Edge Bio acquired substantially all of the assets used solely in connection with the Columns Business and assumed certain liabilities of the Columns Business for a total cash purchase price of approximately $2.1 million (the “Asset Sale”), which was paid on September 8, 2015 upon the closing of the Asset Sale. During the year ended December 31, 2015, we recorded a gain on the sale of the Columns Business of $1.5 million.

On November 25, 2015, we entered into an Asset Purchase Agreement (the “Purchase Agreement”) with ADSTEC Corporation (“ADSTEC”) and ADS Biotec Inc., a wholly-owned subsidiary of ADSTEC (“Buyer”), pursuant to which we sold (1) to ADSTEC our facilities located in Glasgow, Scotland and on Irvington Road in Omaha, Nebraska (together, the “Facilities”) and all of our stock, inventory and raw materials located at the Facilities (collectively, the “Inventory”), and (2) to Buyer (a) all of the remaining assets relating to our Genetic Assays and Platforms business segment (the “Business”), other than the Inventory (the “Purchased Assets”), and (b) all of the ordinary shares of Transgenomic Limited, a wholly-owned subsidiary of ours (the “Shares”).

Pursuant to the Purchase Agreement, ADSTEC and Buyer acquired the Facilities, the Inventory, the Purchased Assets and the Shares for an aggregate purchase price of approximately $300,000, and Buyer assumed our financial and human resources commitments related to the Business (the “Transaction”). During the year ended December 31, 2015, we recorded a loss on the Transaction of $1.7 million.

Together, the Asset Sale and the Transaction represent the divestiture of our Genetic Assays and Platforms business, resulting in a strategic shift that had a major effect on our operations and financial results. Therefore, the divested operations of our Genetic Assays and Platforms business meet the criteria to be reported as discontinued operations.
During the fourth quarter of 2015, our Board of Directors took actions to begin the process of divesting our Patient Testing business in New Haven, Connecticut. In March 2016, we announced that we had suspended testing services in our Patient Testing laboratory as we review and evaluate various strategic alternatives for that business. As a result of these actions, as of December 31, 2015, our Patient Testing business met the criteria to be reported as discontinued operations. We anticipate that we will complete the divestiture of the Patient Testing business during 2016.
The related assets, liabilities, results of operations and cash flows for both the Genetic Assays and Platforms business and Patient Testing business are classified as assets held for sale, liabilities held for sale and discontinued operations for all periods presented.

13
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three and Six Months Ended June 30, 2016 and 2015


Results of the discontinued operations consisted of the following:
 
Three months ended June 30,
 
Six months ended June 30,
(Dollars in thousands)
2016
 
2015
 
2016
 
2015
Net sales
$
574

 
$
6,598

 
$
1,677

 
$
12,361

Cost of goods sold
11

 
3,703

 
1,194

 
6,777

Gross profit
563

 
2,895

 
483

 
5,584

Selling, general and administrative expense
344

 
3,165

 
1,369

 
6,415

Research and development expense
—

 
108

 
68

 
224

Operating income (loss) from discontinued operations
219

 
(378
)
 
(954
)
 
(1,055
)
Gain on sale of business/assets
963

 
—

 
963

 
—

Income (loss) from discontinued operations before income taxes
1,182

 
(378
)
 
9

 
(1,055
)
Income tax expense
—

 
43

 
—

 
89

Income (loss) from discontinued operations, net of taxes
$
1,182

 
$
(421
)
 
$
9

 
$
(1,144
)

Income from discontinued operations for both the three and six month periods ended June 30, 2016, includes approximately $1.0 million in proceeds received from the sale of assets of our discontinued Patient Testing business.
Assets and liabilities of the discontinued operations are classified as assets held for sale and liabilities held for sale in the condensed consolidated balance sheets and consisted of the following:
 
Dollars in Thousands
 
June 30,
2016
 
December 31,
2015
ASSETS
 
 
 
Accounts receivable, net
$
647

 
$
1,905

Other current assets
43

 
82

Total Assets
$
690

 
$
1,987

 
 
 
 
LIABILITIES
 
 
 
Accrued compensation
$
—

 
$
264

Total Liabilities
$
—

 
$
264

 
 
 
 

The following is a summary of activity for the allowance for doubtful accounts from discontinued operations during the three and six months ended June 30, 2016 and 2015. The allowance for doubtful accounts from discontinued operations is included in the assets held for sale in the condensed consolidated balance sheets.

14
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three and Six Months Ended June 30, 2016 and 2015


 
Dollars in Thousands
 
Beginning
Balance
 
Additions
 
Deductions
 
Ending
Balance
Three Months Ended June 30, 2016
$
14,542

 
$
—

 
$
(4,080
)
 
$
10,462

Three Months Ended June 30, 2015
$
9,173

 
$
1,198

 
$
(1,965
)
 
$
8,406

Six Months Ended June 30, 2016
$
14,664

 
$
—

 
$
(4,202
)
 
$
10,462

Six Months Ended June 30, 2015
$
7,927

 
$
2,730

 
$
(2,251
)
 
$
8,406


4. INTANGIBLES AND OTHER ASSETS
We review our amortizable long-lived assets for impairment annually or whenever events indicate that the carrying amount of the asset (group) may not be recoverable. An impairment loss may be needed if the sum of the future undiscounted cash flows is less than the carrying amount of the asset (group). The amount of the loss would be determined by comparing the fair market value of the asset to the carrying amount of the asset (group).
Long-lived intangible assets as of June 30, 2016 and December 31, 2015 consisted of the following:
 
Dollars in Thousands
 
June 30, 2016
 
Cost
 
Accumulated
Amortization
 
Net Book
Value
Patents
695

 
76

 
619

Intellectual property
672

 
262

 
410

 
$
1,367

 
$
338

 
$
1,029



 
Dollars in Thousands
 
December 31, 2015
 
Cost
 
Accumulated
Amortization
 
Net Book
Value
Patents
980

 
274

 
706

Intellectual property
671

 
207

 
464

 
$
1,651

 
$
481

 
$
1,170


 
 
 
Estimated Useful Life
Patents
Life of the patent
Intellectual property
7 years
Other assets include U.S. security deposits and deferred tax assets, net of applicable valuation allowances.
Amortization expense for intangible assets was $0.1 million during each of the six month periods ended June 30, 2016 and 2015. Amortization expense for intangible assets is expected to be $0.1 million for each of the years ending December 31, 2016, 2017, 2018, 2019 and 2020.

5.         DEBT

15
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three and Six Months Ended June 30, 2016 and 2015


 
 
Dollars in Thousands
 
 
June 30, 2016
 
December 31, 2015
Revolving Line of Credit(1)
 
$
3,243

 
$
3,025

Term Loan(2)
 
4,000

 
4,000

Convertible Promissory Notes (3)
 
571

 
571

Total debt
 
7,814

 
7,596

Current portion of long-term debt
 
(7,814
)
 
(7,596
)
Long-term debt, net of current maturities
 
$
—

 
$
—

 
(1)
Revolving Line of Credit. Amounts advanced under the Revolving Line accrue interest at an annual rate equal to the greater of (a) 6.25% or (b) the Wall Street Journal prime rate plus 3%. The current interest rate is 6.50%. Interest is payable on a monthly basis, with the balance payable at the maturity of the Revolving Line. Under the Loan Agreement, we pay the Lenders a commitment fee of $20,000 on each one-year anniversary of March 13, 2013, the Effective Date, during the term of the Revolving Line. In addition, a fee of 0.5% per annum is payable quarterly on the unused portion of the Revolving Line. The Revolving Line matures on November 1, 2017.

(2)
Term Loan. We received $4.0 million under the Term Loan on the Effective Date. Pursuant to the terms of the Loan Agreement, as amended, the maturity date of the Loan Agreement was extended until November 1, 2017 and no principal payments on the Term Loan are due until such date. The current interest rate is 9.1%.

We will pay the Lenders an additional final payment of $120,000 at maturity or prepayment of the Term Loan. In addition, if we repay the Term Loan prior to maturity, we will pay the Lenders a prepayment penalty of 1% of the total outstanding balance under the Term Loan.

Additional Terms.
The Loan Agreement contains affirmative and negative covenants. Under the Term Loan, we agreed not to (i) pledge or otherwise encumber our assets other than to the Lenders, (ii) enter into additional borrowings or guarantees, (iii) repurchase our capital stock, or (iv) enter into certain mergers or acquisitions without the Lenders’ consent. Additionally, the Loan Agreement contains a subjective acceleration clause at the discretion of the Lenders. As of June 30, 2016, the Company was in compliance with the Loan Agreement, as amended by the Ninth Amendment, however, as of August 12, 2016 we have not made the required July 2016 interest payment and have not received a waiver for the non-compliance and as such all debt has been classified as current at June 30, 2016.

To secure the repayment of any amounts borrowed under the Revolving Line and the Term Loan, we granted the Lenders a security interest in all of our assets. The occurrence of an event of default under the Loan Agreement could result in the acceleration of our obligations under the Loan Agreement, would increase the applicable interest rate under the Revolving Line or Term Loan (or both) by 5% and would permit the Lenders to exercise remedies with respect to the collateral under the Loan Agreement. As of the date these financials were available for release, the Lenders have not exercised the remedies under the Loan Agreement.

(3) Convertible Promissory Notes. The Notes accrue interest at a rate of 6% per year and mature on December 31, 2016.

Revolving Line and Term Loan.

On March 13, 2013 (the “Effective Date”), we entered into a Loan and Security Agreement with affiliates of Third Security, LLC (the “Lenders”) for (a) a revolving line of credit (the “Revolving Line”) with borrowing availability of up to $4.0 million, subject to reduction based on our eligible accounts receivable, and (b) a term loan (the “Term Loan” and, together with the Revolving Line, the “Loan Agreement”) of $4.0 million. Proceeds were used to pay off a three year senior secured promissory note payable to PGxHealth, LLC, which was entered into on December 29, 2010 in conjunction with our acquisition of the FAMILION family of genetic tests, and for general corporate and working capital purposes.

16
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three and Six Months Ended June 30, 2016 and 2015


On August 2, 2013, we entered into an amendment to the Loan Agreement (the “Amendment”). The Amendment, which became effective as of June 30, 2013, reduced our future minimum revenue covenants under the Loan Agreement and modified the interest rates applicable to the amounts advanced under the Revolving Line.

On November 14, 2013, we entered into a second amendment to the Loan Agreement (the “Second Amendment”). The Second Amendment, which became effective as of October 31, 2013, reduced our future minimum revenue covenants under the Loan Agreement.

On January 27, 2014, we entered into a third amendment to the Loan Agreement (the “Third Amendment”). Pursuant to the Third Amendment, the Lenders agreed to waive certain events of default under the Loan Agreement, and the parties amended certain provisions of the Loan Agreement, including the minimum liquidity ratio that we must maintain during the term of the Loan Agreement.

On March 3, 2014, we entered into a fourth amendment to the Loan Agreement (the “Fourth Amendment”). Pursuant to the terms of the Fourth Amendment, we were not required to make any principal or interest payments under the Term Loan for the period from March 1, 2014 through March 31, 2015. The interest on the debt that was deferred and not paid was capitalized as part of the Term Loan. The amount of interest that was capitalized from March 1, 2014 to March 31, 2015 was $0.4 million.

On October 22, 2014, we entered into a fifth amendment to the Loan Agreement (the “Fifth Amendment”). Pursuant to the Fifth Amendment, the parties amended certain provisions of the Loan Agreement, including reducing the minimum liquidity and revenue covenants under the Loan Agreement. The Fifth Amendment also reduced the aggregate amount that we may borrow under the Revolving Line from $4.0 million to $3.0 million.

On April 1, 2015, we entered into a sixth amendment to the Loan Agreement (the “Sixth Amendment”). Pursuant to the Sixth Amendment, among other things, (a) the Lenders waived specified events of default under the terms of the Loan Agreement, (b) commencing April 1, 2015, we began making monthly interest payments with respect to the Term Loan to the Lenders, (c) we were not be obligated to make monthly payments of principal under the Term Loan to the Lenders until April 1, 2016, (d) we made an initial prepayment of a portion of the Term Loan balance in the amount of approximately $148,000 on April 1, 2015 and will make one or more additional prepayments to the Lenders under the Loan Agreement upon the occurrence of certain events, as defined in the Loan Agreement, and (e) we were not required to comply with the minimum liquidity ratio under the terms of the Loan Agreement until the earliest to occur of a specified event, as defined in the Loan Agreement, or March 31, 2016. The Sixth Amendment also extends the time period in which we must provide certain reports and statements to the Lenders and amends the circumstances pursuant to which we may engage in certain sales or transfers of our business or property without the consent of the Lenders.
As of June 30, 2015, we were in compliance with all financial covenants of the Loan Agreement, but were not in compliance with the restrictions limiting the amount that we may borrow under the Revolving Line. Accordingly, on August 10, 2015, we received a waiver from the Lenders relating to this non-compliance and paid the Lenders an aggregate of $0.7 million, which brought us back into compliance with the terms of the Revolving Line.

On September 4, 2015, we entered into a seventh amendment to the Loan Agreement (the “Seventh Amendment”). The Seventh Amendment, among other things, (a) provided that the Lenders waived specified events of default under the terms of the Loan Agreement, (b) reduced our future minimum revenue covenants under the Loan Agreement, (c) reduced our borrowing availability under the Revolving Line to approximately $2.3 million, and (d) limited our borrowing base under the Loan Agreement to the amount of the Revolving Line.

On January 6, 2016, we entered into an eighth amendment to the Loan Agreement (the “Eighth Amendment”). The Eighth Amendment, among other things, (a) provided that the Lenders waived specified events of default under the terms of the Loan Agreement, (b) reduced our future minimum revenue covenants under the Loan Agreement, (c) extended the maturity date of the Loan Agreement until November 1, 2017, and (d) provided for the repayment of an overadvance of $750,000 previously provided by the Lenders to us pursuant to the Loan Agreement.

On June 6, 2016, we entered into a ninth amendment to the Loan Agreement (the “Ninth Amendment”). The Ninth Amendment, among other things, (a) provided that the Lenders waived specified events of default under the terms of the Loan Agreement, (b) amended the prepayment terms of the Loan Agreement, (c) provided for the reduction of amounts available under the Revolving Line upon the prepayment or repayment of certain amounts by us, (d) removed the minimum liquidity ratio and minimum net revenue financial covenants applicable to us under the Loan Agreement, (e) amended the circumstances pursuant to which we may

17
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three and Six Months Ended June 30, 2016 and 2015


engage in certain sales or transfers of our business or property without the consent of the Lenders, and (f) capitalized certain amounts owed by us to the Lenders and added such overdue amounts to the outstanding principal amount of the Revolving Line.
 
As a result of the Ninth Amendment, the overadvance that existed at March 31, 2016 was added to the outstanding principal amount of the Revolving Line and no overadvance existed as of June 30, 2016.

Convertible Promissory Notes.

On December 31, 2014, we entered into an Unsecured Convertible Promissory Note Purchase Agreement (the “Note Purchase Agreement”) with an accredited investor (the “Investor”), pursuant to which we agreed to issue and sell to the Investor in a private placement an unsecured convertible promissory note (the “Initial Note”). We issued the Initial Note in the aggregate principal amount of $750,000 to the Investor on December 31, 2014. Pursuant to the terms of the Initial Note, interest accrued at a rate of 6% per year and the Initial Note was set to mature on December 31, 2016. Under the Initial Note, the outstanding principal and unpaid interest accrued was convertible into shares of our common stock as follows: (i) commencing upon the date of issuance of the Initial Note (but no earlier than January 1, 2015), the Investor was entitled to convert, on a one-time basis, up to 50% of the outstanding principal and unpaid interest accrued under the Initial Note, into shares of our common stock at a conversion price equal to the lesser of (a) the average closing price of the common stock on the principal securities exchange or securities market on which our common stock is then traded (the “Market”) for the 20 consecutive trading days immediately preceding the date of conversion, and (b) $2.20 (subject to adjustment for stock splits, stock dividends, other distributions, recapitalizations and the like); and (ii) commencing February 15, 2015, the Investor was entitled to convert, on a one-time basis, any or all of the remaining outstanding principal and unpaid interest accrued under the Initial Note, into shares of our common stock at a conversion price equal to 85% of the average closing price of our common stock on the Market for the 15 consecutive trading days immediately preceding the date of conversion. The Initial Note has been converted in full into 502,786 shares of our common stock, in accordance with the terms of the Initial Note.

On January 15, 2015, we entered into the Note Purchase Agreement with seven accredited investors (the “Additional Investors”) and, on January 20, 2015, issued and sold to the Additional Investors, in a private placement, notes (the “Additional Notes”) in an aggregate principal amount of $925,000. The Additional Notes have the same terms and conditions as the Initial Note. As of June 30, 2016, $400,000 of the aggregate principal amount of the Additional Notes, and accrued interest thereon, has been converted into an aggregate of 281,023 shares of our common stock.

6. COMMITMENTS AND CONTINGENCIES
We are subject to a number of claims of various amounts that arise out of the normal course of our business. In our opinion, the disposition of pending claims, in excess of recorded accruals, could have a material adverse effect on our financial position, results of operations or cash flows. On February 25, 2016, the Board of Regents of the University of Nebraska (“UNMC”) filed a lawsuit against us in the District Court of Douglas County, Nebraska, for breach of contract and seeking recovery of $0.7 million owed by us to UNMC. We and UNMC are currently in discussions to determine a mutually agreeable means by which to settle the outstanding liability. A $0.7 million liability has been recorded at December 31, 2015 and June 30, 2016.
In addition, on April 13, 2016, Fox Chase Cancer Center (“Fox Chase”) filed a lawsuit against us in the Court of Common Pleas of Philadelphia County, First Judicial District of Pennsylvania Civil Trial Division (the “Court of Common Pleas”), alleging, among other things, breach of contract, tortious interference with present and prospective contractual relations, unjust enrichment, fraudulent conversion and conspiracy and seeking punitive damages in addition to damages and other relief. This lawsuit relates to a license agreement we entered into with Fox Chase in August 2000, as amended (the “License Agreement”), as well as the assignment of certain of our rights under the License Agreement to Integrated DNA Technologies, Inc. (“IDT”) pursuant to the Surveyor Kit Patent, Technology and Inventory Purchase Agreement we entered into with IDT effective as of July 1, 2014 (the “IDT Agreement”). Pursuant to the terms of the IDT Agreement, we agreed to indemnify IDT with respect to certain of the claims asserted in the Fox Chase proceeding. On July 8, 2016, the Court of Common Pleas sustained our preliminary objections to several of Fox Chase’s claims and dismissed the claims for tortious interference, fraudulent conversion, conspiracy, punitive damages and attorney’s fees.  Accordingly, the case has been narrowed so that only certain contract claims and an unjust enrichment claim remain pending against us. We believe that we have good and substantial defenses to the claims asserted by Fox Chase. We are unable to determine whether any loss will occur or to estimate the range of such potential loss; therefore, no amount of loss has been accrued by us as of the date of filing of this Quarterly Report on Form 10-Q. Furthermore, there is no guarantee that we will prevail in this suit or receive any damages or other relief if we do prevail.

18
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three and Six Months Ended June 30, 2016 and 2015


On June 23, 2016, the Icahn School of Medicine at Mount Sinai (“Mount Sinai”) filed a lawsuit against us in the Supreme Court of the State of New York, County of New York, alleging, among other things, breach of contract and, alternatively, unjust enrichment and quantum merit, and seeking recovery of $0.7 million owed by us to Mount Sinai for services rendered. We and Mount Sinai are currently in discussions to determine a mutually agreeable means by which to settle the outstanding liability. A $0.7 million liability has been recorded at December 31, 2015 and June 30, 2016.
The outcome of legal proceedings and claims brought against us are subject to significant uncertainty. Therefore, although management considers the likelihood of such an outcome to be remote, if one or more of these legal matters were resolved against us in the same reporting period for amounts in excess of management’s expectations, our financial statements for such reporting period could be materially adversely affected. In general, the resolution of a legal matter could prevent us from offering our services or products to others, could be material to our financial condition or cash flows, or both, or could otherwise adversely affect our operating results.
We lease certain equipment, vehicles and operating facilities under non-cancellable operating leases that expire on various dates through 2022. The future minimum lease payments required under these leases are $0.4 million for the remainder of 2016, $0.7 million in 2017, $0.7 million in 2018, $0.7 million in 2019, $0.7 million in 2020 and $0.4 million thereafter. Rent expense for each of the six month periods ended June 30, 2016 and 2015 was $0.1 million. At June 30, 2016, firm commitments to vendors totaled $0.1 million.

7. INCOME TAXES

Annually, we file U.S. Federal, state and foreign income tax returns.  All U.S. Federal and most state loss carryforwards remain subject to adjustment in the event of an income tax examination.
Income tax expense from continuing operations was zero for the three and six months ended June 30, 2016 and 2015. We maintain a full valuation allowance on our net deferred tax assets, having concluded that we are not more likely than not going to realize the benefit of our deferred tax assets, including our net operating loss carryforwards.
During each of the three and six month periods ended June 30, 2016 and 2015, there were no material changes to the liability for uncertain tax positions.

8. STOCKHOLDERS’ EQUITY
Common Stock.

Pursuant to our Third Amended and Restated Certificate of Incorporation, as amended, we currently have 150,000,000 shares of common stock authorized for issuance.
On February 2, 2012, we entered into definitive agreements with institutional and other accredited investors and raised approximately $22.0 million in a private placement financing (the “Private Placement”), which included an aggregate of $3.0 million in convertible notes issued in December 2011 to entities affiliated with Third Security, LLC, a related party, that automatically converted into shares of our common stock and warrants to purchase such common stock on the same terms as all investors in the Private Placement. Pursuant to the purchase agreement, we issued an aggregate of 1,583,333 shares of our common stock at a price per share of $12.00, as well as five-year warrants to purchase up to an aggregate of 823,333 shares of our common stock with an exercise price of $15.00 per share. In connection with the conversion of the convertible notes issued by us to the entities affiliated with Third Security, LLC, the entities received an aggregate of 250,000 shares of our common stock and 125,000 warrants on the same terms as all investors in the Private Placement. Craig-Hallum Capital Group LLC (“Craig-Hallum”) served as the sole placement agent for the offering. In consideration for services rendered as the placement agent in the offering, we agreed to (a) pay to the placement agent cash commissions equal to $1,330,000, or 7.0% of the gross proceeds received in the offering; (b) issue to the placement agent a five-year warrant to purchase up to 31,666 shares of our common stock (representing 2% of the shares sold in the Private Placement) with an exercise price of $15.00 per share and other terms that are the same as the terms of the warrants issued in the Private Placement; and (c) reimburse the placement agent for reasonable out-of-pocket expenses, including fees paid to the placement agent’s legal counsel, incurred in connection with the offering, which reimbursable expenses were not to exceed $125,000. The costs incurred to complete the Private Placement were recorded as a reduction in equity in the amount of $1.5 million. Net proceeds from this offering were used for general corporate and working capital purposes, primarily to accelerate development of several of our key initiatives.

19

On January 24, 2013, we entered into a Securities Purchase Agreement with certain institutional and other accredited investors pursuant to which we: (a) sold to the investors an aggregate of 1,383,333 shares of our common stock at a price per share of $6.00 for aggregate gross proceeds of approximately $8.3 million; and (b) issued to the investors warrants to purchase up to an aggregate of 691,655 shares of our common stock with an exercise price of $9.00 per share (the “2013 Offering”). The warrants may be exercised, in whole or in part, at any time from January 30, 2013 until January 30, 2018 and contain both cash and “cashless exercise” features. Affiliates of Third Security, LLC purchased an aggregate of 500,000 shares of common stock and warrants to purchase an aggregate of 250,000 shares of common stock in the 2013 Offering on the same terms as the other investors. Net proceeds from the 2013 Offering were used for general corporate and working capital purposes.
In connection with the 2013 Offering, we entered into a registration rights agreement with the investors (the “Registration Rights Agreement”). The Registration Rights Agreement required that we file with the SEC a registration statement to register for resale the shares of common stock sold and the shares of common stock issuable upon exercise of the warrants (the “Warrant Shares”) by March 16, 2013. The registration statement was filed with the SEC on March 15, 2013 and was declared effective by the SEC on March 29, 2013.
The 2013 Offering required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of the warrants decreased from $15.00 per share to $12.96 per share and the number of shares issuable upon exercise of the warrants increased from 948,333 to 1,097,600.
On October 22, 2014, we entered into a Securities Purchase Agreement with certain accredited investors (the “October 2014 Investors”), pursuant to which we, in a private placement, issued and sold to the October 2014 Investors (the “2014 Private Placement”) an aggregate of 730,776 shares of our common stock at a price per share of $3.25 for an aggregate purchase price of approximately $2.4 million, and warrants to purchase up to an aggregate of 365,388 shares of our common stock with an initial exercise price of $4.00 per share that are exercisable for the period from April 22, 2015 through April 22, 2020. In connection with the 2014 Private Placement, we also issued a warrant to purchase up to an aggregate of 9,230 shares of our common stock to one advisor. The warrants issued in the 2014 Private Placement include both cash and “cashless exercise” features.
The 2014 Private Placement required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the February 2012 common stock and warrant sale. The exercise price of the warrants decreased from $11.73 per share to $10.86 per share and the number of shares issuable upon exercise of the warrants increased from 1,212,665 to 1,309,785.
On December 31, 2014, we entered into the Note Purchase Agreement with the Investor pursuant to which we agreed to issue and sell the Initial Note to the Investor (the “Note Private Placement”). See Note 5 - “Debt-Convertible Promissory Notes” for additional information regarding the terms of the Initial Note. Pursuant to the terms of the Note Purchase Agreement, we are subject to certain registration obligations and we may be required to effect one or more other registrations to register for resale the shares of our common stock issued or issuable under the Initial Note in connection with certain “piggy-back” registration rights granted to the Investor.

The Note Private Placement required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the February 2012 common stock and warrant sale. The exercise price of the 2012 warrants decreased from $10.86 per share to $10.25 per share and the number of shares issuable upon exercise of the warrants increased from 1,309,785 to 1,387,685.

On January 15, 2015, we entered into the Note Purchase Agreement with the Additional Investors and, on January 20, 2015, issued and sold to the Additional Investors, in a private placement, the Additional Notes in an aggregate principal amount of $925,000 (the “Additional Note Private Placement”). The Additional Notes have the same terms and conditions as the Initial Note.

Craig-Hallum acted as the sole placement agent for the sale and issuance of the Additional Notes. In connection with the sale and issuance of the Additional Notes, we issued to Craig-Hallum an unsecured convertible promissory note, upon the same terms and conditions as the Notes, in an aggregate principal amount equal to 5% of the proceeds received by us pursuant to the sale and issuance of the Additional Notes, or $46,250 (the “Placement Agent Note”). As of the date of filing of this Quarterly Report on form 10-Q, the Placement Agent Note remains outstanding.

The Additional Note Private Placement required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of these warrants decreased from $10.25 per share to $9.59 per share and the number of shares issuable upon exercise of the warrants increased from 1,387,685 to 1,483,161.



On February 27, 2015, we entered into a purchase agreement with Craig-Hallum (the “Underwriter”) relating to our sale and issuance of 3,573,899 shares of our common stock and corresponding warrants to purchase up to 714,780 shares of our common stock (the “February 2015 Offering”). Each share of common stock was sold in combination with a warrant to purchase 0.20 of a share of common stock. The purchase price to the public for each share of common stock and accompanying warrant was $1.95.
The purchase price paid by the Underwriter to us for the common stock and accompanying warrants was $1.8135. The net proceeds from the February 2015 Offering, after deducting the Underwriter’s discount and other estimated February 2015 Offering expenses, were approximately $6.2 million.
The accompanying warrants are exercisable immediately upon their initial issuance date at an exercise price of $2.24 per share and will expire five years from the date of issuance. The exercise price will also be subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock.
The February 2015 Offering required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of these warrants decreased from $9.59 per share to $7.56 per share and the number of shares issuable upon exercise of the warrants increased from 1,483,161 to 1,881,396.
On June 30, 2015, we entered into a Securities Purchase Agreement with certain accredited investors (the “July 2015 Investors”) pursuant to which, on July 7, 2015, we sold to the July 2015 Investors (a) an aggregate of approximately 1.5 million shares of our common stock at a price per share of $1.42, (b) warrants (the “Series B Warrants”) to purchase up to an aggregate of 0.7 million shares of our common stock with an exercise price of $0.01 per share, and (c) warrants (the “Series A Warrants” and, together with the Series B Warrants, the “July 2015 Warrants”) to purchase up to an aggregate of 1.2 million shares of our common stock, with an exercise price of $1.66 per share (collectively, the “July 2015 Offering”). Each of the July 2015 Warrants has a term of 5 and 1/2 years. The Series B Warrants were immediately exercisable upon issuance. The Series A Warrants became exercisable on January 7, 2016, six months from the date of issuance. The aggregate gross proceeds to us from the July 2015 Offering were approximately $3.0 million.
Craig-Hallum (the “2015 Placement Agent”) served as the sole placement agent for the July 2015 Offering. In consideration for services rendered as the placement agent in the July 2015 Offering, we (a) paid to the 2015 Placement Agent cash commissions equal to approximately $212,783, or 7.0% of the gross proceeds received in the July 2015 Offering; (b) issued to the 2015 Placement Agent a five-year warrant to purchase up to 107,033 shares of our common stock with an exercise price of $1.66 per share and which is subject to other terms that are the same as the terms of the Series A Warrants; and (c) reimbursed the 2015 Placement Agent for reasonable out-of-pocket expenses, including fees paid to the 2015 Placement Agent’s legal counsel, incurred in connection with the July 2015 Offering, which reimbursable expenses did not exceed $50,000.
The July 2015 Offering required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of these warrants decreased from $7.56 per share to $6.50 per share and the number of shares issuable upon exercise of the warrants increased from 1,881,396 to 2,188,177.
On January 6, 2016, we entered into a Securities Purchase Agreement (the “SPA”) with certain accredited investors (the “2016 Investors”), pursuant to which, on January 8, 2016, we sold to the 2016 Investors, and the 2016 Investors purchased from us (the “January 2016 Offering”), an aggregate of approximately $2.2 million of units (the “Units”) consisting of (a) an aggregate of 2,365,243 shares (the “A-1 Preferred Shares”) of our Series A-1 Convertible Preferred Stock (the “A-1 Preferred”), and (b) warrants (the “2016 Warrants”) to purchase up to an aggregate of 1,773,929 shares of our common stock. Each Unit was sold to the 2016 Investors at a purchase price of $0.93 per Unit. The A-1 Preferred Shares are convertible into shares of our common stock at an initial rate of 1-for-1, which conversion rate is subject to further adjustment as set forth in our Certificate of Designation of Series A-1 Convertible Preferred Stock, which was filed with the Secretary of State of the State of Delaware on January 8, 2016 (the “Series A-1 Certificate of Designation”). Pursuant to the terms of the Series A-1 Certificate of Designation, the holders of the A-1 Preferred Shares will generally be entitled to that number of votes as is equal to the product obtained by multiplying: (i) the number of whole shares of our common stock into which the A-1 Preferred may be converted as of the record date of such vote or consent, by (ii) 0.93, rounded down to the nearest whole number. Therefore, every 1.075269 shares of A-1 Preferred will generally initially be entitled to one vote. In May 2016, 2,150,538 of the A-1 Preferred Shares were converted into 2,150,538 shares of our common stock. At June 30, 2016, there were 214,705 A-1 Preferred Shares outstanding.

The 2016 Warrants were immediately exercisable upon issuance, have a term of five years and have an exercise price of $1.21 per share of our common stock. Each 2016 Warrant includes both cash and “cashless exercise” features and an exchange feature whereby the holder of the 2016 Warrant may exchange (the “Exchange Right”) all or any portion of the 2016 Warrant for a number of shares of our common stock equal to the quotient obtained by dividing the “Exchange Amount” by the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrant is exchanged (the “Exchange Price”).


Under the 2016 Warrants, the “Exchange Amount” is based upon a Black Scholes option pricing model, and the aggregate Exchange Amount under all of the 2016 Warrants will be $1,436,882, subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the date of issuance of the 2016 Warrants and the date the 2016 Warrants are exchanged. Each 2016 Warrant provides that the number of shares that may be issued upon exercise of the Exchange Right is limited to the number of shares that may be purchased pursuant to the terms of the 2016 Warrant, unless we have previously obtained stockholder approval or approval from The Nasdaq Stock Market LLC to issue any additional shares of our common stock (the “Additional Shares”) pursuant to the Exchange Right (the “Required Approvals”). For any Exchange Right exercised more than 90 days following the issuance of the 2016 Warrants, if we have not obtained either of the Required Approvals, we will be required to pay the 2016 Warrant holder an amount in cash for any Additional Shares that we cannot issue without the Required Approvals based on the Exchange Amount.

The 2016 Warrants further provide that, to the extent the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrant is exchanged is less than $0.50, the Exchange Price will be deemed to be equal to $0.50, and, in addition to issuing shares of our common stock based on this Exchange Price, we will be required to pay to the 2016 Warrant holder an amount in cash equal to the product obtained by multiplying (a) $0.50 minus the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrant is exchanged, by (b) the aggregate number of shares of our common stock issued to the 2016 Warrant holder by the Company in such exchange at an Exchange Price equal to $0.50. Therefore, if the Required Approvals are obtained, based on the Exchange Amount of $1,436,882 (which, as noted above, is subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the date of the issuance of the 2016 Warrants and the date the 2016 Warrants are exchanged), the maximum number of shares of our common stock issuable pursuant to the Exchange Right in the 2016 Warrants will be 2,873,765. In addition, if, for example, assuming an Exchange Amount of $1,436,882, the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrants are exchanged is $0.25, we would be required to pay to the 2016 Warrant holders cash in an aggregate amount of $718,441 in addition to issuing the 2016 Warrant holders 2,873,765 shares.

In accordance with the terms of the SPA, we amended that certain Series A Warrant to purchase up to an aggregate of 1,161,972 shares of our common stock previously issued by us to an affiliate of one of the 2016 Investors on July 7, 2015 (the “Original Warrant”), as previously reported by us on our Amendment No. 1 to Current Report on Form 8-K/A, filed with the SEC on July 7, 2015 (as so amended, the “Amended Warrant”). The Amended Warrant amends the Original Warrant to provide that the Amended Warrant is subject to the same terms and conditions as the 2016 Warrants and, therefore, includes both cash and “cashless exercise” features and an Exchange Right whereby the number of shares issuable pursuant to the Exchange Right is equal to the “Amended Warrant Exchange Amount”, which is based on a Black Scholes option pricing model, and will be $941,197, subject to adjustment to the extent that the risk-free U.S. treasury rate fluctuates between the date of issuance of the Amended Warrant and the date the Amended Warrant is exchanged. The Amended Warrant is exercisable for up to 1,161,972 shares of our common stock in the event we have obtained either of the Required Approvals with respect to the Amended Warrant. In the event the Amended Warrant holder exercises the Amended Warrant more than 90 days following the issuance of the Amended Warrant, if we have not obtained either of the Required Approvals, we will be required to pay the Amended Warrant holder an amount in cash for the shares of our common stock that we cannot issue under the Amended Warrant pursuant to such exercise without the Required Approvals based on the Amended Warrant Exchange Amount.

The Amended Warrant also provides that, to the extent the closing bid price of our common stock on the second trading day prior to the date the Amended Warrant is exchanged is less than $0.50, the Exchange Price will be deemed to be equal to $0.50, and, in addition to issuing shares of our common stock based on this Exchange Price (assuming receipt of the Required Approvals), we will be required to pay to the Amended Warrant holder an amount in cash equal to the product obtained by multiplying (a) $0.50 minus the closing bid price of our common stock on the second trading day prior to the date the Amended Warrant is exchanged, by (b) the aggregate number of shares of our common stock issued to the Amended Warrant holder by us in such exchange at an Exchange Price equal to $0.50. Therefore, if the Required Approvals are obtained, based on the Amended Warrant Exchange Amount of $941,197 (which, as noted above, is subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the issuance of the Amended Warrant and the date the Amended Warrant is exchanged), the maximum number of shares of our common stock issuable pursuant to the Exchange Right in the Amended Warrant will be 1,882,395. In addition, if, for example, assuming an Amended Warrant Exchange Amount of $941,197, the closing bid price of our common stock on the second trading day prior to the date the Amended Warrant is exchanged is $0.25, we would be required to pay to the Amended Warrant holder cash in an aggregate amount of $470,599 in addition to issuing the Amended Warrant holder 1,882,395 shares.

In connection with entering into the SPA, we also entered into a Registration Rights Agreement, dated January 8, 2016, with the 2016 Investors. Pursuant to the terms of the Registration Rights Agreement, we were required to file with the SEC a registration statement to register for resale the shares of our common stock issuable upon conversion of the A-1 Preferred Shares and the shares


of our common stock issuable upon exercise of the 2016 Warrants and the Amended Warrant by January 25, 2016. We filed the required registration statement with the SEC on January 25, 2016.

Craig-Hallum (the “Placement Agent”) served as the sole placement agent for the January 2016 Offering. In consideration for services rendered as the Placement Agent in the January 2016 Offering, we (1) paid to the Placement Agent cash commissions equal to approximately $140,000, or 7.0% of the gross proceeds received in the January 2016 Offering, excluding any proceeds received from Third Security, LLC or any of its affiliates; (2) issued to the Placement Agent, for a price of $50, a five-year warrant to purchase up to 107,527 shares of our common stock at an exercise price of $1.21 per share (the “Agent Warrant”), which is subject to the same terms as the 2016 Warrants except that the Agent Warrant was not exercisable until July 8, 2016 and does not contain the Exchange Right; and (3) reimbursed the Placement Agent for reasonable out-of-pocket expenses, including fees paid to the Placement Agent’s legal counsel, incurred in connection with the January 2016 Offering, which reimbursable expenses did not exceed $50,000.

The January 2016 Offering and the payment of all accrued and unpaid dividends on the Series A Preferred Stock and Series B Preferred Stock in the form of shares of our common stock at a rate of $1.00 per share of our common stock discussed under “-Conversion of Preferred Stock” below required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of these warrants decreased to $4.39 per share and the number of shares issuable upon exercise of the warrants increased from 2,188,177 to 3,239,827.

On May 31, 2016, we issued to a vendor an aggregate of 78,000 shares of our common stock and, on June 14, 2016, we issued to a second vendor an aggregate of 64,153 shares of our common stock. Such shares of common stock were issued to the vendors in lieu of an aggregate cash amount of approximately $89,000 owed by us to such vendors for services previously performed by such vendors. We issued the shares to the vendors in transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder and in reliance on similar exemptions under applicable state laws. The offering of the shares to the vendors did not involve a public offering, and no general solicitation or advertisement was made in connection with the offering of the shares to the vendors.

On June 7, 2016, we entered into an At the Market Offering Agreement (the “ATM Agreement”) with Craig-Hallum, as sales agent, pursuant to which we may offer and sell, from time to time, through Craig-Hallum, up to $3,500,000 of shares (the “Shares”) of our common stock. Any Shares offered and sold in the offering will be issued pursuant to our effective shelf registration statement on Form S-3 (File No. 333-201907) and the related prospectus previously declared effective by the SEC on February 13, 2015, as supplemented by a prospectus supplement, dated June 7, 2016, that we filed with the SEC pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended (the “Securities Act”). The number of shares eligible for sale under the ATM Agreement will be subject to the limitations of General Instruction I.B.6 of Form S-3.

Under the terms of the ATM Agreement, we will pay Craig-Hallum a placement fee of 3.25% of the gross sales price of the Shares, unless Craig-Hallum acts as principal, in which case we may sell Shares to Craig-Hallum as principal at a price to be agreed upon by us and Craig-Hallum. We will also reimburse Craig-Hallum for certain expenses incurred in connection with the ATM Agreement, and agreed to provide indemnification and contribution to Craig-Hallum with respect to certain liabilities, including liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended.
 
During the three and six months ended June 30, 2016, we sold 115,314 shares under the ATM Agreement.  The average sales price per common share was $0.67 and the aggregate net proceeds from the sales totaled less than $0.1 million.    

During the three months ended June 30, 2016, the issuance of shares to our vendors and the sale of shares under the ATM Agreement required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of these warrants decreased to $4.36 per share and the number of shares issuable upon exercise of the warrants increased from 3,239,827 to 3,262,088.
Common Stock Warrants.
During the six months ended June 30, 2016 and 2015, we issued warrants to purchase 2,933,106 and 1,208,491 shares of common stock, respectively. None of the issued warrants were exercised during such periods. The warrants issued in the six months ended June 30, 2016 included 1,073,911 warrants issued due to repricing requirements of the Private Placement and 1,881,456 warrants issued in connection with the January 2016 Offering. The warrants issued in the six months ended June 30, 2015 included 493,711 warrants issued due to repricing requirements of the Private Placement and 714,780 warrants issued in


connection with the February 2015 Offering. Warrants to purchase an aggregate of 8,876,166 shares of common stock were outstanding at June 30, 2016.
 
Warrant Holder
 
Issue Year
 
Expiration
 
Underlying
Shares
 
Exercise
Price
Various Institutional Holders(1)
 
2012
 
February 2017
 
2,832,069
 
$4.36
Affiliates of Third Security, LLC(1)
 
2012
 
February 2017
 
430,019
 
$4.36
Various Institutional Holders(2)
 
2013
 
January 2018
 
441,655
 
$9.00
Affiliates of Third Security, LLC(2)
 
2013
 
January 2018
 
250,000
 
$9.00
Various Institutional Holders(3)
 
2014
 
April 2020
 
374,618
 
$4.00
Various Institutional Holders(4)
 
2015
 
February 2020
 
714,780
 
$2.24
Various Institutional Holders(5)
 
2015
 
December 2020
 
122,433
 
$1.66
Various Institutional Holders(5)
 
2015
 
December 2020
 
667,164
 
$0.01
Various Institutional Holders(6)
 
2015
 
January 2021
 
1,161,972
 
$1.21
Affiliates of Third Security, LLC(7)
 
2016
 
January 2021
 
161,026
 
$1.21
Various Institutional Holders(7)
 
2016
 
January 2021
 
1,720,430
 
$1.21
 
 
 
 
 
 
8,876,166
 
 

(1)
These warrants were issued in connection with the Private Placement completed in February 2012 and are classified as a liability in our financial statements. See Note 9 - “Fair Value” for additional information. These warrants also contain certain anti-dilution provisions that provide for an adjustment to the exercise price and number of shares issuable upon exercise of the warrant in the event that we engage in certain issuances of shares of our common stock at a price lower than the exercise price of the warrant.
(2)
These warrants were issued in connection with the 2013 Offering, which was completed in January 2013.
(3)
These warrants were issued in connection with the 2014 Private Placement, which was completed in October 2014.
(4)
These warrants were issued in connection with the February 2015 Offering, which was completed in February 2015.
(5)
These warrants were issued in connection with the July 2015 Offering, which was completed in July 2015.
(6)
These warrants were originally issued in connection with the July 2015 Offering, which was completed in July 2015, and were amended in connection with the January 2016 Offering, which was completed in January 2016.
(7)
These warrants were issued in connection with the January 2016 Offering, which was completed in January 2016.
Issuance of Series B Preferred Stock.

On March 5, 2014, we entered into a Series B Convertible Preferred Stock Purchase Agreement (the “Series B Purchase Agreement”) with affiliates of Third Security, LLC (the “2014 Third Security Investors”), pursuant to which we, in a private placement, sold and issued an aggregate of 1,443,297 shares of our Series B Preferred Stock, par value $0.01 per share (the “Series B Preferred Stock”), at a price per share of $4.85 for an aggregate purchase price of approximately $7.0 million. Each share of Series B Preferred Stock issued pursuant to the Series B Purchase Agreement was initially convertible into shares of our common stock at a rate of 1-for-1, which conversion rate was subject to further adjustment as set forth in the Certificate of Designation of Series B Convertible Preferred Stock.

In connection with the Series B financing, we also entered into a Registration Rights Agreement, dated March 5, 2014, with the 2014 Third Security Investors, pursuant to which we granted certain demand, “piggy-back” and S-3 registrations rights covering the resale of the shares of common stock underlying the Series B Preferred Stock issued pursuant to the Series B Purchase Agreement and all shares of common stock issuable upon any dividend or other distribution with respect thereto.

The Series B financing required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of the warrants decreased from $12.96 per share to $11.73 per share and the number of shares issuable upon exercise of the warrants increased from 1,097,600 to 1,212,665.



Conversion of Preferred Stock.

On January 6, 2016, the Company entered into a Conversion Agreement (the “Conversion Agreement”) with the holders (the “Preferred Holders”) of all of the Company’s outstanding shares of Series A Convertible Preferred Stock, par value $0.01 per share (the “Series A Preferred Stock”), and Series B Preferred Stock, pursuant to which, among other things, the Preferred Holders: (a) elected to convert all of the outstanding shares of Series A Preferred Stock and Series B Preferred Stock into shares of our common stock, in each case in accordance with the terms thereof, and (b) agreed that all accrued and unpaid dividends on the Series A Preferred Stock and Series B Preferred Stock would be paid by the Company in shares of our common stock at a rate of $1.00 per share of our common stock (collectively, the “Conversion”).

The outstanding shares of Series A Preferred Stock were convertible into shares of our common stock at a rate of 1-for-3, and the outstanding shares of Series B Preferred Stock were convertible into shares of our common stock at a rate of 1-for-1. Prior to the entry into the Conversion Agreement, there were 2,586,205 shares of Series A Preferred Stock outstanding, which were converted into 862,057 shares of our common stock, and 1,443,297 shares of Series B Preferred Stock outstanding, which were converted into 1,443,297 shares of our common stock, for an aggregate of 2,305,354 shares of our common stock issued upon conversion of the Series A Preferred Stock and Series B Preferred Stock (the “Conversion Shares”). At the time of the entry into the Conversion Agreement, there were $3,681,591.90 in accrued and unpaid dividends on the outstanding shares of Series A Preferred Stock, which were converted, in accordance with the Conversion Agreement, into 3,681,590 shares of our common stock, and $793,236.17 in accrued and unpaid dividends on the outstanding shares of Series B Preferred Stock, which were converted, in accordance with the terms of the Conversion Agreement, into 793,235 shares of our common stock, for an aggregate of 4,474,825 shares of our common stock issued pursuant to the accrued and unpaid dividends on the Series A Preferred Stock and Series B Preferred Stock. Therefore, in connection with the full conversion of the Series A Preferred Stock and Series B Preferred Stock, plus the conversion of all accrued and unpaid dividends thereon, we issued an aggregate of 6,780,179 shares of our common stock to the Preferred Holders on January 6, 2016.

Following the conversion of the shares of Series A Preferred Stock and Series B Preferred Stock into common stock, no shares of Series A Preferred Stock or Series B Preferred Stock remain outstanding.
Preferred Stock Dividends.
We had cumulative undeclared dividends on our Series A Preferred Stock and Series B Preferred Stock of zero and $4.4 million at June 30, 2016 and December 31, 2015, respectively. Since dividends should generally not be recognized as a liability until declared, we had a recorded liability of zero for these undeclared dividends.
We had no undeclared dividends for the three months ended June 30, 2016. For the three months ended June 30, 2015 and the six months ended June 30, 2016 and 2015, we had undeclared dividends. In accordance with the FASB’s Accounting Standards Codification Topic 260-10-45-11, “Earnings per Share”, these dividends were added to the net loss per share calculation.

9. FAIR VALUE

FASB guidance on fair value measurements, which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements for our financial assets and liabilities, as well as for other assets and liabilities that are carried at fair value on a recurring basis in our consolidated financial statements.
FASB guidance establishes a three-level fair value hierarchy based upon the assumptions (inputs) used to price assets or liabilities. The three levels of inputs used to measure fair value are as follows:
Level 1—Unadjusted quoted prices in active markets for identical assets or liabilities;
Level 2—Observable inputs other than those included in Level 1, such as quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets; and
Level 3—Unobservable inputs reflecting our own assumptions and best estimate of what inputs market participants would use in pricing the asset or liability.

Debt.


Our long term debt book value approximates fair market value due to the variable interest rate it bears.

Common Stock Warrant Liabilities.

Certain of our issued and outstanding warrants to purchase shares of common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability.

2012 Warrant Liability
The 2012 Warrant Liability represents the fair value of the 1.2 million warrants issued in February 2012, which, through a series of changes in exercise price since February 2012, are now exercisable for 3.3 million shares of common stock. We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our Statement of Operations. Management does not believe that this liability will be settled by a use of cash.
The 2012 Warrant Liability is considered a Level 3 financial instrument and is valued using a Monte Carlo simulation model. This method is well suited to valuing options with non-standard features, such as anti-dilution protection. A Monte Carlo simulation model uses repeated random sampling to simulate significant uncertainty in inputs. Assumptions and inputs used in the valuation of the common stock warrants are broken down into four sections: Static Business Inputs; Static Technical Inputs; Simulated Business Inputs; and Simulated Technical Inputs.
Static Business Inputs include: our equity value, which was estimated using our stock price of $0.55 as of June 30, 2016; the amount of the down-round financing; the timing of the down-round financing; and the expected exercise period of 0.61 years from the valuation date.
Static Technical Inputs include: volatility of 67% and the risk-free interest rate of 0.42% based on the 1-year U.S. Treasury yield interpolated from the six-month and one-year U.S. Treasury bonds.
Simulated Business Inputs include: the probability of down-round financing, which was estimated to be 100% for simulated equity values below the down-round financing cut-off point.
Simulated Technical Inputs include: our equity value follows a geometric Brownian motion and is simulated over weekly periods; and a down-round financing event that was randomly simulated in an iteration based on the 100% discrete probability of a down-round financing for those iterations where our simulated equity value at the expected timing of a down-round financing event was below the down-round financing cut-off point.

During the three and six months ended June 30, 2016 and 2015, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:
 
 
Dollars in Thousands
 
 
For the Three Months Ended
 
 
June 30, 2016
 
June 30, 2015
Beginning balance at April 1
 
$
20

 
$
290

Total (gains) or losses:
 

 
 
Recognized in earnings
 
(20
)
 
270

Balance at June 30
 
$
—

 
$
560




 
 
Dollars in Thousands
 
 
For the Six Months Ended
 
 
June 30, 2016
 
June 30, 2015
Beginning balance at January 1
 
$
350

 
$
145

Total (gains) or losses:
 
 
 
 
Recognized in earnings
 
(350
)
 
415

Balance at June 30
 
$
—

 
$
560


2016 Warrant Liability
The 2016 Warrant Liability represents the fair value of the 1.8 million warrants issued in January 2016. We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our Statement of Operations.
The Common Stock Warrant Liability is considered a Level 3 financial instrument and is valued using a binomial lattice simulation model. This method is well suited to valuing options with non-standard features. Assumptions and inputs used in the valuation of the common stock warrants include; our equity value, which was estimated using our stock price of $0.55 as of June 30, 2016; volatility of 135%; and a risk-free interest rate of 1.21%.
During the three and six months ended June 30, 2016, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:
 
 
Dollars in Thousands
 
 
 
For the Three Months Ended
 
 
 
June 30, 2016
 
Beginning balance at April 1
 
$
1,446

 
Total (gains) or losses:
 
 
 
Recognized in earnings
 
(4
)
 
Balance at June 30
 
$
1,442

 
 
 
Dollars in Thousands
 
 
 
For the Six Months Ended
 
 
 
June 30, 2016
 
Beginning balance at January 1
 
$
—

 
Additions
 
1,437

 
Total (gains) or losses:
 
 
 
Recognized in earnings
 
5

 
Balance at June 30
 
$
1,442

 
The change in unrealized gains or losses of Level 3 liabilities was included in earnings and was reported in other income (expense) in our Statement of Operations.


10. STOCK OPTIONS
 
Stock Options.



The following table summarizes stock option activity during the six months ended June 30, 2016:
 
 
Number of
Options
 
Weighted-Average
Exercise Price
Outstanding at January 1, 2016
1,107,794

 
$
3.45

Granted
14,000

 
1.07

Forfeited
(121,140
)
 
3.69

Outstanding at June 30, 2016
1,000,654

 
$
3.39

Exercisable at June 30, 2016
648,246

 
$
4.01

    
During the six months ended June 30, 2016, we granted options to purchase 14,000 shares of our common stock at a weighted-average exercise price of $1.07 per share under our 2006 Equity Incentive Plan, as amended (the “Plan”). Options to purchase an aggregate of 608,910 shares of our common stock were granted during the six months ended June 30, 2015.

As of June 30, 2016, there were 648,246 options exercisable and 980,388 options that were vested or expected to vest with an aggregate intrinsic value of zero.

Stock Appreciation Rights (“SARs”)

The following table summarizes SARs activity under the Plan during the six months ended June 30, 2016:
 
Number of
SARs
 
Weighted-Average
Exercise Price
Outstanding at January 1, 2016
98,333

 
$
4.14

Outstanding at June 30, 2016
98,333

 
$
4.14

Exercisable at June 30, 2016
84,445

 
$
4.21


All outstanding SARs were issued solely to our executive officers.

As of June 30, 2016, 84,445 shares subject to outstanding SARs were exercisable and 98,333 shares were vested or expected to vest. The weighted-average exercise price of these SARs was $4.14 per share and the aggregate intrinsic value was zero.

Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Information
This Quarterly Report on Form 10-Q, including this Management’s Discussion and Analysis, contains forward-looking statements. These statements are based on management’s current views, assumptions or beliefs of future events and financial performance and are subject to uncertainty and changes in circumstances. Readers of this report should understand that these statements are not guarantees of performance or results. Many factors could affect our actual financial results and cause them to vary materially from the expectations contained in the forward-looking statements. These factors include, among other things: our expected revenue, income (loss), receivables, operating expenses, supplier pricing, availability and prices of raw materials, insurance reimbursements, product pricing, sources of funding operations and acquisitions, our ability to raise funds, sufficiency of available liquidity, future interest costs, future economic circumstances, business strategy, industry conditions, our ability to execute our operating plans, the success of our cost savings initiatives, competitive environment and related market conditions, expected financial and other benefits from our organizational restructuring activities, actions of governments and regulatory factors affecting our business, retaining key employees and other risks as described in our reports filed with the Securities and Exchange Commission. In some cases these statements are identifiable through the use of words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “target,” “can,” “could,” “may,” “should,” “will,” “would” or the negative versions of these terms and other similar expressions.
You are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements we make are not guarantees of future performance and are subject to various assumptions, risks and other factors that could cause actual results to differ materially from those suggested by these forward-looking statements. Actual results may differ materially from those suggested by the forward-looking statements that we make for a number of reasons, including those described in Part II, Item 1A, “Risk Factors,” of this Quarterly Report on Form 10-Q and in Part I, Item 1A, “Risk Factors,” of our Annual Report


on Form 10-K for the fiscal year ended December 31, 2015, which we filed with the Securities and Exchange Commission on April 14, 2016.
We expressly disclaim any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
The following discussion should be read together with our financial statements and related notes contained in this Quarterly Report on Form 10-Q and with the financial statements, related notes and Management’s Discussion and Analysis included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, which we filed with the Securities and Exchange Commission on April 14, 2016. Results for the three and six months ended June 30, 2016 are not necessarily indicative of results that may be attained in the future.

Overview

Transgenomic, Inc. (“we”, “us”, “our”, the “Company” or “Transgenomic”) is a biotechnology company advancing personalized medicine for the detection and treatment of cancer and inherited diseases through our proprietary molecular technologies and clinical and research services. A key goal is to bring our Multiplexed ICE COLD-PCR (“MX-ICP”) product to the clinical market through strategic partnerships and licensing agreements, enabling the use of blood and other bodily fluids for more effective and patient-friendly diagnosis, monitoring and treatment of cancer.

MX-ICP is technology proprietary to Transgenomic. It is a reagent that improves the ability to detect genetic mutations by 100 - 400 fold over existing technologies. This technology has been validated internally on all currently available sequencing platforms, including Sanger, Next Gen Sequencing and Digital PCR. By enhancing the level of detection of genetic mutations and suppressing the normal, or wild-type, DNA, several benefits are provided. It is generally understood that most current technologies are unable to consistently identify mutations that occur in less than approximately 5% of a sample. However, many mutations found at much lower levels, even as low as 0.01%, are known to be clinically relevant and can have significant consequences to a patient: both in terms of how they will respond to a given drug or treatment and how a given tumor is likely to change over time. More importantly, in our view, is the ability to significantly improve the level of detection while using blood, saliva and even urine as a source for DNA, rather than depending on painful, expensive and potentially dangerous tumor biopsies. We believe that this is an important advancement in patient care with respect to cancer detection, treatment and monitoring and can result in significant cost savings for the healthcare system by replacing invasive procedures with the simple collection of blood or other bodily fluids. By broadening the types of samples that can be used for testing and allowing all sequencing platforms to provide improved identification of low level mutations, MX-ICP has the potential to make testing more readily available and more patient friendly, enable genetic monitoring of disease progression, effectively guide treatment protocols, and reduce the overall cost of diagnosis and monitoring while significantly improving patient outcomes.

Historically, our operations were organized and reviewed by management along our major product lines and presented in two business segments: Laboratory Services and Genetic Assays and Platforms. Beginning with the quarter ended September 30, 2015, our operations are now organized as one business segment, our Laboratory Services segment, and during the fourth quarter of 2015, we began including a portion of our Laboratory Services segment as discontinued operations.

Our laboratory in Omaha, Nebraska is focused on providing genetic analytical services related to oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical and biotechnology companies. Our laboratory employs a variety of genomic testing service technologies, including our proprietary MX-ICP technology. ICE COLD-PCR is a proprietary ultra-high sensitivity platform technology with breakthrough potential to enable wide adoption of personalized, precision medicine in cancer and other diseases. It can be run in any laboratory that contains standard PCR systems. MX-ICP enables detection of multiple known and unknown mutations from virtually any sample type, including tissue biopsies, blood, urine, saliva, cell-free DNA (“cfDNA”) and circulating tumor cells (“CTCs”) at levels greater than 1,000-fold higher than standard DNA sequencing techniques. It is easy to implement and use within existing workflows. Our laboratory in Omaha is certified under the Clinical Laboratory Improvement Amendments (“CLIA”) as a high complexity laboratory and is accredited by the College of American Pathologists.

Our condensed consolidated balance sheets, statements of operations and statements of cash flows for all periods presented reflect our former Genetic Assays and Platforms activities and Patient Testing business as discontinued operations (See Note 3 - “Discontinued Operations” in the Notes to Unaudited Condensed Consolidated Financial Statements contained in this Quarterly Report on Form 10-Q).

Second Quarter 2016 Overview and Recent Highlights

29


Below is a summary of our most recent business activities:

•
Launched First Rapid Turnaround Breast Cancer Analysis Panel - Transgenomic’s new liquid biopsy test uses Multiplexed ICE COLD-PCR to detect actionable tumor mutations in genes relevant to treatment decisions with high sensitivity. Notably, results are available in 7-10 days, in contrast to turnaround times of up to four weeks for other testing methods.
•
Transgenomic Study at ASCO Shows High Concordance between ICE COLD-PCR Liquid Biopsies and Conventional Tissue Biopsies - Study released at ASCO confirmed concordance of ICP-enriched and conventional testing, identifying 97% of the mutations detected by standard tissue biopsy PCR. The study confirmed that ICP’s ultra-high sensitivity enables accurate use of plasma-based liquid biopsies for cancer mutation detection.
•
Licensed Commercial Rights to Long QT Syndrome Testing Portfolio to LabCorp - In July 2016, we signed a commercial license agreement with Laboratory Corporation of America® Holdings for Transgenomic’s portfolio of intellectual property pertaining to DNA testing for Long QT syndrome (LQTS), a congenital heart rhythm disorder. Certain medications and activities can trigger LQTS, so accurately identifying individuals at risk is important.
•
Launched First Commercially Available CLIA Test for Detection of EGFR C797S Mutations that Predict Resistance to New Kinase Therapies for Lung Cancer - In July 2016, we launched high sensitivity Multiplexed ICE COLD-PCR based-assays and panels that can use blood, serum or tissue samples to detect predictors of resistance to 3rd-generation TKI drugs in non-small cell lung cancer patients. The C797S detection test is available as a solo assay and in three EGFR panels.
•
VWR to Distribute Transgenomic’s ICEme Kits that Enable Liquid Biopsies - In July 2016, we signed a non-exclusive agreement with VWR for distribution of ICEme™ Kits to researchers and laboratories in North America. The kits are based on Multiplexed ICE COLD-PCR technology and are designed to facilitate genomics-based cancer research by providing accurate detection of mutations using any type of sample and any downstream sequencing platform.

Uncertainties
We have historically operated at a loss and have not consistently generated sufficient cash from operating activities to cover our operating and other cash expenses. We have been able to historically finance our operating losses through borrowings or from the issuance of additional equity. At June 30, 2016, we had cash and cash equivalents of $0.4 million. Our ability to continue as a going concern is dependent upon a combination of generating additional revenue, improving cash collections, potentially selling underutilized assets and, if necessary, raising additional financing to meet our obligations and pay our liabilities arising from normal business operations when they come due. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that we will be able to continue as a going concern.

Results of Continuing Operations

Three Months Ended June 30, 2016 and 2015
Net Sales. Net sales were as follows:
 
Dollars in Thousands
 
Three Months Ended
 
 
 
June 30,
 
Change
 
2016
 
2015
 
$    
 
%
Total Net Sales
$
505

 
$
442

 
$
63

 
14
%
Net sales increased by $0.1 million, or 14%, during the three months ended June 30, 2016 as compared to the same period in 2015. Sales of our contract laboratory services were flat year over year. The slight increase in total net sales for the current year period reflects higher oncology and grant revenues.
Cost of Goods Sold. Cost of goods sold includes material costs for the products that we sell and other direct costs (primarily personnel costs, rent, supplies and depreciation) associated with the operations of our laboratories.
Gross Profit. Gross profit and gross margins were as follows:

30

 
Dollars in Thousands
 
Three Months Ended
 
 
 
June 30,
 
Margin %
 
2016
 
2015
 
2016
 
2015
Gross Profit
$
(37
)
 
$
(23
)
 
(7
)%
 
(5
)%
Gross profit was a negative $37,000, or (7)% of total net sales, during the second quarter of 2016, compared to negative $23,000, or (5)% of total net sales, during the same quarter of 2015. The negative gross profit during the three months ended June 30, 2016 was flat as compared to the same period of 2015. The negative gross margin during the second quarter of 2016 is due to revenues that were insufficient to cover our laboratory’s fixed direct costs
Selling, General and Administrative Expenses. Selling, general and administrative expenses primarily consist of personnel costs, marketing, travel costs, professional fees, facility costs and bad debt provisions. Our selling, general and administrative costs decreased by $0.5 million to $1.4 million during the three month period ended June 30, 2016 as compared to the same period in 2015. This decrease was due to lower franchise tax fees and lower stock compensation costs in the second quarter of 2016 as compared to the second quarter of 2015.
Research and Development Expenses. Research and development expenses primarily include personnel costs, intellectual property fees, patent costs, outside services, laboratory supplies and facility costs and are expensed in the period in which they are incurred. For the three months ended June 30, 2016, research and development expenses totaled $0.4 million as compared to $0.5 million for the three months ended June 30, 2015. Research and development expenses totaled 80% and 106% of net sales during the three months ended June 30, 2016 and 2015, respectively.
Other Income (Expense). Other expense for the three months ended June 30, 2016 and 2015 includes interest expense of $0.3 million and $0.2 million, respectively. In addition, we recorded less than $0.1 million of other income for the three months ended June 30, 2016 and other expense of $0.3 million for the three months ended June 30, 2015 for the revaluation of common stock warrants, which was due to the change in fair value of the common stock warrant liability. The income and expense associated with the change in fair value of the warrants is a non-cash item.

Six Months Ended June 30, 2016 and 2015
Net Sales. Net sales were as follows:
 
Dollars in Thousands
 
Six Months Ended
 
 
 
June 30,
 
Change
 
2016
 
2015
 
$    
 
%
Total Net Sales
$
741

 
$
1,192

 
$
(451
)
 
(38
)%
Net sales decreased by $0.5 million, or 38%, during the six months ended June 30, 2016 as compared to the same period in 2015. The decrease reflects fewer sales of our contract laboratory services as a result of fewer customers with active projects in the current year.
Cost of Goods Sold. Cost of goods sold includes material costs for the products that we sell and other direct costs (primarily personnel costs, rent, supplies and depreciation) associated with the operations of our laboratories.
Gross Profit. Gross profit and gross margins were as follows:
 
Dollars in Thousands
 
Six Months Ended
 
 
 
June 30,
 
Margin %
 
2016
 
2015
 
2016
 
2015
Gross Profit
$
(306
)
 
$
262

 
(41
)%
 
22
%
Gross profit was a negative $0.3 million, or (41)% of total net sales, during the first half of 2016, compared to $0.3 million, or 22% of total net sales, during the same period of 2015. The decrease in gross profit in the current year is a result of lower revenues during the six months ended June 30, 2016 as compared to the first half of 2015. The negative gross margin in the current year is due to lower revenues that were insufficient to cover our laboratory’s fixed direct costs.


Selling, General and Administrative Expenses. Selling, general and administrative expenses primarily consist of personnel costs, marketing, travel costs, professional fees, facility costs and bad debt provisions. Our selling, general and administrative costs decreased by $0.6 million to $3.1 million during the six month period ended June 30, 2016 as compared to the same period in 2015. This decrease was due to lower professional fees and lower stock compensation costs in the first half of 2016 as compared to the first half of 2015.
Research and Development Expenses. Research and development expenses primarily include personnel costs, intellectual property fees, outside services, collaboration expenses, laboratory supplies and facility costs and are expensed in the period in which they are incurred. For the six months ended June 30, 2016, research and development expenses totaled $0.7 million as compared to $0.9 million for the six months ended June 30, 2015. Research and development expenses totaled 91% and 77% of net sales during the six months ended June 30, 2016 and 2015, respectively.
Other Income (Expense). Other expense for the six months ended June 30, 2016 and 2015 includes interest expense of $0.5 million and $0.4 million, respectively. In addition, we recorded $0.3 million of other income for the six months ended June 30, 2016 and other expense of $0.4 million for the six months ended June 30, 2015 for the revaluation of common stock warrants, which was due to the change in fair value of the common stock warrant liability. The income and expense associated with the change in fair value of the warrants is a non-cash item.

Discontinued Operations For The Three and Six Months Ended June 30, 2016 and 2015

During the third quarter of 2015, we decided to divest our Genetic Assays and Platforms business, resulting in a strategic shift that had a major effect on our operations and financial results. Therefore, the divested Genetic Assays and Platforms operations meet the criteria to be reported as discontinued operations.

During the fourth quarter of 2015, our Board of Directors took actions to begin the process of divesting our Patient Testing business located in New Haven, Connecticut. In March 2016, we announced that we had suspended testing services in our Patient Testing laboratory as we review and evaluate various strategic alternatives for that business. As a result of these actions, our Patient Testing business meets the criteria to be reported as discontinued operations.

The related assets, liabilities, results of operations and cash flows for both the Genetic Assays and Platforms business and Patient Testing business are classified as assets held for sale, liabilities held for sale and discontinued operations for all periods presented.

Net income from discontinued operations for both the three and six months ended June 30, 2016, includes approximately $1.0 million in proceeds received from the sale of assets of our discontinued Patient Testing business.

Revenues and net loss of the discontinued operations consisted of the following:
 
Three months ended June 30,
 
Six months ended June 30,
(Dollars in thousands)
2016
 
2015
 
2016
 
2015
Net sales
$
574

 
$
6,598

 
$
1,677

 
$
12,361

Net income (loss) from discontinued operations, before tax
$
1,182

 
$
(378
)
 
$
9

 
$
(1,055
)
Income tax expense
—

 
43

 
—

 
89

Income (loss) from discontinued operations, net of tax
$
1,182

 
$
(421
)
 
$
9

 
$
(1,144
)


Liquidity and Capital Resources
Our working capital positions at June 30, 2016 and December 31, 2015 were as follows: 


 
Dollars in Thousands
 
June 30,
2016
 
December 31,
2015
 
Change
Current assets (including cash and cash equivalents of $421 and $444, respectively)
$
1,803

 
$
3,282

 
$
(1,479
)
Current liabilities
17,719

 
16,981

 
738

Working capital
$
(15,916
)
 
$
(13,699
)
 
$
(2,217
)

Conversion Agreement

On January 6, 2016, we entered into a Conversion Agreement (the “Conversion Agreement”) with the holders (the “Preferred Holders”) of all of our outstanding shares of Series A Convertible Preferred Stock (the “Series A Preferred”), and Series B Convertible Preferred Stock (the “Series B Preferred”), pursuant to which, among other things, the Preferred Holders: (1) elected to convert all of the outstanding shares of Series A Preferred and Series B Preferred into shares of our common stock in each case in accordance with the terms thereof, and (2) agreed that all accrued and unpaid dividends on the Series A Preferred and Series B Preferred would be paid by us in shares of common stock at a rate of $1.00 per share of common stock (collectively, the “Conversion”).

The outstanding shares of Series A Preferred were convertible into shares of common stock at a rate of 1-for-3, and the outstanding shares of Series B Preferred were convertible into shares of common stock at a rate of 1-for-1. Prior to the entry into the Conversion Agreement, there were 2,586,205 shares of Series A Preferred outstanding, which were converted into 862,057 shares of common stock, and 1,443,297 shares of Series B Preferred outstanding, which were converted into 1,443,297 shares of common stock, for an aggregate of 2,305,354 shares of common stock issued upon conversion of the Series A Preferred and Series B Preferred. At the time of the entry into the Conversion Agreement, there were $3,681,591.90 in accrued and unpaid dividends on the outstanding shares of Series A Preferred, which were converted, in accordance with the Conversion Agreement, into 3,681,590 shares of common stock, and $793,236.17 in accrued and unpaid dividends on the outstanding shares of Series B Preferred, which were converted, in accordance with the terms of the Conversion Agreement, into 793,235 shares of common stock, for an aggregate of 4,474,825 shares of our common stock issued pursuant to the accrued and unpaid dividends on the Series A Preferred and Series B Preferred. Therefore, in connection with the full conversion of the Series A Preferred and Series B Preferred, plus the conversion of all accrued and unpaid dividends thereon, we issued an aggregate of 6,780,179 shares of common Stock to the Preferred Holders on January 6, 2016.

January 2016 Private Placement

On January 6, 2016, we entered into a Securities Purchase Agreement (the “A-1 Preferred Purchase Agreement”) with certain accredited investors (the “A-1 Preferred Investors”), pursuant to which, on January 8, 2016, we sold to the A-1 Preferred Investors, and the A-1 Preferred Investors purchased from us (the “A-1 Preferred Offering”), an aggregate of approximately $2.2 million of units (the “Units”) consisting of (1) an aggregate of 2,365,243 shares (the “A-1 Preferred Shares”) of our Series A-1 Convertible Preferred Stock (the “A-1 Preferred”), and (2) warrants (the “Warrants”) to purchase up to an aggregate of 1,773,929 shares of our common stock. Each Unit was sold to the A-1 Preferred Investors at a purchase price of $0.93 per Unit. The A-1 Preferred Shares are convertible into shares of common stock at an initial rate of 1-for-1, which conversion rate is subject to further adjustment as set forth in our Certificate of Designation of Series A-1 Convertible Preferred Stock, which was filed with the Secretary of State of the State of Delaware on January 8, 2016 (the “Series A-1 Certificate of Designation”). Pursuant to the terms of the Series A-1 Certificate of Designation, the holders of the A-1 Preferred Shares will generally be entitled to that number of votes as is equal to the product obtained by multiplying: (a) the number of whole shares of common stock into which the A-1 Preferred may be converted as of the record date of such vote or consent, by (b) 0.93, rounded down to the nearest whole number. Therefore, every 1.075269 shares of A-1 Preferred will generally initially be entitled to one vote.

The Warrants were immediately exercisable upon issuance, have a term of five years and have an exercise price of $1.21 per share of common stock. Each Warrant also includes both cash and cashless exercise features and an exchange feature whereby the holder of the Warrant may exchange all or any portion of the Warrant for a number of shares of our common stock equal to the quotient obtained by dividing the “Exchange Amount” by the closing bid price of our common stock on the second trading day prior to the date the Warrant is exchanged (the “Exchange Right”). Under the Warrants, the “Exchange Amount” is based upon a Black Scholes option pricing model, and the aggregate Exchange Amount under all of the Warrants will be $1,436,882, subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the date of issuance of the Warrants and the date the Warrants are exchanged. Each Warrant provides that the number of shares that may be issued upon exercise of the Exchange Right is limited to the number of shares that may be purchased pursuant to the terms of the Warrant, unless we have previously obtained stockholder approval or approval from The Nasdaq Stock Market LLC to issue any additional shares of our common

33

stock (the “Additional Shares”) pursuant to the Exchange Right (the “Required Approvals”). For any Exchange Right exercised more than 90 days following the issuance of the Warrants, if we have not obtained either of the Required Approvals, we will be required to pay the Warrant holder an amount in cash for any Additional Shares that we cannot issue without the Required Approvals based on the Exchange Amount.

At the Market Offering

On June 7, 2016, we entered into an At the Market Offering Agreement (the “ATM Agreement”) with Craig-Hallum Capital Group LLC, as sales agent (“Craig-Hallum”), pursuant to which we may offer and sell, from time to time, through Craig-Hallum, up to $3,500,000 of shares (the “Shares”) of our common stock. Any Shares offered and sold in the offering will be issued pursuant to our effective shelf registration statement on Form S-3 (File No. 333-201907) and the related prospectus previously declared effective by the Securities and Exchange Commission (the “SEC”) on February 13, 2015, as supplemented by a prospectus supplement, dated June 7, 2016, that we filed with the SEC pursuant to Rule 424(b)(5) under the Securities Act. The number of shares eligible for sale under the ATM Agreement will be subject to the limitations of General Instruction I.B.6 of Form S-3. During the three months ended June 30, 2016, we sold 115,314 shares under the ATM Agreement.  The average sales price per common share was $0.67 and the aggregate net proceeds from the sales totaled less than $0.1 million.
Please see Note 5 - “Debt” and Note 6 - “Commitments and Contingencies” in the Notes to Unaudited Condensed Consolidated Financial Statements contained in this Quarterly Report on Form 10-Q for additional information regarding our outstanding debt and debt servicing obligations.
At June 30, 2016, we had cash on hand of $0.4 million. Our current operating plan projects improved operating results and monetization of underutilized assets. As with any operating plan, there are risks associated with our ability to execute it. Therefore, there can be no assurance that we will be able to satisfy our obligations, or achieve the operating improvements as contemplated by the current operating plan. If we are unable to execute this plan, we will need to find additional sources of cash not contemplated by the current operating plan and/or raise additional capital to sustain continuing operations as currently contemplated. We could raise additional funds through various potential sources such as through the sale of assets or sale of debt or equity securities. However, there can be no assurance that the additional funding sources will be available to us at reasonable terms or at all. If we are unable to achieve our operating plan or obtain additional financing, our business would be jeopardized and we may not be able to continue as a going concern.

Analysis of Cash Flows - Six Months Ended June 30, 2016 and 2015
Net Change in Cash and Cash Equivalents. Cash and cash equivalents decreased by less than $0.1 million during the six months ended June 30, 2016, compared to an increase of $0.7 million during the six months ended June 30, 2015. These amounts include cash provided by discontinued operations of $1.0 million and cash used in discontinued operations of $2.1 million, for the six months ended June 30, 2016 and 2015, respectively.
Cash Flows From Continuing Operations
Cash Flows Used in Operating Activities. The cash flows used in operating activities of $2.8 million during the six months ended June 30, 2016 included a net loss of $4.3 million and a decrease in accrued expenses of $0.6 million. These were partially offset by an increase in accounts payable of $1.8 million and a decrease in other current assets of $0.3 million. The cash flows used in operating activities in the first six months of 2015 included the net loss of $5.2 million, a decrease in accrued expenses of $0.2 million and an increase in other current assets of $0.2 million. These were partially offset by a decrease in accounts receivable of $0.3 million, an increase in accounts payable of $0.4 million and other non-cash adjustments of $1.0 million.
Cash Flows Used in Investing Activities. Cash flows used in investing activities for continuing operations were less than $0.1 million and $0.2 million for the six months ended June 30, 2016 and 2015, respectively.
Cash Flows Provided by Financing Activities. Cash flows provided by financing activities totaled $1.8 million for the six months ended June 30, 2016, which included net proceeds of approximately $1.8 million from our Unit issuance, $0.1 million from sales under the ATM Agreement and $0.5 million from borrowing on our debt. These proceeds were partially offset by payments on our debt of approximately $0.6 million. Cash flows provided by financing activities during the six months ended June 30, 2015 included net proceeds of $6.2 million from our common stock offering and $0.9 million from the issuance of unsecured convertible promissory notes.

Off-Balance Sheet Arrangements

34

At each of June 30, 2016 and December 31, 2015, we did not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Contractual Obligations and Commitments
There have been no material changes to our contractual obligations outside the normal course of business as compared to those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2015, filed with the Securities and Exchange Commission on April 14, 2016.

Critical Accounting Policies and Estimates
Accounting policies used in the preparation of our consolidated financial statements may involve the use of management judgments and estimates. Certain of our accounting policies are considered critical as they are both important to the portrayal of our financial statements and require significant or complex judgments on the part of management. Our judgments and estimates are based on experience and assumptions that we believe are reasonable under the circumstances. Further, we evaluate our judgments and estimates from time to time as circumstances change. Actual financial results based on judgments or estimates may vary under different assumptions or circumstances. Our critical accounting policies are discussed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, filed with the Securities and Exchange Commission on April 14, 2016.

Recently Issued Accounting Pronouncements
Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, filed with the Securities and Exchange Commission on April 14, 2016. There have been no changes to those accounting pronouncements listed except as noted in Note 2 - “Summary of Significant Accounting Policies-Recent Accounting Pronouncements” in the Notes to Unaudited Condensed Consolidated Financial Statements contained in this Quarterly Report on Form 10-Q.

Impact of Inflation
We do not believe that price inflation or deflation had a material adverse effect on our financial condition or results of operations during the periods presented.

Item 3.    Quantitative and Qualitative Disclosures About Market Risk

We are a smaller reporting company, as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, and are not required to provide the information required under this item.

Item 4.
Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Management performed, with the participation of our Chief Executive Officer and Interim Chief Financial Officer, an evaluation of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Interim Chief Financial Officer, to allow timely decisions regarding required disclosures. Based on the evaluation, our Chief Executive Officer and Interim Chief Financial Officer concluded that, as of June 30, 2016, our disclosure controls and procedures were effective at the reasonable assurance level.
Changes in Internal Control over Financial Reporting
We have evaluated the changes in our internal control over financial reporting that occurred during the three months ended June 30, 2016 and concluded that there have not been any changes that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

35

PART II. OTHER INFORMATION
 
Item 1.
Legal Proceedings
We are subject to a number of claims of various amounts that arise out of the normal course of our business. In our opinion, the disposition of pending claims, in excess of recorded accruals, could have a material adverse effect on our financial position, results of operations or cash flows. On February 25, 2016, the Board of Regents of the University of Nebraska (“UNMC”) filed a lawsuit against us in the District Court of Douglas County, Nebraska, for breach of contract and seeking recovery of $0.7 million owed by us to UNMC. We and UNMC are currently in discussions to determine a mutually agreeable means by which to settle the outstanding liability. A $0.7 million liability has been recorded at December 31, 2015 and June 30, 2016.
In addition, on April 13, 2016, Fox Chase Cancer Center (“Fox Chase”) filed a lawsuit against us in the Court of Common Pleas of Philadelphia County, First Judicial District of Pennsylvania Civil Trial Division (the “Court of Common Pleas”), alleging, among other things, breach of contract, tortious interference with present and prospective contractual relations, unjust enrichment, fraudulent conversion and conspiracy and seeking punitive damages in addition to damages and other relief. This lawsuit relates to a license agreement we entered into with Fox Chase in August 2000, as amended (the “License Agreement”), as well as the assignment of certain of our rights under the License Agreement to Integrated DNA Technologies, Inc. (“IDT”) pursuant to the Surveyor Kit Patent, Technology and Inventory Purchase Agreement we entered into with IDT effective as of July 1, 2014 (the “IDT Agreement”). Pursuant to the terms of the IDT Agreement, we agreed to indemnify IDT with respect to certain of the claims asserted in the Fox Chase proceeding. On July 8, 2016, the Court of Common Pleas sustained our preliminary objections to several of Fox Chase’s claims and dismissed the claims for tortious interference, fraudulent conversion, conspiracy, punitive damages and attorney’s fees.  Accordingly, the case has been narrowed so that only certain contract claims and an unjust enrichment claim remain pending against us. We believe that we have good and substantial defenses to the claims asserted by Fox Chase. We are unable to determine whether any loss will occur or to estimate the range of such potential loss; therefore, no amount of loss has been accrued by us as of the date of filing of this Quarterly Report on Form 10-Q. Furthermore, there is no guarantee that we will prevail in this suit or receive any damages or other relief if we do prevail.
On June 23, 2016, the Icahn School of Medicine at Mount Sinai (“Mount Sinai”) filed a lawsuit against us in the Supreme Court of the State of New York, County of New York, alleging, among other things, breach of contract and, alternatively, unjust enrichment and quantum merit, and seeking recovery of $0.7 million owed by us to Mount Sinai for services rendered. We and Mount Sinai are currently in discussions to determine a mutually agreeable means by which to settle the outstanding liability. A $0.7 million liability has been recorded at December 31, 2015 and June 30, 2016.
The outcome of legal proceedings and claims brought against us are subject to significant uncertainty. Therefore, although management considers the likelihood of such an outcome to be remote, if one or more of these legal matters were resolved against us in the same reporting period for amounts in excess of management’s expectations, our financial statements for such reporting period could be materially adversely affected. In general, the resolution of a legal matter could prevent us from offering our services or products to others, could be material to our financial condition or cash flows, or both, or could otherwise adversely affect our operating results.
 
Item 1A.
Risk Factors
Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below, together with all of the other information in this Quarterly Report on Form 10-Q, before making a decision to invest in our common stock. The risks and uncertainties described below may not be the only ones we face. If any of the risks actually occur, our business, financial condition and results of operations could be materially and adversely affected. In that event, the trading price of our common stock could decline, and you could lose part or all of your investment.
Risk factors marked with an asterisk (*) below include a change from or an update to the risk factors included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 filed with the Securities and Exchange Commission on April 14, 2016.

*We have a history of operating losses and may incur losses in the future.
We have experienced annual losses from continuing operations since inception of our operations. Our operating loss for the years ended December 31, 2015 and 2014 was $9.2 million and $10.6 million, respectively, and for the six months ended June 30, 2016 and 2015 was $4.1 million and $4.4 million, respectively. These historical losses have been due principally to the expenses that we have incurred in order to develop and market our products, the fixed nature of our manufacturing costs and merger and acquisition costs.

36

*Recurring operating losses raise substantial doubt about our ability to continue as a going concern.
We have incurred substantial operating losses and have used cash in our operating activities for the past several years. As of June 30, 2016, we had negative working capital of $15.9 million.
The audit report issued by our independent registered public accounting firm for our financial statements for the fiscal year ended December 31, 2015 states that our independent registered public accounting firm has substantial doubt in our ability to continue as a going concern due to the risk that we may not have sufficient cash and liquid assets at December 31, 2015 to cover our operating and capital requirements for the next 12 months. If that is the case, and if sufficient cash cannot be obtained, we would have to substantially alter, or possibly even discontinue, operations. Additionally, as of June 30, 2016, we do not believe that we will have sufficient cash to meet our operating requirements for at least the next 12 months. Our financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q do not include any adjustments that might result from the outcome of this uncertainty.
Our current operating plan is designed to improve operating results, improve collection rates and monetize underutilized assets. There are no guarantees that these efforts will be successful and, if not, we may use more cash than projected and not be able to meet our current obligations. As with any operating plan, there are risks associated with our ability to execute it. Therefore, there can be no assurance that we will be able to satisfy our obligations, or achieve the operating improvements as contemplated by the current operating plan. If we are unable to execute this plan, we will need to find additional sources of cash not contemplated by the current operating plan and/or raise additional capital to sustain continuing operations as currently contemplated. We could seek to raise additional funds through various potential sources such as through the sale of assets or sale of debt or equity securities. However, there can be no assurance that the additional funding sources will be available to us at reasonable terms or at all. If we are unable to achieve our operating plan or obtain additional financing, our business would be jeopardized and we may not be able to continue as a going concern.
*We have substantial debt and other financial obligations and we may incur even more debt, and we are in default under our loan agreement with affiliates of Third Security, LLC, which means that the lenders under the loan agreement have the right to cease making additional advances, accelerate repayment of all sums due and take action to collect the amounts owed to them, including foreclosing on their security interest, each of which could adversely affect us.
Our revolving line of credit and term loan with affiliates of Third Security, LLC, a related party (the “Lenders”), are governed by a Loan and Security Agreement, as amended (the “Loan and Security Agreement”), which contains certain affirmative and negative covenants. As of June 30, 2016, we had borrowings of $7.2 million under the Loan and Security Agreement. Under the term loan, we agreed not to (i) pledge or otherwise encumber our assets other than to the Lenders, (ii) enter into additional borrowings or guarantees, (iii) repurchase our capital stock, or (iv) enter into certain mergers or acquisitions without the Lenders’ consent. To secure the repayment of amounts borrowed under the revolving line of credit and term loan, we granted the Lenders a security interest in all of our assets. As of June 30, 2016, we were in compliance with the Loan and Security Agreement, as amended by the Ninth Amendment; however, we have not made the required July 2016 interest payment and we are therefore currently in default under the Loan and Security Agreement. Accordingly, under the terms of the Loan and Security Agreement, the Lenders currently have the right to cease making additional advances, accelerate repayment of all sums due and take action to collect the amounts owed to them, including foreclosing on their security interest or forcing us into bankruptcy, which would have a material adverse effect on our financial condition and results of operations.
We may be required to amend our Loan and Security Agreement, refinance all or part of our existing debt, sell assets, incur additional indebtedness or raise equity. Further, based upon our actual performance levels, our covenants relating to income, debt coverage and cash flow and minimum working capital requirements could limit our ability to incur additional debt, which could hinder our ability to execute on our current business strategy. Our ability to make scheduled payments on our debt and other financial obligations and comply with financial covenants depends on our financial and operating performance. Our financial and operating performance will continue to be subject to prevailing economic conditions and to financial, business and other factors, some of which are beyond our control.
*Our existing indebtedness could adversely affect our ability to fulfill our obligations and may place us at a competitive disadvantage in our industry.
We continue to have substantial debt outstanding and we may incur additional indebtedness from time to time to finance working capital, product development efforts, strategic acquisitions, investments and alliances, capital expenditures or other general corporate purposes, subject to the restrictions contained in our existing indebtedness and in any other agreements under which we incur indebtedness. Our outstanding indebtedness and debt service requirements could adversely affect our ability to operate our

37

business and may limit our ability to take advantage of potential business opportunities. For example, our existing level of indebtedness presents the following risks:
•
we will be required to use a substantial portion of our cash flow from operations to pay principal and interest on our indebtedness, thereby reducing the availability of our cash flow to fund working capital, capital expenditures, product development efforts, acquisitions, investments and strategic alliances and other general corporate requirements;
•
our debt service obligations could limit our flexibility in planning for, or reacting to, changes in our business and our industry and could limit our ability to pursue other business opportunities, borrow more money for operations or capital in the future and implement our business strategies;
•
our level of indebtedness and the covenants within our debt instruments may restrict us from raising additional financing on satisfactory terms to fund working capital, capital expenditures, product development efforts, strategic acquisitions, investments and alliances, and other general corporate requirements; and
•
our outstanding indebtedness may make it difficult for us to attract additional financing when needed.

As of June 30, 2016, we were in compliance with the Loan and Security Agreement, as amended by the Ninth Amendment; however, we have not made the required July 2016 interest payment and we are therefore currently in default under the Loan and Security Agreement. Accordingly, we may be required to attempt to renegotiate the terms of the instruments relating to the indebtedness, seek to refinance all or a portion of the indebtedness or obtain additional financing. There can be no assurance that we will be able to successfully renegotiate such terms, that any such refinancing would be possible or that any additional financing could be obtained on terms that are favorable or acceptable to us.

Our future capital needs are uncertain and we may need to raise additional funds in the future.
Our future capital needs are uncertain and we may need to raise additional funds in the future through debt or equity offerings. Our future capital requirements will depend on many factors, including, but not limited to:
•
Revenue generated by sales of our products;
•
Expenses incurred in manufacturing and selling our products;
•
Costs of developing new products or technologies;
•
Costs associated with capital expenditures;
•
The number and timing of strategic transactions; and
•
Working capital requirements related to growing existing business.

We may need additional capital to finance our growth or to compete, which may cause dilution to existing stockholders or limit our flexibility in conducting our business activities.
We may need to raise additional capital in the future to fund expansion, respond to competitive pressures or acquire complementary businesses, technologies or services. Such additional financing may not be available on terms acceptable to us or at all. To the extent that we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution, and to the extent we engage in additional debt financing, if available, we may become subject to additional restrictive covenants that could limit our flexibility in conducting future business activities. If additional financing is not available or not available on acceptable terms, we may not be able to continue as a going concern, fund our expansion, promote our brands, take advantage of acquisition opportunities, develop or enhance services or respond to competitive pressures.
Governmental payers and health care plans have taken steps to control costs.
Medicare, Medicaid and private insurers have increased their efforts to control the costs of health care services, including clinical testing services. They may reduce fee schedules or limit/exclude coverage for certain types of tests that we perform. Medicaid reimbursement varies by state and is subject to administrative and billing requirements and budget pressures. We expect efforts to reduce reimbursements, impose more stringent cost controls and reduce utilization of testing services will continue. These efforts, including changes in laws or regulations, may have a material adverse impact on our business.
Weakness in U.S. or global economic conditions could have an adverse effect on our businesses.
The economies of the United States and other regions of the world in which we do business have experienced significant weakness, which, in the case of the U.S., has recently resulted in significant unemployment and slower growth in economic activity. A decline in economic conditions may adversely affect demand for our services and products, thus reducing our revenue. These conditions could also impair the ability of those with whom we do business to satisfy their obligations to us. The strengthening of the U.S. dollar has the potential to adversely impact U.S. businesses that operate overseas.

38

Sales have been variable.
Our laboratory performs project-based work that changes from quarter to quarter. Therefore, comparison of the results of successive quarters may not accurately reflect trends or results for the full year due to the fact that ICP is a new product and will enable the liquid biopsy market to evolve rapidly and ensure Precision Medicine is adopted globally. We see the ICP business and revenues growing as our commercial strategy is successful and our partnerships and licensing agreements become profitable.
Changes in payer mix could have a material adverse impact on our net sales and profitability.
Testing services are billed to physicians, patients, government payers such as Medicare, and insurance companies. Tests may be billed to different payers depending on a particular patient’s medical insurance coverage. Government payers have increased their efforts to control the cost, utilization and delivery of health care services as well as reimbursement for laboratory testing services. Further reductions of reimbursement for Medicare and Medicaid services or changes in policy regarding coverage of tests or other requirements for payment, such as prior authorization or a physician or qualified practitioner’s signature on test requisitions, may be implemented from time to time. Reimbursement for the laboratory services component of our business is also subject to statutory and regulatory reduction. Reductions in the reimbursement rates and changes in payment policies of other third party payers may occur as well. Such changes in the past have resulted in reduced payments as well as added costs and have decreased test utilization for the clinical laboratory industry by adding more complex new regulatory and administrative requirements. As a result, increases in the percentage of services billed to government payers could have an adverse impact on our net sales.
We may experience temporary disruptions and delays in processing biological samples at our facilities.
We may experience delays in processing biological samples caused by software and other errors. Any delay in processing samples could have an adverse effect on our business, financial condition and results of operations.
Our laboratories require ongoing CLIA certification.
The CLIA extended federal oversight to virtually all clinical laboratories by requiring that they be certified by the federal government or by a federally-approved accreditation agency. The CLIA requires that all clinical laboratories meet quality assurance, quality control and personnel standards. Laboratories must also undergo proficiency testing and are subject to inspections.
The sanctions for failure to comply with the CLIA requirements include suspension, revocation or limitation of a laboratory’s CLIA certificate, which is necessary to conduct business, cancellation or suspension of the laboratory’s approval to receive Medicare and/or Medicaid reimbursement, as well as significant fines and/or criminal penalties. The loss or suspension of a CLIA certification, imposition of a fine or other penalties, or future changes in the CLIA law or regulations (or interpretation of the law or regulations) could have a material adverse effect on us.
We believe that we are in compliance with all applicable laboratory requirements, but no assurances can be given that our laboratories will pass all future certification inspections.
Failure to comply with HIPAA could be costly.
The Health Insurance Portability and Accountability Act (“HIPAA”) and associated regulations protect the privacy and security of certain patient health information and establish standards for electronic health care transactions in the United States. These privacy regulations establish federal standards regarding the uses and disclosures of protected health information. Our Molecular Labs are subject to HIPAA and its associated regulations. If we fail to comply with these laws and regulations we could suffer civil and criminal penalties, fines, exclusion from participation in governmental health care programs and the loss of various licenses, certificates and authorizations necessary to operate our Patient Testing business. We could also incur liabilities from third party claims.
Our business could be adversely impacted by health care reform.
Government attention to the health care industry in the United States is significant and may increase. The Patient Protection and Affordable Care Act passed by Congress and signed into law by President Obama in March 2010 could adversely impact our business. While certain portions of the legislation have already gone into effect, the ultimate impact of the legislation on the health care industry is still unknown, and the overall impact on our business is likely to be extensive and could result in significant changes to our business and our customers’ businesses.

39

*We are subject to a number of claims of various amounts that arise out of the normal course of our business.
We are subject to a number of claims of various amounts that arise out of the normal course of our business. Specifically, on February 25, 2016, the Board of Regents of the University of Nebraska (“UNMC”) filed a lawsuit against us in the District Court of Douglas County, Nebraska for breach of contract and seeking recovery of $0.7 million owed by us to UNMC. We and UNMC are currently in discussions to determine a mutually agreeable means by which to settle the outstanding liability. A $0.7 million liability has been recorded and is reflected in accrued expenses at December 31, 2015 and June 30, 2016.
In addition, on April 13, 2016, Fox Chase Cancer Center (“Fox Chase”) filed a lawsuit against us in the Court of Common Pleas of Philadelphia County, First Judicial District of Pennsylvania Civil Trial Division (the “Court of Common Pleas”), alleging, among other things, breach of contract, tortious interference with present and prospective contractual relations, unjust enrichment, fraudulent conversion and conspiracy and seeking punitive damages in addition to damages and other relief. This lawsuit relates to a license agreement we entered into with Fox Chase in August 2000, as amended (the “License Agreement”), as well as the assignment of certain rights of our rights under the License Agreement to Integrated DNA Technologies, Inc. (“IDT”), pursuant to the Surveyor Kit Patent, Technology and Inventory Purchase Agreement we entered into with IDT effective as of July 1, 2014 (the “IDT Agreement”). Pursuant to the terms of the IDT Agreement, we agreed to indemnify IDT with respect to certain of the claims asserted in the Fox Chase proceeding. On July 8, 2016, the Court of Common Pleas sustained our preliminary objections to several of Fox Chase’s claims and dismissed the claims for tortious interference, fraudulent conversion, conspiracy, punitive damages and attorney’s fees.  Accordingly, the case has been narrowed so that only certain contract claims and an unjust enrichment claim remain pending against us. We believe that we have good and substantial defenses to the claims asserted by Fox Chase. However, there is no guarantee that we will prevail in this suit or receive any damages or other relief if we do prevail.
On June 23, 2016, the Icahn School of Medicine at Mount Sinai (“Mount Sinai”) filed a lawsuit against us in the Supreme Court of the State of New York, County of New York, alleging, among other things, breach of contract and, alternatively, unjust enrichment and quantum merit, and seeking recovery of $0.7 million owed by us to Mount Sinai for services rendered. We and Mount Sinai are currently in discussions to determine a mutually agreeable means by which to settle the outstanding liability. A $0.7 million liability has been recorded at December 31, 2015 and June 30, 2016.
Our ongoing and future litigation could result in significant additional costs and further divert the attention of our management and key personnel from our business operations and the implementation of our business strategy. In addition, the disposition of any of the pending claims against us, in excess of recorded accruals, could have a material adverse effect on our financial position, results of operations or cash flows.
We may be subject to client lawsuits.
Providers of clinical testing services may be subject to lawsuits alleging negligence or other legal claims. Potential suits could involve claims for substantial damages. Litigation could also have an adverse impact on our client base and our reputation. We maintain liability insurance coverage for certain claims that could result from providing or failing to provide clinical testing services, including inaccurate testing results and other exposures. Our insurance coverage limits our maximum recovery on individual claims and, therefore, there is no assurance that such coverage will be adequate.
*The sale of our products and business operations in international markets subjects us to additional risks.
During the past several years, international sales have represented a significant portion of our total net sales. As a result, a major portion of our net sales are subject to risks associated with international sales and operations. These risks include:
•
Payment cycles in foreign markets are typically longer than in the U.S., and capital spending budgets for research agencies can vary over time with foreign governments;
•
Changes in foreign currency exchange rates can make our products more costly in local currencies because our foreign sales are typically paid for in British Pounds or in Euros;
•
The potential for changes in U.S. and foreign laws or regulations that result in additional import or export restrictions, higher tariffs or other taxes, more burdensome licensing requirements or similar impediments may limit our ability to sell products and services profitably in these markets; and
•
The fluctuation of foreign currency exchange rates to the U.S. Dollar and the Euro to the British Pound can cause our net sales and expenses to increase or decrease, which adds risk to our financial statements.

In addition, many of the countries in which we have sales, including the U.S. and several of the members of the European Union, have experienced and continue to experience uncertain economic conditions resulting from global as well as local factors. For example, on June 23, 2016, the United Kingdom (the “UK”) held a referendum pursuant to which voters elected to leave the

40

European Union, commonly referred to as Brexit. As a result of UK voters’ election to leave the European Union, the British government is expected to begin negotiating the terms of the UK’s future relationship with the European Union. Although the long-term effects of Brexit will depend on any agreements the UK makes to retain access to the European Union markets, Brexit has created additional uncertainties that may ultimately result in new regulatory costs and challenges for companies and increased restrictions on imports and exports throughout Europe, which could adversely affect our ability to conduct and expand our operations in Europe and which may have an adverse effect on our business, financial condition and results of operations. In addition, Brexit may also increase the possibility that other countries may decide to leave the European Union in the future.

Our dependence on our suppliers exposes us to certain risks.
We rely on various suppliers for products and materials to produce our products. In the event that they would be unable to deliver these items due to product shortages or business closures, we may be unable to deliver our products to our customers in a timely manner or may need to increase our prices. The current economy poses the additional risk of our suppliers’ inability to continue their businesses as usual.
Our markets are very competitive.
Many of our competitors have greater resources than we do and may enjoy other competitive advantages. This may allow them to more effectively market their products to our customers or potential customers, to develop products that make our products obsolete or to produce and sell products less expensively than us. As a result of these competitive factors, demand for and pricing of our products and services could be negatively affected.
Our patents may not protect us from others using our technology, which could harm our business and competitive position.
Patent law relating to the scope of claims in the technology fields in which we operate is still evolving. The degree of future protection for our proprietary rights is uncertain. Furthermore, we cannot be certain that others will not independently develop similar or alternative products or technology, duplicate any of our products, or, if patents are issued to us, design around the patented products developed by us. Our patents or licenses could be challenged by litigation and, if the outcome of such litigation were adverse to us, our competitors could be free to use our technology. We may not be able to obtain additional patents for our technology, or if we are able to do so, patents may not provide us with adequate protection or be commercially beneficial. In addition, we could incur substantial costs in litigation if we are required to defend ourselves in patent suits brought by third parties or if we initiate such suits.
We cannot be certain that other measures taken to protect our intellectual property will be effective.
We rely upon trade secrets, copyright and trademark laws, non-disclosure agreements and other contractual confidentiality provisions to protect some of our confidential and proprietary information that we are not seeking patent protection for various reasons. Such measures, however, may not provide adequate protection for our trade secrets or other proprietary information. If such measures do not protect our rights, third parties could use our technology and our ability to compete in the market would be reduced.
We are dependent upon licensed technologies and may need to obtain additional licenses in the future to offer our products and remain competitive.
We have licensed key components of our technologies from third parties. If these agreements were to terminate prematurely due to our breach of the terms of these licenses or we otherwise fail to maintain our rights to such technologies, we may lose the right to manufacture or sell a substantial portion of our products. In addition, we may need to obtain licenses to additional technologies in the future in order to keep our products competitive. If we fail to license or otherwise acquire necessary technologies, we may not be able to develop new products that we need to remain competitive.
The protection of intellectual property in foreign countries is uncertain.
A significant percentage of our sales are to customers located outside the U.S. Patent and other intellectual property laws of some foreign countries may not protect our intellectual property rights to the same extent as U.S. laws. We may need to bring proceedings to defend our patent rights or to determine the validity of our competitors’ foreign patents. These proceedings could result in substantial cost and diversion of our other efforts. Finally, some of the patent protections available to us in the U.S. are not available to us in foreign countries due to the laws of those countries.

41

Our products could infringe on the intellectual property rights of others.
There are a significant number of U.S. and foreign patents and patent applications submitted for technologies in, or related to, our area of business. As a result, our use of our technology could infringe patents or proprietary rights of others. This may lead others to assert patent infringement or other intellectual property claims against us. We could incur substantial costs in litigation if we are required to defend against intellectual property claims by third parties. Additionally, any licenses that we might need as a result of any actual infringement might not be available to us on commercially reasonable terms, if at all.
Our failure to comply with any applicable government laws and regulations or otherwise respond to claims relating to improper handling, storage or disposal of hazardous chemicals that we use may adversely affect our results of operations.
Our research and development and manufacturing activities involve the controlled use of hazardous materials and chemicals. We are subject to federal, state, local and international laws and regulations governing the use, storage, handling and disposal of hazardous materials and waste products. If we fail to comply with applicable laws or regulations, we could be required to pay penalties or be held liable for any damages that result and this liability could exceed our financial resources. We cannot be certain that accidental contamination or injury will not occur. Any such accident could damage our research and manufacturing facilities and operations, resulting in delays and increased costs.
*We may issue a substantial amount of our common stock to holders of options and warrants and this could reduce the market price for our stock.
At June 30, 2016, we had obligations to issue 10,721,464 shares of common stock upon exercise of outstanding stock options, warrants or conversion rights. The issuance of these securities may be dilutive to our current stockholders and could negatively impact the market price of our common stock.
*Our common stock is thinly traded and a large percentage of our shares are held by a small group of unrelated, institutional owners.
At June 30, 2016, we had 23,103,875 shares of common stock outstanding. The sale of a significant number of shares into the public market has the potential to cause significant downward pressure on the price of our common stock. This is particularly the case if the shares being placed into the market exceed the market’s ability to absorb the stock. This presents an opportunity for short sellers to contribute to the further decline of our stock price. If there are significant short sales of our stock, the price decline that would result from this activity will cause the share price to decline more so, which, in turn, may cause long holders of the stock to sell their shares, thereby contributing to sales of our stock in the market. In addition, the large concentration of our shares are held by a small group of stockholders which could result in increased volatility in our stock price due to the limited number of shares available in the market.
We have previously identified material weaknesses and ineffective internal controls could impact our business and financial results.
Our internal control over financial reporting may not prevent or detect misstatements because of its inherent limitations, including the possibility of human error, the circumvention or overriding of controls, or fraud. In the course of auditing our financial statements as of and for the year ended December 31, 2014, our independent registered public accounting firm identified material weaknesses in our internal control over financial reporting relating to proper timing and recognition of revenue and the elements used in our analysis and evaluation of the allowance for doubtful accounts to ensure that the allowance for doubtful accounts is reasonably stated. We remediated these material weaknesses in the year ended December 31, 2015.
Even effective internal controls can provide only reasonable assurance with respect to the preparation and fair presentation of financial statements. If we fail to maintain the adequacy of our internal controls, including any failure to implement required new or improved controls, or if we experience difficulties in their implementation, our business and financial results could be harmed, we could fail to meet our financial reporting obligations and we may not be able to accurately report financial results or prevent fraud.
*As we are currently not in compliance with the continued listing requirements of The Nasdaq Stock Market LLC (“Nasdaq”), Nasdaq may delist our shares of common stock, which would have an adverse impact on the trading volume, liquidity and market price of our common shares. 
On February 23, 2016, we received written notice (the “First Notice”) from Nasdaq indicating that, based on the closing bid price of our common stock for the preceding 30 consecutive business days, we were not in compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market (the “Minimum Bid Price Requirement”), as set forth

42

in Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have a period of 180 calendar days, or until August 22, 2016, to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of our common stock must meet or exceed $1.00 per share for at least ten consecutive business days during this 180 calendar day period.
As of August 8, 2016, the date that is 10 business days prior to August 22, 2016, the closing price of our common stock had not met or exceeded $1.00 per share. Therefore, we will not regain compliance with the Minimum Bid Price Requirement within the 180 calendar day period. Since we will not be in compliance with the Minimum Bid Price Requirement by August 22, 2016, Nasdaq may provide us with a second 180 calendar day period to regain compliance. To qualify for the second 180 calendar day period, we would be required to (i) meet the continued listing requirement for the Nasdaq Capital Market for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, except for the Minimum Bid Price Requirement, and (ii) notify Nasdaq of our intent to cure our noncompliance with the Minimum Bid Price, including by effecting a reverse stock split, if necessary. If we do not indicate our intent to cure the deficiency or if it does not appear to Nasdaq that it would be possible for us to cure the deficiency, we would not be eligible for the second 180 calendar day period, and our common stock would then be subject to delisting from the Nasdaq Capital Market.

If we do not regain compliance within the allotted compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that our common stock will be subject to delisting. We would then be entitled to appeal the Nasdaq Staff’s determination to a Nasdaq Listing Qualifications Panel and request a hearing. Additionally, if Nasdaq determines not to provide us with a second 180 calendar day period to regain compliance with the Minimum Bid Price Requirement, our common stock will be subject to delisting from the Nasdaq Capital Market. If our common stock is not then eligible for quotation on another market or exchange, trading of our common stock could be conducted in the over-the-counter market or on an electronic bulletin board established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board. In such event, it is likely that there would be significantly less liquidity in the trading of our common stock; decreases in institutional and other investor demand for our common stock, coverage by securities analysts, market making activity and information available concerning trading prices and volume; and fewer broker-dealers willing to execute trades in our common stock. Also, it may be difficult for us to raise additional capital if we are not listed on a major exchange. The occurrence of any of these events could result in a further decline in the market price of our common stock and could have a material adverse effect on us.
On April 20, 2016, we received a second written notice (the “Second Notice”) from Nasdaq indicating that, based on the stockholders’ equity reported in our Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on April 14, 2016, we are not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market, which requires listed companies to maintain stockholders’ equity of at least $2,500,000 (the “Minimum Stockholders’ Equity Requirement”), as set forth in Nasdaq Listing Rule 5550(b)(1). In accordance with Nasdaq Listing Rule 5810(c)(2)(C), we had a period of 45 calendar days, or until June 6, 2016, to submit a plan to regain compliance with the Minimum Stockholders’ Equity Requirement. Nasdaq indicated that, if our plan is accepted, Nasdaq may grant an extension of up to 180 calendar days, or until October 17, 2016, to evidence compliance. We initially submitted our plan to regain compliance with the Minimum Stockholders’ Equity Requirement to Nasdaq on May 31, 2016 and provided Nasdaq with supplemental information on June 22, 2016 and June 29, 2016. On June 30, 2016, based on the information we submitted to Nasdaq, Nasdaq granted us the maximum allowable 180 day extension to October 17, 2016 to evidence compliance with the Minimum Stockholders’ Equity Requirement.
Neither the First Notice nor the Second Notice has an immediate effect on the listing of our common stock, and our common stock will continue to trade on the Nasdaq Capital Market under the symbol “TBIO” at this time.
We intend to monitor the closing bid price of our common stock and consider our available options to resolve our noncompliance with the Minimum Bid Price Requirement and the Minimum Stockholders’ Equity Requirement. There can be no assurance that we will be able to regain compliance with the Minimum Bid Price Requirement or the Minimum Stockholders’ Equity Requirement or will otherwise be in compliance with the other listing standards for the Nasdaq Capital Market. A suspension or delisting of our common stock could adversely affect our relationships with our business partners and suppliers and customers’ and potential customers’ decisions to purchase our products and services, and could have a material, adverse impact on our business and operating results. In addition, a suspension or delisting could impair our ability to raise additional capital through equity or debt financings and our ability to attract and retain employees by means of equity compensation.


43

Item 2.     Unregistered Sales of Equity Securities and Use of Proceeds

On May 31, 2016, we issued to a vendor an aggregate of 78,000 shares of our common stock and, on June 14, 2016, we issued to a second vendor an aggregate of 64,153 shares of our common stock. Such shares of common stock were issued to the vendors in lieu of an aggregate cash amount of approximately $89,000 owed by us to such vendors for services previously performed by such vendors. We issued the shares to the vendors in transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder and in reliance on similar exemptions under applicable state laws. The offering of the shares to the vendors did not involve a public offering, and no general solicitation or advertisement was made in connection with the offering of the shares to the vendors.

Item 6.
Exhibits
(a)
Exhibits
†2.1

 
Asset Purchase Agreement among the Registrant, Scoli Acquisition Sub, Inc. and Axial Biotech, Inc. dated August 27, 2012 (incorporated by reference to Exhibit 2.1 to the Registrant’s Quarterly Report on Form 10-Q filed on November 8, 2012).
 
 
 
3.1

  
Third Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q filed on November 14, 2005).
 
 
 
3.2

  
Certificate of Amendment of Third Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on May 29, 2012).
 
 
 
3.3

  
Certificate of Amendment of Third Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on January 28, 2014).
 
 
 
3.4

 
Certificate of Designation of Series A-1 Convertible Preferred Stock of the Registrant, as filed with the Secretary of State of the State of Delaware on January 8, 2016 (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on January 11, 2016 at 7:33 a.m. Eastern Time).
 
 
 
3.5

 
Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3(ii) to the Registrant’s Current Report on Form 8-K filed on May 25, 2007).
 
 
 
4.1

  
Form of Certificate of the Registrant’s Common Stock (incorporated by reference to Exhibit 4 to the Registrant’s Registration Statement on Form S-1 (Registration No. 333-32174) filed on March 10, 2000).
 
 
 
4.2

 
Form of Warrant issued by the Registrant to the Third Security Entities on February 7, 2012 (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed on February 7, 2012).
 
 
 
4.3

 
Form of Warrant issued by the Registrant to the Investors on February 7, 2012 (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed on February 7, 2012).
 
 
 
4.4

 
Form of Registration Rights Agreement entered into by and among the Registrant, the Third Security Entities and the Investors dated February 2, 2012 (incorporated by reference to Exhibit 10.4 to the Registrant’s Current Report on Form 8-K filed on February 7, 2012).
 
 
 
4.5

 
Registration Rights Agreement, entered into by and among the Registrant and the Investors, dated January 24, 2013 (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K/A filed on January 31, 2013).
 
 
 
4.6

 
Form of Warrant issued by the Registrant to the Investors on January 30, 2013 (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K/A filed on January 31, 2013).
 
 
 
4.7

 
Registration Rights Agreement, dated as of March 5, 2014, by and among the Registrant, Third Security Senior Staff 2008 LLC, Third Security Staff 2014 LLC and Third Security Incentive 2010 LLC (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed on March 6, 2014).
 
 
 
4.8

 
Securities Purchase Agreement, dated as of October 22, 2014, by and among Transgenomic, Inc. and the Investors (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed on October 22, 2014).
 
 
 
4.9

 
Form of Warrant issued by Transgenomic, Inc. to the Investors and the advisor on October 22, 2014 (incorporated by reference to Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed on October 22, 2014).
 
 
 

44

4.10

 
Unsecured Convertible Promissory Note Purchase Agreement, dated as of December 31, 2014, by and among Transgenomic, Inc. and the Investors (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on January 7, 2015).
 
 
 
4.11

 
Form of Unsecured Convertible Promissory Note issued by Transgenomic, Inc. to the Investor pursuant to the Unsecured Convertible Promissory Note Purchase Agreement, dated as of December 31, 2014 (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed on January 7, 2015).
 
 
 
4.12

 
Form of Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed on February 27, 2015).
 
 
 
4.13

 
Registration Rights Agreement, dated June 30, 2015, by and among Transgenomic, Inc. and the Investors (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K/A filed on July 7, 2015).
 
 
 
4.14

 
Form of Series B Warrant to Purchase Common Stock issued by Transgenomic, Inc. to an Investor on July 7, 2015 (incorporated by reference to Exhibit 4.2 to the Registrant’s Current Report on Form 8-K/A filed on July 7, 2015).
 
 
 
4.15

 
Form of Series A Warrant to Purchase Common Stock issued by Transgenomic, Inc. to Investors on July 7, 2015 (incorporated by reference to Exhibit 4.3 to the Registrant’s Current Report on Form 8-K/A filed on July 7, 2015).
 
 
 
4.16

 
Form of Warrant to Purchase Common Stock issued by Transgenomic, Inc. to the Placement Agent on July 7, 2015 (incorporated by reference to Exhibit 4.4 to the Registrant’s Current Report on Form 8-K/A filed on July 7, 2015).
 
 
 
4.17

 
Registration Rights Agreement, by and among Transgenomic, Inc. and the Investors, dated January 8, 2016 (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed on January 11, 2016 at 7:33 a.m. Eastern Time).
 
 
 
4.18

 
Form of Warrant, issued by Transgenomic, Inc. to the Investors on January 8, 2016 (incorporated by reference to Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed on January 11, 2016 at 7:33 a.m. Eastern Time).
 
 
 
4.19

 
Form of Amended Warrant, issued by Transgenomic, Inc. to an affiliate of an Investor on January 8, 2016 (incorporated by reference to Exhibit 4.3 to the Registrant’s Current Report on Form 8-K filed on January 11, 2016 at 7:33 a.m. Eastern Time).
 
 
 
4.20

 
Form of Warrant, issued by Transgenomic, Inc. to the Placement Agent on January 8, 2016 (incorporated by reference to Exhibit 4.4 to the Registrant’s Current Report on Form 8-K filed on January 11, 2016 at 7:33 a.m. Eastern Time).
 
 
 
10.1

 
Limited Waiver and Ninth Amendment to Loan and Security Agreement, dated June 6, 2016, by and among Transgenomic, Inc., Third Security Senior Staff 2008 LLC, as administrative agent and a lender, and the other lenders party thereto (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on June 7, 2016).
 
 
 
10.2

 
At the Market Offering Agreement, dated June 7, 2016, by and between Transgenomic, Inc. and Craig-Hallum Capital Group LLC (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed on June 7, 2016).
 
 
 
31.1

 
Certification of Paul Kinnon, President, Chief Executive Officer and Interim Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as amended.
 
 
 
32.1

  
Certification of Paul Kinnon, President, Chief Executive Officer and Interim Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, as amended.
 
 
 
101.INS

 
XBRL Instance Document
 
 
 
101.SCH

 
XBRL Taxonomy Extension Schema Document
 
 
 
101.CAL

 
XBRL Taxonomy Extension Calculation Linkbase Document
 
 
 
101.DEF

 
XBRL Taxonomy Extension Definition Linkbase Document
 
 
 
101.LAB

 
XBRL Taxonomy Extension Label Linkbase Document
 
 
 
101.PRE

 
XBRL Taxonomy Extension Presentation Linkbase Document
 
 
 

45

†


 
Pursuant to Item 601(b)(2) of Regulation S-K, the schedules to this agreement have been omitted. The Registrant agrees to furnish supplementally a copy of any omitted schedule to the Securities and Exchange Commission upon request.
 
 
 

46

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
 
 
 
 
TRANSGENOMIC, INC.
 
 
 
 
Date:
August 12, 2016
By:
/S/ PAUL KINNON



Paul Kinnon
President, Chief Executive Officer and Interim Chief Financial Officer (Principal Executive Officer and Principal Financial Officer)
 
 
 
 

47
 EX-31.1 2 tbio-ex311_20160630x10q.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER
I, Paul Kinnon, certify that:
1.
I have reviewed this quarterly report on Form 10-Q of Transgenomic, Inc. (the Registrant);
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and I have:
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiary, is made known to me by others within those entities, particularly during the period in which this report is being prepared;
b)
Designed such internal control over financial reporting, or caused internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
Disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and
5.
I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent function):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.


/s/ PAUL KINNON
 
Paul Kinnon
President, Chief Executive Officer and Interim Chief Financial Officer (Principal Executive Officer and Principal Financial Officer)
Date: August 12, 2016


EX-32.1 3 tbio-ex321_20160630x10q.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350
In connection with the accompanying Quarterly Report on Form 10-Q of Transgenomic, Inc. for the period ended June 30, 2016, I, Paul Kinnon, Chief Executive Officer and Interim Chief Financial Officer of Transgenomic, Inc., hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge, that:
(1)
Such Quarterly Report on Form 10-Q of Transgenomic, Inc. for the period ended June 30, 2016, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in such Quarterly Report on Form 10-Q of Transgenomic, Inc. for the period ended June 30, 2016, fairly presents, in all material respects, the financial condition and results of operations of Transgenomic, Inc.
 
/s/ PAUL KINNON
 
Paul Kinnon
President, Chief Executive Officer and Interim Chief Financial Officer (Principal Executive Officer and Principal Financial Officer)

Date: August 12, 2016
A signed original of the certification required by Section 906 has been provided to Transgenomic, Inc. and will be retained by Transgenomic, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.



EX-101.INS 4 tbio-20160630.xml XBRL INSTANCE DOCUMENT 0001043961 2016-01-01 2016-06-30 0001043961 2016-07-31 0001043961 2015-12-31 0001043961 2016-06-30 0001043961 2015-04-01 2015-06-30 0001043961 2015-01-01 2015-06-30 0001043961 2016-04-01 2016-06-30 0001043961 us-gaap:SegmentContinuingOperationsMember 2016-01-01 2016-06-30 0001043961 us-gaap:SegmentDiscontinuedOperationsMember 2016-04-01 2016-06-30 0001043961 us-gaap:SegmentContinuingOperationsMember 2016-04-01 2016-06-30 0001043961 us-gaap:SegmentContinuingOperationsMember 2015-01-01 2015-06-30 0001043961 us-gaap:SegmentContinuingOperationsMember 2015-04-01 2015-06-30 0001043961 us-gaap:SegmentDiscontinuedOperationsMember 2015-01-01 2015-06-30 0001043961 us-gaap:SegmentDiscontinuedOperationsMember 2016-01-01 2016-06-30 0001043961 us-gaap:SegmentDiscontinuedOperationsMember 2015-04-01 2015-06-30 0001043961 us-gaap:RetainedEarningsMember 2016-06-30 0001043961 us-gaap:CommonStockMember 2015-12-31 0001043961 us-gaap:RetainedEarningsMember 2016-01-01 2016-06-30 0001043961 us-gaap:AdditionalPaidInCapitalMember 2016-06-30 0001043961 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-06-30 0001043961 us-gaap:CommonStockMember 2016-06-30 0001043961 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-06-30 0001043961 us-gaap:PreferredStockMember 2015-12-31 0001043961 us-gaap:PreferredStockMember 2016-01-01 2016-06-30 0001043961 us-gaap:PreferredStockMember 2016-06-30 0001043961 us-gaap:PreferredStockMember us-gaap:PrivatePlacementMember 2016-01-01 2016-06-30 0001043961 us-gaap:CommonStockMember 2016-01-01 2016-06-30 0001043961 us-gaap:AdditionalPaidInCapitalMember us-gaap:PrivatePlacementMember 2016-01-01 2016-06-30 0001043961 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001043961 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-06-30 0001043961 us-gaap:RetainedEarningsMember 2015-12-31 0001043961 us-gaap:PrivatePlacementMember 2016-01-01 2016-06-30 0001043961 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0001043961 2015-06-30 0001043961 2014-12-31 0001043961 2015-03-31 0001043961 2016-03-31 0001043961 us-gaap:ExecutiveOfficerMember 2016-01-01 2016-06-30 0001043961 tbio:PharmacogenomicServicesMember 2016-06-30 0001043961 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-04-01 2015-06-30 0001043961 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-01-01 2015-06-30 0001043961 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-01-01 2016-06-30 0001043961 us-gaap:MaximumMember 2016-01-01 2016-06-30 0001043961 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-04-01 2016-06-30 0001043961 us-gaap:OtherMachineryAndEquipmentMember us-gaap:MaximumMember 2016-01-01 2016-06-30 0001043961 us-gaap:FurnitureAndFixturesMember us-gaap:MinimumMember 2016-01-01 2016-06-30 0001043961 us-gaap:ComputerEquipmentMember us-gaap:MaximumMember 2016-01-01 2016-06-30 0001043961 us-gaap:ComputerEquipmentMember us-gaap:MinimumMember 2016-01-01 2016-06-30 0001043961 us-gaap:LeaseholdImprovementsMember us-gaap:MaximumMember 2016-01-01 2016-06-30 0001043961 us-gaap:LeaseholdImprovementsMember us-gaap:MinimumMember 2016-01-01 2016-06-30 0001043961 us-gaap:FurnitureAndFixturesMember us-gaap:MaximumMember 2016-01-01 2016-06-30 0001043961 us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember us-gaap:MinimumMember 2016-01-01 2016-06-30 0001043961 us-gaap:OtherMachineryAndEquipmentMember us-gaap:MinimumMember 2016-01-01 2016-06-30 0001043961 us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember us-gaap:MaximumMember 2016-01-01 2016-06-30 0001043961 tbio:PharmacogenomicServicesMember 2015-12-31 0001043961 us-gaap:SegmentDiscontinuedOperationsMember tbio:PatientTestingMember 2016-04-01 2016-06-30 0001043961 tbio:GeneticAssaysAndPlatformsBusinessMember 2015-09-08 0001043961 tbio:ADSTECCorporationMember tbio:GeneticAssaysAndPlatformsBusinessMember 2015-11-25 0001043961 tbio:GeneticAssaysAndPlatformsBusinessMember 2015-01-01 2015-12-31 0001043961 tbio:ADSTECCorporationMember tbio:GeneticAssaysAndPlatformsBusinessMember 2015-01-01 2015-12-31 0001043961 us-gaap:SegmentDiscontinuedOperationsMember tbio:GeneticAssaysandPlatformsandPatientTestingMember 2016-06-30 0001043961 us-gaap:SegmentDiscontinuedOperationsMember tbio:GeneticAssaysandPlatformsandPatientTestingMember 2015-12-31 0001043961 us-gaap:SegmentDiscontinuedOperationsMember tbio:GeneticAssaysandPlatformsandPatientTestingMember 2015-04-01 2015-06-30 0001043961 tbio:GeneticAssaysandPlatformsandPatientTestingMember 2016-01-01 2016-06-30 0001043961 tbio:GeneticAssaysandPlatformsandPatientTestingMember 2015-01-01 2015-06-30 0001043961 us-gaap:SegmentDiscontinuedOperationsMember tbio:GeneticAssaysandPlatformsandPatientTestingMember 2016-04-01 2016-06-30 0001043961 us-gaap:SegmentDiscontinuedOperationsMember tbio:GeneticAssaysandPlatformsandPatientTestingMember 2016-01-01 2016-06-30 0001043961 tbio:GeneticAssaysandPlatformsandPatientTestingMember 2016-04-01 2016-06-30 0001043961 tbio:GeneticAssaysandPlatformsandPatientTestingMember 2015-04-01 2015-06-30 0001043961 us-gaap:SegmentDiscontinuedOperationsMember tbio:GeneticAssaysandPlatformsandPatientTestingMember 2015-01-01 2015-06-30 0001043961 us-gaap:SegmentDiscontinuedOperationsMember tbio:GeneticAssaysandPlatformsandPatientTestingMember 2015-06-30 0001043961 us-gaap:SegmentDiscontinuedOperationsMember tbio:GeneticAssaysandPlatformsandPatientTestingMember 2014-12-31 0001043961 us-gaap:SegmentDiscontinuedOperationsMember tbio:GeneticAssaysandPlatformsandPatientTestingMember 2016-03-31 0001043961 us-gaap:SegmentDiscontinuedOperationsMember tbio:GeneticAssaysandPlatformsandPatientTestingMember 2015-03-31 0001043961 us-gaap:SegmentDiscontinuedOperationsMember tbio:PatientTestingMember 2016-01-01 2016-06-30 0001043961 us-gaap:PatentsMember 2015-12-31 0001043961 us-gaap:IntellectualPropertyMember 2015-12-31 0001043961 us-gaap:IntellectualPropertyMember 2016-01-01 2016-06-30 0001043961 us-gaap:PatentsMember 2016-06-30 0001043961 us-gaap:IntellectualPropertyMember 2016-06-30 0001043961 tbio:TermLoanMember 2015-12-31 0001043961 tbio:TermLoanMember 2016-06-30 0001043961 us-gaap:ConvertibleNotesPayableMember 2015-12-31 0001043961 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2015-12-31 0001043961 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2016-06-30 0001043961 us-gaap:ConvertibleNotesPayableMember 2016-06-30 0001043961 us-gaap:ConvertibleNotesPayableMember 2014-12-31 0001043961 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2015-08-10 2015-08-10 0001043961 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2014-10-22 0001043961 us-gaap:ConvertibleNotesPayableMember tbio:AdditionalNotePrivatePlacementMember 2016-01-01 2016-06-30 0001043961 us-gaap:ConvertibleNotesPayableMember 2016-01-01 2016-06-30 0001043961 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2014-10-21 0001043961 us-gaap:ConvertibleNotesPayableMember tbio:AdditionalNotePrivatePlacementMember 2015-01-20 0001043961 tbio:AdditionalNotePrivatePlacementMember 2015-01-15 0001043961 tbio:ThirdSecurityLlcAndAffiliatesMember tbio:TermLoanMember 2013-03-13 0001043961 tbio:TermLoanMember 2016-01-01 2016-06-30 0001043961 tbio:TermLoanMember 2015-04-01 0001043961 tbio:PGxHealthLLCMember us-gaap:SeniorNotesMember 2013-03-13 2013-03-13 0001043961 tbio:DebtInstrumentConversionPeriodTwoMember us-gaap:ConvertibleNotesPayableMember 2014-12-31 2014-12-31 0001043961 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2016-01-01 2016-06-30 0001043961 us-gaap:RevolvingCreditFacilityMember tbio:ThirdSecurityLlcAndAffiliatesMember us-gaap:LineOfCreditMember 2013-03-13 0001043961 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember tbio:WallStreetJournalPrimeRateMember 2016-01-01 2016-06-30 0001043961 tbio:DebtInstrumentConversionPeriodOneMember us-gaap:ConvertibleNotesPayableMember 2014-12-31 0001043961 tbio:DebtInstrumentConversionPeriodOneMember us-gaap:ConvertibleNotesPayableMember 2014-12-31 2014-12-31 0001043961 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2015-09-04 0001043961 tbio:TermLoanMember 2014-03-01 2015-03-31 0001043961 tbio:UniversityofNebraskaMember us-gaap:ThreatenedLitigationMember us-gaap:PerformanceGuaranteeMember 2016-06-30 0001043961 tbio:IcahnSchoolofMedicineMember us-gaap:ThreatenedLitigationMember us-gaap:PerformanceGuaranteeMember 2016-06-23 2016-06-23 0001043961 tbio:UniversityofNebraskaMember us-gaap:ThreatenedLitigationMember us-gaap:PerformanceGuaranteeMember 2016-02-25 2016-02-25 0001043961 tbio:IcahnSchoolofMedicineMember us-gaap:ThreatenedLitigationMember us-gaap:PerformanceGuaranteeMember 2016-06-30 0001043961 tbio:UniversityofNebraskaMember us-gaap:ThreatenedLitigationMember us-gaap:PerformanceGuaranteeMember 2015-12-31 0001043961 tbio:IcahnSchoolofMedicineMember us-gaap:ThreatenedLitigationMember us-gaap:PerformanceGuaranteeMember 2015-12-31 0001043961 tbio:VariousInstitutionalHoldersFebruary2020Member 2016-06-30 0001043961 tbio:AffiliatesofThirdSecurityLLCJanuary2021Member 2016-06-30 0001043961 tbio:VariousInstitutionalHoldersJanuary2018Member 2016-06-30 0001043961 tbio:VariousInstitutionalHoldersApril2020Member 2016-06-30 0001043961 tbio:VariousInstitutionalHoldersFebruary2017Member 2016-06-30 0001043961 tbio:VariousInstitutionalHoldersJanuary2021OneMember 2016-06-30 0001043961 tbio:AffiliatesofThirdSecurityLLCJanuary2018Member 2016-06-30 0001043961 tbio:VariousInstitutionalHoldersDecember2020OneMember 2016-06-30 0001043961 tbio:AffiliatesofThirdSecurityLLCFebruary2017Member 2016-06-30 0001043961 tbio:VariousInstitutionalHoldersJanuary2021TwoMember 2016-06-30 0001043961 tbio:VariousInstitutionalHoldersDecember2020TwoMember 2016-06-30 0001043961 us-gaap:PrivatePlacementMember 2012-02-02 2012-02-02 0001043961 us-gaap:PrivatePlacementMember 2016-06-30 0001043961 tbio:AffiliatesofThirdSecurityLLCJanuary2018Member tbio:OfferingMember 2013-01-24 2013-01-24 0001043961 tbio:SeriesA1WarrantMember us-gaap:MaximumMember 2016-01-06 0001043961 us-gaap:PrivatePlacementMember 2015-02-27 0001043961 us-gaap:SeriesAPreferredStockMember 2016-01-06 2016-01-06 0001043961 tbio:SeriesBWarrantsMember 2015-07-07 0001043961 us-gaap:PrivatePlacementMember 2016-01-06 0001043961 tbio:OfferingMember 2015-01-01 2015-06-30 0001043961 tbio:SeriesAWarrantsMember 2016-01-06 0001043961 tbio:SeriesAWarrantsMember 2016-01-06 2016-01-06 0001043961 tbio:SeriesA1WarrantMember 2016-01-06 0001043961 2015-07-07 0001043961 tbio:CraigHallumCapitalGroupLLCMember tbio:TwoThousandFifteenOfferingMember 2015-02-27 0001043961 tbio:SeriesA1WarrantMember us-gaap:ProFormaMember 2016-01-06 0001043961 us-gaap:PrivatePlacementMember 2012-02-02 0001043961 us-gaap:SeriesBPreferredStockMember 2016-01-06 2016-01-06 0001043961 tbio:SeriesAWarrantCashlessExchangeMember us-gaap:MaximumMember us-gaap:ProFormaMember 2016-01-06 0001043961 tbio:CraigHallumCapitalGroupLLCMember 2015-07-07 2015-07-07 0001043961 us-gaap:SeriesAPreferredStockMember 2016-01-06 0001043961 tbio:SeriesAWarrantCashlessExchangeMember us-gaap:MaximumMember 2016-01-06 0001043961 tbio:AffiliatesofThirdSecurityLLCJanuary2018Member tbio:OfferingMember 2013-01-24 0001043961 2015-07-07 2015-07-07 0001043961 tbio:CraigHallumCapitalGroupLLCMember tbio:TwoThousandFifteenOfferingMember 2015-02-27 2015-02-27 0001043961 tbio:SeriesAWarrantsMember us-gaap:ProFormaMember 2016-01-06 2016-01-06 0001043961 tbio:TwoThousandFourteenPrivatePlacementMember 2014-10-22 2014-10-22 0001043961 us-gaap:PrivatePlacementMember 2014-10-21 0001043961 tbio:ThirdSecurityLlcAndAffiliatesMember us-gaap:PrivatePlacementMember 2012-02-02 0001043961 tbio:OfferingMember 2013-01-24 0001043961 tbio:ThirdSecurityLlcAndAffiliatesMember 2013-01-24 0001043961 tbio:CraigHallumCapitalGroupLLCMember 2016-01-06 2016-01-06 0001043961 tbio:ThirdSecurityLlcAndAffiliatesMember us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2014-03-05 2014-03-05 0001043961 us-gaap:PrivatePlacementMember 2015-01-15 0001043961 tbio:TwoThousandFourteenPrivatePlacementMember 2014-10-22 0001043961 tbio:SeriesA1ConvertiblePreferredStockMember 2016-06-30 0001043961 us-gaap:PrivatePlacementMember 2015-07-07 0001043961 us-gaap:CommonStockMember 2016-04-01 2016-06-30 0001043961 tbio:AttheMarketOfferingMember 2016-04-01 2016-06-30 0001043961 tbio:SeriesAWarrantsMember us-gaap:MaximumMember 2016-01-06 0001043961 tbio:CraigHallumCapitalGroupLLCMember 2016-01-06 0001043961 tbio:CraigHallumCapitalGroupLLCMember 2015-07-07 0001043961 tbio:SeriesA1ConvertiblePreferredStockMember 2016-01-06 0001043961 tbio:OfferingMember 2013-01-24 2013-01-24 0001043961 us-gaap:PrivatePlacementMember 2014-10-22 0001043961 us-gaap:PrivatePlacementMember 2014-12-31 0001043961 us-gaap:SeriesAPreferredStockMember 2015-12-31 0001043961 tbio:TwoThousandFourteenPrivatePlacementMember tbio:AdvisorMember 2014-10-22 0001043961 tbio:CraigHallumCapitalGroupLLCMember us-gaap:ConvertibleNotesPayableMember tbio:AdditionalNotePrivatePlacementMember 2015-01-15 0001043961 tbio:SeriesAWarrantsMember us-gaap:ProFormaMember 2016-01-06 0001043961 tbio:ThirdSecurityLlcAndAffiliatesMember 2014-03-05 0001043961 us-gaap:CommonStockMember tbio:AttheMarketOfferingMember 2016-04-01 2016-06-30 0001043961 tbio:SeriesA1WarrantMember 2016-01-06 2016-01-06 0001043961 tbio:SeriesBWarrantsMember us-gaap:MaximumMember 2015-07-07 0001043961 tbio:SeriesA1ConvertiblePreferredStockMember 2016-05-01 2016-05-31 0001043961 us-gaap:CommonStockMember 2016-06-14 2016-06-14 0001043961 tbio:OfferingMember 2016-01-01 2016-06-30 0001043961 us-gaap:PrivatePlacementMember 2013-01-24 0001043961 us-gaap:CommonStockMember 2016-05-31 2016-05-31 0001043961 tbio:SeriesA1WarrantMember us-gaap:ProFormaMember 2016-01-06 2016-01-06 0001043961 tbio:SeriesA1ConvertiblePreferredStockandWarrantsMember 2016-01-06 2016-01-06 0001043961 us-gaap:PrivatePlacementMember 2012-12-31 0001043961 us-gaap:WeightedAverageMember us-gaap:CommonStockMember tbio:AttheMarketOfferingMember 2016-06-30 0001043961 tbio:ThirdSecurityLlcAndAffiliatesMember us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2014-03-05 0001043961 tbio:SeriesAWarrantsMember 2015-07-07 2015-07-07 0001043961 tbio:SeriesA1ConvertiblePreferredStockandWarrantsMember 2016-01-06 0001043961 us-gaap:PrivatePlacementMember 2015-01-01 2015-06-30 0001043961 tbio:CraigHallumCapitalGroupLLCMember us-gaap:CommonStockMember tbio:AttheMarketOfferingMember 2016-06-07 2016-06-07 0001043961 us-gaap:CommonStockMember 2016-05-01 2016-05-31 0001043961 us-gaap:CommonStockMember 2016-01-06 2016-01-06 0001043961 us-gaap:PrivatePlacementMember 2011-12-01 2011-12-31 0001043961 tbio:SeriesAandSeriesBWarrantsMember us-gaap:MaximumMember 2015-07-07 0001043961 tbio:SeriesAandSeriesBWarrantsMember 2015-07-07 0001043961 2016-01-06 2016-01-06 0001043961 us-gaap:CommonStockMember tbio:AttheMarketOfferingMember 2016-06-07 0001043961 us-gaap:SeriesBPreferredStockMember 2015-12-31 0001043961 tbio:SeriesA1WarrantMember us-gaap:MaximumMember us-gaap:ProFormaMember 2016-01-06 0001043961 us-gaap:CommonStockMember tbio:AttheMarketOfferingMember 2016-01-01 2016-06-30 0001043961 tbio:AttheMarketOfferingMember 2016-01-01 2016-06-30 0001043961 tbio:SeriesBWarrantsMember 2015-07-07 2015-07-07 0001043961 us-gaap:SeriesBPreferredStockMember 2016-01-06 0001043961 tbio:A2012WarrantLiabilityMember 2012-02-01 2015-09-29 0001043961 tbio:A2016WarrantLiabilityMember 2016-01-01 2016-01-31 0001043961 tbio:A2012WarrantLiabilityMember 2016-01-01 2016-06-30 0001043961 tbio:A2016WarrantLiabilityMember 2016-01-01 2016-06-30 0001043961 tbio:A2012WarrantLiabilityMember 2015-09-30 2015-09-30 0001043961 tbio:A2016WarrantLiabilityMember 2016-06-30 0001043961 tbio:A2016WarrantLiabilityMember 2015-12-31 0001043961 tbio:A2016WarrantLiabilityMember 2016-03-31 0001043961 tbio:A2016WarrantLiabilityMember 2016-04-01 2016-06-30 0001043961 tbio:A2012WarrantLiabilityMember 2015-04-01 2015-06-30 0001043961 tbio:A2012WarrantLiabilityMember 2016-03-31 0001043961 tbio:A2012WarrantLiabilityMember 2016-06-30 0001043961 tbio:A2012WarrantLiabilityMember 2016-04-01 2016-06-30 0001043961 tbio:A2012WarrantLiabilityMember 2015-03-31 0001043961 tbio:A2012WarrantLiabilityMember 2015-06-30 0001043961 tbio:A2012WarrantLiabilityMember 2014-12-31 0001043961 tbio:A2012WarrantLiabilityMember 2015-12-31 0001043961 tbio:A2012WarrantLiabilityMember 2015-01-01 2015-06-30 0001043961 us-gaap:EmployeeStockOptionMember 2016-06-30 0001043961 us-gaap:EmployeeStockOptionMember 2015-12-31 0001043961 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-06-30 0001043961 us-gaap:StockAppreciationRightsSARSMember 2016-06-30 0001043961 tbio:EquityIncentivePlan2006Member 2016-01-01 2016-06-30 0001043961 us-gaap:StockAppreciationRightsSARSMember 2015-12-31 xbrli:pure iso4217:USD iso4217:USD xbrli:shares tbio:investor xbrli:shares iso4217:USD tbio:unit tbio:operating_segments false --12-31 Q2 2016 2016-06-30 10-Q 0001043961 23547946 Smaller Reporting Company TRANSGENOMIC INC P30D 1200000 3300000 1800000 1208491 714780 493711 2933106 1881456 1073911 98333 9.00 1436882 1436882 941197 941197 0.50 0.50 P90D P90D P5Y P5Y6M P5Y6M P5Y P5Y P5Y P6M P5Y 1.95 1.8135 3500000 250000 125000 0.85 0.5 0.05 0.05 120000 7 0.01 264000 0 1965000 2251000 4080000 4202000 1198000 2730000 0 0 108000 224000 0 68000 3165000 6415000 344000 1369000 7927000 9173000 8406000 14664000 14542000 10462000 4400000 0 1.00 100000 1565000 1565000 -270000 -415000 24000 345000 -186000 -376000 -328000 -497000 0 0 0 0 P0Y7M8D -456000 -804000 -304000 -152000 1500000 0.07 0.07 0.07 0.0325 31666 107033 107527 0.02 1.00 1.075269 148000 6200000 3000000 22000000 0 0 49000 70000 84445 4.21 125000 50000 50000 1 1 0.3333 1 -15900000 3781000 5620000 264000 328000 3734000 2847000 6899000 6953000 10000 0 200403000 201140000 141000 141000 20000 20000 20000 87000 108000 157000 0 0 0 0 100000 100000 8286963 10721464 4816000 3094000 3282000 1803000 1987000 690000 1987000 690000 1609000 2309000 444000 421000 700000 -23000 0 962000 -2074000 79000 15.00 10.25 4.36 9 1.21 4.00 1.66 0.01 4.36 2.24 9 1.21 1.21 4.36 15.00 12.96 12.96 11.73 11.73 4.00 10.86 2.24 7.56 9.59 1.66 0.01 1.66 6.50 1.21 1.21 4.39 0.20 948333 1387685 3262088 823333 250000 1097600 691655 1097600 1212665 1212665 365388 9230 1309785 714780 1881396 1483161 1200000.0 700000.0 2188177 1773929 2873765 2873765 1882395 1882395 1161972 3239827 8876166 430019 250000 161026 374618 122433 667164 2832069 714780 441655 1161972 1720430 4474825 3681590 793235 0.01 0.01 150000000 150000000 13915691 23103875 1583333 13915691 23103875 139000 231000 -3233000 -6308000 -997000 -4261000 2150538 862057 1443297 2305354 465000 930000 542000 1047000 7596000 3025000 4000000 571000 7814000 3243000 4000000 571000 400000 502786 281023 0.03 2.20 P20D P15D 750000 4000000 46250 925000 0.0650 0.06 0.0625 0.06 P3Y 217000 100000 111000 100000 100000 100000 100000 100000 156000 189000 0 0 -1700000 1500000 963000 963000 -378000 -1055000 1182000 9000 -378000 -1055000 219000 -954000 43000 89000 0 0 1905000 647000 2100000 300000 3703000 6777000 11000 1194000 2895000 5584000 563000 483000 82000 43000 6598000 12361000 574000 1677000 4475000 4475000 -0.30 -0.26 -0.03 -0.65 -0.54 -0.11 -0.05 -0.10 0.05 -0.20 -0.20 0.00 2000 0 321000 259000 200000 415000 -345000 P1Y0M 0.67 1.35 0.0042 0.0121 -270000 -415000 20000 4000 350000 -5000 1437000 145000 290000 560000 350000 0 20000 1446000 0 1442000 P7Y 481000 207000 274000 338000 262000 76000 100000 100000 100000 100000 1651000 671000 980000 1367000 672000 695000 1170000 464000 706000 1029000 410000 619000 -14000 0 -23000 262000 -37000 -306000 -2854000 -5172000 -2179000 -4270000 -2855000 -5173000 -2179000 -4270000 -421000 -421000 -1144000 -1144000 1182000 1182000 1000000 9000 1000000 9000 -1000 -1000 0 0 367000 1839000 -301000 134000 -81000 0 61000 47000 0 -11000 -240000 -613000 243000 -253000 1170000 1029000 400000 222000 0 50000 39000 100000 0 0 0 63000 63000 63000 0 0 0 0 17636000 19384000 4816000 3094000 16981000 17719000 264000 0 264000 0 20000 4000000 4000000 3000000 2300000 0.005 7596000 7814000 0 0 0.091 700000 700000 700000 700000 700000 700000 5593000 5592000 6950000 1796000 -240000 936000 -240000 -26000 -6012000 -2755000 -3938000 -2834000 -3275000 -6316000 -997000 -4261000 -4261000 -3606000 -3185000 -421000 -6978000 -5834000 -1144000 -997000 -2179000 1182000 -4282000 -4291000 9000 2 1 2376000 4631000 1838000 3812000 -2399000 -4369000 -1875000 -4118000 700000 700000 700000 700000 400000 400000 100000 100000 537000 325000 105000 58000 42000 8000 0 0 -10000 10000 1068000 1068000 305000 223000 0 -13000 0 0 200000 46000 7000 718441 470599 1330000 212783 140000 194000 19000 3681591.90 793236.17 331000 662000 0 21000 0.01 0.01 0.01 0.01 15000000 15000000 4029502 214705 2365243 4029502 2586205 1443297 214705 214705 0 0 40000 2000 100000 6209000 100000 68000 100000 2200000 4000000 0 1779000 50 3000000 923000 500000 7158000 7157000 259000 204000 P7Y P3Y P7Y P3Y P10Y P1Y P7Y P2Y P7Y P3Y 0 70000 100000 34000 1000 700000 148000 550000 468000 919000 402000 672000 -213412000 -217663000 12 442000 1192000 505000 741000 1908000 3712000 1436000 3140000 200000 322000 300000 100000 119000 100000 P3Y P3Y 98333 4.14 4.14 P1Y2M1D 0 0.85 0.0191 98333 98333 648246 4.01 121140 608910 0 14000 14000 14000 1107794 1000654 3.45 3.39 0 980388 3.69 1.07 1.07 0.55 0.55 0.67 6.00 4.85 3.25 1.42 0.25 0.25 0 P10Y P6Y0M0D 0.93 13915691 4029502 23103875 214705 2150538 8930717 -6180040 64153 78000 500000 1383333 1443297 730776 3573899 1500000 6780179 115314 257467 115314 2365243 4475000 4447000 90000 -62000 89000 8300000 7000000 2400000 107000 105000 519000 2000 24000 543000 -12820000 10000 200403000 139000 40000 -213412000 -16290000 0 201140000 231000 2000 -217663000 350000 1442000 12149632 10778857 21797442 21060387 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of activity for the allowance for obsolete inventory during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">:</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Beginning</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Additions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Deductions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Ending</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended June 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Six Months Ended June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Six Months Ended June 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock Warrants.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain of our issued and outstanding warrants to purchase common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability (&#8220;Common Stock Warrant Liability&#8221;). We are required to present these instruments at fair value at each reporting date and any changes in fair values are recorded as an adjustment to earnings. The Common Stock Warrant Liabilities are considered Level Three financial instruments for purposes of fair value measurement.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of Cash.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, we may maintain a cash position with financial institutions in amounts that exceed federally insured limits.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INTANGIBLES AND OTHER ASSETS</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We review our amortizable long-lived assets for impairment annually or whenever events indicate that the carrying amount of the asset (group) may not be recoverable. An impairment loss may be needed if the sum of the future undiscounted cash flows is less than the carrying amount of the asset (group). The amount of the loss would be determined by comparing the fair market value of the asset to the carrying amount of the asset (group).</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-lived intangible assets as of June 30, 2016 and December 31, 2015 consisted of the following: </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:87.5%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net&#160;Book</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">695</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">619</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">672</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">410</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,367</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">338</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,029</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:87.5%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net&#160;Book</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">980</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">706</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">671</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">207</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">464</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,651</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">481</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,170</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:87.3046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:27%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated&#160;Useful&#160;Life</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Life of the patent</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7 years</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets include U.S. security deposits and deferred tax assets, net of applicable valuation allowances.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization expense for intangible assets was </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> during each of the six month periods ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">. Amortization expense for intangible assets is expected to be </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> for each of the years ending December 31, 2016, 2017, 2018, 2019 and 2020.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Risks and Uncertainties.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain risks and uncertainties are inherent in our day-to-day operations and in the process of preparing our financial statements. The more significant of those risks are presented below and throughout the notes to the unaudited condensed consolidated financial statements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-lived intangible assets as of June 30, 2016 and December 31, 2015 consisted of the following: </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:87.5%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net&#160;Book</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">695</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">619</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">672</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">410</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,367</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">338</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,029</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:87.5%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net&#160;Book</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">980</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">706</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">671</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">207</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">464</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,651</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">481</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,170</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:87.3046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:27%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated&#160;Useful&#160;Life</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Life of the patent</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7 years</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of activity for the allowance for doubtful accounts from continuing operations during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">:</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Beginning</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Additions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Deductions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Ending</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended June 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Six Months Ended June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Six Months Ended June 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements are presented in conformity with GAAP. All amounts are presented in U.S. Dollars (&#8220;$&#8221;). Supplemental cash flows from discontinued operations are presented in Note 3 - &#8220;Discontinued Operations&#8221;. We have evaluated events occurring subsequent to June 30, 2016 for potential recognition or disclosure in the consolidated financial statements and concluded there were no subsequent events that required recognition or disclosure.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated balance sheet as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> was derived from our audited balance sheet as of that date. There has been no change in the balance sheet from December 31, 2015. The accompanying condensed consolidated financial statements as of and for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;"> are unaudited and reflect all adjustments (consisting of only normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the interim periods. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> contained in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on April 14, 2016. The results of operations for the interim periods presented are not necessarily indicative of the results for fiscal year 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">BUSINESS DESCRIPTION</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Business Description.</font></div><div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transgenomic, Inc. (&#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, the &#8220;Company&#8221; or &#8220;Transgenomic&#8221;) is a biotechnology company advancing personalized medicine for the detection and treatment of cancer and inherited diseases through our proprietary molecular technologies and clinical and research services. A key goal is to bring our Multiplexed ICE COLD-PCR (&#8220;MX-ICP&#8221;) product to the clinical market through strategic partnerships and licensing agreements, enabling the use of blood and other bodily fluids for more effective and patient-friendly diagnosis, monitoring and treatment of cancer.</font></div><div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MX-ICP is technology proprietary to Transgenomic. It is a reagent that improves the ability to detect genetic mutations. This technology has been validated internally on all currently available sequencing platforms, including Sanger, Next Gen Sequencing and Digital PCR. By enhancing the level of detection of genetic mutations and suppressing the normal or wild-type DNA, several benefits are provided.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Historically, our operations were organized and reviewed by management along our major product lines and presented in </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> business segments: Laboratory Services and Genetic Assays and Platforms. Beginning with the quarter ended September 30, 2015, our operations are now organized as </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> business segment, our Laboratory Services segment, and during the second half of 2015, we began presenting our Genetic Assays and Platforms segment and a portion of our Laboratory Services segment in discontinued operations.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our current Laboratory Services business consists of our laboratory in Omaha, Nebraska, which is focused on providing genetic analytical services related to Oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical and biotechnology companies. Our laboratory employs a variety of genomic testing service technologies, including our proprietary MX-ICP technology. Our laboratory in Omaha is certified under the Clinical Laboratory Improvement Amendments (&#8220;CLIA&#8221;) as a high complexity laboratory and is accredited by the College of American Pathologists.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our condensed consolidated balance sheets, statements of operations and statements of cash flows for all periods presented reflect our former Genetic Assays and Platforms activities and Patient Testing business as discontinued operations (See Note 3 - &#8220;Discontinued Operations&#8221;).</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Going Concern.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements have been prepared using accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) applicable for a going concern, which assume that we will realize our assets and discharge our liabilities in the ordinary course of business. We have incurred substantial operating losses and have used cash in our operating activities for the past few years. As of June 30, 2016, we had negative working capital of </font><font style="font-family:inherit;font-size:10pt;">$15.9 million</font><font style="font-family:inherit;font-size:10pt;">. Our ability to continue as a going concern is dependent upon a combination of generating additional revenue, improving cash collections, potentially selling underutilized assets and, if necessary, raising additional financing to meet our obligations and pay our liabilities arising from normal business operations when they come due. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that we will be able to continue as a going concern. These condensed consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern. We cannot be certain that additional financing will be available on acceptable terms, or at all, and our failure to raise capital when needed could limit our ability to continue our operations.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and Cash Equivalents and Other Current Assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents include cash and investments with original maturities at the date of acquisition of three months or less.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">COMMITMENTS AND CONTINGENCIES</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to a number of claims of various amounts that arise out of the normal course of our business. In our opinion, the disposition of pending claims, in excess of recorded accruals, could have a material adverse effect on our financial position, results of operations or cash flows. On February 25, 2016, the Board of Regents of the University of Nebraska (&#8220;UNMC&#8221;) filed a lawsuit against us in the District Court of Douglas County, Nebraska, for breach of contract and seeking recovery of </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> owed by us to UNMC. We and UNMC are currently in discussions to determine a mutually agreeable means by which to settle the outstanding liability. A </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> liability has been recorded at December 31, 2015 and June 30, 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> In addition, on April 13, 2016, Fox Chase Cancer Center (&#8220;Fox Chase&#8221;) filed a lawsuit against us in the Court of Common Pleas of Philadelphia County, First Judicial District of Pennsylvania Civil Trial Division (the &#8220;Court of Common Pleas&#8221;), alleging, among other things, breach of contract, tortious interference with present and prospective contractual relations, unjust enrichment, fraudulent conversion and conspiracy and seeking punitive damages in addition to damages and other relief. This lawsuit relates to a license agreement we entered into with Fox Chase in August 2000, as amended (the &#8220;License Agreement&#8221;), as well as the assignment of certain of our rights under the License Agreement to Integrated DNA Technologies, Inc. (&#8220;IDT&#8221;) pursuant to the Surveyor Kit Patent, Technology and Inventory Purchase Agreement we entered into with IDT effective as of July 1, 2014 (the &#8220;IDT Agreement&#8221;). Pursuant to the terms of the IDT Agreement, we agreed to indemnify IDT with respect to certain of the claims asserted in the Fox Chase proceeding. On July 8, 2016, the Court of Common Pleas sustained our preliminary objections to several of Fox Chase&#8217;s claims and dismissed the claims for tortious interference, fraudulent conversion, conspiracy, punitive damages and attorney&#8217;s fees.&#160; Accordingly, the case has been narrowed so that only certain contract claims and an unjust enrichment claim remain pending against us. We believe that we have good and substantial defenses to the claims asserted by Fox Chase. We are unable to determine whether any loss will occur or to estimate the range of such potential loss; therefore, no amount of loss has been accrued by us as of the date of filing of this Quarterly Report on Form 10-Q. Furthermore, there is no guarantee that we will prevail in this suit or receive any damages or other relief if we do prevail. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 23, 2016, the Icahn School of Medicine at Mount Sinai (&#8220;Mount Sinai&#8221;) filed a lawsuit against us in the Supreme Court of the State of New York, County of New York, alleging, among other things, breach of contract and, alternatively, unjust enrichment and quantum merit, and seeking recovery of </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> owed by us to Mount Sinai for services rendered. We and Mount Sinai are currently in discussions to determine a mutually agreeable means by which to settle the outstanding liability. A </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> liability has been recorded at December 31, 2015 and June 30, 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The outcome of legal proceedings and claims brought against us are subject to significant uncertainty. Therefore, although management considers the likelihood of such an outcome to be remote, if one or more of these legal matters were resolved against us in the same reporting period for amounts in excess of management&#8217;s expectations, our financial statements for such reporting period could be materially adversely affected. In general, the resolution of a legal matter could prevent us from offering our services or products to others, could be material to our financial condition or cash flows, or both, or could otherwise adversely affect our operating results.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We lease certain equipment, vehicles and operating facilities under non-cancellable operating leases that expire on various dates through 2022. The future minimum lease payments required under these leases are </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> for the remainder of </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> in </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> in </font><font style="font-family:inherit;font-size:10pt;">2020</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">thereafter</font><font style="font-family:inherit;font-size:10pt;">. Rent expense for each of the </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">. At </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, firm commitments to vendors totaled </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Principles of Consolidation.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements include the accounts of Transgenomic, Inc. and our wholly owned subsidiary. All inter-company balances and transactions have been eliminated in consolidation.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DEBT</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dollars&#160;in&#160;Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revolving Line of Credit</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,243</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Term Loan</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible Promissory Notes </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">571</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">571</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,814</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,596</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of long-term debt</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,814</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,596</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt, net of current maturities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;"> </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revolving Line of Credit.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;">Amounts advanced under the Revolving Line accrue interest at an annual rate equal to the greater of (a) </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">6.25%</font><font style="font-family:inherit;font-size:10pt;"> or (b) the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Wall Street Journal</font><font style="font-family:inherit;font-size:10pt;"> prime rate plus </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">3%</font><font style="font-family:inherit;font-size:10pt;">. The current interest rate is </font><font style="font-family:inherit;font-size:10pt;">6.50%</font><font style="font-family:inherit;font-size:10pt;">. Interest is payable on a monthly basis, with the balance payable at the maturity of the Revolving Line. Under the Loan Agreement, we pay the Lenders a commitment fee of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$20,000</font><font style="font-family:inherit;font-size:10pt;"> on each one-year anniversary of March 13, 2013, the Effective Date, during the term of the Revolving Line. In addition, a fee of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">0.5%</font><font style="font-family:inherit;font-size:10pt;"> per annum is payable quarterly on the unused portion of the Revolving Line. The Revolving Line matures on November 1, 2017.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Term Loan.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">We received </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> under the Term Loan on the Effective Date. Pursuant to the terms of the Loan Agreement, as amended, the maturity date of the Loan Agreement was extended until November 1, 2017 and no principal payments on the Term Loan are due until such date. The current interest rate is </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">9.1%</font><font style="font-family:inherit;font-size:10pt;">. </font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will pay the Lenders an additional final payment of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$120,000</font><font style="font-family:inherit;font-size:10pt;"> at maturity or prepayment of the Term Loan. In addition, if we repay the Term Loan prior to maturity, we will pay the Lenders a prepayment penalty of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1%</font><font style="font-family:inherit;font-size:10pt;"> of the total outstanding balance under the Term Loan.</font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Additional Terms.</font></div><div style="line-height:120%;padding-left:4px;padding-top:12px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Loan Agreement contains affirmative and negative covenants. Under the Term Loan, we agreed not to (i) pledge or otherwise encumber our assets other than to the Lenders, (ii) enter into additional borrowings or guarantees, (iii) repurchase our capital stock, or (iv) enter into certain mergers or acquisitions without the Lenders&#8217; consent. Additionally, the Loan Agreement contains a subjective acceleration clause at the discretion of the Lenders. As of June 30, 2016, the Company was in compliance with the Loan Agreement, as amended by the Ninth Amendment, however, as of </font><font style="font-family:inherit;font-size:10pt;">August&#160;12, 2016</font><font style="font-family:inherit;font-size:10pt;"> we have not made the required July 2016 interest payment and have not received a waiver for the non-compliance and as such all debt has been classified as current at June 30, 2016.</font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To secure the repayment of any amounts borrowed under the Revolving Line and the Term Loan, we granted the Lenders a security interest in all of our assets. The occurrence of an event of default under the Loan Agreement could result in the acceleration of our obligations under the Loan Agreement, would increase the applicable interest rate under the Revolving Line or Term Loan (or both) by </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;"> and would permit the Lenders to exercise remedies with respect to the collateral under the Loan Agreement. As of the date these financials were available for release, the Lenders have not exercised the remedies under the Loan Agreement.</font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> Convertible Promissory Notes. </font><font style="font-family:inherit;font-size:10pt;">The Notes accrue interest at a rate of </font><font style="font-family:inherit;font-size:10pt;">6%</font><font style="font-family:inherit;font-size:10pt;"> per year and mature on December 31, 2016. </font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revolving Line and Term Loan.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 13, 2013 (the &#8220;Effective Date&#8221;), we entered into a Loan and Security Agreement with affiliates of Third Security, LLC (the &#8220;Lenders&#8221;) for (a) a revolving line of credit (the &#8220;Revolving Line&#8221;) with borrowing availability of up to </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">, subject to reduction based on our eligible accounts receivable, and (b) a term loan (the &#8220;Term Loan&#8221; and, together with the Revolving Line, the &#8220;Loan Agreement&#8221;) of </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">. Proceeds were used to pay off a </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> year senior secured promissory note payable to PGxHealth, LLC, which was entered into on December 29, 2010 in conjunction with our acquisition of the FAMILION family of genetic tests, and for general corporate and working capital purposes.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 2, 2013, we entered into an amendment to the Loan Agreement (the &#8220;Amendment&#8221;). The Amendment, which became effective as of June&#160;30, 2013, reduced our future minimum revenue covenants under the Loan Agreement and modified the interest rates applicable to the amounts advanced under the Revolving Line. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 14, 2013, we entered into a second amendment to the Loan Agreement (the &#8220;Second Amendment&#8221;). The Second Amendment, which became effective as of October 31, 2013, reduced our future minimum revenue covenants under the Loan Agreement.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 27, 2014, we entered into a third amendment to the Loan Agreement (the &#8220;Third Amendment&#8221;). Pursuant to the Third Amendment, the Lenders agreed to waive certain events of default under the Loan Agreement, and the parties amended certain provisions of the Loan Agreement, including the minimum liquidity ratio that we must maintain during the term of the Loan Agreement.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 3, 2014, we entered into a fourth amendment to the Loan Agreement (the &#8220;Fourth Amendment&#8221;). Pursuant to the terms of the Fourth Amendment, we were not required to make any principal or interest payments under the Term Loan for the period from March 1, 2014 through March 31, 2015. The interest on the debt that was deferred and not paid was capitalized as part of the Term Loan. The amount of interest that was capitalized from March 1, 2014 to March 31, 2015 was </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 22, 2014, we entered into a fifth amendment to the Loan Agreement (the &#8220;Fifth Amendment&#8221;). Pursuant to the Fifth Amendment, the parties amended certain provisions of the Loan Agreement, including reducing the minimum liquidity and revenue covenants under the Loan Agreement. The Fifth Amendment also reduced the aggregate amount that we may borrow under the Revolving Line from </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 1, 2015, we entered into a sixth amendment to the Loan Agreement (the &#8220;Sixth Amendment&#8221;). Pursuant to the Sixth Amendment, among other things, (a) the Lenders waived specified events of default under the terms of the Loan Agreement, (b) commencing April 1, 2015, we began making monthly interest payments with respect to the Term Loan to the Lenders, (c) we were not be obligated to make monthly payments of principal under the Term Loan to the Lenders until April 1, 2016, (d) we made an initial prepayment of a portion of the Term Loan balance in the amount of approximately </font><font style="font-family:inherit;font-size:10pt;">$148,000</font><font style="font-family:inherit;font-size:10pt;"> on April 1, 2015 and will make one or more additional prepayments to the Lenders under the Loan Agreement upon the occurrence of certain events, as defined in the Loan Agreement, and (e) we were not required to comply with the minimum liquidity ratio under the terms of the Loan Agreement until the earliest to occur of a specified event, as defined in the Loan Agreement, or March 31, 2016. The Sixth Amendment also extends the time period in which we must provide certain reports and statements to the Lenders and amends the circumstances pursuant to which we may engage in certain sales or transfers of our business or property without the consent of the Lenders. </font></div><div style="line-height:120%;padding-left:4px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of June 30, 2015, we were in compliance with all financial covenants of the Loan Agreement, but were not in compliance with the restrictions limiting the amount that we may borrow under the Revolving Line. Accordingly, on August 10, 2015, we received a waiver from the Lenders relating to this non-compliance and paid the Lenders an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">, which brought us back into compliance with the terms of the Revolving Line. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 4, 2015, we entered into a seventh amendment to the Loan Agreement (the &#8220;Seventh Amendment&#8221;). The Seventh Amendment, among other things, (a) provided that the Lenders waived specified events of default under the terms of the Loan Agreement, (b) reduced our future minimum revenue covenants under the Loan Agreement, (c) reduced our borrowing availability under the Revolving Line to approximately </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;">, and (d) limited our borrowing base under the Loan Agreement to the amount of the Revolving Line.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 6, 2016, we entered into an eighth amendment to the Loan Agreement (the &#8220;Eighth Amendment&#8221;). The Eighth Amendment, among other things, (a) provided that the Lenders waived specified events of default under the terms of the Loan Agreement, (b) reduced our future minimum revenue covenants under the Loan Agreement, (c) extended the maturity date of the Loan Agreement until November 1, 2017, and (d) provided for the repayment of an overadvance of </font><font style="font-family:inherit;font-size:10pt;">$750,000</font><font style="font-family:inherit;font-size:10pt;"> previously provided by the Lenders to us pursuant to the Loan Agreement.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 6, 2016, we entered into a ninth amendment to the Loan Agreement (the &#8220;Ninth Amendment&#8221;). The Ninth Amendment, among other things, (a) provided that the Lenders waived specified events of default under the terms of the Loan Agreement, (b) amended the prepayment terms of the Loan Agreement, (c) provided for the reduction of amounts available under the Revolving Line upon the prepayment or repayment of certain amounts by us, (d) removed the minimum liquidity ratio and minimum net revenue financial covenants applicable to us under the Loan Agreement, (e) amended the circumstances pursuant to which we may engage in certain sales or transfers of our business or property without the consent of the Lenders, and (f) capitalized certain amounts owed by us to the Lenders and added such overdue amounts to the outstanding principal amount of the Revolving Line. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the Ninth Amendment, the overadvance that existed at March 31, 2016 was added to the outstanding principal amount of the Revolving Line and no overadvance existed as of June 30, 2016.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Convertible Promissory Notes.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 31, 2014, we entered into an Unsecured Convertible Promissory Note Purchase Agreement (the &#8220;Note Purchase Agreement&#8221;) with an accredited investor (the &#8220;Investor&#8221;), pursuant to which we agreed to issue and sell to the Investor in a private placement an unsecured convertible promissory note (the &#8220;Initial Note&#8221;). We issued the Initial Note in the aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$750,000</font><font style="font-family:inherit;font-size:10pt;"> to the Investor on December 31, 2014. Pursuant to the terms of the Initial Note, interest accrued at a rate of </font><font style="font-family:inherit;font-size:10pt;">6%</font><font style="font-family:inherit;font-size:10pt;"> per year and the Initial Note was set to mature on December 31, 2016. Under the Initial Note, the outstanding principal and unpaid interest accrued was convertible into shares of our common stock as follows: (i) commencing upon the date of issuance of the Initial Note (but no earlier than January 1, 2015), the Investor was entitled to convert, on a one-time basis, up to </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> of the outstanding principal and unpaid interest accrued under the Initial Note, into shares of our common stock at a conversion price equal to the lesser of (a) the average closing price of the common stock on the principal securities exchange or securities market on which our common stock is then traded (the &#8220;Market&#8221;) for the </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;"> consecutive trading days immediately preceding the date of conversion, and (b) </font><font style="font-family:inherit;font-size:10pt;">$2.20</font><font style="font-family:inherit;font-size:10pt;"> (subject to adjustment for stock splits, stock dividends, other distributions, recapitalizations and the like); and (ii) commencing February 15, 2015, the Investor was entitled to convert, on a one-time basis, any or all of the remaining outstanding principal and unpaid interest accrued under the Initial Note, into shares of our common stock at a conversion price equal to </font><font style="font-family:inherit;font-size:10pt;">85%</font><font style="font-family:inherit;font-size:10pt;"> of the average closing price of our common stock on the Market for the </font><font style="font-family:inherit;font-size:10pt;">15</font><font style="font-family:inherit;font-size:10pt;"> consecutive trading days immediately preceding the date of conversion. The Initial Note has been converted in full into </font><font style="font-family:inherit;font-size:10pt;">502,786</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock, in accordance with the terms of the Initial Note. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 15, 2015, we entered into the Note Purchase Agreement with </font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;"> accredited investors (the &#8220;Additional Investors&#8221;) and, on January 20, 2015, issued and sold to the Additional Investors, in a private placement, notes (the &#8220;Additional Notes&#8221;) in an aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$925,000</font><font style="font-family:inherit;font-size:10pt;">. The Additional Notes have the same terms and conditions as the Initial Note. As of June 30, 2016, </font><font style="font-family:inherit;font-size:10pt;">$400,000</font><font style="font-family:inherit;font-size:10pt;"> of the aggregate principal amount of the Additional Notes, and accrued interest thereon, has been converted into an aggregate of </font><font style="font-family:inherit;font-size:10pt;">281,023</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">STOCK OPTIONS </font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Options.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock option activity during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at January&#160;1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,107,794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.07</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(121,140</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at June 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000,654</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.39</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at June 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">648,246</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.01</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, we granted options to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">14,000</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock at a weighted-average exercise price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.07</font><font style="font-family:inherit;font-size:10pt;"> per share under our 2006 Equity Incentive Plan, as amended (the &#8220;Plan&#8221;). Options to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">608,910</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock were granted during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">648,246</font><font style="font-family:inherit;font-size:10pt;"> options exercisable and </font><font style="font-family:inherit;font-size:10pt;">980,388</font><font style="font-family:inherit;font-size:10pt;"> options that were vested or expected to vest with an aggregate intrinsic value of </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Appreciation Rights (</font><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">SARs</font><font style="font-family:inherit;font-size:10pt;">&#8221;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes SARs activity under the Plan during the </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">SARs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at January&#160;1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at June 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98,333</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.14</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at June 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84,445</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All outstanding SARs were issued solely to our executive officers.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">84,445</font><font style="font-family:inherit;font-size:10pt;"> shares subject to outstanding SARs were exercisable and </font><font style="font-family:inherit;font-size:10pt;">98,333</font><font style="font-family:inherit;font-size:10pt;"> shares were vested or expected to vest. The weighted-average exercise price of these SARs was </font><font style="font-family:inherit;font-size:10pt;">$4.14</font><font style="font-family:inherit;font-size:10pt;"> per share and the aggregate intrinsic value was </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock option activity during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at January&#160;1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,107,794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.07</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(121,140</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at June 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000,654</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.39</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at June 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">648,246</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.01</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DISCONTINUED OPERATIONS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 8, 2015, we entered into an Asset Purchase Agreement (the &#8220;Asset Purchase Agreement&#8221;) with Edge BioSystems, Inc. (&#8220;Edge Bio&#8221;), pursuant to which we sold our manufacturing, marketing and selling of high quality polymer and silica based beads and resin and chromatography columns business (collectively, the &#8220;Columns Business&#8221;). The Columns Business was part of our former segment, Genetic Assays and Platforms. Pursuant to the Asset Purchase Agreement, Edge Bio acquired substantially all of the assets used solely in connection with the Columns Business and assumed certain liabilities of the Columns Business for a total cash purchase price of approximately </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;"> (the &#8220;Asset Sale&#8221;), which was paid on September 8, 2015 upon the closing of the Asset Sale. During the year ended December 31, 2015, we recorded a gain on the sale of the Columns Business of </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 25, 2015, we entered into an Asset Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with ADSTEC Corporation (&#8220;ADSTEC&#8221;) and ADS Biotec Inc., a wholly-owned subsidiary of ADSTEC (&#8220;Buyer&#8221;), pursuant to which we sold (1) to ADSTEC our facilities located in Glasgow, Scotland and on Irvington Road in Omaha, Nebraska (together, the &#8220;Facilities&#8221;) and all of our stock, inventory and raw materials located at the Facilities (collectively, the &#8220;Inventory&#8221;), and (2) to Buyer (a) all of the remaining assets relating to our Genetic Assays and Platforms business segment (the &#8220;Business&#8221;), other than the Inventory (the &#8220;Purchased Assets&#8221;), and (b) all of the ordinary shares of Transgenomic Limited, a wholly-owned subsidiary of ours (the &#8220;Shares&#8221;). </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the Purchase Agreement, ADSTEC and Buyer acquired the Facilities, the Inventory, the Purchased Assets and the Shares for an aggregate purchase price of approximately </font><font style="font-family:inherit;font-size:10pt;">$300,000</font><font style="font-family:inherit;font-size:10pt;">, and Buyer assumed our financial and human resources commitments related to the Business (the &#8220;Transaction&#8221;). During the year ended December 31, 2015, we recorded a loss on the Transaction of </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Together, the Asset Sale and the Transaction represent the divestiture of our Genetic Assays and Platforms business, resulting in a strategic shift that had a major effect on our operations and financial results. Therefore, the divested operations of our Genetic Assays and Platforms business meet the criteria to be reported as discontinued operations.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the fourth quarter of 2015, our Board of Directors took actions to begin the process of divesting our Patient Testing business in New Haven, Connecticut. In March 2016, we announced that we had suspended testing services in our Patient Testing laboratory as we review and evaluate various strategic alternatives for that business. As a result of these actions, as of December 31, 2015, our Patient Testing business met the criteria to be reported as discontinued operations. We anticipate that we will complete the divestiture of the Patient Testing business during 2016.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The related assets, liabilities, results of operations and cash flows for both the Genetic Assays and Platforms business and Patient Testing business are classified as assets held for sale, liabilities held for sale and discontinued operations for all periods presented.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Results of the discontinued operations consisted of the following:</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:85.546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three months ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Six months ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Dollars in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">574</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,598</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,677</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,361</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of goods sold</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,703</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,194</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,777</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">563</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,895</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">483</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,584</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">344</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,165</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,369</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,415</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">224</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating income (loss) from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">219</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(378</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(954</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,055</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain on sale of business/assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">963</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">963</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,182</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(378</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,055</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations, net of taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,182</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(421</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,144</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income from discontinued operations for both the three and six month periods ended June 30, 2016, includes approximately </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> in proceeds received from the sale of assets of our discontinued Patient Testing business.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets and liabilities of the discontinued operations are classified as assets held for sale and liabilities held for sale in the condensed consolidated balance sheets and consisted of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ASSETS</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">647</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,905</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">690</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,987</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LIABILITIES</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">264</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of activity for the allowance for doubtful accounts from discontinued operations during the three and six months ended June 30, 2016 and 2015. The allowance for doubtful accounts from discontinued operations is included in the assets held for sale in the condensed consolidated balance sheets.</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:42%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Beginning</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Additions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Deductions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Ending</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,542</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,462</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended June 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,173</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,198</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,965</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,406</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Six Months Ended June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,664</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,202</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,462</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Six Months Ended June 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,927</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,730</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,251</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,406</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Loss Per Share.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic loss per share is calculated based on the weighted-average number of common shares outstanding during each period. Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three and six months ended June 30, 2016, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:86.9140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three Months Ended</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance at April 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,446</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total (gains) or losses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recognized in earnings</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at June 30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,442</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:86.9140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Six Months Ended</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance at January 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,437</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total (gains) or losses:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recognized in earnings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at June 30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,442</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three and six months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and 2015, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance at April 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">290</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total (gains) or losses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recognized in earnings</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">270</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at June 30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">560</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance at January 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total (gains) or losses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recognized in earnings</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(350</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">415</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at June 30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">560</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless otherwise specified, book value approximates fair market value. The common stock warrant liability is recorded at fair value.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:30px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FAIR VALUE</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FASB guidance on fair value measurements, which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements for our financial assets and liabilities, as well as for other assets and liabilities that are carried at fair value on a recurring basis in our consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FASB guidance establishes a three-level fair value hierarchy based upon the assumptions (inputs) used to price assets or liabilities. The three levels of inputs used to measure fair value are as follows:</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;1&#8212;Unadjusted quoted prices in active markets for identical assets or liabilities;</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;2&#8212;Observable inputs other than those included in Level&#160;1, such as quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets;&#160;and</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;3&#8212;Unobservable inputs reflecting our own assumptions and best estimate of what inputs market participants would use in pricing the asset or liability.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Debt.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our long term debt book value approximates fair market value due to the variable interest rate it bears. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock Warrant Liabilities.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain of our issued and outstanding warrants to purchase shares of common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2012 Warrant Liability</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2012 Warrant Liability represents the fair value of the </font><font style="font-family:inherit;font-size:10pt;">1.2 million</font><font style="font-family:inherit;font-size:10pt;"> warrants issued in February 2012, which, through a series of changes in exercise price since February 2012, are now exercisable for </font><font style="font-family:inherit;font-size:10pt;">3.3 million</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock. We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our Statement of Operations. Management does not believe that this liability will be settled by a use of cash.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2012 Warrant Liability is considered a Level 3 financial instrument and is valued using a Monte Carlo simulation model. This method is well suited to valuing options with non-standard features, such as anti-dilution protection. A Monte Carlo simulation model uses repeated random sampling to simulate significant uncertainty in inputs. Assumptions and inputs used in the valuation of the common stock warrants are broken down into four sections: Static Business Inputs; Static Technical Inputs; Simulated Business Inputs; and Simulated Technical Inputs.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Static Business Inputs include: our equity value, which was estimated using our stock price of </font><font style="font-family:inherit;font-size:10pt;">$0.55</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">; the amount of the down-round financing; the timing of the down-round financing; and the expected exercise period of </font><font style="font-family:inherit;font-size:10pt;">0.61</font><font style="font-family:inherit;font-size:10pt;"> years from the valuation date.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Static Technical Inputs include: volatility of </font><font style="font-family:inherit;font-size:10pt;">67%</font><font style="font-family:inherit;font-size:10pt;"> and the risk-free interest rate of </font><font style="font-family:inherit;font-size:10pt;">0.42%</font><font style="font-family:inherit;font-size:10pt;"> based on the </font><font style="font-family:inherit;font-size:10pt;">1</font><font style="font-family:inherit;font-size:10pt;">-year U.S. Treasury yield interpolated from the six-month and one-year U.S. Treasury bonds. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Simulated Business Inputs include: the probability of down-round financing, which was estimated to be </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> for simulated equity values below the down-round financing cut-off point.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Simulated Technical Inputs include: our equity value follows a geometric Brownian motion and is simulated over weekly periods; and a down-round financing event that was randomly simulated in an iteration based on the </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> discrete probability of a down-round financing for those iterations where our simulated equity value at the expected timing of a down-round financing event was below the down-round financing cut-off point.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three and six months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and 2015, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance at April 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">290</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total (gains) or losses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recognized in earnings</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">270</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at June 30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">560</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance at January 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total (gains) or losses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recognized in earnings</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(350</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">415</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at June 30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">560</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2016 Warrant Liability</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2016 Warrant Liability represents the fair value of the </font><font style="font-family:inherit;font-size:10pt;">1.8 million</font><font style="font-family:inherit;font-size:10pt;"> warrants issued in January 2016. We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our Statement of Operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Common Stock Warrant Liability is considered a Level 3 financial instrument and is valued using a binomial lattice simulation model. This method is well suited to valuing options with non-standard features. Assumptions and inputs used in the valuation of the common stock warrants include; our equity value, which was estimated using our stock price of </font><font style="font-family:inherit;font-size:10pt;">$0.55</font><font style="font-family:inherit;font-size:10pt;"> as of June 30, 2016; volatility of </font><font style="font-family:inherit;font-size:10pt;">135%</font><font style="font-family:inherit;font-size:10pt;">; and a risk-free interest rate of </font><font style="font-family:inherit;font-size:10pt;">1.21%</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three and six months ended June 30, 2016, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:86.9140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three Months Ended</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance at April 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,446</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total (gains) or losses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recognized in earnings</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at June 30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,442</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:86.9140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Six Months Ended</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance at January 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,437</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total (gains) or losses:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recognized in earnings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at June 30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,442</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The change in unrealized gains or losses of Level 3 liabilities was included in earnings and was reported in other income (expense) in our Statement of Operations.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangible Assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets include intellectual property and patents.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:57px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1. Intellectual Property.&#160;&#160;&#160;&#160;Initial costs paid to license intellectual property from independent third parties are capitalized and amortized using the straight-line method over the license period. Ongoing royalties related to such licenses are expensed as incurred.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:57px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2. Patents.&#160;&#160;&#160;&#160;We capitalize legal costs, filing fees and other expenses associated with obtaining patents on new discoveries and amortize these costs using the straight-line method over the shorter of the legal life of the patent or its economic life beginning on the date the patent is issued.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INCOME TAXES</font></div><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Annually, we file U.S. Federal, state and foreign income tax returns.&#160; All U.S. Federal and most state loss carryforwards remain subject to adjustment in the event of an income tax examination.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense from continuing operations was </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and 2015. We maintain a full valuation allowance on our net deferred tax assets,&#160;having concluded that we are not more likely than not going to realize the benefit of our deferred tax assets, including our net operating loss carryforwards.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During each of the </font><font style="font-family:inherit;font-size:10pt;">three and six</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, there were no material changes to the liability for uncertain tax positions.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, Revenue from Contracts with Customers (&#8220;ASU No. 2014-09&#8221;). This guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to a customer. ASU No. 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. In July 2015, the FASB decided to defer the effective date of this new accounting guidance by one year. As a result, ASU No. 2014-09 will be effective for us for all annual and interim reporting periods beginning after December 15, 2017 and early adoption would be permitted as of the original effective date. The new standard permits the use of either the retrospective or cumulative effect transition method. We do not expect to early adopt this guidance and we have not selected a transition method. We are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40)(&#8220;ASU No. 2014-15&#8221;)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">. </font><font style="font-family:inherit;font-size:10pt;">This guidance addresses management&#8217;s responsibility to evaluate whether there is substantial doubt about an entity&#8217;s ability to continue as a going concern and to provide related footnote disclosures. The standard will be effective for the first interim period within annual reporting periods beginning after December&#160;15, 2016. Early adoption is permitted. We do not expect to early adopt this guidance and do not believe that the adoption of this guidance will have a material impact on our consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard amends the recognition of lease assets and lease liabilities by lessees for those leases currently classified as operating leases and amends disclosure requirements associated with leasing arrangements. The new standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently assessing the impact that the adoption of this ASU will have on our consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard simplifies several aspects related to the accounting for share-based payment transactions, including the accounting for income taxes, statutory tax withholding requirements, forfeitures and classification on the statement of cash flows. This guidance is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2016; however, early adoption is permitted. We do not expect to early adopt this guidance and are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain prior year amounts have been reclassified to conform to the current year presentation in our condensed consolidated financial statements, which consists of the effects of reclassifications from the presentation of our discontinued operations.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Property and Equipment.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets as follows:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1&#160;to&#160;10&#160;years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 to 7 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Production equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 to 7 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 to 7 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2 to 7 years</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation is computed using the straight-line method over the estimated useful lives of the related assets as follows:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1&#160;to&#160;10&#160;years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 to 7 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Production equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 to 7 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 to 7 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2 to 7 years</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Sales Recognition.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:66px;text-indent:-36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue is realized and earned when all of the following criteria are met:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Persuasive evidence of an arrangement exists;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Delivery has occurred or services have been rendered;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The seller&#8217;s price to the buyer is fixed or determinable; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collectability is reasonably assured.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> In our Biomarker Identification laboratory, we perform services on a project by project basis. When we receive payment in advance, we initially defer the revenue and recognize it when we deliver the service. These projects typically do not extend beyond one year. At each of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and December 31, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, deferred net sales associated with pharmacogenomics research projects included in the balance sheet in deferred revenue was </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:174%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net sales from Patient Testing laboratories, reported as part of discontinued operations, are recognized on an individual test basis and take place when the test report is completed, reviewed and sent to the client less the reserve for insurance, Medicare and Medicaid contractual adjustments. There are no deferred net sales associated with our Patient Testing services. Adjustments to the allowances, based on actual receipts from third party payers, are reflected in the estimated contractual allowance applied prospectively. In the fourth quarter of 2015, we adjusted our contractual allowance rates to better reflect the reimbursement level we expect to achieve on Patient Testing billings. The adjustment negatively impacted our Patient Testing revenues for all periods after the third quarter of 2015. (See Note 3 - &#8220;Discontinued Operations&#8221;).</font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net sales of Genetic Assays and Platforms products, reported as discontinued operations (See Note 3 - &#8220;Discontinued Operations&#8221;) are recognized in accordance with the terms of the sales arrangement. Such recognition is based on receipt of an unconditional customer order and transfer of title and risk of ownership to the customer, typically upon shipment of the product under a purchase order. Our sales terms do not provide for the right of return unless the product is damaged or defective. Net sales from certain services associated with the analytical instruments, to be performed subsequent to shipment of the products, is deferred and recognized when the services are provided. Such services, mainly limited to installation and training services that are not essential to the functionality of the instruments, typically are performed in a timely manner subsequent to shipment of the instrument. We also enter into various service contracts that cover installed instruments. These contracts cover specific time periods and net sales associated with these contracts are deferred and recognized ratably over the service period.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dollars&#160;in&#160;Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revolving Line of Credit</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,243</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Term Loan</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible Promissory Notes </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">571</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">571</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,814</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,596</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of long-term debt</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,814</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,596</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt, net of current maturities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;"> </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revolving Line of Credit.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;">Amounts advanced under the Revolving Line accrue interest at an annual rate equal to the greater of (a) </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">6.25%</font><font style="font-family:inherit;font-size:10pt;"> or (b) the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Wall Street Journal</font><font style="font-family:inherit;font-size:10pt;"> prime rate plus </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">3%</font><font style="font-family:inherit;font-size:10pt;">. The current interest rate is </font><font style="font-family:inherit;font-size:10pt;">6.50%</font><font style="font-family:inherit;font-size:10pt;">. Interest is payable on a monthly basis, with the balance payable at the maturity of the Revolving Line. Under the Loan Agreement, we pay the Lenders a commitment fee of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$20,000</font><font style="font-family:inherit;font-size:10pt;"> on each one-year anniversary of March 13, 2013, the Effective Date, during the term of the Revolving Line. In addition, a fee of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">0.5%</font><font style="font-family:inherit;font-size:10pt;"> per annum is payable quarterly on the unused portion of the Revolving Line. The Revolving Line matures on November 1, 2017.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Term Loan.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">We received </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> under the Term Loan on the Effective Date. Pursuant to the terms of the Loan Agreement, as amended, the maturity date of the Loan Agreement was extended until November 1, 2017 and no principal payments on the Term Loan are due until such date. The current interest rate is </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">9.1%</font><font style="font-family:inherit;font-size:10pt;">. </font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will pay the Lenders an additional final payment of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$120,000</font><font style="font-family:inherit;font-size:10pt;"> at maturity or prepayment of the Term Loan. In addition, if we repay the Term Loan prior to maturity, we will pay the Lenders a prepayment penalty of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1%</font><font style="font-family:inherit;font-size:10pt;"> of the total outstanding balance under the Term Loan.</font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Additional Terms.</font></div><div style="line-height:120%;padding-left:4px;padding-top:12px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Loan Agreement contains affirmative and negative covenants. Under the Term Loan, we agreed not to (i) pledge or otherwise encumber our assets other than to the Lenders, (ii) enter into additional borrowings or guarantees, (iii) repurchase our capital stock, or (iv) enter into certain mergers or acquisitions without the Lenders&#8217; consent. Additionally, the Loan Agreement contains a subjective acceleration clause at the discretion of the Lenders. As of June 30, 2016, the Company was in compliance with the Loan Agreement, as amended by the Ninth Amendment, however, as of </font><font style="font-family:inherit;font-size:10pt;">August&#160;12, 2016</font><font style="font-family:inherit;font-size:10pt;"> we have not made the required July 2016 interest payment and have not received a waiver for the non-compliance and as such all debt has been classified as current at June 30, 2016.</font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To secure the repayment of any amounts borrowed under the Revolving Line and the Term Loan, we granted the Lenders a security interest in all of our assets. The occurrence of an event of default under the Loan Agreement could result in the acceleration of our obligations under the Loan Agreement, would increase the applicable interest rate under the Revolving Line or Term Loan (or both) by </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;"> and would permit the Lenders to exercise remedies with respect to the collateral under the Loan Agreement. As of the date these financials were available for release, the Lenders have not exercised the remedies under the Loan Agreement.</font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> Convertible Promissory Notes. </font><font style="font-family:inherit;font-size:10pt;">The Notes accrue interest at a rate of </font><font style="font-family:inherit;font-size:10pt;">6%</font><font style="font-family:inherit;font-size:10pt;"> per year and mature on December 31, 2016. </font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">esults of the discontinued operations consisted of the following:</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:85.546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three months ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Six months ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Dollars in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">574</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,598</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,677</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,361</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of goods sold</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,703</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,194</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,777</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">563</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,895</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">483</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,584</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">344</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,165</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,369</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,415</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">224</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating income (loss) from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">219</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(378</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(954</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,055</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain on sale of business/assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">963</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">963</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,182</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(378</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,055</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations, net of taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,182</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(421</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,144</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets and liabilities of the discontinued operations are classified as assets held for sale and liabilities held for sale in the condensed consolidated balance sheets and consisted of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ASSETS</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">647</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,905</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">690</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,987</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LIABILITIES</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">264</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of activity for the allowance for doubtful accounts from discontinued operations during the three and six months ended June 30, 2016 and 2015. The allowance for doubtful accounts from discontinued operations is included in the assets held for sale in the condensed consolidated balance sheets.</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:42%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Beginning</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Additions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Deductions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Ending</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,542</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,462</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended June 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,173</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,198</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,965</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,406</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Six Months Ended June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,664</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,202</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,462</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Six Months Ended June 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,927</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,730</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,251</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,406</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes SARs activity under the Plan during the </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">SARs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at January&#160;1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at June 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98,333</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.14</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at June 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84,445</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrant Holder</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Issue&#160;Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expiration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Underlying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,832,069</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.36</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Affiliates of Third Security, LLC</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">430,019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.36</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,655</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.00</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Affiliates of Third Security, LLC</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.00</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">April 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">374,618</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.00</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">714,780</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.24</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(5)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122,433</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.66</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(5)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">667,164</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.01</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(6)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,161,972</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Affiliates of Third Security, LLC</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(7)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">161,026</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(7)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,720,430</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,876,166</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;padding-top:8px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with the Private Placement completed in February 2012 and are classified as a liability in our financial statements. See Note 9 - &#8220;Fair Value&#8221; for additional information. These warrants also contain certain anti-dilution provisions that provide for an adjustment to the exercise price and number of shares issuable upon exercise of the warrant in the event that we engage in certain issuances of shares of our common stock at a price lower than the exercise price of the warrant.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with the 2013 Offering, which was completed in January 2013. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with the 2014 Private Placement, which was completed in October 2014.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with the February 2015 Offering, which was completed in February 2015.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(5)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with the July 2015 Offering, which was completed in July 2015.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(6)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were originally issued in connection with the July 2015 Offering, which was completed in July 2015, and were amended in connection with the January 2016 Offering, which was completed in January 2016.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(7)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with the January 2016 Offering, which was completed in January 2016.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-Based Compensation.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All stock-based awards to date have exercise prices equal to the market value of the shares at the date of grant and have </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;">-year contractual terms. Unvested awards as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> had vesting periods of up to </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> years from the date of grant. None of the awards outstanding at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> are subject to performance or market-based vesting conditions.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We measure and recognize compensation expense for all stock-based awards made to employees and directors. Compensation expense, net of estimated forfeitures, is based on the calculated fair value of the awards as measured at the grant date and is expensed over the service period of the awards.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements are presented in conformity with GAAP. All amounts are presented in U.S. Dollars (&#8220;$&#8221;). Supplemental cash flows from discontinued operations are presented in Note 3 - &#8220;Discontinued Operations&#8221;. We have evaluated events occurring subsequent to June 30, 2016 for potential recognition or disclosure in the consolidated financial statements and concluded there were no subsequent events that required recognition or disclosure.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated balance sheet as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> was derived from our audited balance sheet as of that date. There has been no change in the balance sheet from December 31, 2015. The accompanying condensed consolidated financial statements as of and for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;"> are unaudited and reflect all adjustments (consisting of only normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the interim periods. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> contained in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on April 14, 2016. The results of operations for the interim periods presented are not necessarily indicative of the results for fiscal year 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain prior year amounts have been reclassified to conform to the current year presentation in our condensed consolidated financial statements, which consists of the effects of reclassifications from the presentation of our discontinued operations.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Principles of Consolidation.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements include the accounts of Transgenomic, Inc. and our wholly owned subsidiary. All inter-company balances and transactions have been eliminated in consolidation.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Risks and Uncertainties.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain risks and uncertainties are inherent in our day-to-day operations and in the process of preparing our financial statements. The more significant of those risks are presented below and throughout the notes to the unaudited condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of net sales and expenses during the reporting period. In addition, estimates and assumptions associated with the determination of the fair value of certain assets and related impairments require considerable judgment by management. Actual results could differ from the estimates and assumptions used in preparing these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless otherwise specified, book value approximates fair market value. The common stock warrant liability is recorded at fair value. See Note 9 - &#8220;Fair Value&#8221; for additional information.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and Cash Equivalents and Other Current Assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents include cash and investments with original maturities at the date of acquisition of three months or less. Other current assets as of June 30, 2016 of </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> include prepaid assets of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and other receivables of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of Cash.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, we may maintain a cash position with financial institutions in amounts that exceed federally insured limits. We have not experienced any losses on such accounts as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounts Receivable.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of activity for the allowance for doubtful accounts from continuing operations during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">:</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Beginning</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Additions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Deductions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Ending</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended June 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Six Months Ended June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Six Months Ended June 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:4px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While payment terms are generally </font><font style="font-family:inherit;font-size:10pt;">30 days</font><font style="font-family:inherit;font-size:10pt;">, we have also provided extended payment terms in certain cases. Accounts receivable are carried at original invoice amount and shown net of allowance for doubtful accounts. The estimate made for doubtful accounts is based on a review of all outstanding amounts on a quarterly basis. We determine the allowance for doubtful accounts by regularly evaluating individual payor receivables and considering a payor&#8217;s financial condition, credit history, reimbursement rates and current economic conditions. Accounts receivable are written off when deemed uncollectible and after all collection efforts have been exhausted. Recoveries of accounts receivable previously written off are recorded as a reduction in bad debt expense when received.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inventories.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories are stated at the lower of cost or market net of allowance for obsolete inventory. Cost is computed using standard costs for finished goods and average or latest actual cost for raw materials and work in process, which approximates the first-in, first-out (FIFO) method. At June 30, 2016, our net inventories were less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and were comprised predominantly of raw materials. </font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of activity for the allowance for obsolete inventory during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">:</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Beginning</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Additions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Deductions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Ending</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended June 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Six Months Ended June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Six Months Ended June 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:4px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We determine the allowance for obsolescence by evaluating inventory quarterly for items deemed to be slow moving or obsolete.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Property and Equipment.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets as follows:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1&#160;to&#160;10&#160;years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 to 7 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Production equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 to 7 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 to 7 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2 to 7 years</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense in continuing operations related to property and equipment was less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> for each of the three month periods ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">. Depreciation expense was </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> for each of the </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">. Depreciation expense during each period includes depreciation related to equipment acquired under capital leases. </font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangible Assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets include intellectual property and patents.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:57px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1. Intellectual Property.&#160;&#160;&#160;&#160;Initial costs paid to license intellectual property from independent third parties are capitalized and amortized using the straight-line method over the license period. Ongoing royalties related to such licenses are expensed as incurred.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:57px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2. Patents.&#160;&#160;&#160;&#160;We capitalize legal costs, filing fees and other expenses associated with obtaining patents on new discoveries and amortize these costs using the straight-line method over the shorter of the legal life of the patent or its economic life beginning on the date the patent is issued.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-Based Compensation.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All stock-based awards to date have exercise prices equal to the market value of the shares at the date of grant and have </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;">-year contractual terms. Unvested awards as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> had vesting periods of up to </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> years from the date of grant. None of the awards outstanding at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> are subject to performance or market-based vesting conditions.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We measure and recognize compensation expense for all stock-based awards made to employees and directors. Compensation expense, net of estimated forfeitures, is based on the calculated fair value of the awards as measured at the grant date and is expensed over the service period of the awards.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, we recorded compensation expense for all stock awards of less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, within selling, general and administrative expense. During the </font><font style="font-family:inherit;font-size:10pt;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, we recorded compensation expense for all stock awards of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the unrecognized compensation expense related to unvested stock awards was </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">, which is expected to be recognized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">1.2 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We granted stock options to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">14,000</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock during the three and </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. The fair value of the stock options granted was estimated on the grant date using the Black-Scholes option pricing model with the following assumptions: risk-free interest rates of </font><font style="font-family:inherit;font-size:10pt;">1.91%</font><font style="font-family:inherit;font-size:10pt;"> based on the U.S. Treasury yield in effect at the time of grant; dividend yields of </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> percent; expected lives of </font><font style="font-family:inherit;font-size:10pt;">6.00</font><font style="font-family:inherit;font-size:10pt;"> years, based on expected exercise activity behavior; and volatility of </font><font style="font-family:inherit;font-size:10pt;">85%</font><font style="font-family:inherit;font-size:10pt;"> based on the historical volatility of our common stock over a time that is consistent with the expected life of the options. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in our stock awards outstanding as of June 30, 2016 were stock appreciation rights (&#8220;SARs&#8221;)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">to purchase </font><font style="font-family:inherit;font-size:10pt;">98,333</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock. The SARs were issued solely to our executive officers and will vest over </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> years from the date of grant. </font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Sales Recognition.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:66px;text-indent:-36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue is realized and earned when all of the following criteria are met:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Persuasive evidence of an arrangement exists;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Delivery has occurred or services have been rendered;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The seller&#8217;s price to the buyer is fixed or determinable; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collectability is reasonably assured.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> In our Biomarker Identification laboratory, we perform services on a project by project basis. When we receive payment in advance, we initially defer the revenue and recognize it when we deliver the service. These projects typically do not extend beyond one year. At each of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and December 31, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, deferred net sales associated with pharmacogenomics research projects included in the balance sheet in deferred revenue was </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:174%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net sales from Patient Testing laboratories, reported as part of discontinued operations, are recognized on an individual test basis and take place when the test report is completed, reviewed and sent to the client less the reserve for insurance, Medicare and Medicaid contractual adjustments. There are no deferred net sales associated with our Patient Testing services. Adjustments to the allowances, based on actual receipts from third party payers, are reflected in the estimated contractual allowance applied prospectively. In the fourth quarter of 2015, we adjusted our contractual allowance rates to better reflect the reimbursement level we expect to achieve on Patient Testing billings. The adjustment negatively impacted our Patient Testing revenues for all periods after the third quarter of 2015. (See Note 3 - &#8220;Discontinued Operations&#8221;).</font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net sales of Genetic Assays and Platforms products, reported as discontinued operations (See Note 3 - &#8220;Discontinued Operations&#8221;) are recognized in accordance with the terms of the sales arrangement. Such recognition is based on receipt of an unconditional customer order and transfer of title and risk of ownership to the customer, typically upon shipment of the product under a purchase order. Our sales terms do not provide for the right of return unless the product is damaged or defective. Net sales from certain services associated with the analytical instruments, to be performed subsequent to shipment of the products, is deferred and recognized when the services are provided. Such services, mainly limited to installation and training services that are not essential to the functionality of the instruments, typically are performed in a timely manner subsequent to shipment of the instrument. We also enter into various service contracts that cover installed instruments. These contracts cover specific time periods and net sales associated with these contracts are deferred and recognized ratably over the service period.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock Warrants.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain of our issued and outstanding warrants to purchase common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability (&#8220;Common Stock Warrant Liability&#8221;). We are required to present these instruments at fair value at each reporting date and any changes in fair values are recorded as an adjustment to earnings. The Common Stock Warrant Liabilities are considered Level Three financial instruments for purposes of fair value measurement. See Note 9 - &#8220;Fair Value&#8221; for additional information.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Loss Per Share.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic loss per share is calculated based on the weighted-average number of common shares outstanding during each period. Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock. Options, warrants and conversion rights pertaining to </font><font style="font-family:inherit;font-size:10pt;">10,721,464</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">8,286,963</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock have been excluded from the computation of diluted loss per share at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, because the effect is anti-dilutive due to the net loss. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, Revenue from Contracts with Customers (&#8220;ASU No. 2014-09&#8221;). This guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to a customer. ASU No. 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. In July 2015, the FASB decided to defer the effective date of this new accounting guidance by one year. As a result, ASU No. 2014-09 will be effective for us for all annual and interim reporting periods beginning after December 15, 2017 and early adoption would be permitted as of the original effective date. The new standard permits the use of either the retrospective or cumulative effect transition method. We do not expect to early adopt this guidance and we have not selected a transition method. We are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40)(&#8220;ASU No. 2014-15&#8221;)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">. </font><font style="font-family:inherit;font-size:10pt;">This guidance addresses management&#8217;s responsibility to evaluate whether there is substantial doubt about an entity&#8217;s ability to continue as a going concern and to provide related footnote disclosures. The standard will be effective for the first interim period within annual reporting periods beginning after December&#160;15, 2016. Early adoption is permitted. We do not expect to early adopt this guidance and do not believe that the adoption of this guidance will have a material impact on our consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard amends the recognition of lease assets and lease liabilities by lessees for those leases currently classified as operating leases and amends disclosure requirements associated with leasing arrangements. The new standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently assessing the impact that the adoption of this ASU will have on our consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard simplifies several aspects related to the accounting for share-based payment transactions, including the accounting for income taxes, statutory tax withholding requirements, forfeitures and classification on the statement of cash flows. This guidance is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2016; however, early adoption is permitted. We do not expect to early adopt this guidance and are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:36px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">STOCKHOLDERS&#8217; EQUITY</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to our Third Amended and Restated Certificate of Incorporation, as amended, we currently have </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">150,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock authorized for issuance.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 2, 2012, we entered into definitive agreements with institutional and other accredited investors and raised approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$22.0 million</font><font style="font-family:inherit;font-size:10pt;"> in a private placement financing (the &#8220;Private Placement&#8221;), which included an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;"> in convertible notes issued in December 2011 to entities affiliated with Third Security, LLC, a related party, that automatically converted into shares of our common stock and warrants to purchase such common stock on the same terms as all investors in the Private Placement. Pursuant to the purchase agreement, we issued an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1,583,333</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock at a price per share of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$12.00</font><font style="font-family:inherit;font-size:10pt;">, as well as </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">five</font><font style="font-family:inherit;font-size:10pt;">-year warrants to purchase up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">823,333</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock with an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$15.00</font><font style="font-family:inherit;font-size:10pt;"> per share. In connection with the conversion of the convertible notes issued by us to the entities affiliated with Third Security, LLC, the entities received an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">250,000</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock and </font><font style="font-family:inherit;font-size:10pt;">125,000</font><font style="font-family:inherit;font-size:10pt;"> warrants on the same terms as all investors in the Private Placement. Craig-Hallum Capital Group LLC (&#8220;Craig-Hallum&#8221;) served as the sole placement agent for the offering. In consideration for services rendered as the placement agent in the offering, we agreed to (a) pay to the placement agent cash commissions equal to </font><font style="font-family:inherit;font-size:10pt;">$1,330,000</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">7.0%</font><font style="font-family:inherit;font-size:10pt;"> of the gross proceeds received in the offering; (b) issue to the placement agent a </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year warrant to purchase up to </font><font style="font-family:inherit;font-size:10pt;">31,666</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock (representing </font><font style="font-family:inherit;font-size:10pt;">2%</font><font style="font-family:inherit;font-size:10pt;"> of the shares sold in the Private Placement) with an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$15.00</font><font style="font-family:inherit;font-size:10pt;"> per share and other terms that are the same as the terms of the warrants issued in the Private Placement; and (c) reimburse the placement agent for reasonable out-of-pocket expenses, including fees paid to the placement agent&#8217;s legal counsel, incurred in connection with the offering, which reimbursable expenses were not to exceed </font><font style="font-family:inherit;font-size:10pt;">$125,000</font><font style="font-family:inherit;font-size:10pt;">. The costs incurred to complete the Private Placement were recorded as a reduction in equity in the amount of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">. Net proceeds from this offering were used for general corporate and working capital purposes, primarily to accelerate development of several of our key initiatives.</font></div><div style="line-height:120%;padding-top:15px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 24, 2013, we entered into a Securities Purchase Agreement with certain institutional and other accredited investors pursuant to which we: (a) sold to the investors an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1,383,333</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock at a price per share of </font><font style="font-family:inherit;font-size:10pt;">$6.00</font><font style="font-family:inherit;font-size:10pt;"> for aggregate gross proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$8.3 million</font><font style="font-family:inherit;font-size:10pt;">; and (b) issued to the investors warrants to purchase up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">691,655</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock with an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$9.00</font><font style="font-family:inherit;font-size:10pt;"> per share (the &#8220;2013 Offering&#8221;). The warrants may be exercised, in whole or in part, at any time from January 30, 2013 until January 30, 2018 and contain both cash and &#8220;cashless exercise&#8221; features. Affiliates of Third Security, LLC purchased an aggregate of </font><font style="font-family:inherit;font-size:10pt;">500,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock and warrants to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">250,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock in the 2013 Offering on the same terms as the other investors. Net proceeds from the 2013 Offering were used for general corporate and working capital purposes.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the 2013 Offering, we entered into a registration rights agreement with the investors (the &#8220;Registration Rights Agreement&#8221;). The Registration Rights Agreement required that we file with the SEC a registration statement to register for resale the shares of common stock sold and the shares of common stock issuable upon exercise of the warrants (the &#8220;Warrant Shares&#8221;) by March 16, 2013. The registration statement was filed with the SEC on March 15, 2013 and was declared effective by the SEC on March 29, 2013.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2013 Offering required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of the warrants decreased from </font><font style="font-family:inherit;font-size:10pt;">$15.00</font><font style="font-family:inherit;font-size:10pt;"> per share to </font><font style="font-family:inherit;font-size:10pt;">$12.96</font><font style="font-family:inherit;font-size:10pt;"> per share and the number of shares issuable upon exercise of the warrants increased from </font><font style="font-family:inherit;font-size:10pt;">948,333</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">1,097,600</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 22, 2014, we entered into a Securities Purchase Agreement with certain accredited investors (the &#8220;October 2014 Investors&#8221;), pursuant to which we, in a private placement, issued and sold to the October 2014 Investors (the &#8220;2014 Private Placement&#8221;) an aggregate of </font><font style="font-family:inherit;font-size:10pt;">730,776</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock at a price per share of </font><font style="font-family:inherit;font-size:10pt;">$3.25</font><font style="font-family:inherit;font-size:10pt;"> for an aggregate purchase price of approximately </font><font style="font-family:inherit;font-size:10pt;">$2.4 million</font><font style="font-family:inherit;font-size:10pt;">, and warrants to purchase up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">365,388</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock with an initial exercise price of </font><font style="font-family:inherit;font-size:10pt;">$4.00</font><font style="font-family:inherit;font-size:10pt;"> per share that are exercisable for the period from April 22, 2015 through April 22, 2020. In connection with the 2014 Private Placement, we also issued a warrant to purchase up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">9,230</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock to one advisor. The warrants issued in the 2014 Private Placement include both cash and &#8220;cashless exercise&#8221; features.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2014 Private Placement required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the February 2012 common stock and warrant sale. The exercise price of the warrants decreased from </font><font style="font-family:inherit;font-size:10pt;">$11.73</font><font style="font-family:inherit;font-size:10pt;"> per share to </font><font style="font-family:inherit;font-size:10pt;">$10.86</font><font style="font-family:inherit;font-size:10pt;"> per share and the number of shares issuable upon exercise of the warrants increased from </font><font style="font-family:inherit;font-size:10pt;">1,212,665</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">1,309,785</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 31, 2014, we entered into the Note Purchase Agreement with the Investor pursuant to which we agreed to issue and sell the Initial Note to the Investor (the &#8220;Note Private Placement&#8221;). See Note 5 - &#8220;Debt-</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Convertible Promissory Notes</font><font style="font-family:inherit;font-size:10pt;">&#8221; for additional information regarding the terms of the Initial Note. Pursuant to the terms of the Note Purchase Agreement, we are subject to certain registration obligations and we may be required to effect one or more other registrations to register for resale the shares of our common stock issued or issuable under the Initial Note in connection with certain &#8220;piggy-back&#8221; registration rights granted to the Investor.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Note Private Placement required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the February 2012 common stock and warrant sale. The exercise price of the 2012 warrants decreased from </font><font style="font-family:inherit;font-size:10pt;">$10.86</font><font style="font-family:inherit;font-size:10pt;"> per share to </font><font style="font-family:inherit;font-size:10pt;">$10.25</font><font style="font-family:inherit;font-size:10pt;"> per share and the number of shares issuable upon exercise of the warrants increased from </font><font style="font-family:inherit;font-size:10pt;">1,309,785</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">1,387,685</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 15, 2015, we entered into the Note Purchase Agreement with the Additional Investors and, on January 20, 2015, issued and sold to the Additional Investors, in a private placement, the Additional Notes in an aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$925,000</font><font style="font-family:inherit;font-size:10pt;"> (the &#8220;Additional Note Private Placement&#8221;). The Additional Notes have the same terms and conditions as the Initial Note.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Craig-Hallum acted as the sole placement agent for the sale and issuance of the Additional Notes. In connection with the sale and issuance of the Additional Notes, we issued to Craig-Hallum an unsecured convertible promissory note, upon the same terms and conditions as the Notes, in an aggregate principal amount equal to </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;"> of the proceeds received by us pursuant to the sale and issuance of the Additional Notes, or </font><font style="font-family:inherit;font-size:10pt;">$46,250</font><font style="font-family:inherit;font-size:10pt;"> (the &#8220;Placement Agent Note&#8221;). As of the date of filing of this Quarterly Report on form 10-Q, the Placement Agent Note remains outstanding.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Additional Note Private Placement required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of these warrants decreased from </font><font style="font-family:inherit;font-size:10pt;">$10.25</font><font style="font-family:inherit;font-size:10pt;"> per share to </font><font style="font-family:inherit;font-size:10pt;">$9.59</font><font style="font-family:inherit;font-size:10pt;"> per share and the number of shares issuable upon exercise of the warrants increased from </font><font style="font-family:inherit;font-size:10pt;">1,387,685</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">1,483,161</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:6px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 27, 2015, we entered into a purchase agreement with Craig-Hallum (the &#8220;Underwriter&#8221;) relating to our sale and issuance of </font><font style="font-family:inherit;font-size:10pt;">3,573,899</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock and corresponding warrants to purchase up to </font><font style="font-family:inherit;font-size:10pt;">714,780</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock (the &#8220;February 2015 Offering&#8221;). Each share of common stock was sold in combination with a warrant to purchase </font><font style="font-family:inherit;font-size:10pt;">0.20</font><font style="font-family:inherit;font-size:10pt;"> of a share of common stock. The purchase price to the public for each share of common stock and accompanying warrant was </font><font style="font-family:inherit;font-size:10pt;">$1.95</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The purchase price paid by the Underwriter to us for the common stock and accompanying warrants was </font><font style="font-family:inherit;font-size:10pt;">$1.8135</font><font style="font-family:inherit;font-size:10pt;">. The net proceeds from the February 2015 Offering, after deducting the Underwriter&#8217;s discount and other estimated February 2015 Offering expenses, were approximately </font><font style="font-family:inherit;font-size:10pt;">$6.2 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying warrants are exercisable immediately upon their initial issuance date at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$2.24</font><font style="font-family:inherit;font-size:10pt;"> per share and will expire </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years from the date of issuance. The exercise price will also be subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The February 2015 Offering required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of these warrants decreased from </font><font style="font-family:inherit;font-size:10pt;">$9.59</font><font style="font-family:inherit;font-size:10pt;"> per share to </font><font style="font-family:inherit;font-size:10pt;">$7.56</font><font style="font-family:inherit;font-size:10pt;"> per share and the number of shares issuable upon exercise of the warrants increased from </font><font style="font-family:inherit;font-size:10pt;">1,483,161</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">1,881,396</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 30, 2015, we entered into a Securities Purchase Agreement with certain accredited investors (the &#8220;July 2015 Investors&#8221;) pursuant to which, on July 7, 2015, we sold to the July 2015 Investors (a) an aggregate of approximately </font><font style="font-family:inherit;font-size:10pt;">1.5 million</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock at a price per share of </font><font style="font-family:inherit;font-size:10pt;">$1.42</font><font style="font-family:inherit;font-size:10pt;">, (b) warrants (the &#8220;Series B Warrants&#8221;) to purchase up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">0.7 million</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock with an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;"> per share, and (c) warrants (the &#8220;Series A Warrants&#8221; and, together with the Series B Warrants, the &#8220;July 2015 Warrants&#8221;) to purchase up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1.2 million</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock, with an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$1.66</font><font style="font-family:inherit;font-size:10pt;"> per share (collectively, the &#8220;July 2015 Offering&#8221;). Each of the July 2015 Warrants has a term of </font><font style="font-family:inherit;font-size:10pt;">5 and 1/2 years</font><font style="font-family:inherit;font-size:10pt;">. The Series B Warrants were immediately exercisable upon issuance. The Series A Warrants became exercisable on January 7, 2016, </font><font style="font-family:inherit;font-size:10pt;">six months</font><font style="font-family:inherit;font-size:10pt;"> from the date of issuance. The aggregate gross proceeds to us from the July 2015 Offering were approximately </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Craig-Hallum (the &#8220;2015 Placement Agent&#8221;) served as the sole placement agent for the July 2015 Offering. In consideration for services rendered as the placement agent in the July 2015 Offering, we (a) paid to the 2015 Placement Agent cash commissions equal to approximately </font><font style="font-family:inherit;font-size:10pt;">$212,783</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">7.0%</font><font style="font-family:inherit;font-size:10pt;"> of the gross proceeds received in the July 2015 Offering; (b) issued to the 2015 Placement Agent a </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year warrant to purchase up to </font><font style="font-family:inherit;font-size:10pt;">107,033</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock with an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$1.66</font><font style="font-family:inherit;font-size:10pt;"> per share and which is subject to other terms that are the same as the terms of the Series A Warrants; and (c) reimbursed the 2015 Placement Agent for reasonable out-of-pocket expenses, including fees paid to the 2015 Placement Agent&#8217;s legal counsel, incurred in connection with the July 2015 Offering, which reimbursable expenses did not exceed </font><font style="font-family:inherit;font-size:10pt;">$50,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The July 2015 Offering required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of these warrants decreased from </font><font style="font-family:inherit;font-size:10pt;">$7.56</font><font style="font-family:inherit;font-size:10pt;"> per share to </font><font style="font-family:inherit;font-size:10pt;">$6.50</font><font style="font-family:inherit;font-size:10pt;"> per share and the number of shares issuable upon exercise of the warrants increased from </font><font style="font-family:inherit;font-size:10pt;">1,881,396</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">2,188,177</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 6, 2016, we entered into a Securities Purchase Agreement (the &#8220;SPA&#8221;) with certain accredited investors (the &#8220;2016 Investors&#8221;), pursuant to which, on January 8, 2016, we sold to the 2016 Investors, and the 2016 Investors purchased from us (the &#8220;January 2016 Offering&#8221;), an aggregate of approximately </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;"> of units (the &#8220;Units&#8221;) consisting of (a) an aggregate of </font><font style="font-family:inherit;font-size:10pt;">2,365,243</font><font style="font-family:inherit;font-size:10pt;"> shares (the &#8220;A-1 Preferred Shares&#8221;) of our Series A-1 Convertible Preferred Stock (the &#8220;A-1 Preferred&#8221;), and (b) warrants (the &#8220;2016 Warrants&#8221;) to purchase up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1,773,929</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock. Each Unit was sold to the 2016 Investors at a purchase price of </font><font style="font-family:inherit;font-size:10pt;">$0.93</font><font style="font-family:inherit;font-size:10pt;"> per Unit. The A-1 Preferred Shares are convertible into shares of our common stock at an initial rate of 1-for-1, which conversion rate is subject to further adjustment as set forth in our Certificate of Designation of Series A-1 Convertible Preferred Stock, which was filed with the Secretary of State of the State of Delaware on January 8, 2016 (the &#8220;Series A-1 Certificate of Designation&#8221;). Pursuant to the terms of the Series A-1 Certificate of Designation, the holders of the A-1 Preferred Shares will generally be entitled to that number of votes as is equal to the product obtained by multiplying: (i) the number of whole shares of our common stock into which the A-1 Preferred may be converted as of the record date of such vote or consent, by (ii) 0.93, rounded down to the nearest whole number. Therefore, every </font><font style="font-family:inherit;font-size:10pt;">1.075269</font><font style="font-family:inherit;font-size:10pt;"> shares of A-1 Preferred will generally initially be entitled to one vote. In May 2016, </font><font style="font-family:inherit;font-size:10pt;">2,150,538</font><font style="font-family:inherit;font-size:10pt;"> of the A-1 Preferred Shares were converted into </font><font style="font-family:inherit;font-size:10pt;">2,150,538</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock. At June 30, 2016, there were </font><font style="font-family:inherit;font-size:10pt;">214,705</font><font style="font-family:inherit;font-size:10pt;"> A-1 Preferred Shares outstanding.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2016 Warrants were immediately exercisable upon issuance, have a term of </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years and have an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$1.21</font><font style="font-family:inherit;font-size:10pt;"> per share of our common stock. Each 2016 Warrant includes both cash and &#8220;cashless exercise&#8221; features and an exchange feature whereby the holder of the 2016 Warrant may exchange (the &#8220;Exchange Right&#8221;) all or any portion of the 2016 Warrant for a number of shares of our common stock equal to the quotient obtained by dividing the &#8220;Exchange Amount&#8221; by the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrant is exchanged (the &#8220;Exchange Price&#8221;). Under the 2016 Warrants, the &#8220;Exchange Amount&#8221; is based upon a Black Scholes option pricing model, and the aggregate Exchange Amount under all of the 2016 Warrants will be </font><font style="font-family:inherit;font-size:10pt;">$1,436,882</font><font style="font-family:inherit;font-size:10pt;">, subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the date of issuance of the 2016 Warrants and the date the 2016 Warrants are exchanged. Each 2016 Warrant provides that the number of shares that may be issued upon exercise of the Exchange Right is limited to the number of shares that may be purchased pursuant to the terms of the 2016 Warrant, unless we have previously obtained stockholder approval or approval from The Nasdaq Stock Market LLC to issue any additional shares of our common stock (the &#8220;Additional Shares&#8221;) pursuant to the Exchange Right (the &#8220;Required Approvals&#8221;). For any Exchange Right exercised more than </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;"> days following the issuance of the 2016 Warrants, if we have not obtained either of the Required Approvals, we will be required to pay the 2016 Warrant holder an amount in cash for any Additional Shares that we cannot issue without the Required Approvals based on the Exchange Amount.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2016 Warrants further provide that, to the extent the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrant is exchanged is less than </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;">, the Exchange Price will be deemed to be equal to </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;">, and, in addition to issuing shares of our common stock based on this Exchange Price, we will be required to pay to the 2016 Warrant holder an amount in cash equal to the product obtained by multiplying (a) </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;"> minus the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrant is exchanged, by (b) the aggregate number of shares of our common stock issued to the 2016 Warrant holder by the Company in such exchange at an Exchange Price equal to </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;">. Therefore, if the Required Approvals are obtained, based on the Exchange Amount of </font><font style="font-family:inherit;font-size:10pt;">$1,436,882</font><font style="font-family:inherit;font-size:10pt;"> (which, as noted above, is subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the date of the issuance of the 2016 Warrants and the date the 2016 Warrants are exchanged), the maximum number of shares of our common stock issuable pursuant to the Exchange Right in the 2016 Warrants will be </font><font style="font-family:inherit;font-size:10pt;">2,873,765</font><font style="font-family:inherit;font-size:10pt;">. In addition, if, for example, assuming an Exchange Amount of </font><font style="font-family:inherit;font-size:10pt;">$1,436,882</font><font style="font-family:inherit;font-size:10pt;">, the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrants are exchanged is </font><font style="font-family:inherit;font-size:10pt;">$0.25</font><font style="font-family:inherit;font-size:10pt;">, we would be required to pay to the 2016 Warrant holders cash in an aggregate amount of </font><font style="font-family:inherit;font-size:10pt;">$718,441</font><font style="font-family:inherit;font-size:10pt;"> in addition to issuing the 2016 Warrant holders </font><font style="font-family:inherit;font-size:10pt;">2,873,765</font><font style="font-family:inherit;font-size:10pt;"> shares.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with the terms of the SPA, we amended that certain Series A Warrant to purchase up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1,161,972</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock previously issued by us to an affiliate of one of the 2016 Investors on July 7, 2015 (the &#8220;Original Warrant&#8221;), as previously reported by us on our Amendment No. 1 to Current Report on Form 8-K/A, filed with the SEC on July 7, 2015 (as so amended, the &#8220;Amended Warrant&#8221;). The Amended Warrant amends the Original Warrant to provide that the Amended Warrant is subject to the same terms and conditions as the 2016 Warrants and, therefore, includes both cash and &#8220;cashless exercise&#8221; features and an Exchange Right whereby the number of shares issuable pursuant to the Exchange Right is equal to the &#8220;Amended Warrant Exchange Amount&#8221;, which is based on a Black Scholes option pricing model, and will be </font><font style="font-family:inherit;font-size:10pt;">$941,197</font><font style="font-family:inherit;font-size:10pt;">, subject to adjustment to the extent that the risk-free U.S. treasury rate fluctuates between the date of issuance of the Amended Warrant and the date the Amended Warrant is exchanged. The Amended Warrant is exercisable for up to </font><font style="font-family:inherit;font-size:10pt;">1,161,972</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock in the event we have obtained either of the Required Approvals with respect to the Amended Warrant. In the event the Amended Warrant holder exercises the Amended Warrant more than </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;"> days following the issuance of the Amended Warrant, if we have not obtained either of the Required Approvals, we will be required to pay the Amended Warrant holder an amount in cash for the shares of our common stock that we cannot issue under the Amended Warrant pursuant to such exercise without the Required Approvals based on the Amended Warrant Exchange Amount.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Amended Warrant also provides that, to the extent the closing bid price of our common stock on the second trading day prior to the date the Amended Warrant is exchanged is less than </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;">, the Exchange Price will be deemed to be equal to </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;">, and, in addition to issuing shares of our common stock based on this Exchange Price (assuming receipt of the Required Approvals), we will be required to pay to the Amended Warrant holder an amount in cash equal to the product obtained by multiplying (a) </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;"> minus the closing bid price of our common stock on the second trading day prior to the date the Amended Warrant is exchanged, by (b) the aggregate number of shares of our common stock issued to the Amended Warrant holder by us in such exchange at an Exchange Price equal to </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;">. Therefore, if the Required Approvals are obtained, based on the Amended Warrant Exchange Amount of </font><font style="font-family:inherit;font-size:10pt;">$941,197</font><font style="font-family:inherit;font-size:10pt;"> (which, as noted above, is subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the issuance of the Amended Warrant and the date the Amended Warrant is exchanged), the maximum number of shares of our common stock issuable pursuant to the Exchange Right in the Amended Warrant will be </font><font style="font-family:inherit;font-size:10pt;">1,882,395</font><font style="font-family:inherit;font-size:10pt;">. In addition, if, for example, assuming an Amended Warrant Exchange Amount of </font><font style="font-family:inherit;font-size:10pt;">$941,197</font><font style="font-family:inherit;font-size:10pt;">, the closing bid price of our common stock on the second trading day prior to the date the Amended Warrant is exchanged is </font><font style="font-family:inherit;font-size:10pt;">$0.25</font><font style="font-family:inherit;font-size:10pt;">, we would be required to pay to the Amended Warrant holder cash in an aggregate amount of </font><font style="font-family:inherit;font-size:10pt;">$470,599</font><font style="font-family:inherit;font-size:10pt;"> in addition to issuing the Amended Warrant holder </font><font style="font-family:inherit;font-size:10pt;">1,882,395</font><font style="font-family:inherit;font-size:10pt;"> shares.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with entering into the SPA, we also entered into a Registration Rights Agreement, dated January 8, 2016, with the 2016 Investors. Pursuant to the terms of the Registration Rights Agreement, we were required to file with the SEC a registration statement to register for resale the shares of our common stock issuable upon conversion of the A-1 Preferred Shares and the shares of our common stock issuable upon exercise of the 2016 Warrants and the Amended Warrant by January 25, 2016. We filed the required registration statement with the SEC on January 25, 2016.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Craig-Hallum (the &#8220;Placement Agent&#8221;) served as the sole placement agent for the January 2016 Offering. In consideration for services rendered as the Placement Agent in the January 2016 Offering, we (1) paid to the Placement Agent cash commissions equal to approximately </font><font style="font-family:inherit;font-size:10pt;">$140,000</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">7.0%</font><font style="font-family:inherit;font-size:10pt;"> of the gross proceeds received in the January 2016 Offering, excluding any proceeds received from Third Security, LLC or any of its affiliates; (2) issued to the Placement Agent, for a price of </font><font style="font-family:inherit;font-size:10pt;">$50</font><font style="font-family:inherit;font-size:10pt;">, a </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year warrant to purchase up to </font><font style="font-family:inherit;font-size:10pt;">107,527</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$1.21</font><font style="font-family:inherit;font-size:10pt;"> per share (the &#8220;Agent Warrant&#8221;), which is subject to the same terms as the 2016 Warrants except that the Agent Warrant was not exercisable until July 8, 2016 and does not contain the Exchange Right; and (3) reimbursed the Placement Agent for reasonable out-of-pocket expenses, including fees paid to the Placement Agent&#8217;s legal counsel, incurred in connection with the January 2016 Offering, which reimbursable expenses did not exceed </font><font style="font-family:inherit;font-size:10pt;">$50,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The January 2016 Offering and the payment of all accrued and unpaid dividends on the Series A Preferred Stock and Series B Preferred Stock in the form of shares of our common stock at a rate of </font><font style="font-family:inherit;font-size:10pt;">$1.00</font><font style="font-family:inherit;font-size:10pt;"> per share of our common stock discussed under &#8220;-Conversion of Preferred Stock&#8221; below required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of these warrants decreased to </font><font style="font-family:inherit;font-size:10pt;">$4.39</font><font style="font-family:inherit;font-size:10pt;"> per share and the number of shares issuable upon exercise of the warrants increased from </font><font style="font-family:inherit;font-size:10pt;">2,188,177</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">3,239,827</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 31, 2016, we issued to a vendor an aggregate of </font><font style="font-family:inherit;font-size:10pt;">78,000</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock and, on June 14, 2016, we issued to a second vendor an aggregate of </font><font style="font-family:inherit;font-size:10pt;">64,153</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock. Such shares of common stock were issued to the vendors in lieu of an aggregate cash amount of approximately </font><font style="font-family:inherit;font-size:10pt;">$89,000</font><font style="font-family:inherit;font-size:10pt;"> owed by us to such vendors for services previously performed by such vendors. We issued the shares to the vendors in transactions exempt from registration under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder and in reliance on similar exemptions under applicable state laws. The offering of the shares to the vendors did not involve a public offering, and no general solicitation or advertisement was made in connection with the offering of the shares to the vendors.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 7, 2016, we entered into an At the Market Offering Agreement (the &#8220;ATM Agreement&#8221;) with Craig-Hallum, as sales agent, pursuant to which we may offer and sell, from time to time, through Craig-Hallum, up to </font><font style="font-family:inherit;font-size:10pt;">$3,500,000</font><font style="font-family:inherit;font-size:10pt;"> of shares (the &#8220;Shares&#8221;) of our common stock. Any Shares offered and sold in the offering will be issued pursuant to our effective shelf registration statement on Form S-3 (File No. 333-201907) and the related prospectus previously declared effective by the SEC on February 13, 2015, as supplemented by a prospectus supplement, dated June 7, 2016, that we filed with the SEC pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The number of shares eligible for sale under the ATM Agreement will be subject to the limitations of General Instruction I.B.6 of Form S-3.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the ATM Agreement, we will pay Craig-Hallum a placement fee of </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> of the gross sales price of the Shares, unless Craig-Hallum acts as principal, in which case we may sell Shares to Craig-Hallum as principal at a price to be agreed upon by us and Craig-Hallum. We will also reimburse Craig-Hallum for certain expenses incurred in connection with the ATM Agreement, and agreed to provide indemnification and contribution to Craig-Hallum with respect to certain liabilities, including liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three and six months ended June 30, 2016, we sold </font><font style="font-family:inherit;font-size:10pt;">115,314</font><font style="font-family:inherit;font-size:10pt;"> shares under the ATM Agreement.&#160; The average sales price per common share was </font><font style="font-family:inherit;font-size:10pt;">$0.67</font><font style="font-family:inherit;font-size:10pt;"> and the aggregate net proceeds from the sales totaled less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three months ended June 30, 2016, the issuance of shares to our vendors and the sale of shares under the ATM Agreement required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of these warrants decreased to </font><font style="font-family:inherit;font-size:10pt;">$4.36</font><font style="font-family:inherit;font-size:10pt;"> per share and the number of shares issuable upon exercise of the warrants increased from </font><font style="font-family:inherit;font-size:10pt;">3,239,827</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">3,262,088</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock Warrants.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and 2015, we issued warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">2,933,106</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">1,208,491</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, respectively. None of the issued warrants were exercised during such periods. The warrants issued in the six months ended June 30, 2016 included </font><font style="font-family:inherit;font-size:10pt;">1,073,911</font><font style="font-family:inherit;font-size:10pt;"> warrants issued due to repricing requirements of the Private Placement and </font><font style="font-family:inherit;font-size:10pt;">1,881,456</font><font style="font-family:inherit;font-size:10pt;"> warrants issued in connection with the January 2016 Offering. The warrants issued in the six months ended June 30, 2015 included </font><font style="font-family:inherit;font-size:10pt;">493,711</font><font style="font-family:inherit;font-size:10pt;"> warrants issued due to repricing requirements of the Private Placement and </font><font style="font-family:inherit;font-size:10pt;">714,780</font><font style="font-family:inherit;font-size:10pt;"> warrants issued in connection with the February 2015 Offering. Warrants to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">8,876,166</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock were outstanding at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrant Holder</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Issue&#160;Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expiration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Underlying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,832,069</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.36</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Affiliates of Third Security, LLC</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">430,019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.36</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,655</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.00</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Affiliates of Third Security, LLC</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.00</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">April 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">374,618</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.00</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">714,780</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.24</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(5)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122,433</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.66</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(5)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">667,164</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.01</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(6)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,161,972</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Affiliates of Third Security, LLC</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(7)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">161,026</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(7)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,720,430</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,876,166</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;padding-top:8px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with the Private Placement completed in February 2012 and are classified as a liability in our financial statements. See Note 9 - &#8220;Fair Value&#8221; for additional information. These warrants also contain certain anti-dilution provisions that provide for an adjustment to the exercise price and number of shares issuable upon exercise of the warrant in the event that we engage in certain issuances of shares of our common stock at a price lower than the exercise price of the warrant.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with the 2013 Offering, which was completed in January 2013. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with the 2014 Private Placement, which was completed in October 2014.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with the February 2015 Offering, which was completed in February 2015.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(5)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with the July 2015 Offering, which was completed in July 2015.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(6)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were originally issued in connection with the July 2015 Offering, which was completed in July 2015, and were amended in connection with the January 2016 Offering, which was completed in January 2016.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(7)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with the January 2016 Offering, which was completed in January 2016.</font></div></td></tr></table><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Issuance of Series B Preferred Stock.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 5, 2014, we entered into a Series B Convertible Preferred Stock Purchase Agreement (the &#8220;Series B Purchase Agreement&#8221;) with affiliates of Third Security, LLC (the &#8220;2014 Third Security Investors&#8221;), pursuant to which we, in a private placement, sold and issued an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1,443,297</font><font style="font-family:inherit;font-size:10pt;"> shares of our Series B Preferred Stock, par value </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;"> per share (the &#8220;Series B Preferred Stock&#8221;), at a price per share of </font><font style="font-family:inherit;font-size:10pt;">$4.85</font><font style="font-family:inherit;font-size:10pt;"> for an aggregate purchase price of approximately </font><font style="font-family:inherit;font-size:10pt;">$7.0 million</font><font style="font-family:inherit;font-size:10pt;">. Each share of Series B Preferred Stock issued pursuant to the Series B Purchase Agreement was initially convertible into shares of our common stock at a rate of </font><font style="font-family:inherit;font-size:10pt;">1</font><font style="font-family:inherit;font-size:10pt;">-for-1, which conversion rate was subject to further adjustment as set forth in the Certificate of Designation of Series B Convertible Preferred Stock.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Series B financing, we also entered into a Registration Rights Agreement, dated March 5, 2014, with the 2014 Third Security Investors, pursuant to which we granted certain demand, &#8220;piggy-back&#8221; and S-3 registrations rights covering the resale of the shares of common stock underlying the Series B Preferred Stock issued pursuant to the Series B Purchase Agreement and all shares of common stock issuable upon any dividend or other distribution with respect thereto.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Series B financing required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of the warrants decreased from </font><font style="font-family:inherit;font-size:10pt;">$12.96</font><font style="font-family:inherit;font-size:10pt;"> per share to </font><font style="font-family:inherit;font-size:10pt;">$11.73</font><font style="font-family:inherit;font-size:10pt;"> per share and the number of shares issuable upon exercise of the warrants increased from </font><font style="font-family:inherit;font-size:10pt;">1,097,600</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">1,212,665</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Conversion of Preferred Stock.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 6, 2016, the Company entered into a Conversion Agreement (the &#8220;Conversion Agreement&#8221;) with the holders (the &#8220;Preferred Holders&#8221;) of all of the Company&#8217;s outstanding shares of Series A Convertible Preferred Stock, par value </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;"> per share (the &#8220;Series A Preferred Stock&#8221;), and Series B Preferred Stock, pursuant to which, among other things, the Preferred Holders: (a) elected to convert all of the outstanding shares of Series A Preferred Stock and Series B Preferred Stock into shares of our common stock, in each case in accordance with the terms thereof, and (b) agreed that all accrued and unpaid dividends on the Series A Preferred Stock and Series B Preferred Stock would be paid by the Company in shares of our common stock at a rate of </font><font style="font-family:inherit;font-size:10pt;">$1.00</font><font style="font-family:inherit;font-size:10pt;"> per share of our common stock (collectively, the &#8220;Conversion&#8221;).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The outstanding shares of Series A Preferred Stock were convertible into shares of our common stock at a rate of 1-for-3, and the outstanding shares of Series B Preferred Stock were convertible into shares of our common stock at a rate of 1-for-1. Prior to the entry into the Conversion Agreement, there were </font><font style="font-family:inherit;font-size:10pt;">2,586,205</font><font style="font-family:inherit;font-size:10pt;"> shares of Series A Preferred Stock outstanding, which were converted into </font><font style="font-family:inherit;font-size:10pt;">862,057</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock, and </font><font style="font-family:inherit;font-size:10pt;">1,443,297</font><font style="font-family:inherit;font-size:10pt;"> shares of Series B Preferred Stock outstanding, which were converted into </font><font style="font-family:inherit;font-size:10pt;">1,443,297</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock, for an aggregate of </font><font style="font-family:inherit;font-size:10pt;">2,305,354</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock issued upon conversion of the Series A Preferred Stock and Series B Preferred Stock (the &#8220;Conversion Shares&#8221;). At the time of the entry into the Conversion Agreement, there were </font><font style="font-family:inherit;font-size:10pt;">$3,681,591.90</font><font style="font-family:inherit;font-size:10pt;"> in accrued and unpaid dividends on the outstanding shares of Series A Preferred Stock, which were converted, in accordance with the Conversion Agreement, into </font><font style="font-family:inherit;font-size:10pt;">3,681,590</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock, and </font><font style="font-family:inherit;font-size:10pt;">$793,236.17</font><font style="font-family:inherit;font-size:10pt;"> in accrued and unpaid dividends on the outstanding shares of Series B Preferred Stock, which were converted, in accordance with the terms of the Conversion Agreement, into </font><font style="font-family:inherit;font-size:10pt;">793,235</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock, for an aggregate of </font><font style="font-family:inherit;font-size:10pt;">4,474,825</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock issued pursuant to the accrued and unpaid dividends on the Series A Preferred Stock and Series B Preferred Stock. Therefore, in connection with the full conversion of the Series A Preferred Stock and Series B Preferred Stock, plus the conversion of all accrued and unpaid dividends thereon, we issued an aggregate of </font><font style="font-family:inherit;font-size:10pt;">6,780,179</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock to the Preferred Holders on January 6, 2016.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following the conversion of the shares of Series A Preferred Stock and Series B Preferred Stock into common stock, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> shares of Series A Preferred Stock or Series B Preferred Stock remain outstanding.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preferred Stock Dividends.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> We had cumulative undeclared dividends on our Series A Preferred Stock and Series B Preferred Stock of </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4.4 million</font><font style="font-family:inherit;font-size:10pt;"> at June 30, 2016 and December 31, 2015, respectively. Since dividends should generally not be recognized as a liability until declared, we had a recorded liability of zero for these undeclared dividends.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We had no undeclared dividends for the three months ended June 30, 2016. For the three months ended June 30, 2015 and the six months ended June 30, 2016 and 2015, we had undeclared dividends. In accordance with the FASB&#8217;s Accounting Standards Codification Topic 260-10-45-11, &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Earnings per Share</font><font style="font-family:inherit;font-size:10pt;">&#8221;, these dividends were added to the net loss per share calculation.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:4px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While payment terms are generally </font><font style="font-family:inherit;font-size:10pt;">30 days</font><font style="font-family:inherit;font-size:10pt;">, we have also provided extended payment terms in certain cases. Accounts receivable are carried at original invoice amount and shown net of allowance for doubtful accounts. The estimate made for doubtful accounts is based on a review of all outstanding amounts on a quarterly basis. We determine the allowance for doubtful accounts by regularly evaluating individual payor receivables and considering a payor&#8217;s financial condition, credit history, reimbursement rates and current economic conditions. Accounts receivable are written off when deemed uncollectible and after all collection efforts have been exhausted. Recoveries of accounts receivable previously written off are recorded as a reduction in bad debt expense when received.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of net sales and expenses during the reporting period. In addition, estimates and assumptions associated with the determination of the fair value of certain assets and related impairments require considerable judgment by management. Actual results could differ from the estimates and assumptions used in preparing these condensed consolidated financial statements.</font></div></div> EX-101.SCH 5 tbio-20160630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2101100 - Disclosure - BUSINESS DESCRIPTION link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - BUSINESS DESCRIPTION (Details) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 2408401 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1001001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICALS) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - DEBT (Convertible Promissory Notes) (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - DEBT (Revolving Line and Term Loan) (Details) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - DEBT (Schedule of Debt) (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - DISCONTINUED OPERATIONS link:presentationLink link:calculationLink link:definitionLink 2405405 - Disclosure - DISCONTINUED OPERATIONS (Allowance for Doubtful Accounts) (Details) link:presentationLink link:calculationLink link:definitionLink 2405404 - Disclosure - DISCONTINUED OPERATIONS (Assets and Liabilities Held for Sale) (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - DISCONTINUED OPERATIONS (Narratives) (Details) link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - DISCONTINUED OPERATIONS (Revenues and Net Income (Loss)) (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - DISCONTINUED OPERATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - DOCUMENT AND ENTITY INFORMATION link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - FAIR VALUE link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - FAIR VALUE (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - FAIR VALUE (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 2409401 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - INTANGIBLES AND OTHER ASSETS link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - INTANGIBLES AND OTHER ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - INTANGIBLES AND OTHER ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - STOCK OPTIONS link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - STOCK OPTIONS (Stock Appreciation Rights) (Details) link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - STOCK OPTIONS (Stock Options) (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - STOCK OPTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - STOCKHOLDERS' EQUITY (Common Stock) (Details) link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - STOCKHOLDERS' EQUITY (Common Stock Warrants) (Details) link:presentationLink link:calculationLink link:definitionLink 2410405 - Disclosure - STOCKHOLDERS' EQUITY (Conversion of Preferred Stock) (Details) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - STOCKHOLDERS' EQUITY (Issuance of Series B Preferred Stock) (Details) link:presentationLink link:calculationLink link:definitionLink 2410406 - Disclosure - STOCKHOLDERS' EQUITY (Preferred Stock Dividends) (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Accounts Receivable) (Details) link:presentationLink link:calculationLink link:definitionLink 2402405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Inventories) (Details) link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narratives) (Details) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 2402406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Property, Plant and Equipment) (Details) link:presentationLink link:calculationLink link:definitionLink 2302302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 tbio-20160630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 tbio-20160630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 tbio-20160630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Fair Value Disclosures [Abstract] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Liability Class [Axis] Liability Class [Axis] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] 2012 Warrant Liability 2012 Warrant Liability [Member] 2012 Warrant Liability [Member] 2016 Warrant Liability 2016 Warrant Liability [Member] 2016 Warrant Liability [Member] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Common stock warrants issued (in shares) Class of Warrant or Right, Number of Issued Warrants or Rights Class of Warrant or Right, Number of Issued Warrants or Rights Share price (in dollars per share) Share Price Stock options, fair value assumptions, expected life Issuance of Warrants, Expected Exercise Period Issuance of Warrants, Expected Exercise Period Volatility (as a percent) Fair Value Assumptions, Expected Volatility Rate Risk-free interest rate (as a percent) Fair Value Assumptions, Risk Free Interest Rate Fair value assumptions, expected term Fair Value Assumptions, Expected Term Percentage of simulated equity values below the down-round financing cut-off point Fair Value Assumptions, Percentage of Simulated Equity Values Below the Down-Round Financing Cut-Off Point Fair Value Assumptions, Percentage of Simulated Equity Values Below the Down-Round Financing Cut-Off Point Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Beginning balance Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Additions Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases Total (gains) or losses: Total gains or losses [Abstract] Total gains or losses [Abstract] Recognized in earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Balance at end of period Accounting Policies [Abstract] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Reclassification Reclassification, Policy [Policy Text Block] Principles of Consolidation Consolidation, Policy [Policy Text Block] Risks and Uncertainties Risks and Uncertainties [Policy Text Block] Risks and Uncertainties [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Fair Value Fair Value Measurement, Policy [Policy Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Concentrations of Cash Concentration of Cash Policy [Policy Text Block] Concentration of Cash Policy [Policy Text Block] Accounts Receivable Trade and Other Accounts Receivable, Policy [Policy Text Block] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Intangible Assets Goodwill and Intangible Assets, Policy [Policy Text Block] Stock-Based Compensation Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Net Sales Recognition Revenue Recognition, Policy [Policy Text Block] Common Stock Warrants Common stock warrants [Policy Text Block] Common stock warrants [Policy Text Block] Loss Per Share Earnings Per Share, Policy [Policy Text Block] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] FAIR VALUE Financial Instruments Disclosure [Text Block] Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Discontinued Operations and Disposal Groups [Abstract] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Discontinued operations Discontinued Operations [Member] Disposal Group Name [Axis] Disposal Group Name [Axis] Disposal Group Name [Domain] Disposal Group Name [Domain] Genetic Assays and Platforms and Patient Testing Genetic Assays and Platforms and Patient Testing [Member] Genetic Assays and Platforms and Patient Testing [Member] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] ASSETS Disposal Group, Including Discontinued Operation, Assets [Abstract] Accounts receivable, net Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net Other current assets Disposal Group, Including Discontinued Operation, Other Assets, Current Total Assets Disposal Group, Including Discontinued Operation, Assets LIABILITIES Disposal Group, Including Discontinued Operation, Liabilities [Abstract] Accrued compensation Disposal Group, Including Discontinued Operation, Accrued Employee-Related Liabilities, Current Disposal Group, Including Discontinued Operation, Accrued Employee-related Liabilities, Current Total Liabilities Disposal Group, Including Discontinued Operation, Liabilities Disclosure of Compensation Related Costs, Share-based Payments [Abstract] STOCK OPTIONS Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Net raw materials inventory Inventory, Raw Materials, Net of Reserves Obsolete inventory [Roll Forward] Obsolete inventory [Roll Forward] Obsolete inventory [Roll Forward] Beginning Balance Inventory Valuation Reserves Additions Inventory, Additions Inventory, Additions Deductions Inventory Write-down Ending Balance Allowance for Doubtful Accounts Receivable [Roll Forward] Allowance for Doubtful Accounts Receivable [Roll Forward] Beginning balance Allowance for Doubtful Accounts Receivable Additions Provision for Doubtful Accounts, Excluding Amounts Not Included in Provision Provision for Doubtful Accounts, Excluding Amounts Not Included in Provision Deductions Allowance for Doubtful Accounts Receivable, Write-offs Ending balance Accounts receivable, general payment terms Accounts Receivable, General Payment Terms1 Accounts Receivable, General Payment Terms1 Debt Disclosure [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Convertible notes payable Convertible Notes Payable [Member] Debt Instrument, Conversion, Period [Axis] Debt Instrument, Conversion, Period [Axis] Debt Instrument, Conversion, Period [Axis] Debt Instrument, Conversion, Period [Domain] Debt Instrument, Conversion, Period [Domain] [Domain] for Debt Instrument, Conversion, Period [Axis] Conversion, period one Debt Instrument, Conversion, Period One [Member] Debt Instrument, Conversion, Period One [Member] Conversion, period two Debt Instrument, Conversion, Period Two [Member] Debt Instrument, Conversion, Period Two [Member] Sale of Stock [Axis] Sale of Stock [Axis] Sale of Stock [Domain] Sale of Stock [Domain] Additional notes Additional Note Private Placement [Member] Additional Note Private Placement [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Face amount Debt Instrument, Face Amount Interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Percentage of debt convertible Debt Instrument, Convertible, Percentage of Debt Debt Instrument, Convertible, Percentage of Debt Threshold consecutive trading days Debt Instrument, Convertible, Threshold Consecutive Trading Days Conversion price (in dollars per share) Debt Instrument, Convertible, Conversion Price Conversion price as percentage of average closing price Debt Instrument, Convertible, Conversion Percentage of Average Closing Price Debt Instrument, Convertible, Conversion Percentage of Average Closing Price Number of shares converted Debt Conversion, Converted Instrument, Shares Issued Number of additional accredited investors Debt Instrument, Number of Additional Accredited Investors Debt Instrument, Number of Additional Accredited Investors Conversion of convertible promissory notes Debt Conversion, Converted Instrument, Amount Goodwill and Intangible Assets Disclosure [Abstract] Schedule of Indefinite-Lived and Finite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived and Finite-Lived Intangible Assets [Table] [Table] Schedule of Indefinite-Lived and Finite-Lived Intangible Assets [Table] [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Patents Patents [Member] Intellectual property Intellectual Property [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets, Net [Abstract] Finite-Lived Intangible Assets, Net [Abstract] Cost Finite-Lived Intangible Assets, Gross Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Net Book Value Finite-Lived Intangible Assets, Net Estimated Useful Life Finite-Lived Intangible Asset, Useful Life Amortization expense for intangible assets Amortization of Intangible Assets Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Amortization expense, 2016 Finite-Lived Intangible Assets, Amortization Expense, Current Fiscal Year Finite-Lived Intangible Assets, Amortization Expense, Current Fiscal Year Amortization expense, 2017 Finite-Lived Intangible Assets, Amortization Expense, Year Two Amortization expense, 2018 Finite-Lived Intangible Assets, Amortization Expense, Year Three Amortization expense, 2019 Finite-Lived Intangible Assets, Amortization Expense, Year Four Amortization expense, 2020 Finite-Lived Intangible Assets, Amortization Expense, Year Five Income Statement [Abstract] Statement [Table] Statement [Table] Operating Activities [Axis] Operating Activities [Axis] Operating Activities [Domain] Operating Activities [Domain] Continuing operations Continuing Operations [Member] Statement [Line Items] Statement [Line Items] NET SALES Revenue, Net COST OF GOODS SOLD Cost of Goods and Services Sold Gross profit Gross Profit OPERATING EXPENSES: Operating Expenses [Abstract] Selling, general and administrative Selling, General and Administrative Expense Research and development Research and Development Expense Operating Expenses Operating Expenses OPERATING LOSS FROM CONTINUING OPERATIONS Operating Income (Loss) OTHER INCOME (EXPENSE): Nonoperating Income (Expense) [Abstract] Interest expense, net Interest income and (expense), net Interest income and (expense), net Warrant revaluation Gain (Loss) On Stock Warrants Revaluation Other, net Other Nonoperating Income (Expense) Other Income (Expense) Other Income (Expense) Other Income (Expense) LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest INCOME TAX BENEFIT Income Tax Expense (Benefit) LOSS FROM CONTINUING OPERATIONS Income (Loss) from Continuing Operations Attributable to Parent INCOME (LOSS) FROM DISCONTINUED OPERATIONS, NET OF TAXES Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent NET LOSS Net Income (Loss) Attributable to Parent PREFERRED STOCK DIVIDENDS Preferred Stock Dividends, Income Statement Impact NET LOSS AVAILABLE TO COMMON STOCKHOLDERS Net Income (Loss) Available to Common Stockholders, Basic BASIC AND DILUTED LOSS PER COMMON SHARE (IN DOLLARS PER SHARE) Earnings Per Share, Basic and Diluted BASIC AND DILUTED WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING (IN SHARES) Weighted Average Number of Shares Outstanding, Basic and Diluted Equity [Abstract] Conversion of Stock [Table] Conversion of Stock [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock Common Stock [Member] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Series A Preferred Stock Series A Preferred Stock [Member] Series B preferred stock Series B Preferred Stock [Member] Series A-1 Convertible Preferred Stock and Warrants Series A-1 Convertible Preferred Stock and Warrants [Member] Series A-1 Convertible Preferred Stock and Warrants [Member] Conversion of Stock [Line Items] Conversion of Stock [Line Items] Conversion ratio Stockholders' Equity Note, Conversion Ratio Stockholders' Equity Note, Conversion Ratio Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Dividend conversion rate per share Preferred Stock, Dividend Conversion Rate, Per Share Preferred Stock, Dividend Conversion Rate, Per Share Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Number of common stock converted into Conversion of Stock, Shares Issued Amount of preferred dividends in arrears Preferred Stock, Amount of Preferred Dividends in Arrears Number of shares of common stock dividends Common Stock Dividends, Shares Private placement, net (in shares) Stock Issued During Period, Shares, New Issues Lender Name [Axis] Lender Name [Axis] Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Third Security LLC and affiliates Third Security LLC And Affiliates [Member] Third Security LLC And Affiliates [Member] PGxHealth, LLC PGxHealth, LLC [Member] PGxHealth, LLC [Member] Line of credit Line of Credit [Member] Term loan Term Loan [Member] Term Loan [Member] Senior secured promissory note Senior Notes [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Revolving credit facility Revolving Credit Facility [Member] Current borrowing capacity Line of Credit Facility, Current Borrowing Capacity Debt term of note payable that was paid off Debt Instrument, Term Interest costs capitalized Interest Costs Capitalized Initial prepayment of a portion of the loan balance Principal Amount Outstanding of Loans, Initial Prepayment Principal Amount Outstanding of Loans, Initial Prepayment Payment to lenders to support the amount advanced Repayments of Long-term Lines of Credit Repayments of Notes Payable Repayments of Notes Payable Proceeds from borrowings Proceeds from Notes Payable Overadvance on Loan Agreement Long-term Debt, Current Maturities Convertible promissory notes Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] Wall Street Journal prime rate Wall Street Journal Prime Rate [Member] Wall Street Journal Prime Rate [Member] Total debt Debt and Capital Lease Obligations Current portion of long-term debt Long-term debt, net of current maturities Long-term Debt, Excluding Current Maturities Annual interest rate (as a percent) Basis spread on variable rate (as a percent) Debt Instrument, Basis Spread on Variable Rate Effective interest rate (as a percent) Debt Instrument, Interest Rate, Effective Percentage Commitment fee amount Line of Credit Facility, Commitment Fee Amount Commitment fee (as a percent) Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Proceeds from issuance of long-term debt Proceeds from Issuance of Long-term Debt Current interest rate (as a percent) Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate Future debt extinguishment costs Debt Instrument, Future Debt Extinguishment Costs Debt Instrument, Future Debt Extinguishment Costs Prepayment penalty percentage of outstanding balance (as a percent) Debt Instrument, Prepayment Penalty Percent Debt Instrument, Prepayment Penalty Percent Increase in interest rate in case of debt default (as a percent) Debt Instrument, Debt Default, Interest Rate, Stated Percentage Increase Debt Instrument, Debt Default, Interest Rate, Stated Percentage Increase Statement of Cash Flows [Abstract] CASH FLOWS USED IN OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Less income from discontinued operations, net of tax Loss from continuing operations Adjustments to reconcile net loss to net cash flows used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Stock-based compensation Share-based Compensation Provision for losses on doubtful accounts Provision for Doubtful Accounts Warrant revaluation Fair Value Adjustment of Warrants Loss on sale of fixed assets Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Deferred interest Increase (Decrease) in Interest Payable, Net Deferred tax provision Increase (Decrease) in Deferred Income Taxes Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Other current assets Increase (Decrease) in Prepaid Expense and Other Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued expenses and other liabilities Increase (Decrease) in Other Accounts Payable and Accrued Liabilities Net cash used in continuing operations Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash provided by (used in) discontinued operations Cash Provided by (Used in) Operating Activities, Discontinued Operations Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities CASH FLOWS PROVIDED BY (USED IN) INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Other assets Payments for (Proceeds from) Other Investing Activities Net cash used in continuing operations Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash provided by discontinued operations Cash Provided by (Used in) Investing Activities, Discontinued Operations Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities CASH FLOWS PROVIDED BY FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Principal payments on capital lease obligations Repayments of Long-term Capital Lease Obligations Issuance of preferred stock, net Proceeds from Issuance of Preferred Stock and Preference Stock Issuance of common stock, net Proceeds from Issuance of Common Stock Principal payment on note payable Net cash flows provided by financing activities Net Cash Provided by (Used in) Financing Activities EFFECT OF FOREIGN CURRENCY EXCHANGE RATE CHANGES ON CASH Effect of Exchange Rate on Cash and Cash Equivalents NET CHANGE IN CASH AND CASH EQUIVALENTS Cash and Cash Equivalents, Period Increase (Decrease) CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD Cash and Cash Equivalents, at Carrying Value CASH AND CASH EQUIVALENTS AT END OF PERIOD SUPPLEMENTAL CASH FLOW INFORMATION Supplemental Cash Flow Information [Abstract] Cash paid during the period for: Cash Paid During The Period For: [Abstract] Cash Paid During The Period For: [Abstract] Interest Interest Paid Stockholders' Equity Note [Abstract] STOCKHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] Schedule of stockholders' equity, including warrants and rights Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Number of operating segments Number of Operating Segments Working capital Working Capital (Deficiency) Working Capital (Deficiency) Statement of Financial Position [Abstract] ASSETS Assets [Abstract] CURRENT ASSETS: Assets, Current [Abstract] Cash and cash equivalents Accounts receivable, net Accounts Receivable, Net, Current Inventories, net Inventory, Net Other current assets Other Assets, Current Assets held for sale Disposal Group, Including Discontinued Operation, Assets, Current Total current assets Assets, Current PROPERTY AND EQUIPMENT: Property, Plant and Equipment [Abstract] Equipment Machinery and Equipment, Gross Furniture, fixtures & leasehold improvements Furniture Fixtures And Leasehold Improvements Gross Furniture Fixtures And Leasehold Improvements Gross Property and equipment, gross Property, Plant and Equipment, Gross Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, net Property, Plant and Equipment, Net OTHER ASSETS: Assets, Noncurrent [Abstract] Intangibles, net Intangible Assets, Net (Excluding Goodwill) Other assets Other Assets, Noncurrent Assets Assets LIABILITIES AND STOCKHOLDERS’ DEFICIT Liabilities and Equity [Abstract] CURRENT LIABILITIES: Liabilities, Current [Abstract] Current maturities of long-term debt Accounts payable Accounts Payable, Current Accrued compensation Employee-related Liabilities, Current Accrued expenses Accrued Liabilities, Current Deferred revenue Deferred Revenue, Current Other liabilities Other Liabilities, Current Liabilities held for sale Disposal Group, Including Discontinued Operation, Liabilities, Current Total current liabilities Liabilities, Current LONG TERM LIABILITIES: Liabilities, Noncurrent [Abstract] Common stock warrant liability Warrants and Rights Outstanding Other long-term liabilities Other Liabilities, Noncurrent Total liabilities Liabilities STOCKHOLDERS’ DEFICIT: Stockholders' Equity Attributable to Parent [Abstract] Convertible preferred stock, $0.01 par value, 15,000,000 shares authorized, 214,705 and 4,029,502 shares issued and outstanding, respectively Preferred Stock, Value, Issued Common stock, $0.01 par value, 150,000,000 shares authorized, 23,103,875 and 13,915,691 shares issued and outstanding, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated deficit Retained Earnings (Accumulated Deficit) Total stockholders’ deficit Stockholders' Equity Attributable to Parent Liabilities and stockholders' equity Liabilities and Equity Cumulative undeclared dividends, preferred stock Dividends, Preferred Stock, Cash, Not Declared Dividends, Preferred Stock, Cash, Not Declared Schedule of changes in fair value of liability Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] INTANGIBLES AND OTHER ASSETS Intangibles And Other Assets [Text Block] Intangibles And Other Assets [Text Block] Income Tax Disclosure [Abstract] INCOME TAXES Income Tax Disclosure [Text Block] Statement of Comprehensive Income [Abstract] Net Loss Other comprehensive loss - foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Comprehensive Loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Private Placement Private Placement [Member] Offering Offering [Member] Offering [Member] Warranty Holders and Issuance [Axis] Warranty Holders and Issuance [Axis] Warranty Holders and Issuance [Axis] Warranty Holders and Issuance [Domain] Warranty Holders and Issuance [Domain] Warranty Holders and Issuance [Domain] Various Institutional Holders; February 2017 Various Institutional Holders; February 2017 [Member] Various Institutional Holders; February 2017 [Member] Affiliates of Third Security, LLC; February 2017 Affiliates of Third Security, LLC; February 2017 [Member] Affiliates of Third Security, LLC; February 2017 [Member] Various Institutional Holders; January 2018 Various Institutional Holders; January 2018 [Member] Various Institutional Holders; January 2018 [Member] Affiliates of Third Security, LLC; January 2018 Affiliates of Third Security, LLC; January 2018 [Member] Affiliates of Third Security, LLC; January 2018 [Member] Various Institutional Holders; April 2020 Various Institutional Holders; April 2020 [Member] Various Institutional Holders; April 2020 [Member] Various Institutional Holders; February 2020 Various Institutional Holders; February 2020 [Member] Various Institutional Holders; February 2020 [Member] Various Institutional Holders; December 2020 Various Institutional Holders; December 2020 One [Member] Various Institutional Holders; December 2020 One [Member] Various Institutional Holders; December 2020 Various Institutional Holders; December 2020 Two [Member] Various Institutional Holders; December 2020 Two [Member] Various Institutional Holders; January 2021 Various Institutional Holders; January 2021 One [Member] Various Institutional Holders; January 2021 One [Member] Affiliates of Third Security, LLC; January 2021 Affiliates of Third Security, LLC; January 2021 [Member] Affiliates of Third Security, LLC; January 2021 [Member] Various Institutional Holders; January 2021 Various Institutional Holders; January 2021 Two [Member] Various Institutional Holders; January 2021 Two [Member] Class of Stock [Line Items] Class of Stock [Line Items] Underlying Shares Class of Warrant or Right, Outstanding Exercise Price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] Loss Contingencies [Table] Loss Contingencies [Table] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] UNMC University of Nebraska [Member] University of Nebraska [Member] Mount Sinai Icahn School of Medicine [Member] Icahn School of Medicine [Member] Litigation Status [Axis] Litigation Status [Axis] Litigation Status [Domain] Litigation Status [Domain] Threatened Litigation Threatened Litigation [Member] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Breach of contract Performance Guarantee [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Damages sought in a lawsuit Loss Contingency, Damages Sought, Value Accrual of possible loss in a lawsuit Loss Contingency, Estimate of Possible Loss Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] Future minimum payments due, remainder of 2016 Operating Leases, Future Minimum Payments, Remainder of Fiscal Year Future minimum payments due, 2017 Operating Leases, Future Minimum Payments, Due in Two Years Future minimum payments due, 2018 Operating Leases, Future Minimum Payments, Due in Three Years Future minimum payments due, 2019 Operating Leases, Future Minimum Payments, Due in Four Years Future minimum payments due, 2020 Operating Leases, Future Minimum Payments, Due in Five Years Future minimum payments, due thereafter Operating Leases, Future Minimum Payments, Due Thereafter Rent expense Operating Leases, Rent Expense, Net Firm commitments to vendors Purchase Commitment, Remaining Minimum Amount Committed Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Employee Stock Option Employee Stock Option [Member] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Equity Incentive Plan 2006 Equity Incentive Plan 2006 [Member] Equity Incentive Plan 2006 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Outstanding at beginning of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Outstanding at end of period (in shares) Exercisable at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Weighted-Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Outstanding at beginning of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Forfeited (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Outstanding at end of period (in dollars per share) Exercisable at end of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Stock options, expected to vest, outstanding (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Stock options, expected to vest, outstanding, aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Preferred stock Preferred Stock [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Maximum Maximum [Member] Minimum Minimum [Member] Private placement, net Stock Issued During Period, Value, New Issues Common stock warrant, exercise price (in dollars per share) Common stock warrant, common stock called (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Summary of stock option activity Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Summary of SARs activity Schedule of Other Share-based Compensation, Activity [Table Text Block] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares issued (in shares) Common Stock, Shares, Issued Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Selling, General and Administrative Expenses Selling, General and Administrative Expenses [Member] Title of Individual [Axis] Title of Individual [Axis] Relationship to Entity [Domain] Relationship to Entity [Domain] Executive Officers Executive Officer [Member] Business segments Segments [Axis] Segments Segments [Domain] Pharmacogenomic Services Pharmacogenomic services [Member] Pharmacogenomic services [Member] Current prepaid expense Prepaid Expense, Current Other current receivables Other Receivables, Net, Current Share-based compensation arrangement by share-based payment award, expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Stock options, unvested options, vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Stock-based compensation expense Unrecognized compensation expense related to unvested stock awards, not yet recognized Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Unvested stock options, unrecognized compensation expense weighted average recognition period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Stock options, granted (in shares) Stock options, fair value assumptions, risk free interest rate (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Stock options, fair value assumptions, dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Stock options, fair value assumptions, expected life Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Stock options, fair value assumptions, historical volatility rate (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Common stock rights issued (in shares) Deferred revenue Options, warrants and conversion rights, common stock callable and antidilutive (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Schedule of Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Leasehold Improvements Leasehold Improvements [Member] Furniture and Fixtures Furniture and Fixtures [Member] Production Equipment Other Machinery and Equipment [Member] Computer Equipment Computer Equipment [Member] Research and Development Equipment Other Capitalized Property Plant and Equipment [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property and equipment, estimated useful lives Property, Plant and Equipment, Useful Life Depreciation expense Depreciation ADSTEC Corporation ADSTEC Corporation [Member] ADSTEC Corporation [Member] Genetic Assays and Platforms business Genetic Assays And Platforms Business [Member] Genetic Assays And Platforms Business [Member] Patient Testing [Member] Patient Testing [Member] Patient Testing [Member] Purchase price Disposal Group, Including Discontinued Operation, Consideration (Loss) gain on sale of business Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax Statement of Stockholders' Equity [Abstract] Private Placement Preferred Stock Additional Paid-in Capital Additional Paid-in Capital [Member] Accumulated Deficit Retained Earnings [Member] Accumulated Other Comprehensive Income AOCI Attributable to Parent [Member] Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance at beginning of period (in shares) Shares, Outstanding Balance at beginning of period Net loss Foreign currency translation adjustment Stock-based compensation Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock issued during period (in shares) Stock issued during period Dividends on preferred stock Dividends, Preferred Stock, Cash Conversion of preferred stock and preferred stock dividends (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Conversion of preferred stock and preferred stock dividends Stock Issued During Period, Value, Conversion of Convertible Securities Balance at end of period (in shares) Balance at end of period Disposal Group, Including Discontinued Operations, Allowance for Doubtful Accounts [Roll Forward] Disposal Group, Including Discontinued Operations, Allowance for Doubtful Accounts [Roll Forward] Disposal Group, Including Discontinued Operations, Allowance for Doubtful Accounts [Roll Forward] Beginning Balance Disposal Group, Including Discontinued Operations, Allowance for Doubtful Accounts Receivable Disposal Group, Including Discontinued Operations, Allowance for Doubtful Accounts Receivable Additions Disposal Group, Including Discontinued Operation, Provision for Doubtful Accounts Disposal Group, Including Discontinued Operation, Provision for Doubtful Accounts Deductions Disposal Group, Including Discontinued Operation, Allowance for Doubtful Accounts Receivable, Write-offs Disposal Group, Including Discontinued Operation, Allowance for Doubtful Accounts Receivable, Write-offs Ending Balance BUSINESS DESCRIPTION Business Description and Basis of Presentation [Text Block] Schedule of long-lived intangible assets Schedule of Indefinite-Lived and Finite-Lived Intangible Assets [Table Text Block] Schedule of Indefinite-Lived and Finite-Lived Intangible Assets [Table Text Block] DISCONTINUED OPERATIONS Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Summary of activity for the allowance for doubtful accounts Allowance for Credit Losses on Financing Receivables [Table Text Block] Activity for the allowance for obsolete inventory Activity for the allowance for obsolete inventory [Table Text Block] Activity for the allowance for obsolete inventory [Table Text Block] Schedule of property and equipment, useful lives Property, Plant and Equipment [Table Text Block] Document and Entity Information [Abstract] Document and Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding SARs Stock Appreciation Rights (SARs) [Member] Number of SARs Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Outstanding (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercisable, Number Weighted-Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Outstanding (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Exercisable (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercisable, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercisable, Weighted Average Grant Date Fair Value Stock appreciation rights, nonvested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Stock appreciation rights, aggregate intrinsic value, outstanding Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Schedule of discontinued operations impact on income statement and balance sheets Disposal Groups, Including Discontinued Operations [Table Text Block] Net sales Disposal Group, Including Discontinued Operation, Revenue Cost of goods sold Disposal Group, Including Discontinued Operation, Costs of Goods Sold Gross profit Disposal Group, Including Discontinued Operation, Gross Profit (Loss) Selling, general and administrative expense Disposal Group, Including Discontinued Operation, Selling, General And Administrative Expense Disposal Group, Including Discontinued Operation, Selling, General And Administrative Expense Research and development expense Disposal Group, Including Discontinued Operation, Research and Development Expense Disposal Group, Including Discontinued Operation, Research and Development Expense Operating income (loss) from discontinued operations Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, before Income Tax Gain on sale of business/assets Income (loss) from discontinued operations before income taxes Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax Income tax expense Discontinued Operation, Tax Effect of Discontinued Operation Income (loss) from discontinued operations, net of taxes DEBT Debt Disclosure [Text Block] Income tax expense (benefit) Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Pro Forma Pro Forma [Member] Series A-1 Convertible Preferred Stock Series A-1 Convertible Preferred Stock [Member] Series A-1 Convertible Preferred Stock [Member] At the Market Offering [Member] At the Market Offering [Member] At the Market Offering [Member] 2014 Private Placement Two Thousand Fourteen Private Placement [Member] Two Thousand Fourteen Private Placement [Member] Additional Note Private Placement 2015 Offering Two Thousand Fifteen Offering [Member] Two Thousand Fifteen Offering [Member] Series A Warrants Series A Warrants [Member] Series A Warrants [Member] Series A Warrant, Cashless Exchange Series A Warrant, Cashless Exchange [Member] Series A Warrant, Cashless Exchange [Member] Series A-1 Warrant Series A-1 Warrant [Member] Series A-1 Warrant [Member] Series B Warrants Series B Warrants [Member] Series B Warrants [Member] Warrants Series A and Series B Warrants [Member] Series A and Series B Warrants [Member] Weighted Average Weighted Average [Member] Advisor Advisor [Member] Advisor [Member] Craig-Hallum Capital Group LLC Craig-Hallum Capital Group LLC [Member] Craig-Hallum Capital Group LLC [Member] Proceeds from issuance of common stock and convertible notes Proceeds from issuance of common stock and convertible notes Proceeds from issuance of common stock and convertible notes Common stock, sale price per share (in dollars per share) Sale of Stock, Price Per Share Warrants term Class of Warrant or Right, Exercise Term1 Class of Warrant or Right, Exercise Term1 Convertible notes, common stock callable (in shares) Convertible notes, Number of Securities Called by Note Convertible notes, Number of Securities Called by Note Convertible notes, warrants callable (in shares) Convertible Notes, Number of Warrants Called by Notes Convertible Notes, Number of Warrants Called by Notes Payments of stock issuance costs Payments of Stock Issuance Costs Payments of stock issuance costs, percentage of gross offering proceeds Payments of Stock Issuance Costs, Percentage of Gross Offering Proceeds Payments of Stock Issuance Costs, Percentage of Gross Offering Proceeds Payments of stock issuance costs, warrant right to purchase common stock shares Payments of Stock Issuance Costs, Warrant Right To Purchase Common Stock Shares Payments of Stock Issuance Costs, Warrant Right To Purchase Common Stock Shares Payments of stock issuance costs, warrant right to purchase common stock shares, percentage of shares in offering Payments of Stock Issuance Costs, Warrant Right To Purchase Common Stock Shares, Percentage of Shares in Offering Payments of Stock Issuance Costs, Warrant Right To Purchase Common Stock Shares, Percentage of Shares in Offering Stock issuance costs, reimbursable expenses (not to exceed) Stock Issuance Costs, Reimbursable Expenses Stock Issuance Costs, Reimbursable Expenses Payments of stock issuance costs, reduction to equity Payments of Stock Issuance Costs, Reduction To Equity Payments of Stock Issuance Costs, Reduction To Equity Payments for Repurchase of Warrants Payments for Repurchase of Warrants Class of warrant or right, number of securities called by warrants or rights, price per share (in dollars per share) Class of Warrant or Right, Number of Securities Called by Warrants or Rights, Price Per Share Class of Warrant or Right, Number of Securities Called by Warrants or Rights, Price Per Share Face amount as percentage of proceeds from debt issuance Debt Instrument, Face Amount, Percentage of Proceeds from Debt Issuance Debt Instrument, Face Amount, Percentage of Proceeds from Debt Issuance Class of warrant or right, number of securities called by each warrant or right (in shares) Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Class of warrant or right, purchase price per share, public (in dollars per share) Class of Warrant or Right, Purchase Price Per Unit, Public Class of Warrant or Right, Purchase Price Per Unit, Public Class of warrant or right, purchase price per share, underwriter (in dollars per share) Class of Warrant or Right, Purchase Price Per Unit, Underwriter Class of Warrant or Right, Purchase Price Per Unit, Underwriter Proceeds from issuance of common stock and warrants, net Proceeds from Issuance of Common Stock and Warrants, Net Proceeds from Issuance of Common Stock and Warrants, Net Class of warrant or right, expiration period Class of Warrant or Right, Expiration Period Class of Warrant or Right, Expiration Period Warrants, period exercisable Class of Warrant or Right, Period from which Warrants or Rights Exercisable Class of Warrant or Right, Period from which Warrants or Rights Exercisable Proceeds from issuance of common stock and warrants Proceeds from Issuance or Sale of Equity Proceeds from issuance of convertible preferred stock Proceeds from Issuance of Convertible Preferred Stock Price per share of shares issued (in dollars per share) Shares Issued, Price Per Share Voting rights, number of shares per one vote Preferred Stock, Voting Rights, Number of Shares Per One Vote Preferred Stock, Voting Rights, Number of Shares Per One Vote Number of shares converted Conversion of Stock, Shares Converted Shares issued upon conversion of preferred stock (in shares) Warrant exchange amount Class of Warrant or Right, Exchange Amount Class of Warrant or Right, Exchange Amount Warrant exercise period not subject to cash payment Class of Warrant or Right, Exercise Period Not Subject to Cash Payment Class of Warrant or Right, Exercise Period Not Subject to Cash Payment Warrant exchange price threshold (in dollars per share) Class of Warrant or Right, Exchange Price Threshold Class of Warrant or Right, Exchange Price Threshold Proceeds from issuance of warrants Proceeds from Issuance of Warrants Stock issued during period for services (in shares) Stock Issued During Period, Shares, Issued for Services Stock issued during period for services Stock Issued During Period, Value, Issued for Services Aggregate authorized amount under At the Market Offering Agreement Common Stock, Aggregate Authorized Amount Common Stock, Aggregate Authorized Amount Schedule of debt Schedule of Debt [Table Text Block] EX-101.PRE 9 tbio-20160630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 R1.htm IDEA: XBRL DOCUMENT v3.5.0.2
DOCUMENT AND ENTITY INFORMATION - shares
 6 Months Ended
Jun. 30, 2016
Jul. 31, 2016
Document and Entity Information [Abstract]    
Entity Registrant Name TRANSGENOMIC INC  
Entity Central Index Key 0001043961  
Current Fiscal Year End Date --12-31  
Entity Filer Category Smaller Reporting Company  
Document Type 10-Q  
Document Period End Date Jun. 30, 2016  
Document Fiscal Year Focus 2016  
Document Fiscal Period Focus Q2  
Amendment Flag false  
Entity Common Stock, Shares Outstanding   23,547,946
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
CURRENT ASSETS:    
Cash and cash equivalents $ 421 $ 444
Accounts receivable, net 328 264
Inventories, net 39 50
Other current assets 325 537
Assets held for sale 690 1,987
Total current assets 1,803 3,282
PROPERTY AND EQUIPMENT:    
Equipment 5,592 5,593
Furniture, fixtures & leasehold improvements 1,565 1,565
Property and equipment, gross 7,157 7,158
Less: accumulated depreciation (6,953) (6,899)
Property and equipment, net 204 259
OTHER ASSETS:    
Intangibles, net 1,029 1,170
Other assets 58 105
Assets 3,094 4,816
CURRENT LIABILITIES:    
Current maturities of long-term debt 7,814 7,596
Accounts payable 5,620 3,781
Accrued compensation 259 321
Accrued expenses 2,847 3,734
Deferred revenue 111 217
Other liabilities 1,068 1,068
Liabilities held for sale 0 264
Total current liabilities 17,719 16,981
LONG TERM LIABILITIES:    
Common stock warrant liability 1,442 350
Other long-term liabilities 223 305
Total liabilities 19,384 17,636
STOCKHOLDERS’ DEFICIT:    
Convertible preferred stock, $0.01 par value, 15,000,000 shares authorized, 214,705 and 4,029,502 shares issued and outstanding, respectively 2 40
Common stock, $0.01 par value, 150,000,000 shares authorized, 23,103,875 and 13,915,691 shares issued and outstanding, respectively 231 139
Additional paid-in capital 201,140 200,403
Accumulated other comprehensive income 0 10
Accumulated deficit (217,663) (213,412)
Total stockholders’ deficit (16,290) (12,820)
Liabilities and stockholders' equity $ 3,094 $ 4,816
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICALS) - $ / shares
Jun. 30, 2016
Dec. 31, 2015
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 15,000,000 15,000,000
Preferred stock, shares issued (in shares) 214,705 4,029,502
Preferred stock, shares outstanding (in shares) 214,705 4,029,502
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 150,000,000 150,000,000
Common stock, shares issued (in shares) 23,103,875 13,915,691
Common stock, shares outstanding (in shares) 23,103,875 13,915,691
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.5.0.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
NET SALES $ 505 $ 442 $ 741 $ 1,192
COST OF GOODS SOLD 542 465 1,047 930
Gross profit (37) (23) (306) 262
OPERATING EXPENSES:        
Selling, general and administrative 1,436 1,908 3,140 3,712
Research and development 402 468 672 919
Operating Expenses 1,838 2,376 3,812 4,631
OPERATING LOSS FROM CONTINUING OPERATIONS (1,875) (2,399) (4,118) (4,369)
OTHER INCOME (EXPENSE):        
Interest expense, net (328) (186) (497) (376)
Warrant revaluation 24 (270) 345 (415)
Other, net 0 0 0 (13)
Other Income (Expense) (304) (456) (152) (804)
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES (2,179) (2,855) (4,270) (5,173)
INCOME TAX BENEFIT 0 (1) 0 (1)
LOSS FROM CONTINUING OPERATIONS (2,179) (2,854) (4,270) (5,172)
INCOME (LOSS) FROM DISCONTINUED OPERATIONS, NET OF TAXES 1,182 (421) 9 (1,144)
NET LOSS (997) (3,275) (4,261) (6,316)
PREFERRED STOCK DIVIDENDS 0 (331) (21) (662)
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS $ (997) $ (3,606) $ (4,282) $ (6,978)
BASIC AND DILUTED LOSS PER COMMON SHARE (IN DOLLARS PER SHARE) $ (0.05) $ (0.30) $ (0.20) $ (0.65)
BASIC AND DILUTED WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING (IN SHARES) 21,797,442 12,149,632 21,060,387 10,778,857
Continuing operations        
OTHER INCOME (EXPENSE):        
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS $ (2,179) $ (3,185) $ (4,291) $ (5,834)
BASIC AND DILUTED LOSS PER COMMON SHARE (IN DOLLARS PER SHARE) $ (0.10) $ (0.26) $ (0.20) $ (0.54)
Discontinued operations        
OTHER INCOME (EXPENSE):        
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS $ 1,182 $ (421) $ 9 $ (1,144)
BASIC AND DILUTED LOSS PER COMMON SHARE (IN DOLLARS PER SHARE) $ 0.05 $ (0.03) $ 0.00 $ (0.11)
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.5.0.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Statement of Comprehensive Income [Abstract]        
Net Loss $ (997) $ (3,275) $ (4,261) $ (6,316)
Other comprehensive loss - foreign currency translation adjustment 0 42 0 8
Comprehensive Loss $ (997) $ (3,233) $ (4,261) $ (6,308)
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.5.0.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - 6 months ended Jun. 30, 2016 - USD ($)
$ in Thousands
Total
Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Income
Private Placement
Private Placement
Preferred Stock
Private Placement
Additional Paid-in Capital
Balance at beginning of period (in shares) at Dec. 31, 2015   4,029,502 13,915,691            
Balance at beginning of period at Dec. 31, 2015 $ (12,820) $ 40 $ 139 $ 200,403 $ (213,412) $ 10      
Increase (Decrease) in Stockholders' Equity                  
Net loss (4,261)       (4,261)        
Foreign currency translation adjustment 0       10 (10)      
Stock-based compensation 141     141          
Stock issued during period (in shares)     257,467         2,365,243  
Stock issued during period 107   $ 2 105     $ 543 $ 24 $ 519
Dividends on preferred stock (4,475)     (4,475)          
Conversion of preferred stock and preferred stock dividends (in shares)   (6,180,040) 8,930,717            
Conversion of preferred stock and preferred stock dividends 4,475 $ (62) $ 90 4,447          
Balance at end of period (in shares) at Jun. 30, 2016   214,705 23,103,875            
Balance at end of period at Jun. 30, 2016 $ (16,290) $ 2 $ 231 $ 201,140 $ (217,663) $ 0      
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.5.0.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
CASH FLOWS USED IN OPERATING ACTIVITIES:    
NET LOSS $ (4,261) $ (6,316)
Less income from discontinued operations, net of tax 9 (1,144)
Loss from continuing operations (4,270) (5,172)
Adjustments to reconcile net loss to net cash flows used in operating activities:    
Depreciation and amortization 189 156
Stock-based compensation 119 322
Provision for losses on doubtful accounts 70 0
Warrant revaluation (345) 415
Loss on sale of fixed assets 0 14
Deferred interest 47 61
Deferred tax provision 0 81
Changes in operating assets and liabilities:    
Accounts receivable (134) 301
Inventories 11 0
Other current assets 253 (243)
Accounts payable 1,839 367
Accrued expenses and other liabilities (613) (240)
Net cash used in continuing operations (2,834) (3,938)
Net cash provided by (used in) discontinued operations 79 (2,074)
Net cash used in operating activities (2,755) (6,012)
CASH FLOWS PROVIDED BY (USED IN) INVESTING ACTIVITIES:    
Purchases of property and equipment (19) (194)
Other assets (7) (46)
Net cash used in continuing operations (26) (240)
Net cash provided by discontinued operations 962 0
Net cash provided by (used in) investing activities 936 (240)
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES:    
Principal payments on capital lease obligations (1) (34)
Issuance of preferred stock, net 1,779 0
Issuance of common stock, net 68 6,209
Proceeds from borrowings 500 923
Principal payment on note payable (550) (148)
Net cash flows provided by financing activities 1,796 6,950
EFFECT OF FOREIGN CURRENCY EXCHANGE RATE CHANGES ON CASH 0 2
NET CHANGE IN CASH AND CASH EQUIVALENTS (23) 700
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 444 1,609
CASH AND CASH EQUIVALENTS AT END OF PERIOD 421 2,309
Cash paid during the period for:    
Interest $ 0 $ 222
XML 17 R8.htm IDEA: XBRL DOCUMENT v3.5.0.2
BUSINESS DESCRIPTION
 6 Months Ended
Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BUSINESS DESCRIPTION
BUSINESS DESCRIPTION
Business Description.

Transgenomic, Inc. (“we”, “us”, “our”, the “Company” or “Transgenomic”) is a biotechnology company advancing personalized medicine for the detection and treatment of cancer and inherited diseases through our proprietary molecular technologies and clinical and research services. A key goal is to bring our Multiplexed ICE COLD-PCR (“MX-ICP”) product to the clinical market through strategic partnerships and licensing agreements, enabling the use of blood and other bodily fluids for more effective and patient-friendly diagnosis, monitoring and treatment of cancer.

MX-ICP is technology proprietary to Transgenomic. It is a reagent that improves the ability to detect genetic mutations. This technology has been validated internally on all currently available sequencing platforms, including Sanger, Next Gen Sequencing and Digital PCR. By enhancing the level of detection of genetic mutations and suppressing the normal or wild-type DNA, several benefits are provided.

Historically, our operations were organized and reviewed by management along our major product lines and presented in two business segments: Laboratory Services and Genetic Assays and Platforms. Beginning with the quarter ended September 30, 2015, our operations are now organized as one business segment, our Laboratory Services segment, and during the second half of 2015, we began presenting our Genetic Assays and Platforms segment and a portion of our Laboratory Services segment in discontinued operations.

Our current Laboratory Services business consists of our laboratory in Omaha, Nebraska, which is focused on providing genetic analytical services related to Oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical and biotechnology companies. Our laboratory employs a variety of genomic testing service technologies, including our proprietary MX-ICP technology. Our laboratory in Omaha is certified under the Clinical Laboratory Improvement Amendments (“CLIA”) as a high complexity laboratory and is accredited by the College of American Pathologists.

Our condensed consolidated balance sheets, statements of operations and statements of cash flows for all periods presented reflect our former Genetic Assays and Platforms activities and Patient Testing business as discontinued operations (See Note 3 - “Discontinued Operations”).

Going Concern.

The condensed consolidated financial statements have been prepared using accounting principles generally accepted in the United States of America (“GAAP”) applicable for a going concern, which assume that we will realize our assets and discharge our liabilities in the ordinary course of business. We have incurred substantial operating losses and have used cash in our operating activities for the past few years. As of June 30, 2016, we had negative working capital of $15.9 million. Our ability to continue as a going concern is dependent upon a combination of generating additional revenue, improving cash collections, potentially selling underutilized assets and, if necessary, raising additional financing to meet our obligations and pay our liabilities arising from normal business operations when they come due. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that we will be able to continue as a going concern. These condensed consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern. We cannot be certain that additional financing will be available on acceptable terms, or at all, and our failure to raise capital when needed could limit our ability to continue our operations.
XML 18 R9.htm IDEA: XBRL DOCUMENT v3.5.0.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 6 Months Ended
Jun. 30, 2016
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation.
The accompanying condensed consolidated financial statements are presented in conformity with GAAP. All amounts are presented in U.S. Dollars (“$”). Supplemental cash flows from discontinued operations are presented in Note 3 - “Discontinued Operations”. We have evaluated events occurring subsequent to June 30, 2016 for potential recognition or disclosure in the consolidated financial statements and concluded there were no subsequent events that required recognition or disclosure.
The condensed consolidated balance sheet as of December 31, 2015 was derived from our audited balance sheet as of that date. There has been no change in the balance sheet from December 31, 2015. The accompanying condensed consolidated financial statements as of and for the three and six months ended June 30, 2016 and 2015 are unaudited and reflect all adjustments (consisting of only normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the interim periods. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2015 contained in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on April 14, 2016. The results of operations for the interim periods presented are not necessarily indicative of the results for fiscal year 2016.
Certain prior year amounts have been reclassified to conform to the current year presentation in our condensed consolidated financial statements, which consists of the effects of reclassifications from the presentation of our discontinued operations.
Principles of Consolidation.
The condensed consolidated financial statements include the accounts of Transgenomic, Inc. and our wholly owned subsidiary. All inter-company balances and transactions have been eliminated in consolidation.
Risks and Uncertainties.
Certain risks and uncertainties are inherent in our day-to-day operations and in the process of preparing our financial statements. The more significant of those risks are presented below and throughout the notes to the unaudited condensed consolidated financial statements.
Use of Estimates.
The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of net sales and expenses during the reporting period. In addition, estimates and assumptions associated with the determination of the fair value of certain assets and related impairments require considerable judgment by management. Actual results could differ from the estimates and assumptions used in preparing these condensed consolidated financial statements.
Fair Value.
Unless otherwise specified, book value approximates fair market value. The common stock warrant liability is recorded at fair value. See Note 9 - “Fair Value” for additional information.
Cash and Cash Equivalents and Other Current Assets.
Cash and cash equivalents include cash and investments with original maturities at the date of acquisition of three months or less. Other current assets as of June 30, 2016 of $0.3 million include prepaid assets of $0.1 million and other receivables of $0.2 million.
Concentrations of Cash.
From time to time, we may maintain a cash position with financial institutions in amounts that exceed federally insured limits. We have not experienced any losses on such accounts as of June 30, 2016.
Accounts Receivable.
The following is a summary of activity for the allowance for doubtful accounts from continuing operations during the three and six months ended June 30, 2016 and 2015: 
 
Dollars in Thousands
 
Beginning
Balance
 
Additions
 
Deductions
 
Ending
Balance
Three Months Ended June 30, 2016
$
108

 
$
49

 
$
—

 
$
157

Three Months Ended June 30, 2015
$
20

 
$
—

 
$
—

 
$
20

Six Months Ended June 30, 2016
$
87

 
$
70

 
$
—

 
$
157

Six Months Ended June 30, 2015
$
20

 
$
—

 
$
—

 
$
20


While payment terms are generally 30 days, we have also provided extended payment terms in certain cases. Accounts receivable are carried at original invoice amount and shown net of allowance for doubtful accounts. The estimate made for doubtful accounts is based on a review of all outstanding amounts on a quarterly basis. We determine the allowance for doubtful accounts by regularly evaluating individual payor receivables and considering a payor’s financial condition, credit history, reimbursement rates and current economic conditions. Accounts receivable are written off when deemed uncollectible and after all collection efforts have been exhausted. Recoveries of accounts receivable previously written off are recorded as a reduction in bad debt expense when received.
Inventories.
Inventories are stated at the lower of cost or market net of allowance for obsolete inventory. Cost is computed using standard costs for finished goods and average or latest actual cost for raw materials and work in process, which approximates the first-in, first-out (FIFO) method. At June 30, 2016, our net inventories were less than $0.1 million and were comprised predominantly of raw materials.
 
The following is a summary of activity for the allowance for obsolete inventory during the three and six months ended June 30, 2016 and 2015: 
 
Dollars in Thousands
 
Beginning
Balance
 
Additions
 
Deductions
 
Ending
Balance
Three Months Ended June 30, 2016
$
63

 
$
—

 
$
—

 
$
63

Three Months Ended June 30, 2015
$
—

 
$
—

 
$
—

 
$
—

Six Months Ended June 30, 2016
$
63

 
$
—

 
$
—

 
$
63

Six Months Ended June 30, 2015
$
—

 
$
—

 
$
—

 
$
—


We determine the allowance for obsolescence by evaluating inventory quarterly for items deemed to be slow moving or obsolete.
Property and Equipment.
Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets as follows:
 
Leasehold improvements
1 to 10 years
Furniture and fixtures
3 to 7 years
Production equipment
3 to 7 years
Computer equipment
3 to 7 years
Research and development equipment
2 to 7 years

Depreciation expense in continuing operations related to property and equipment was less than $0.1 million for each of the three month periods ended June 30, 2016 and 2015. Depreciation expense was $0.1 million for each of the six month periods ended June 30, 2016 and 2015. Depreciation expense during each period includes depreciation related to equipment acquired under capital leases.
Intangible Assets.
Intangible assets include intellectual property and patents.
1. Intellectual Property.    Initial costs paid to license intellectual property from independent third parties are capitalized and amortized using the straight-line method over the license period. Ongoing royalties related to such licenses are expensed as incurred.
2. Patents.    We capitalize legal costs, filing fees and other expenses associated with obtaining patents on new discoveries and amortize these costs using the straight-line method over the shorter of the legal life of the patent or its economic life beginning on the date the patent is issued.
Stock-Based Compensation.
All stock-based awards to date have exercise prices equal to the market value of the shares at the date of grant and have 10-year contractual terms. Unvested awards as of June 30, 2016 had vesting periods of up to three years from the date of grant. None of the awards outstanding at June 30, 2016 are subject to performance or market-based vesting conditions.
We measure and recognize compensation expense for all stock-based awards made to employees and directors. Compensation expense, net of estimated forfeitures, is based on the calculated fair value of the awards as measured at the grant date and is expensed over the service period of the awards.
During the three and six months ended June 30, 2016, we recorded compensation expense for all stock awards of less than $0.1 million and $0.1 million, respectively, within selling, general and administrative expense. During the three and six months ended June 30, 2015, we recorded compensation expense for all stock awards of $0.2 million and $0.3 million, respectively. As of June 30, 2016, the unrecognized compensation expense related to unvested stock awards was $0.2 million, which is expected to be recognized over a weighted-average period of 1.2 years.
We granted stock options to purchase an aggregate of zero and 14,000 shares of our common stock during the three and six months ended June 30, 2016, respectively. The fair value of the stock options granted was estimated on the grant date using the Black-Scholes option pricing model with the following assumptions: risk-free interest rates of 1.91% based on the U.S. Treasury yield in effect at the time of grant; dividend yields of zero percent; expected lives of 6.00 years, based on expected exercise activity behavior; and volatility of 85% based on the historical volatility of our common stock over a time that is consistent with the expected life of the options.
Included in our stock awards outstanding as of June 30, 2016 were stock appreciation rights (“SARs”) to purchase 98,333 shares of our common stock. The SARs were issued solely to our executive officers and will vest over three years from the date of grant.
Net Sales Recognition.
Revenue is realized and earned when all of the following criteria are met:
•
Persuasive evidence of an arrangement exists;
•
Delivery has occurred or services have been rendered;
•
The seller’s price to the buyer is fixed or determinable; and
•
Collectability is reasonably assured.

In our Biomarker Identification laboratory, we perform services on a project by project basis. When we receive payment in advance, we initially defer the revenue and recognize it when we deliver the service. These projects typically do not extend beyond one year. At each of June 30, 2016 and December 31, 2015, deferred net sales associated with pharmacogenomics research projects included in the balance sheet in deferred revenue was $0.1 million.

Net sales from Patient Testing laboratories, reported as part of discontinued operations, are recognized on an individual test basis and take place when the test report is completed, reviewed and sent to the client less the reserve for insurance, Medicare and Medicaid contractual adjustments. There are no deferred net sales associated with our Patient Testing services. Adjustments to the allowances, based on actual receipts from third party payers, are reflected in the estimated contractual allowance applied prospectively. In the fourth quarter of 2015, we adjusted our contractual allowance rates to better reflect the reimbursement level we expect to achieve on Patient Testing billings. The adjustment negatively impacted our Patient Testing revenues for all periods after the third quarter of 2015. (See Note 3 - “Discontinued Operations”).

Net sales of Genetic Assays and Platforms products, reported as discontinued operations (See Note 3 - “Discontinued Operations”) are recognized in accordance with the terms of the sales arrangement. Such recognition is based on receipt of an unconditional customer order and transfer of title and risk of ownership to the customer, typically upon shipment of the product under a purchase order. Our sales terms do not provide for the right of return unless the product is damaged or defective. Net sales from certain services associated with the analytical instruments, to be performed subsequent to shipment of the products, is deferred and recognized when the services are provided. Such services, mainly limited to installation and training services that are not essential to the functionality of the instruments, typically are performed in a timely manner subsequent to shipment of the instrument. We also enter into various service contracts that cover installed instruments. These contracts cover specific time periods and net sales associated with these contracts are deferred and recognized ratably over the service period.
Common Stock Warrants.
Certain of our issued and outstanding warrants to purchase common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability (“Common Stock Warrant Liability”). We are required to present these instruments at fair value at each reporting date and any changes in fair values are recorded as an adjustment to earnings. The Common Stock Warrant Liabilities are considered Level Three financial instruments for purposes of fair value measurement. See Note 9 - “Fair Value” for additional information.
Loss Per Share.
Basic loss per share is calculated based on the weighted-average number of common shares outstanding during each period. Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock. Options, warrants and conversion rights pertaining to 10,721,464 and 8,286,963 shares of our common stock have been excluded from the computation of diluted loss per share at June 30, 2016 and 2015, respectively, because the effect is anti-dilutive due to the net loss.
Recent Accounting Pronouncements.
In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (“ASU No. 2014-09”). This guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to a customer. ASU No. 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. In July 2015, the FASB decided to defer the effective date of this new accounting guidance by one year. As a result, ASU No. 2014-09 will be effective for us for all annual and interim reporting periods beginning after December 15, 2017 and early adoption would be permitted as of the original effective date. The new standard permits the use of either the retrospective or cumulative effect transition method. We do not expect to early adopt this guidance and we have not selected a transition method. We are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows.

In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40)(“ASU No. 2014-15”). This guidance addresses management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2016. Early adoption is permitted. We do not expect to early adopt this guidance and do not believe that the adoption of this guidance will have a material impact on our consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard amends the recognition of lease assets and lease liabilities by lessees for those leases currently classified as operating leases and amends disclosure requirements associated with leasing arrangements. The new standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently assessing the impact that the adoption of this ASU will have on our consolidated financial statements.
In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard simplifies several aspects related to the accounting for share-based payment transactions, including the accounting for income taxes, statutory tax withholding requirements, forfeitures and classification on the statement of cash flows. This guidance is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2016; however, early adoption is permitted. We do not expect to early adopt this guidance and are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows.
XML 19 R10.htm IDEA: XBRL DOCUMENT v3.5.0.2
DISCONTINUED OPERATIONS
 6 Months Ended
Jun. 30, 2016
Discontinued Operations and Disposal Groups [Abstract]  
DISCONTINUED OPERATIONS
DISCONTINUED OPERATIONS

On September 8, 2015, we entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Edge BioSystems, Inc. (“Edge Bio”), pursuant to which we sold our manufacturing, marketing and selling of high quality polymer and silica based beads and resin and chromatography columns business (collectively, the “Columns Business”). The Columns Business was part of our former segment, Genetic Assays and Platforms. Pursuant to the Asset Purchase Agreement, Edge Bio acquired substantially all of the assets used solely in connection with the Columns Business and assumed certain liabilities of the Columns Business for a total cash purchase price of approximately $2.1 million (the “Asset Sale”), which was paid on September 8, 2015 upon the closing of the Asset Sale. During the year ended December 31, 2015, we recorded a gain on the sale of the Columns Business of $1.5 million.

On November 25, 2015, we entered into an Asset Purchase Agreement (the “Purchase Agreement”) with ADSTEC Corporation (“ADSTEC”) and ADS Biotec Inc., a wholly-owned subsidiary of ADSTEC (“Buyer”), pursuant to which we sold (1) to ADSTEC our facilities located in Glasgow, Scotland and on Irvington Road in Omaha, Nebraska (together, the “Facilities”) and all of our stock, inventory and raw materials located at the Facilities (collectively, the “Inventory”), and (2) to Buyer (a) all of the remaining assets relating to our Genetic Assays and Platforms business segment (the “Business”), other than the Inventory (the “Purchased Assets”), and (b) all of the ordinary shares of Transgenomic Limited, a wholly-owned subsidiary of ours (the “Shares”).

Pursuant to the Purchase Agreement, ADSTEC and Buyer acquired the Facilities, the Inventory, the Purchased Assets and the Shares for an aggregate purchase price of approximately $300,000, and Buyer assumed our financial and human resources commitments related to the Business (the “Transaction”). During the year ended December 31, 2015, we recorded a loss on the Transaction of $1.7 million.

Together, the Asset Sale and the Transaction represent the divestiture of our Genetic Assays and Platforms business, resulting in a strategic shift that had a major effect on our operations and financial results. Therefore, the divested operations of our Genetic Assays and Platforms business meet the criteria to be reported as discontinued operations.
During the fourth quarter of 2015, our Board of Directors took actions to begin the process of divesting our Patient Testing business in New Haven, Connecticut. In March 2016, we announced that we had suspended testing services in our Patient Testing laboratory as we review and evaluate various strategic alternatives for that business. As a result of these actions, as of December 31, 2015, our Patient Testing business met the criteria to be reported as discontinued operations. We anticipate that we will complete the divestiture of the Patient Testing business during 2016.
The related assets, liabilities, results of operations and cash flows for both the Genetic Assays and Platforms business and Patient Testing business are classified as assets held for sale, liabilities held for sale and discontinued operations for all periods presented.
Results of the discontinued operations consisted of the following:
 
Three months ended June 30,
 
Six months ended June 30,
(Dollars in thousands)
2016
 
2015
 
2016
 
2015
Net sales
$
574

 
$
6,598

 
$
1,677

 
$
12,361

Cost of goods sold
11

 
3,703

 
1,194

 
6,777

Gross profit
563

 
2,895

 
483

 
5,584

Selling, general and administrative expense
344

 
3,165

 
1,369

 
6,415

Research and development expense
—

 
108

 
68

 
224

Operating income (loss) from discontinued operations
219

 
(378
)
 
(954
)
 
(1,055
)
Gain on sale of business/assets
963

 
—

 
963

 
—

Income (loss) from discontinued operations before income taxes
1,182

 
(378
)
 
9

 
(1,055
)
Income tax expense
—

 
43

 
—

 
89

Income (loss) from discontinued operations, net of taxes
$
1,182

 
$
(421
)
 
$
9

 
$
(1,144
)


Income from discontinued operations for both the three and six month periods ended June 30, 2016, includes approximately $1.0 million in proceeds received from the sale of assets of our discontinued Patient Testing business.
Assets and liabilities of the discontinued operations are classified as assets held for sale and liabilities held for sale in the condensed consolidated balance sheets and consisted of the following:
 
Dollars in Thousands
 
June 30,
2016
 
December 31,
2015
ASSETS
 
 
 
Accounts receivable, net
$
647

 
$
1,905

Other current assets
43

 
82

Total Assets
$
690

 
$
1,987

 
 
 
 
LIABILITIES
 
 
 
Accrued compensation
$
—

 
$
264

Total Liabilities
$
—

 
$
264

 
 
 
 

The following is a summary of activity for the allowance for doubtful accounts from discontinued operations during the three and six months ended June 30, 2016 and 2015. The allowance for doubtful accounts from discontinued operations is included in the assets held for sale in the condensed consolidated balance sheets.
 
Dollars in Thousands
 
Beginning
Balance
 
Additions
 
Deductions
 
Ending
Balance
Three Months Ended June 30, 2016
$
14,542

 
$
—

 
$
(4,080
)
 
$
10,462

Three Months Ended June 30, 2015
$
9,173

 
$
1,198

 
$
(1,965
)
 
$
8,406

Six Months Ended June 30, 2016
$
14,664

 
$
—

 
$
(4,202
)
 
$
10,462

Six Months Ended June 30, 2015
$
7,927

 
$
2,730

 
$
(2,251
)
 
$
8,406
XML 20 R11.htm IDEA: XBRL DOCUMENT v3.5.0.2
INTANGIBLES AND OTHER ASSETS
 6 Months Ended
Jun. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]  
INTANGIBLES AND OTHER ASSETS
INTANGIBLES AND OTHER ASSETS
We review our amortizable long-lived assets for impairment annually or whenever events indicate that the carrying amount of the asset (group) may not be recoverable. An impairment loss may be needed if the sum of the future undiscounted cash flows is less than the carrying amount of the asset (group). The amount of the loss would be determined by comparing the fair market value of the asset to the carrying amount of the asset (group).
Long-lived intangible assets as of June 30, 2016 and December 31, 2015 consisted of the following:
 
Dollars in Thousands
 
June 30, 2016
 
Cost
 
Accumulated
Amortization
 
Net Book
Value
Patents
695

 
76

 
619

Intellectual property
672

 
262

 
410

 
$
1,367

 
$
338

 
$
1,029




 
Dollars in Thousands
 
December 31, 2015
 
Cost
 
Accumulated
Amortization
 
Net Book
Value
Patents
980

 
274

 
706

Intellectual property
671

 
207

 
464

 
$
1,651

 
$
481

 
$
1,170


 
 
 
Estimated Useful Life
Patents
Life of the patent
Intellectual property
7 years

Other assets include U.S. security deposits and deferred tax assets, net of applicable valuation allowances.
Amortization expense for intangible assets was $0.1 million during each of the six month periods ended June 30, 2016 and 2015. Amortization expense for intangible assets is expected to be $0.1 million for each of the years ending December 31, 2016, 2017, 2018, 2019 and 2020.
XML 21 R12.htm IDEA: XBRL DOCUMENT v3.5.0.2
DEBT
 6 Months Ended
Jun. 30, 2016
Debt Disclosure [Abstract]  
DEBT
DEBT
 
 
Dollars in Thousands
 
 
June 30, 2016
 
December 31, 2015
Revolving Line of Credit(1)
 
$
3,243

 
$
3,025

Term Loan(2)
 
4,000

 
4,000

Convertible Promissory Notes (3)
 
571

 
571

Total debt
 
7,814

 
7,596

Current portion of long-term debt
 
(7,814
)
 
(7,596
)
Long-term debt, net of current maturities
 
$
—

 
$
—

 
(1)
Revolving Line of Credit. Amounts advanced under the Revolving Line accrue interest at an annual rate equal to the greater of (a) 6.25% or (b) the Wall Street Journal prime rate plus 3%. The current interest rate is 6.50%. Interest is payable on a monthly basis, with the balance payable at the maturity of the Revolving Line. Under the Loan Agreement, we pay the Lenders a commitment fee of $20,000 on each one-year anniversary of March 13, 2013, the Effective Date, during the term of the Revolving Line. In addition, a fee of 0.5% per annum is payable quarterly on the unused portion of the Revolving Line. The Revolving Line matures on November 1, 2017.

(2)
Term Loan. We received $4.0 million under the Term Loan on the Effective Date. Pursuant to the terms of the Loan Agreement, as amended, the maturity date of the Loan Agreement was extended until November 1, 2017 and no principal payments on the Term Loan are due until such date. The current interest rate is 9.1%.

We will pay the Lenders an additional final payment of $120,000 at maturity or prepayment of the Term Loan. In addition, if we repay the Term Loan prior to maturity, we will pay the Lenders a prepayment penalty of 1% of the total outstanding balance under the Term Loan.

Additional Terms.
The Loan Agreement contains affirmative and negative covenants. Under the Term Loan, we agreed not to (i) pledge or otherwise encumber our assets other than to the Lenders, (ii) enter into additional borrowings or guarantees, (iii) repurchase our capital stock, or (iv) enter into certain mergers or acquisitions without the Lenders’ consent. Additionally, the Loan Agreement contains a subjective acceleration clause at the discretion of the Lenders. As of June 30, 2016, the Company was in compliance with the Loan Agreement, as amended by the Ninth Amendment, however, as of August 12, 2016 we have not made the required July 2016 interest payment and have not received a waiver for the non-compliance and as such all debt has been classified as current at June 30, 2016.

To secure the repayment of any amounts borrowed under the Revolving Line and the Term Loan, we granted the Lenders a security interest in all of our assets. The occurrence of an event of default under the Loan Agreement could result in the acceleration of our obligations under the Loan Agreement, would increase the applicable interest rate under the Revolving Line or Term Loan (or both) by 5% and would permit the Lenders to exercise remedies with respect to the collateral under the Loan Agreement. As of the date these financials were available for release, the Lenders have not exercised the remedies under the Loan Agreement.

(3) Convertible Promissory Notes. The Notes accrue interest at a rate of 6% per year and mature on December 31, 2016.

Revolving Line and Term Loan.

On March 13, 2013 (the “Effective Date”), we entered into a Loan and Security Agreement with affiliates of Third Security, LLC (the “Lenders”) for (a) a revolving line of credit (the “Revolving Line”) with borrowing availability of up to $4.0 million, subject to reduction based on our eligible accounts receivable, and (b) a term loan (the “Term Loan” and, together with the Revolving Line, the “Loan Agreement”) of $4.0 million. Proceeds were used to pay off a three year senior secured promissory note payable to PGxHealth, LLC, which was entered into on December 29, 2010 in conjunction with our acquisition of the FAMILION family of genetic tests, and for general corporate and working capital purposes.
On August 2, 2013, we entered into an amendment to the Loan Agreement (the “Amendment”). The Amendment, which became effective as of June 30, 2013, reduced our future minimum revenue covenants under the Loan Agreement and modified the interest rates applicable to the amounts advanced under the Revolving Line.

On November 14, 2013, we entered into a second amendment to the Loan Agreement (the “Second Amendment”). The Second Amendment, which became effective as of October 31, 2013, reduced our future minimum revenue covenants under the Loan Agreement.

On January 27, 2014, we entered into a third amendment to the Loan Agreement (the “Third Amendment”). Pursuant to the Third Amendment, the Lenders agreed to waive certain events of default under the Loan Agreement, and the parties amended certain provisions of the Loan Agreement, including the minimum liquidity ratio that we must maintain during the term of the Loan Agreement.

On March 3, 2014, we entered into a fourth amendment to the Loan Agreement (the “Fourth Amendment”). Pursuant to the terms of the Fourth Amendment, we were not required to make any principal or interest payments under the Term Loan for the period from March 1, 2014 through March 31, 2015. The interest on the debt that was deferred and not paid was capitalized as part of the Term Loan. The amount of interest that was capitalized from March 1, 2014 to March 31, 2015 was $0.4 million.

On October 22, 2014, we entered into a fifth amendment to the Loan Agreement (the “Fifth Amendment”). Pursuant to the Fifth Amendment, the parties amended certain provisions of the Loan Agreement, including reducing the minimum liquidity and revenue covenants under the Loan Agreement. The Fifth Amendment also reduced the aggregate amount that we may borrow under the Revolving Line from $4.0 million to $3.0 million.

On April 1, 2015, we entered into a sixth amendment to the Loan Agreement (the “Sixth Amendment”). Pursuant to the Sixth Amendment, among other things, (a) the Lenders waived specified events of default under the terms of the Loan Agreement, (b) commencing April 1, 2015, we began making monthly interest payments with respect to the Term Loan to the Lenders, (c) we were not be obligated to make monthly payments of principal under the Term Loan to the Lenders until April 1, 2016, (d) we made an initial prepayment of a portion of the Term Loan balance in the amount of approximately $148,000 on April 1, 2015 and will make one or more additional prepayments to the Lenders under the Loan Agreement upon the occurrence of certain events, as defined in the Loan Agreement, and (e) we were not required to comply with the minimum liquidity ratio under the terms of the Loan Agreement until the earliest to occur of a specified event, as defined in the Loan Agreement, or March 31, 2016. The Sixth Amendment also extends the time period in which we must provide certain reports and statements to the Lenders and amends the circumstances pursuant to which we may engage in certain sales or transfers of our business or property without the consent of the Lenders.
As of June 30, 2015, we were in compliance with all financial covenants of the Loan Agreement, but were not in compliance with the restrictions limiting the amount that we may borrow under the Revolving Line. Accordingly, on August 10, 2015, we received a waiver from the Lenders relating to this non-compliance and paid the Lenders an aggregate of $0.7 million, which brought us back into compliance with the terms of the Revolving Line.

On September 4, 2015, we entered into a seventh amendment to the Loan Agreement (the “Seventh Amendment”). The Seventh Amendment, among other things, (a) provided that the Lenders waived specified events of default under the terms of the Loan Agreement, (b) reduced our future minimum revenue covenants under the Loan Agreement, (c) reduced our borrowing availability under the Revolving Line to approximately $2.3 million, and (d) limited our borrowing base under the Loan Agreement to the amount of the Revolving Line.

On January 6, 2016, we entered into an eighth amendment to the Loan Agreement (the “Eighth Amendment”). The Eighth Amendment, among other things, (a) provided that the Lenders waived specified events of default under the terms of the Loan Agreement, (b) reduced our future minimum revenue covenants under the Loan Agreement, (c) extended the maturity date of the Loan Agreement until November 1, 2017, and (d) provided for the repayment of an overadvance of $750,000 previously provided by the Lenders to us pursuant to the Loan Agreement.

On June 6, 2016, we entered into a ninth amendment to the Loan Agreement (the “Ninth Amendment”). The Ninth Amendment, among other things, (a) provided that the Lenders waived specified events of default under the terms of the Loan Agreement, (b) amended the prepayment terms of the Loan Agreement, (c) provided for the reduction of amounts available under the Revolving Line upon the prepayment or repayment of certain amounts by us, (d) removed the minimum liquidity ratio and minimum net revenue financial covenants applicable to us under the Loan Agreement, (e) amended the circumstances pursuant to which we may engage in certain sales or transfers of our business or property without the consent of the Lenders, and (f) capitalized certain amounts owed by us to the Lenders and added such overdue amounts to the outstanding principal amount of the Revolving Line.
 
As a result of the Ninth Amendment, the overadvance that existed at March 31, 2016 was added to the outstanding principal amount of the Revolving Line and no overadvance existed as of June 30, 2016.

Convertible Promissory Notes.

On December 31, 2014, we entered into an Unsecured Convertible Promissory Note Purchase Agreement (the “Note Purchase Agreement”) with an accredited investor (the “Investor”), pursuant to which we agreed to issue and sell to the Investor in a private placement an unsecured convertible promissory note (the “Initial Note”). We issued the Initial Note in the aggregate principal amount of $750,000 to the Investor on December 31, 2014. Pursuant to the terms of the Initial Note, interest accrued at a rate of 6% per year and the Initial Note was set to mature on December 31, 2016. Under the Initial Note, the outstanding principal and unpaid interest accrued was convertible into shares of our common stock as follows: (i) commencing upon the date of issuance of the Initial Note (but no earlier than January 1, 2015), the Investor was entitled to convert, on a one-time basis, up to 50% of the outstanding principal and unpaid interest accrued under the Initial Note, into shares of our common stock at a conversion price equal to the lesser of (a) the average closing price of the common stock on the principal securities exchange or securities market on which our common stock is then traded (the “Market”) for the 20 consecutive trading days immediately preceding the date of conversion, and (b) $2.20 (subject to adjustment for stock splits, stock dividends, other distributions, recapitalizations and the like); and (ii) commencing February 15, 2015, the Investor was entitled to convert, on a one-time basis, any or all of the remaining outstanding principal and unpaid interest accrued under the Initial Note, into shares of our common stock at a conversion price equal to 85% of the average closing price of our common stock on the Market for the 15 consecutive trading days immediately preceding the date of conversion. The Initial Note has been converted in full into 502,786 shares of our common stock, in accordance with the terms of the Initial Note.

On January 15, 2015, we entered into the Note Purchase Agreement with seven accredited investors (the “Additional Investors”) and, on January 20, 2015, issued and sold to the Additional Investors, in a private placement, notes (the “Additional Notes”) in an aggregate principal amount of $925,000. The Additional Notes have the same terms and conditions as the Initial Note. As of June 30, 2016, $400,000 of the aggregate principal amount of the Additional Notes, and accrued interest thereon, has been converted into an aggregate of 281,023 shares of our common stock.
XML 22 R13.htm IDEA: XBRL DOCUMENT v3.5.0.2
COMMITMENTS AND CONTINGENCIES
 6 Months Ended
Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES
We are subject to a number of claims of various amounts that arise out of the normal course of our business. In our opinion, the disposition of pending claims, in excess of recorded accruals, could have a material adverse effect on our financial position, results of operations or cash flows. On February 25, 2016, the Board of Regents of the University of Nebraska (“UNMC”) filed a lawsuit against us in the District Court of Douglas County, Nebraska, for breach of contract and seeking recovery of $0.7 million owed by us to UNMC. We and UNMC are currently in discussions to determine a mutually agreeable means by which to settle the outstanding liability. A $0.7 million liability has been recorded at December 31, 2015 and June 30, 2016.
In addition, on April 13, 2016, Fox Chase Cancer Center (“Fox Chase”) filed a lawsuit against us in the Court of Common Pleas of Philadelphia County, First Judicial District of Pennsylvania Civil Trial Division (the “Court of Common Pleas”), alleging, among other things, breach of contract, tortious interference with present and prospective contractual relations, unjust enrichment, fraudulent conversion and conspiracy and seeking punitive damages in addition to damages and other relief. This lawsuit relates to a license agreement we entered into with Fox Chase in August 2000, as amended (the “License Agreement”), as well as the assignment of certain of our rights under the License Agreement to Integrated DNA Technologies, Inc. (“IDT”) pursuant to the Surveyor Kit Patent, Technology and Inventory Purchase Agreement we entered into with IDT effective as of July 1, 2014 (the “IDT Agreement”). Pursuant to the terms of the IDT Agreement, we agreed to indemnify IDT with respect to certain of the claims asserted in the Fox Chase proceeding. On July 8, 2016, the Court of Common Pleas sustained our preliminary objections to several of Fox Chase’s claims and dismissed the claims for tortious interference, fraudulent conversion, conspiracy, punitive damages and attorney’s fees.  Accordingly, the case has been narrowed so that only certain contract claims and an unjust enrichment claim remain pending against us. We believe that we have good and substantial defenses to the claims asserted by Fox Chase. We are unable to determine whether any loss will occur or to estimate the range of such potential loss; therefore, no amount of loss has been accrued by us as of the date of filing of this Quarterly Report on Form 10-Q. Furthermore, there is no guarantee that we will prevail in this suit or receive any damages or other relief if we do prevail.
On June 23, 2016, the Icahn School of Medicine at Mount Sinai (“Mount Sinai”) filed a lawsuit against us in the Supreme Court of the State of New York, County of New York, alleging, among other things, breach of contract and, alternatively, unjust enrichment and quantum merit, and seeking recovery of $0.7 million owed by us to Mount Sinai for services rendered. We and Mount Sinai are currently in discussions to determine a mutually agreeable means by which to settle the outstanding liability. A $0.7 million liability has been recorded at December 31, 2015 and June 30, 2016.
The outcome of legal proceedings and claims brought against us are subject to significant uncertainty. Therefore, although management considers the likelihood of such an outcome to be remote, if one or more of these legal matters were resolved against us in the same reporting period for amounts in excess of management’s expectations, our financial statements for such reporting period could be materially adversely affected. In general, the resolution of a legal matter could prevent us from offering our services or products to others, could be material to our financial condition or cash flows, or both, or could otherwise adversely affect our operating results.
We lease certain equipment, vehicles and operating facilities under non-cancellable operating leases that expire on various dates through 2022. The future minimum lease payments required under these leases are $0.4 million for the remainder of 2016, $0.7 million in 2017, $0.7 million in 2018, $0.7 million in 2019, $0.7 million in 2020 and $0.4 million thereafter. Rent expense for each of the six month periods ended June 30, 2016 and 2015 was $0.1 million. At June 30, 2016, firm commitments to vendors totaled $0.1 million.
XML 23 R14.htm IDEA: XBRL DOCUMENT v3.5.0.2
INCOME TAXES
 6 Months Ended
Jun. 30, 2016
Income Tax Disclosure [Abstract]  
INCOME TAXES
INCOME TAXES

Annually, we file U.S. Federal, state and foreign income tax returns.  All U.S. Federal and most state loss carryforwards remain subject to adjustment in the event of an income tax examination.
Income tax expense from continuing operations was zero for the three and six months ended June 30, 2016 and 2015. We maintain a full valuation allowance on our net deferred tax assets, having concluded that we are not more likely than not going to realize the benefit of our deferred tax assets, including our net operating loss carryforwards.
During each of the three and six month periods ended June 30, 2016 and 2015, there were no material changes to the liability for uncertain tax positions.
XML 24 R15.htm IDEA: XBRL DOCUMENT v3.5.0.2
STOCKHOLDERS' EQUITY
 6 Months Ended
Jun. 30, 2016
Stockholders' Equity Note [Abstract]  
STOCKHOLDERS' EQUITY
STOCKHOLDERS’ EQUITY
Common Stock.

Pursuant to our Third Amended and Restated Certificate of Incorporation, as amended, we currently have 150,000,000 shares of common stock authorized for issuance.
On February 2, 2012, we entered into definitive agreements with institutional and other accredited investors and raised approximately $22.0 million in a private placement financing (the “Private Placement”), which included an aggregate of $3.0 million in convertible notes issued in December 2011 to entities affiliated with Third Security, LLC, a related party, that automatically converted into shares of our common stock and warrants to purchase such common stock on the same terms as all investors in the Private Placement. Pursuant to the purchase agreement, we issued an aggregate of 1,583,333 shares of our common stock at a price per share of $12.00, as well as five-year warrants to purchase up to an aggregate of 823,333 shares of our common stock with an exercise price of $15.00 per share. In connection with the conversion of the convertible notes issued by us to the entities affiliated with Third Security, LLC, the entities received an aggregate of 250,000 shares of our common stock and 125,000 warrants on the same terms as all investors in the Private Placement. Craig-Hallum Capital Group LLC (“Craig-Hallum”) served as the sole placement agent for the offering. In consideration for services rendered as the placement agent in the offering, we agreed to (a) pay to the placement agent cash commissions equal to $1,330,000, or 7.0% of the gross proceeds received in the offering; (b) issue to the placement agent a five-year warrant to purchase up to 31,666 shares of our common stock (representing 2% of the shares sold in the Private Placement) with an exercise price of $15.00 per share and other terms that are the same as the terms of the warrants issued in the Private Placement; and (c) reimburse the placement agent for reasonable out-of-pocket expenses, including fees paid to the placement agent’s legal counsel, incurred in connection with the offering, which reimbursable expenses were not to exceed $125,000. The costs incurred to complete the Private Placement were recorded as a reduction in equity in the amount of $1.5 million. Net proceeds from this offering were used for general corporate and working capital purposes, primarily to accelerate development of several of our key initiatives.
On January 24, 2013, we entered into a Securities Purchase Agreement with certain institutional and other accredited investors pursuant to which we: (a) sold to the investors an aggregate of 1,383,333 shares of our common stock at a price per share of $6.00 for aggregate gross proceeds of approximately $8.3 million; and (b) issued to the investors warrants to purchase up to an aggregate of 691,655 shares of our common stock with an exercise price of $9.00 per share (the “2013 Offering”). The warrants may be exercised, in whole or in part, at any time from January 30, 2013 until January 30, 2018 and contain both cash and “cashless exercise” features. Affiliates of Third Security, LLC purchased an aggregate of 500,000 shares of common stock and warrants to purchase an aggregate of 250,000 shares of common stock in the 2013 Offering on the same terms as the other investors. Net proceeds from the 2013 Offering were used for general corporate and working capital purposes.
In connection with the 2013 Offering, we entered into a registration rights agreement with the investors (the “Registration Rights Agreement”). The Registration Rights Agreement required that we file with the SEC a registration statement to register for resale the shares of common stock sold and the shares of common stock issuable upon exercise of the warrants (the “Warrant Shares”) by March 16, 2013. The registration statement was filed with the SEC on March 15, 2013 and was declared effective by the SEC on March 29, 2013.
The 2013 Offering required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of the warrants decreased from $15.00 per share to $12.96 per share and the number of shares issuable upon exercise of the warrants increased from 948,333 to 1,097,600.
On October 22, 2014, we entered into a Securities Purchase Agreement with certain accredited investors (the “October 2014 Investors”), pursuant to which we, in a private placement, issued and sold to the October 2014 Investors (the “2014 Private Placement”) an aggregate of 730,776 shares of our common stock at a price per share of $3.25 for an aggregate purchase price of approximately $2.4 million, and warrants to purchase up to an aggregate of 365,388 shares of our common stock with an initial exercise price of $4.00 per share that are exercisable for the period from April 22, 2015 through April 22, 2020. In connection with the 2014 Private Placement, we also issued a warrant to purchase up to an aggregate of 9,230 shares of our common stock to one advisor. The warrants issued in the 2014 Private Placement include both cash and “cashless exercise” features.
The 2014 Private Placement required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the February 2012 common stock and warrant sale. The exercise price of the warrants decreased from $11.73 per share to $10.86 per share and the number of shares issuable upon exercise of the warrants increased from 1,212,665 to 1,309,785.
On December 31, 2014, we entered into the Note Purchase Agreement with the Investor pursuant to which we agreed to issue and sell the Initial Note to the Investor (the “Note Private Placement”). See Note 5 - “Debt-Convertible Promissory Notes” for additional information regarding the terms of the Initial Note. Pursuant to the terms of the Note Purchase Agreement, we are subject to certain registration obligations and we may be required to effect one or more other registrations to register for resale the shares of our common stock issued or issuable under the Initial Note in connection with certain “piggy-back” registration rights granted to the Investor.

The Note Private Placement required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the February 2012 common stock and warrant sale. The exercise price of the 2012 warrants decreased from $10.86 per share to $10.25 per share and the number of shares issuable upon exercise of the warrants increased from 1,309,785 to 1,387,685.

On January 15, 2015, we entered into the Note Purchase Agreement with the Additional Investors and, on January 20, 2015, issued and sold to the Additional Investors, in a private placement, the Additional Notes in an aggregate principal amount of $925,000 (the “Additional Note Private Placement”). The Additional Notes have the same terms and conditions as the Initial Note.

Craig-Hallum acted as the sole placement agent for the sale and issuance of the Additional Notes. In connection with the sale and issuance of the Additional Notes, we issued to Craig-Hallum an unsecured convertible promissory note, upon the same terms and conditions as the Notes, in an aggregate principal amount equal to 5% of the proceeds received by us pursuant to the sale and issuance of the Additional Notes, or $46,250 (the “Placement Agent Note”). As of the date of filing of this Quarterly Report on form 10-Q, the Placement Agent Note remains outstanding.

The Additional Note Private Placement required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of these warrants decreased from $10.25 per share to $9.59 per share and the number of shares issuable upon exercise of the warrants increased from 1,387,685 to 1,483,161.

On February 27, 2015, we entered into a purchase agreement with Craig-Hallum (the “Underwriter”) relating to our sale and issuance of 3,573,899 shares of our common stock and corresponding warrants to purchase up to 714,780 shares of our common stock (the “February 2015 Offering”). Each share of common stock was sold in combination with a warrant to purchase 0.20 of a share of common stock. The purchase price to the public for each share of common stock and accompanying warrant was $1.95.
The purchase price paid by the Underwriter to us for the common stock and accompanying warrants was $1.8135. The net proceeds from the February 2015 Offering, after deducting the Underwriter’s discount and other estimated February 2015 Offering expenses, were approximately $6.2 million.
The accompanying warrants are exercisable immediately upon their initial issuance date at an exercise price of $2.24 per share and will expire five years from the date of issuance. The exercise price will also be subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock.
The February 2015 Offering required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of these warrants decreased from $9.59 per share to $7.56 per share and the number of shares issuable upon exercise of the warrants increased from 1,483,161 to 1,881,396.
On June 30, 2015, we entered into a Securities Purchase Agreement with certain accredited investors (the “July 2015 Investors”) pursuant to which, on July 7, 2015, we sold to the July 2015 Investors (a) an aggregate of approximately 1.5 million shares of our common stock at a price per share of $1.42, (b) warrants (the “Series B Warrants”) to purchase up to an aggregate of 0.7 million shares of our common stock with an exercise price of $0.01 per share, and (c) warrants (the “Series A Warrants” and, together with the Series B Warrants, the “July 2015 Warrants”) to purchase up to an aggregate of 1.2 million shares of our common stock, with an exercise price of $1.66 per share (collectively, the “July 2015 Offering”). Each of the July 2015 Warrants has a term of 5 and 1/2 years. The Series B Warrants were immediately exercisable upon issuance. The Series A Warrants became exercisable on January 7, 2016, six months from the date of issuance. The aggregate gross proceeds to us from the July 2015 Offering were approximately $3.0 million.
Craig-Hallum (the “2015 Placement Agent”) served as the sole placement agent for the July 2015 Offering. In consideration for services rendered as the placement agent in the July 2015 Offering, we (a) paid to the 2015 Placement Agent cash commissions equal to approximately $212,783, or 7.0% of the gross proceeds received in the July 2015 Offering; (b) issued to the 2015 Placement Agent a five-year warrant to purchase up to 107,033 shares of our common stock with an exercise price of $1.66 per share and which is subject to other terms that are the same as the terms of the Series A Warrants; and (c) reimbursed the 2015 Placement Agent for reasonable out-of-pocket expenses, including fees paid to the 2015 Placement Agent’s legal counsel, incurred in connection with the July 2015 Offering, which reimbursable expenses did not exceed $50,000.
The July 2015 Offering required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of these warrants decreased from $7.56 per share to $6.50 per share and the number of shares issuable upon exercise of the warrants increased from 1,881,396 to 2,188,177.
On January 6, 2016, we entered into a Securities Purchase Agreement (the “SPA”) with certain accredited investors (the “2016 Investors”), pursuant to which, on January 8, 2016, we sold to the 2016 Investors, and the 2016 Investors purchased from us (the “January 2016 Offering”), an aggregate of approximately $2.2 million of units (the “Units”) consisting of (a) an aggregate of 2,365,243 shares (the “A-1 Preferred Shares”) of our Series A-1 Convertible Preferred Stock (the “A-1 Preferred”), and (b) warrants (the “2016 Warrants”) to purchase up to an aggregate of 1,773,929 shares of our common stock. Each Unit was sold to the 2016 Investors at a purchase price of $0.93 per Unit. The A-1 Preferred Shares are convertible into shares of our common stock at an initial rate of 1-for-1, which conversion rate is subject to further adjustment as set forth in our Certificate of Designation of Series A-1 Convertible Preferred Stock, which was filed with the Secretary of State of the State of Delaware on January 8, 2016 (the “Series A-1 Certificate of Designation”). Pursuant to the terms of the Series A-1 Certificate of Designation, the holders of the A-1 Preferred Shares will generally be entitled to that number of votes as is equal to the product obtained by multiplying: (i) the number of whole shares of our common stock into which the A-1 Preferred may be converted as of the record date of such vote or consent, by (ii) 0.93, rounded down to the nearest whole number. Therefore, every 1.075269 shares of A-1 Preferred will generally initially be entitled to one vote. In May 2016, 2,150,538 of the A-1 Preferred Shares were converted into 2,150,538 shares of our common stock. At June 30, 2016, there were 214,705 A-1 Preferred Shares outstanding.

The 2016 Warrants were immediately exercisable upon issuance, have a term of five years and have an exercise price of $1.21 per share of our common stock. Each 2016 Warrant includes both cash and “cashless exercise” features and an exchange feature whereby the holder of the 2016 Warrant may exchange (the “Exchange Right”) all or any portion of the 2016 Warrant for a number of shares of our common stock equal to the quotient obtained by dividing the “Exchange Amount” by the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrant is exchanged (the “Exchange Price”). Under the 2016 Warrants, the “Exchange Amount” is based upon a Black Scholes option pricing model, and the aggregate Exchange Amount under all of the 2016 Warrants will be $1,436,882, subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the date of issuance of the 2016 Warrants and the date the 2016 Warrants are exchanged. Each 2016 Warrant provides that the number of shares that may be issued upon exercise of the Exchange Right is limited to the number of shares that may be purchased pursuant to the terms of the 2016 Warrant, unless we have previously obtained stockholder approval or approval from The Nasdaq Stock Market LLC to issue any additional shares of our common stock (the “Additional Shares”) pursuant to the Exchange Right (the “Required Approvals”). For any Exchange Right exercised more than 90 days following the issuance of the 2016 Warrants, if we have not obtained either of the Required Approvals, we will be required to pay the 2016 Warrant holder an amount in cash for any Additional Shares that we cannot issue without the Required Approvals based on the Exchange Amount.

The 2016 Warrants further provide that, to the extent the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrant is exchanged is less than $0.50, the Exchange Price will be deemed to be equal to $0.50, and, in addition to issuing shares of our common stock based on this Exchange Price, we will be required to pay to the 2016 Warrant holder an amount in cash equal to the product obtained by multiplying (a) $0.50 minus the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrant is exchanged, by (b) the aggregate number of shares of our common stock issued to the 2016 Warrant holder by the Company in such exchange at an Exchange Price equal to $0.50. Therefore, if the Required Approvals are obtained, based on the Exchange Amount of $1,436,882 (which, as noted above, is subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the date of the issuance of the 2016 Warrants and the date the 2016 Warrants are exchanged), the maximum number of shares of our common stock issuable pursuant to the Exchange Right in the 2016 Warrants will be 2,873,765. In addition, if, for example, assuming an Exchange Amount of $1,436,882, the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrants are exchanged is $0.25, we would be required to pay to the 2016 Warrant holders cash in an aggregate amount of $718,441 in addition to issuing the 2016 Warrant holders 2,873,765 shares.

In accordance with the terms of the SPA, we amended that certain Series A Warrant to purchase up to an aggregate of 1,161,972 shares of our common stock previously issued by us to an affiliate of one of the 2016 Investors on July 7, 2015 (the “Original Warrant”), as previously reported by us on our Amendment No. 1 to Current Report on Form 8-K/A, filed with the SEC on July 7, 2015 (as so amended, the “Amended Warrant”). The Amended Warrant amends the Original Warrant to provide that the Amended Warrant is subject to the same terms and conditions as the 2016 Warrants and, therefore, includes both cash and “cashless exercise” features and an Exchange Right whereby the number of shares issuable pursuant to the Exchange Right is equal to the “Amended Warrant Exchange Amount”, which is based on a Black Scholes option pricing model, and will be $941,197, subject to adjustment to the extent that the risk-free U.S. treasury rate fluctuates between the date of issuance of the Amended Warrant and the date the Amended Warrant is exchanged. The Amended Warrant is exercisable for up to 1,161,972 shares of our common stock in the event we have obtained either of the Required Approvals with respect to the Amended Warrant. In the event the Amended Warrant holder exercises the Amended Warrant more than 90 days following the issuance of the Amended Warrant, if we have not obtained either of the Required Approvals, we will be required to pay the Amended Warrant holder an amount in cash for the shares of our common stock that we cannot issue under the Amended Warrant pursuant to such exercise without the Required Approvals based on the Amended Warrant Exchange Amount.

The Amended Warrant also provides that, to the extent the closing bid price of our common stock on the second trading day prior to the date the Amended Warrant is exchanged is less than $0.50, the Exchange Price will be deemed to be equal to $0.50, and, in addition to issuing shares of our common stock based on this Exchange Price (assuming receipt of the Required Approvals), we will be required to pay to the Amended Warrant holder an amount in cash equal to the product obtained by multiplying (a) $0.50 minus the closing bid price of our common stock on the second trading day prior to the date the Amended Warrant is exchanged, by (b) the aggregate number of shares of our common stock issued to the Amended Warrant holder by us in such exchange at an Exchange Price equal to $0.50. Therefore, if the Required Approvals are obtained, based on the Amended Warrant Exchange Amount of $941,197 (which, as noted above, is subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the issuance of the Amended Warrant and the date the Amended Warrant is exchanged), the maximum number of shares of our common stock issuable pursuant to the Exchange Right in the Amended Warrant will be 1,882,395. In addition, if, for example, assuming an Amended Warrant Exchange Amount of $941,197, the closing bid price of our common stock on the second trading day prior to the date the Amended Warrant is exchanged is $0.25, we would be required to pay to the Amended Warrant holder cash in an aggregate amount of $470,599 in addition to issuing the Amended Warrant holder 1,882,395 shares.

In connection with entering into the SPA, we also entered into a Registration Rights Agreement, dated January 8, 2016, with the 2016 Investors. Pursuant to the terms of the Registration Rights Agreement, we were required to file with the SEC a registration statement to register for resale the shares of our common stock issuable upon conversion of the A-1 Preferred Shares and the shares of our common stock issuable upon exercise of the 2016 Warrants and the Amended Warrant by January 25, 2016. We filed the required registration statement with the SEC on January 25, 2016.

Craig-Hallum (the “Placement Agent”) served as the sole placement agent for the January 2016 Offering. In consideration for services rendered as the Placement Agent in the January 2016 Offering, we (1) paid to the Placement Agent cash commissions equal to approximately $140,000, or 7.0% of the gross proceeds received in the January 2016 Offering, excluding any proceeds received from Third Security, LLC or any of its affiliates; (2) issued to the Placement Agent, for a price of $50, a five-year warrant to purchase up to 107,527 shares of our common stock at an exercise price of $1.21 per share (the “Agent Warrant”), which is subject to the same terms as the 2016 Warrants except that the Agent Warrant was not exercisable until July 8, 2016 and does not contain the Exchange Right; and (3) reimbursed the Placement Agent for reasonable out-of-pocket expenses, including fees paid to the Placement Agent’s legal counsel, incurred in connection with the January 2016 Offering, which reimbursable expenses did not exceed $50,000.

The January 2016 Offering and the payment of all accrued and unpaid dividends on the Series A Preferred Stock and Series B Preferred Stock in the form of shares of our common stock at a rate of $1.00 per share of our common stock discussed under “-Conversion of Preferred Stock” below required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of these warrants decreased to $4.39 per share and the number of shares issuable upon exercise of the warrants increased from 2,188,177 to 3,239,827.

On May 31, 2016, we issued to a vendor an aggregate of 78,000 shares of our common stock and, on June 14, 2016, we issued to a second vendor an aggregate of 64,153 shares of our common stock. Such shares of common stock were issued to the vendors in lieu of an aggregate cash amount of approximately $89,000 owed by us to such vendors for services previously performed by such vendors. We issued the shares to the vendors in transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder and in reliance on similar exemptions under applicable state laws. The offering of the shares to the vendors did not involve a public offering, and no general solicitation or advertisement was made in connection with the offering of the shares to the vendors.

On June 7, 2016, we entered into an At the Market Offering Agreement (the “ATM Agreement”) with Craig-Hallum, as sales agent, pursuant to which we may offer and sell, from time to time, through Craig-Hallum, up to $3,500,000 of shares (the “Shares”) of our common stock. Any Shares offered and sold in the offering will be issued pursuant to our effective shelf registration statement on Form S-3 (File No. 333-201907) and the related prospectus previously declared effective by the SEC on February 13, 2015, as supplemented by a prospectus supplement, dated June 7, 2016, that we filed with the SEC pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended (the “Securities Act”). The number of shares eligible for sale under the ATM Agreement will be subject to the limitations of General Instruction I.B.6 of Form S-3.

Under the terms of the ATM Agreement, we will pay Craig-Hallum a placement fee of 3.25% of the gross sales price of the Shares, unless Craig-Hallum acts as principal, in which case we may sell Shares to Craig-Hallum as principal at a price to be agreed upon by us and Craig-Hallum. We will also reimburse Craig-Hallum for certain expenses incurred in connection with the ATM Agreement, and agreed to provide indemnification and contribution to Craig-Hallum with respect to certain liabilities, including liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended.
 
During the three and six months ended June 30, 2016, we sold 115,314 shares under the ATM Agreement.  The average sales price per common share was $0.67 and the aggregate net proceeds from the sales totaled less than $0.1 million.    

During the three months ended June 30, 2016, the issuance of shares to our vendors and the sale of shares under the ATM Agreement required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of these warrants decreased to $4.36 per share and the number of shares issuable upon exercise of the warrants increased from 3,239,827 to 3,262,088.
Common Stock Warrants.
During the six months ended June 30, 2016 and 2015, we issued warrants to purchase 2,933,106 and 1,208,491 shares of common stock, respectively. None of the issued warrants were exercised during such periods. The warrants issued in the six months ended June 30, 2016 included 1,073,911 warrants issued due to repricing requirements of the Private Placement and 1,881,456 warrants issued in connection with the January 2016 Offering. The warrants issued in the six months ended June 30, 2015 included 493,711 warrants issued due to repricing requirements of the Private Placement and 714,780 warrants issued in connection with the February 2015 Offering. Warrants to purchase an aggregate of 8,876,166 shares of common stock were outstanding at June 30, 2016.
 
Warrant Holder
 
Issue Year
 
Expiration
 
Underlying
Shares
 
Exercise
Price
Various Institutional Holders(1)
 
2012
 
February 2017
 
2,832,069
 
$4.36
Affiliates of Third Security, LLC(1)
 
2012
 
February 2017
 
430,019
 
$4.36
Various Institutional Holders(2)
 
2013
 
January 2018
 
441,655
 
$9.00
Affiliates of Third Security, LLC(2)
 
2013
 
January 2018
 
250,000
 
$9.00
Various Institutional Holders(3)
 
2014
 
April 2020
 
374,618
 
$4.00
Various Institutional Holders(4)
 
2015
 
February 2020
 
714,780
 
$2.24
Various Institutional Holders(5)
 
2015
 
December 2020
 
122,433
 
$1.66
Various Institutional Holders(5)
 
2015
 
December 2020
 
667,164
 
$0.01
Various Institutional Holders(6)
 
2015
 
January 2021
 
1,161,972
 
$1.21
Affiliates of Third Security, LLC(7)
 
2016
 
January 2021
 
161,026
 
$1.21
Various Institutional Holders(7)
 
2016
 
January 2021
 
1,720,430
 
$1.21
 
 
 
 
 
 
8,876,166
 
 


(1)
These warrants were issued in connection with the Private Placement completed in February 2012 and are classified as a liability in our financial statements. See Note 9 - “Fair Value” for additional information. These warrants also contain certain anti-dilution provisions that provide for an adjustment to the exercise price and number of shares issuable upon exercise of the warrant in the event that we engage in certain issuances of shares of our common stock at a price lower than the exercise price of the warrant.
(2)
These warrants were issued in connection with the 2013 Offering, which was completed in January 2013.
(3)
These warrants were issued in connection with the 2014 Private Placement, which was completed in October 2014.
(4)
These warrants were issued in connection with the February 2015 Offering, which was completed in February 2015.
(5)
These warrants were issued in connection with the July 2015 Offering, which was completed in July 2015.
(6)
These warrants were originally issued in connection with the July 2015 Offering, which was completed in July 2015, and were amended in connection with the January 2016 Offering, which was completed in January 2016.
(7)
These warrants were issued in connection with the January 2016 Offering, which was completed in January 2016.
Issuance of Series B Preferred Stock.

On March 5, 2014, we entered into a Series B Convertible Preferred Stock Purchase Agreement (the “Series B Purchase Agreement”) with affiliates of Third Security, LLC (the “2014 Third Security Investors”), pursuant to which we, in a private placement, sold and issued an aggregate of 1,443,297 shares of our Series B Preferred Stock, par value $0.01 per share (the “Series B Preferred Stock”), at a price per share of $4.85 for an aggregate purchase price of approximately $7.0 million. Each share of Series B Preferred Stock issued pursuant to the Series B Purchase Agreement was initially convertible into shares of our common stock at a rate of 1-for-1, which conversion rate was subject to further adjustment as set forth in the Certificate of Designation of Series B Convertible Preferred Stock.

In connection with the Series B financing, we also entered into a Registration Rights Agreement, dated March 5, 2014, with the 2014 Third Security Investors, pursuant to which we granted certain demand, “piggy-back” and S-3 registrations rights covering the resale of the shares of common stock underlying the Series B Preferred Stock issued pursuant to the Series B Purchase Agreement and all shares of common stock issuable upon any dividend or other distribution with respect thereto.

The Series B financing required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of the warrants decreased from $12.96 per share to $11.73 per share and the number of shares issuable upon exercise of the warrants increased from 1,097,600 to 1,212,665.

Conversion of Preferred Stock.

On January 6, 2016, the Company entered into a Conversion Agreement (the “Conversion Agreement”) with the holders (the “Preferred Holders”) of all of the Company’s outstanding shares of Series A Convertible Preferred Stock, par value $0.01 per share (the “Series A Preferred Stock”), and Series B Preferred Stock, pursuant to which, among other things, the Preferred Holders: (a) elected to convert all of the outstanding shares of Series A Preferred Stock and Series B Preferred Stock into shares of our common stock, in each case in accordance with the terms thereof, and (b) agreed that all accrued and unpaid dividends on the Series A Preferred Stock and Series B Preferred Stock would be paid by the Company in shares of our common stock at a rate of $1.00 per share of our common stock (collectively, the “Conversion”).

The outstanding shares of Series A Preferred Stock were convertible into shares of our common stock at a rate of 1-for-3, and the outstanding shares of Series B Preferred Stock were convertible into shares of our common stock at a rate of 1-for-1. Prior to the entry into the Conversion Agreement, there were 2,586,205 shares of Series A Preferred Stock outstanding, which were converted into 862,057 shares of our common stock, and 1,443,297 shares of Series B Preferred Stock outstanding, which were converted into 1,443,297 shares of our common stock, for an aggregate of 2,305,354 shares of our common stock issued upon conversion of the Series A Preferred Stock and Series B Preferred Stock (the “Conversion Shares”). At the time of the entry into the Conversion Agreement, there were $3,681,591.90 in accrued and unpaid dividends on the outstanding shares of Series A Preferred Stock, which were converted, in accordance with the Conversion Agreement, into 3,681,590 shares of our common stock, and $793,236.17 in accrued and unpaid dividends on the outstanding shares of Series B Preferred Stock, which were converted, in accordance with the terms of the Conversion Agreement, into 793,235 shares of our common stock, for an aggregate of 4,474,825 shares of our common stock issued pursuant to the accrued and unpaid dividends on the Series A Preferred Stock and Series B Preferred Stock. Therefore, in connection with the full conversion of the Series A Preferred Stock and Series B Preferred Stock, plus the conversion of all accrued and unpaid dividends thereon, we issued an aggregate of 6,780,179 shares of our common stock to the Preferred Holders on January 6, 2016.

Following the conversion of the shares of Series A Preferred Stock and Series B Preferred Stock into common stock, no shares of Series A Preferred Stock or Series B Preferred Stock remain outstanding.
Preferred Stock Dividends.
We had cumulative undeclared dividends on our Series A Preferred Stock and Series B Preferred Stock of zero and $4.4 million at June 30, 2016 and December 31, 2015, respectively. Since dividends should generally not be recognized as a liability until declared, we had a recorded liability of zero for these undeclared dividends.
We had no undeclared dividends for the three months ended June 30, 2016. For the three months ended June 30, 2015 and the six months ended June 30, 2016 and 2015, we had undeclared dividends. In accordance with the FASB’s Accounting Standards Codification Topic 260-10-45-11, “Earnings per Share”, these dividends were added to the net loss per share calculation.
XML 25 R16.htm IDEA: XBRL DOCUMENT v3.5.0.2
FAIR VALUE
 6 Months Ended
Jun. 30, 2016
Fair Value Disclosures [Abstract]  
FAIR VALUE
FAIR VALUE

FASB guidance on fair value measurements, which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements for our financial assets and liabilities, as well as for other assets and liabilities that are carried at fair value on a recurring basis in our consolidated financial statements.
FASB guidance establishes a three-level fair value hierarchy based upon the assumptions (inputs) used to price assets or liabilities. The three levels of inputs used to measure fair value are as follows:
Level 1—Unadjusted quoted prices in active markets for identical assets or liabilities;
Level 2—Observable inputs other than those included in Level 1, such as quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets; and
Level 3—Unobservable inputs reflecting our own assumptions and best estimate of what inputs market participants would use in pricing the asset or liability.

Debt.
Our long term debt book value approximates fair market value due to the variable interest rate it bears.

Common Stock Warrant Liabilities.

Certain of our issued and outstanding warrants to purchase shares of common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability.

2012 Warrant Liability
The 2012 Warrant Liability represents the fair value of the 1.2 million warrants issued in February 2012, which, through a series of changes in exercise price since February 2012, are now exercisable for 3.3 million shares of common stock. We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our Statement of Operations. Management does not believe that this liability will be settled by a use of cash.
The 2012 Warrant Liability is considered a Level 3 financial instrument and is valued using a Monte Carlo simulation model. This method is well suited to valuing options with non-standard features, such as anti-dilution protection. A Monte Carlo simulation model uses repeated random sampling to simulate significant uncertainty in inputs. Assumptions and inputs used in the valuation of the common stock warrants are broken down into four sections: Static Business Inputs; Static Technical Inputs; Simulated Business Inputs; and Simulated Technical Inputs.
Static Business Inputs include: our equity value, which was estimated using our stock price of $0.55 as of June 30, 2016; the amount of the down-round financing; the timing of the down-round financing; and the expected exercise period of 0.61 years from the valuation date.
Static Technical Inputs include: volatility of 67% and the risk-free interest rate of 0.42% based on the 1-year U.S. Treasury yield interpolated from the six-month and one-year U.S. Treasury bonds.
Simulated Business Inputs include: the probability of down-round financing, which was estimated to be 100% for simulated equity values below the down-round financing cut-off point.
Simulated Technical Inputs include: our equity value follows a geometric Brownian motion and is simulated over weekly periods; and a down-round financing event that was randomly simulated in an iteration based on the 100% discrete probability of a down-round financing for those iterations where our simulated equity value at the expected timing of a down-round financing event was below the down-round financing cut-off point.

During the three and six months ended June 30, 2016 and 2015, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:
 
 
Dollars in Thousands
 
 
For the Three Months Ended
 
 
June 30, 2016
 
June 30, 2015
Beginning balance at April 1
 
$
20

 
$
290

Total (gains) or losses:
 

 
 
Recognized in earnings
 
(20
)
 
270

Balance at June 30
 
$
—

 
$
560


 
 
Dollars in Thousands
 
 
For the Six Months Ended
 
 
June 30, 2016
 
June 30, 2015
Beginning balance at January 1
 
$
350

 
$
145

Total (gains) or losses:
 
 
 
 
Recognized in earnings
 
(350
)
 
415

Balance at June 30
 
$
—

 
$
560



2016 Warrant Liability
The 2016 Warrant Liability represents the fair value of the 1.8 million warrants issued in January 2016. We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our Statement of Operations.
The Common Stock Warrant Liability is considered a Level 3 financial instrument and is valued using a binomial lattice simulation model. This method is well suited to valuing options with non-standard features. Assumptions and inputs used in the valuation of the common stock warrants include; our equity value, which was estimated using our stock price of $0.55 as of June 30, 2016; volatility of 135%; and a risk-free interest rate of 1.21%.
During the three and six months ended June 30, 2016, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:
 
 
Dollars in Thousands
 
 
 
For the Three Months Ended
 
 
 
June 30, 2016
 
Beginning balance at April 1
 
$
1,446

 
Total (gains) or losses:
 
 
 
Recognized in earnings
 
(4
)
 
Balance at June 30
 
$
1,442

 
 
 
Dollars in Thousands
 
 
 
For the Six Months Ended
 
 
 
June 30, 2016
 
Beginning balance at January 1
 
$
—

 
Additions
 
1,437

 
Total (gains) or losses:
 
 
 
Recognized in earnings
 
5

 
Balance at June 30
 
$
1,442

 

The change in unrealized gains or losses of Level 3 liabilities was included in earnings and was reported in other income (expense) in our Statement of Operations.
XML 26 R17.htm IDEA: XBRL DOCUMENT v3.5.0.2
STOCK OPTIONS
 6 Months Ended
Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
STOCK OPTIONS
STOCK OPTIONS
 
Stock Options.

The following table summarizes stock option activity during the six months ended June 30, 2016:
 
 
Number of
Options
 
Weighted-Average
Exercise Price
Outstanding at January 1, 2016
1,107,794

 
$
3.45

Granted
14,000

 
1.07

Forfeited
(121,140
)
 
3.69

Outstanding at June 30, 2016
1,000,654

 
$
3.39

Exercisable at June 30, 2016
648,246

 
$
4.01


    
During the six months ended June 30, 2016, we granted options to purchase 14,000 shares of our common stock at a weighted-average exercise price of $1.07 per share under our 2006 Equity Incentive Plan, as amended (the “Plan”). Options to purchase an aggregate of 608,910 shares of our common stock were granted during the six months ended June 30, 2015.

As of June 30, 2016, there were 648,246 options exercisable and 980,388 options that were vested or expected to vest with an aggregate intrinsic value of zero.

Stock Appreciation Rights (“SARs”)

The following table summarizes SARs activity under the Plan during the six months ended June 30, 2016:
 
Number of
SARs
 
Weighted-Average
Exercise Price
Outstanding at January 1, 2016
98,333

 
$
4.14

Outstanding at June 30, 2016
98,333

 
$
4.14

Exercisable at June 30, 2016
84,445

 
$
4.21



All outstanding SARs were issued solely to our executive officers.

As of June 30, 2016, 84,445 shares subject to outstanding SARs were exercisable and 98,333 shares were vested or expected to vest. The weighted-average exercise price of these SARs was $4.14 per share and the aggregate intrinsic value was zero.
XML 27 R18.htm IDEA: XBRL DOCUMENT v3.5.0.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 6 Months Ended
Jun. 30, 2016
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation.
The accompanying condensed consolidated financial statements are presented in conformity with GAAP. All amounts are presented in U.S. Dollars (“$”). Supplemental cash flows from discontinued operations are presented in Note 3 - “Discontinued Operations”. We have evaluated events occurring subsequent to June 30, 2016 for potential recognition or disclosure in the consolidated financial statements and concluded there were no subsequent events that required recognition or disclosure.
The condensed consolidated balance sheet as of December 31, 2015 was derived from our audited balance sheet as of that date. There has been no change in the balance sheet from December 31, 2015. The accompanying condensed consolidated financial statements as of and for the three and six months ended June 30, 2016 and 2015 are unaudited and reflect all adjustments (consisting of only normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the interim periods. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2015 contained in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on April 14, 2016. The results of operations for the interim periods presented are not necessarily indicative of the results for fiscal year 2016.
Reclassification
Certain prior year amounts have been reclassified to conform to the current year presentation in our condensed consolidated financial statements, which consists of the effects of reclassifications from the presentation of our discontinued operations.
Principles of Consolidation
Principles of Consolidation.
The condensed consolidated financial statements include the accounts of Transgenomic, Inc. and our wholly owned subsidiary. All inter-company balances and transactions have been eliminated in consolidation.
Risks and Uncertainties
Risks and Uncertainties.
Certain risks and uncertainties are inherent in our day-to-day operations and in the process of preparing our financial statements. The more significant of those risks are presented below and throughout the notes to the unaudited condensed consolidated financial statements.
Use of Estimates
Use of Estimates.
The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of net sales and expenses during the reporting period. In addition, estimates and assumptions associated with the determination of the fair value of certain assets and related impairments require considerable judgment by management. Actual results could differ from the estimates and assumptions used in preparing these condensed consolidated financial statements.
Fair Value
Fair Value.
Unless otherwise specified, book value approximates fair market value. The common stock warrant liability is recorded at fair value.
Cash and Cash Equivalents
Cash and Cash Equivalents and Other Current Assets.
Cash and cash equivalents include cash and investments with original maturities at the date of acquisition of three months or less.
Concentrations of Cash
Concentrations of Cash.
From time to time, we may maintain a cash position with financial institutions in amounts that exceed federally insured limits.
Accounts Receivable
While payment terms are generally 30 days, we have also provided extended payment terms in certain cases. Accounts receivable are carried at original invoice amount and shown net of allowance for doubtful accounts. The estimate made for doubtful accounts is based on a review of all outstanding amounts on a quarterly basis. We determine the allowance for doubtful accounts by regularly evaluating individual payor receivables and considering a payor’s financial condition, credit history, reimbursement rates and current economic conditions. Accounts receivable are written off when deemed uncollectible and after all collection efforts have been exhausted. Recoveries of accounts receivable previously written off are recorded as a reduction in bad debt expense when received.
Property and Equipment
Property and Equipment.
Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets as follows:
 
Leasehold improvements
1 to 10 years
Furniture and fixtures
3 to 7 years
Production equipment
3 to 7 years
Computer equipment
3 to 7 years
Research and development equipment
2 to 7 years
Intangible Assets
Intangible Assets.
Intangible assets include intellectual property and patents.
1. Intellectual Property.    Initial costs paid to license intellectual property from independent third parties are capitalized and amortized using the straight-line method over the license period. Ongoing royalties related to such licenses are expensed as incurred.
2. Patents.    We capitalize legal costs, filing fees and other expenses associated with obtaining patents on new discoveries and amortize these costs using the straight-line method over the shorter of the legal life of the patent or its economic life beginning on the date the patent is issued.
Stock-Based Compensation
Stock-Based Compensation.
All stock-based awards to date have exercise prices equal to the market value of the shares at the date of grant and have 10-year contractual terms. Unvested awards as of June 30, 2016 had vesting periods of up to three years from the date of grant. None of the awards outstanding at June 30, 2016 are subject to performance or market-based vesting conditions.
We measure and recognize compensation expense for all stock-based awards made to employees and directors. Compensation expense, net of estimated forfeitures, is based on the calculated fair value of the awards as measured at the grant date and is expensed over the service period of the awards.
Net Sales Recognition
Net Sales Recognition.
Revenue is realized and earned when all of the following criteria are met:
•
Persuasive evidence of an arrangement exists;
•
Delivery has occurred or services have been rendered;
•
The seller’s price to the buyer is fixed or determinable; and
•
Collectability is reasonably assured.

In our Biomarker Identification laboratory, we perform services on a project by project basis. When we receive payment in advance, we initially defer the revenue and recognize it when we deliver the service. These projects typically do not extend beyond one year. At each of June 30, 2016 and December 31, 2015, deferred net sales associated with pharmacogenomics research projects included in the balance sheet in deferred revenue was $0.1 million.

Net sales from Patient Testing laboratories, reported as part of discontinued operations, are recognized on an individual test basis and take place when the test report is completed, reviewed and sent to the client less the reserve for insurance, Medicare and Medicaid contractual adjustments. There are no deferred net sales associated with our Patient Testing services. Adjustments to the allowances, based on actual receipts from third party payers, are reflected in the estimated contractual allowance applied prospectively. In the fourth quarter of 2015, we adjusted our contractual allowance rates to better reflect the reimbursement level we expect to achieve on Patient Testing billings. The adjustment negatively impacted our Patient Testing revenues for all periods after the third quarter of 2015. (See Note 3 - “Discontinued Operations”).

Net sales of Genetic Assays and Platforms products, reported as discontinued operations (See Note 3 - “Discontinued Operations”) are recognized in accordance with the terms of the sales arrangement. Such recognition is based on receipt of an unconditional customer order and transfer of title and risk of ownership to the customer, typically upon shipment of the product under a purchase order. Our sales terms do not provide for the right of return unless the product is damaged or defective. Net sales from certain services associated with the analytical instruments, to be performed subsequent to shipment of the products, is deferred and recognized when the services are provided. Such services, mainly limited to installation and training services that are not essential to the functionality of the instruments, typically are performed in a timely manner subsequent to shipment of the instrument. We also enter into various service contracts that cover installed instruments. These contracts cover specific time periods and net sales associated with these contracts are deferred and recognized ratably over the service period.
Common Stock Warrants
Common Stock Warrants.
Certain of our issued and outstanding warrants to purchase common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability (“Common Stock Warrant Liability”). We are required to present these instruments at fair value at each reporting date and any changes in fair values are recorded as an adjustment to earnings. The Common Stock Warrant Liabilities are considered Level Three financial instruments for purposes of fair value measurement.
Loss Per Share
Loss Per Share.
Basic loss per share is calculated based on the weighted-average number of common shares outstanding during each period. Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock.
Recent Accounting Pronouncements
Recent Accounting Pronouncements.
In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (“ASU No. 2014-09”). This guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to a customer. ASU No. 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. In July 2015, the FASB decided to defer the effective date of this new accounting guidance by one year. As a result, ASU No. 2014-09 will be effective for us for all annual and interim reporting periods beginning after December 15, 2017 and early adoption would be permitted as of the original effective date. The new standard permits the use of either the retrospective or cumulative effect transition method. We do not expect to early adopt this guidance and we have not selected a transition method. We are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows.

In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40)(“ASU No. 2014-15”). This guidance addresses management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2016. Early adoption is permitted. We do not expect to early adopt this guidance and do not believe that the adoption of this guidance will have a material impact on our consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard amends the recognition of lease assets and lease liabilities by lessees for those leases currently classified as operating leases and amends disclosure requirements associated with leasing arrangements. The new standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently assessing the impact that the adoption of this ASU will have on our consolidated financial statements.
In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard simplifies several aspects related to the accounting for share-based payment transactions, including the accounting for income taxes, statutory tax withholding requirements, forfeitures and classification on the statement of cash flows. This guidance is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2016; however, early adoption is permitted. We do not expect to early adopt this guidance and are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows.
XML 28 R19.htm IDEA: XBRL DOCUMENT v3.5.0.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 6 Months Ended
Jun. 30, 2016
Accounting Policies [Abstract]  
Summary of activity for the allowance for doubtful accounts
The following is a summary of activity for the allowance for doubtful accounts from continuing operations during the three and six months ended June 30, 2016 and 2015: 
 
Dollars in Thousands
 
Beginning
Balance
 
Additions
 
Deductions
 
Ending
Balance
Three Months Ended June 30, 2016
$
108

 
$
49

 
$
—

 
$
157

Three Months Ended June 30, 2015
$
20

 
$
—

 
$
—

 
$
20

Six Months Ended June 30, 2016
$
87

 
$
70

 
$
—

 
$
157

Six Months Ended June 30, 2015
$
20

 
$
—

 
$
—

 
$
20
Activity for the allowance for obsolete inventory
The following is a summary of activity for the allowance for obsolete inventory during the three and six months ended June 30, 2016 and 2015: 
 
Dollars in Thousands
 
Beginning
Balance
 
Additions
 
Deductions
 
Ending
Balance
Three Months Ended June 30, 2016
$
63

 
$
—

 
$
—

 
$
63

Three Months Ended June 30, 2015
$
—

 
$
—

 
$
—

 
$
—

Six Months Ended June 30, 2016
$
63

 
$
—

 
$
—

 
$
63

Six Months Ended June 30, 2015
$
—

 
$
—

 
$
—

 
$
—
Schedule of property and equipment, useful lives
Depreciation is computed using the straight-line method over the estimated useful lives of the related assets as follows:
 
Leasehold improvements
1 to 10 years
Furniture and fixtures
3 to 7 years
Production equipment
3 to 7 years
Computer equipment
3 to 7 years
Research and development equipment
2 to 7 years
XML 29 R20.htm IDEA: XBRL DOCUMENT v3.5.0.2
DISCONTINUED OPERATIONS (Tables)
 6 Months Ended
Jun. 30, 2016
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of discontinued operations impact on income statement and balance sheets
esults of the discontinued operations consisted of the following:
 
Three months ended June 30,
 
Six months ended June 30,
(Dollars in thousands)
2016
 
2015
 
2016
 
2015
Net sales
$
574

 
$
6,598

 
$
1,677

 
$
12,361

Cost of goods sold
11

 
3,703

 
1,194

 
6,777

Gross profit
563

 
2,895

 
483

 
5,584

Selling, general and administrative expense
344

 
3,165

 
1,369

 
6,415

Research and development expense
—

 
108

 
68

 
224

Operating income (loss) from discontinued operations
219

 
(378
)
 
(954
)
 
(1,055
)
Gain on sale of business/assets
963

 
—

 
963

 
—

Income (loss) from discontinued operations before income taxes
1,182

 
(378
)
 
9

 
(1,055
)
Income tax expense
—

 
43

 
—

 
89

Income (loss) from discontinued operations, net of taxes
$
1,182

 
$
(421
)
 
$
9

 
$
(1,144
)
Assets and liabilities of the discontinued operations are classified as assets held for sale and liabilities held for sale in the condensed consolidated balance sheets and consisted of the following:
 
Dollars in Thousands
 
June 30,
2016
 
December 31,
2015
ASSETS
 
 
 
Accounts receivable, net
$
647

 
$
1,905

Other current assets
43

 
82

Total Assets
$
690

 
$
1,987

 
 
 
 
LIABILITIES
 
 
 
Accrued compensation
$
—

 
$
264

Total Liabilities
$
—

 
$
264

 
 
 
 

The following is a summary of activity for the allowance for doubtful accounts from discontinued operations during the three and six months ended June 30, 2016 and 2015. The allowance for doubtful accounts from discontinued operations is included in the assets held for sale in the condensed consolidated balance sheets.
 
Dollars in Thousands
 
Beginning
Balance
 
Additions
 
Deductions
 
Ending
Balance
Three Months Ended June 30, 2016
$
14,542

 
$
—

 
$
(4,080
)
 
$
10,462

Three Months Ended June 30, 2015
$
9,173

 
$
1,198

 
$
(1,965
)
 
$
8,406

Six Months Ended June 30, 2016
$
14,664

 
$
—

 
$
(4,202
)
 
$
10,462

Six Months Ended June 30, 2015
$
7,927

 
$
2,730

 
$
(2,251
)
 
$
8,406
XML 30 R21.htm IDEA: XBRL DOCUMENT v3.5.0.2
INTANGIBLES AND OTHER ASSETS (Tables)
 6 Months Ended
Jun. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of long-lived intangible assets
Long-lived intangible assets as of June 30, 2016 and December 31, 2015 consisted of the following:
 
Dollars in Thousands
 
June 30, 2016
 
Cost
 
Accumulated
Amortization
 
Net Book
Value
Patents
695

 
76

 
619

Intellectual property
672

 
262

 
410

 
$
1,367

 
$
338

 
$
1,029




 
Dollars in Thousands
 
December 31, 2015
 
Cost
 
Accumulated
Amortization
 
Net Book
Value
Patents
980

 
274

 
706

Intellectual property
671

 
207

 
464

 
$
1,651

 
$
481

 
$
1,170


 
 
 
Estimated Useful Life
Patents
Life of the patent
Intellectual property
7 years
XML 31 R22.htm IDEA: XBRL DOCUMENT v3.5.0.2
DEBT (Tables)
 6 Months Ended
Jun. 30, 2016
Debt Disclosure [Abstract]  
Schedule of debt
 
 
Dollars in Thousands
 
 
June 30, 2016
 
December 31, 2015
Revolving Line of Credit(1)
 
$
3,243

 
$
3,025

Term Loan(2)
 
4,000

 
4,000

Convertible Promissory Notes (3)
 
571

 
571

Total debt
 
7,814

 
7,596

Current portion of long-term debt
 
(7,814
)
 
(7,596
)
Long-term debt, net of current maturities
 
$
—

 
$
—

 
(1)
Revolving Line of Credit. Amounts advanced under the Revolving Line accrue interest at an annual rate equal to the greater of (a) 6.25% or (b) the Wall Street Journal prime rate plus 3%. The current interest rate is 6.50%. Interest is payable on a monthly basis, with the balance payable at the maturity of the Revolving Line. Under the Loan Agreement, we pay the Lenders a commitment fee of $20,000 on each one-year anniversary of March 13, 2013, the Effective Date, during the term of the Revolving Line. In addition, a fee of 0.5% per annum is payable quarterly on the unused portion of the Revolving Line. The Revolving Line matures on November 1, 2017.

(2)
Term Loan. We received $4.0 million under the Term Loan on the Effective Date. Pursuant to the terms of the Loan Agreement, as amended, the maturity date of the Loan Agreement was extended until November 1, 2017 and no principal payments on the Term Loan are due until such date. The current interest rate is 9.1%.

We will pay the Lenders an additional final payment of $120,000 at maturity or prepayment of the Term Loan. In addition, if we repay the Term Loan prior to maturity, we will pay the Lenders a prepayment penalty of 1% of the total outstanding balance under the Term Loan.

Additional Terms.
The Loan Agreement contains affirmative and negative covenants. Under the Term Loan, we agreed not to (i) pledge or otherwise encumber our assets other than to the Lenders, (ii) enter into additional borrowings or guarantees, (iii) repurchase our capital stock, or (iv) enter into certain mergers or acquisitions without the Lenders’ consent. Additionally, the Loan Agreement contains a subjective acceleration clause at the discretion of the Lenders. As of June 30, 2016, the Company was in compliance with the Loan Agreement, as amended by the Ninth Amendment, however, as of August 12, 2016 we have not made the required July 2016 interest payment and have not received a waiver for the non-compliance and as such all debt has been classified as current at June 30, 2016.

To secure the repayment of any amounts borrowed under the Revolving Line and the Term Loan, we granted the Lenders a security interest in all of our assets. The occurrence of an event of default under the Loan Agreement could result in the acceleration of our obligations under the Loan Agreement, would increase the applicable interest rate under the Revolving Line or Term Loan (or both) by 5% and would permit the Lenders to exercise remedies with respect to the collateral under the Loan Agreement. As of the date these financials were available for release, the Lenders have not exercised the remedies under the Loan Agreement.

(3) Convertible Promissory Notes. The Notes accrue interest at a rate of 6% per year and mature on December 31, 2016.

XML 32 R23.htm IDEA: XBRL DOCUMENT v3.5.0.2
STOCKHOLDERS' EQUITY (Tables)
 6 Months Ended
Jun. 30, 2016
Stockholders' Equity Note [Abstract]  
Schedule of stockholders' equity, including warrants and rights
Warrant Holder
 
Issue Year
 
Expiration
 
Underlying
Shares
 
Exercise
Price
Various Institutional Holders(1)
 
2012
 
February 2017
 
2,832,069
 
$4.36
Affiliates of Third Security, LLC(1)
 
2012
 
February 2017
 
430,019
 
$4.36
Various Institutional Holders(2)
 
2013
 
January 2018
 
441,655
 
$9.00
Affiliates of Third Security, LLC(2)
 
2013
 
January 2018
 
250,000
 
$9.00
Various Institutional Holders(3)
 
2014
 
April 2020
 
374,618
 
$4.00
Various Institutional Holders(4)
 
2015
 
February 2020
 
714,780
 
$2.24
Various Institutional Holders(5)
 
2015
 
December 2020
 
122,433
 
$1.66
Various Institutional Holders(5)
 
2015
 
December 2020
 
667,164
 
$0.01
Various Institutional Holders(6)
 
2015
 
January 2021
 
1,161,972
 
$1.21
Affiliates of Third Security, LLC(7)
 
2016
 
January 2021
 
161,026
 
$1.21
Various Institutional Holders(7)
 
2016
 
January 2021
 
1,720,430
 
$1.21
 
 
 
 
 
 
8,876,166
 
 


(1)
These warrants were issued in connection with the Private Placement completed in February 2012 and are classified as a liability in our financial statements. See Note 9 - “Fair Value” for additional information. These warrants also contain certain anti-dilution provisions that provide for an adjustment to the exercise price and number of shares issuable upon exercise of the warrant in the event that we engage in certain issuances of shares of our common stock at a price lower than the exercise price of the warrant.
(2)
These warrants were issued in connection with the 2013 Offering, which was completed in January 2013.
(3)
These warrants were issued in connection with the 2014 Private Placement, which was completed in October 2014.
(4)
These warrants were issued in connection with the February 2015 Offering, which was completed in February 2015.
(5)
These warrants were issued in connection with the July 2015 Offering, which was completed in July 2015.
(6)
These warrants were originally issued in connection with the July 2015 Offering, which was completed in July 2015, and were amended in connection with the January 2016 Offering, which was completed in January 2016.
(7)
These warrants were issued in connection with the January 2016 Offering, which was completed in January 2016.
XML 33 R24.htm IDEA: XBRL DOCUMENT v3.5.0.2
FAIR VALUE (Tables)
 6 Months Ended
Jun. 30, 2016
Fair Value Disclosures [Abstract]  
Schedule of changes in fair value of liability
During the three and six months ended June 30, 2016, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:
 
 
Dollars in Thousands
 
 
 
For the Three Months Ended
 
 
 
June 30, 2016
 
Beginning balance at April 1
 
$
1,446

 
Total (gains) or losses:
 
 
 
Recognized in earnings
 
(4
)
 
Balance at June 30
 
$
1,442

 
 
 
Dollars in Thousands
 
 
 
For the Six Months Ended
 
 
 
June 30, 2016
 
Beginning balance at January 1
 
$
—

 
Additions
 
1,437

 
Total (gains) or losses:
 
 
 
Recognized in earnings
 
5

 
Balance at June 30
 
$
1,442

 
During the three and six months ended June 30, 2016 and 2015, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:
 
 
Dollars in Thousands
 
 
For the Three Months Ended
 
 
June 30, 2016
 
June 30, 2015
Beginning balance at April 1
 
$
20

 
$
290

Total (gains) or losses:
 

 
 
Recognized in earnings
 
(20
)
 
270

Balance at June 30
 
$
—

 
$
560


 
 
Dollars in Thousands
 
 
For the Six Months Ended
 
 
June 30, 2016
 
June 30, 2015
Beginning balance at January 1
 
$
350

 
$
145

Total (gains) or losses:
 
 
 
 
Recognized in earnings
 
(350
)
 
415

Balance at June 30
 
$
—

 
$
560
XML 34 R25.htm IDEA: XBRL DOCUMENT v3.5.0.2
STOCK OPTIONS (Tables)
 6 Months Ended
Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Summary of stock option activity
The following table summarizes stock option activity during the six months ended June 30, 2016:
 
 
Number of
Options
 
Weighted-Average
Exercise Price
Outstanding at January 1, 2016
1,107,794

 
$
3.45

Granted
14,000

 
1.07

Forfeited
(121,140
)
 
3.69

Outstanding at June 30, 2016
1,000,654

 
$
3.39

Exercisable at June 30, 2016
648,246

 
$
4.01
Summary of SARs activity
The following table summarizes SARs activity under the Plan during the six months ended June 30, 2016:
 
Number of
SARs
 
Weighted-Average
Exercise Price
Outstanding at January 1, 2016
98,333

 
$
4.14

Outstanding at June 30, 2016
98,333

 
$
4.14

Exercisable at June 30, 2016
84,445

 
$
4.21
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.5.0.2
BUSINESS DESCRIPTION (Details)
$ in Millions
 6 Months Ended
Jun. 30, 2016
USD ($)
operating_segments
Jun. 30, 2015
operating_segments
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Number of operating segments | operating_segments 1 2
Working capital | $ $ (15.9)  
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.5.0.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narratives) (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Other current assets $ 325   $ 325   $ 537
Current prepaid expense 100   100    
Other current receivables 200   $ 200    
Share-based compensation arrangement by share-based payment award, expiration period     10 years    
Stock-based compensation expense     $ 119 $ 322  
Unrecognized compensation expense related to unvested stock awards, not yet recognized $ 200   $ 200    
Unvested stock options, unrecognized compensation expense weighted average recognition period     1 year 2 months 1 day    
Stock options, granted (in shares) 0   14,000 608,910  
Stock options, fair value assumptions, risk free interest rate (as a percent)     1.91%    
Stock options, fair value assumptions, dividend yield     0.00%    
Stock options, fair value assumptions, expected life     6 years    
Stock options, fair value assumptions, historical volatility rate (as a percent)     85.00%    
Common stock rights issued (in shares)     2,933,106 1,208,491  
Deferred revenue $ 111   $ 111   217
Options, warrants and conversion rights, common stock callable and antidilutive (in shares)     10,721,464 8,286,963  
Pharmacogenomic Services          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Deferred revenue 100   $ 100   $ 100
Executive Officers          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock options, unvested options, vesting period     3 years    
Common stock rights issued (in shares)     98,333    
Selling, General and Administrative Expenses          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock-based compensation expense $ 100 $ 200 $ 100 $ 300  
Maximum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock options, unvested options, vesting period     3 years    
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.5.0.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Accounts Receivable) (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Allowance for Doubtful Accounts Receivable [Roll Forward]        
Beginning balance $ 108 $ 20 $ 87 $ 20
Additions 49 0 70 0
Deductions 0 0 0 0
Ending balance $ 157 $ 20 $ 157 $ 20
Accounts receivable, general payment terms     30 days  
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.5.0.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Inventories) (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Accounting Policies [Abstract]        
Net raw materials inventory $ 100   $ 100  
Obsolete inventory [Roll Forward]        
Beginning Balance 63 $ 0 63 $ 0
Additions 0 0 0 0
Deductions 0 0 0 0
Ending Balance $ 63 $ 0 $ 63 $ 0
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.5.0.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Property, Plant and Equipment) (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Property, Plant and Equipment [Line Items]        
Depreciation expense $ 0.1 $ 0.1 $ 0.1 $ 0.1
Leasehold Improvements | Minimum        
Property, Plant and Equipment [Line Items]        
Property and equipment, estimated useful lives     1 year  
Leasehold Improvements | Maximum        
Property, Plant and Equipment [Line Items]        
Property and equipment, estimated useful lives     10 years  
Furniture and Fixtures | Minimum        
Property, Plant and Equipment [Line Items]        
Property and equipment, estimated useful lives     3 years  
Furniture and Fixtures | Maximum        
Property, Plant and Equipment [Line Items]        
Property and equipment, estimated useful lives     7 years  
Production Equipment | Minimum        
Property, Plant and Equipment [Line Items]        
Property and equipment, estimated useful lives     3 years  
Production Equipment | Maximum        
Property, Plant and Equipment [Line Items]        
Property and equipment, estimated useful lives     7 years  
Computer Equipment | Minimum        
Property, Plant and Equipment [Line Items]        
Property and equipment, estimated useful lives     3 years  
Computer Equipment | Maximum        
Property, Plant and Equipment [Line Items]        
Property and equipment, estimated useful lives     7 years  
Research and Development Equipment | Minimum        
Property, Plant and Equipment [Line Items]        
Property and equipment, estimated useful lives     2 years  
Research and Development Equipment | Maximum        
Property, Plant and Equipment [Line Items]        
Property and equipment, estimated useful lives     7 years  
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.5.0.2
DISCONTINUED OPERATIONS (Narratives) (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Dec. 31, 2015
Nov. 25, 2015
Sep. 08, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
INCOME (LOSS) FROM DISCONTINUED OPERATIONS, NET OF TAXES $ 1,182 $ (421) $ 9 $ (1,144)      
Genetic Assays and Platforms business              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Purchase price             $ 2,100
(Loss) gain on sale of business         $ 1,500    
ADSTEC Corporation | Genetic Assays and Platforms business              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Purchase price           $ 300  
(Loss) gain on sale of business         $ (1,700)    
Discontinued operations | Patient Testing [Member]              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
INCOME (LOSS) FROM DISCONTINUED OPERATIONS, NET OF TAXES $ 1,000   $ 1,000        
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.5.0.2
DISCONTINUED OPERATIONS (Revenues and Net Income (Loss)) (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Dec. 31, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Income (loss) from discontinued operations, net of taxes $ 1,182 $ (421) $ 9 $ (1,144)  
Genetic Assays and Platforms business          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Gain on sale of business/assets         $ 1,500
Genetic Assays and Platforms and Patient Testing          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Net sales     1,677 12,361  
Cost of goods sold     1,194 6,777  
Gross profit     483 5,584  
Selling, general and administrative expense     1,369 6,415  
Operating income (loss) from discontinued operations 219 (378) (954) (1,055)  
Gain on sale of business/assets 963 0 963 0  
Income (loss) from discontinued operations before income taxes     9 (1,055)  
Income tax expense     0 89  
Income (loss) from discontinued operations, net of taxes     9 (1,144)  
Discontinued operations | Genetic Assays and Platforms and Patient Testing          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Net sales 574 6,598      
Cost of goods sold 11 3,703      
Gross profit 563 2,895      
Selling, general and administrative expense 344 3,165      
Research and development expense 0 108 $ 68 $ 224  
Income (loss) from discontinued operations before income taxes 1,182 (378)      
Income tax expense 0 43      
Income (loss) from discontinued operations, net of taxes $ 1,182 $ (421)      
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.5.0.2
DISCONTINUED OPERATIONS (Assets and Liabilities Held for Sale) (Details) - Discontinued operations - Genetic Assays and Platforms and Patient Testing - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
ASSETS    
Accounts receivable, net $ 647 $ 1,905
Other current assets 43 82
Total Assets 690 1,987
LIABILITIES    
Accrued compensation 0 264
Total Liabilities $ 0 $ 264
XML 43 R34.htm IDEA: XBRL DOCUMENT v3.5.0.2
DISCONTINUED OPERATIONS (Allowance for Doubtful Accounts) (Details) - Genetic Assays and Platforms and Patient Testing - Discontinued operations - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Disposal Group, Including Discontinued Operations, Allowance for Doubtful Accounts [Roll Forward]        
Beginning Balance $ 14,542 $ 9,173 $ 14,664 $ 7,927
Additions 0 1,198 0 2,730
Deductions (4,080) (1,965) (4,202) (2,251)
Ending Balance $ 10,462 $ 8,406 $ 10,462 $ 8,406
XML 44 R35.htm IDEA: XBRL DOCUMENT v3.5.0.2
INTANGIBLES AND OTHER ASSETS (Details) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Dec. 31, 2015
Finite-Lived Intangible Assets, Net [Abstract]      
Cost $ 1,367   $ 1,651
Accumulated Amortization 338   481
Net Book Value 1,029   1,170
Amortization expense for intangible assets 100 $ 100  
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]      
Amortization expense, 2016 100    
Amortization expense, 2017 100    
Amortization expense, 2018 100    
Amortization expense, 2019 100    
Amortization expense, 2020 100    
Patents      
Finite-Lived Intangible Assets, Net [Abstract]      
Cost 695   980
Accumulated Amortization 76   274
Net Book Value 619   706
Intellectual property      
Finite-Lived Intangible Assets, Net [Abstract]      
Cost 672   671
Accumulated Amortization 262   207
Net Book Value $ 410   $ 464
Estimated Useful Life 7 years    
XML 45 R36.htm IDEA: XBRL DOCUMENT v3.5.0.2
DEBT (Schedule of Debt) (Details) - USD ($)
 6 Months Ended
Jun. 30, 2016
Dec. 31, 2015
Dec. 31, 2014
Debt Instrument [Line Items]      
Total debt $ 7,814,000 $ 7,596,000  
Current portion of long-term debt (7,814,000) (7,596,000)  
Long-term debt, net of current maturities 0 0  
Line of credit | Revolving credit facility      
Debt Instrument [Line Items]      
Total debt $ 3,243,000 3,025,000  
Annual interest rate (as a percent) 6.25%    
Effective interest rate (as a percent) 6.50%    
Commitment fee amount $ 20,000    
Commitment fee (as a percent) 0.50%    
Line of credit | Revolving credit facility | Wall Street Journal prime rate      
Debt Instrument [Line Items]      
Basis spread on variable rate (as a percent) 3.00%    
Term loan      
Debt Instrument [Line Items]      
Total debt $ 4,000,000 4,000,000  
Proceeds from issuance of long-term debt $ 4,000,000    
Current interest rate (as a percent) 9.10%    
Future debt extinguishment costs $ 120,000    
Prepayment penalty percentage of outstanding balance (as a percent) 1.00%    
Increase in interest rate in case of debt default (as a percent) 5.00%    
Convertible promissory notes      
Debt Instrument [Line Items]      
Total debt $ 571,000 $ 571,000  
Annual interest rate (as a percent) 6.00%   6.00%
XML 46 R37.htm IDEA: XBRL DOCUMENT v3.5.0.2
DEBT (Revolving Line and Term Loan) (Details) - USD ($)
 6 Months Ended 13 Months Ended
Aug. 10, 2015
Mar. 13, 2013
Jun. 30, 2016
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2015
Sep. 04, 2015
Apr. 01, 2015
Dec. 31, 2014
Oct. 22, 2014
Oct. 21, 2014
Debt Instrument [Line Items]                      
Repayments of Notes Payable     $ 550,000 $ 148,000              
Proceeds from borrowings     500,000 $ 923,000              
Overadvance on Loan Agreement     $ 7,814,000     $ 7,596,000          
Line of credit | Revolving credit facility                      
Debt Instrument [Line Items]                      
Current borrowing capacity             $ 2,300,000     $ 3,000,000 $ 4,000,000
Payment to lenders to support the amount advanced $ 700,000                    
Term loan                      
Debt Instrument [Line Items]                      
Interest costs capitalized         $ 400,000            
Initial prepayment of a portion of the loan balance               $ 148,000      
Convertible notes payable                      
Debt Instrument [Line Items]                      
Face amount                 $ 750,000    
Third Security LLC and affiliates | Line of credit | Revolving credit facility                      
Debt Instrument [Line Items]                      
Current borrowing capacity   $ 4,000,000                  
Third Security LLC and affiliates | Term loan                      
Debt Instrument [Line Items]                      
Face amount   $ 4,000,000                  
PGxHealth, LLC | Senior secured promissory note                      
Debt Instrument [Line Items]                      
Debt term of note payable that was paid off   3 years                  
XML 47 R38.htm IDEA: XBRL DOCUMENT v3.5.0.2
DEBT (Convertible Promissory Notes) (Details)
 6 Months Ended
Dec. 31, 2014
USD ($)
$ / shares
Jun. 30, 2016
USD ($)
shares
Jan. 20, 2015
USD ($)
Jan. 15, 2015
investor
Additional notes        
Debt Instrument [Line Items]        
Number of additional accredited investors | investor       7
Convertible notes payable        
Debt Instrument [Line Items]        
Face amount $ 750,000      
Interest rate (as a percent) 6.00% 6.00%    
Number of shares converted | shares   502,786    
Convertible notes payable | Additional notes        
Debt Instrument [Line Items]        
Face amount     $ 925,000  
Number of shares converted | shares   281,023    
Conversion of convertible promissory notes   $ 400,000    
Convertible notes payable | Conversion, period one        
Debt Instrument [Line Items]        
Percentage of debt convertible 50.00%      
Threshold consecutive trading days 20 days      
Conversion price (in dollars per share) | $ / shares $ 2.20      
Convertible notes payable | Conversion, period two        
Debt Instrument [Line Items]        
Threshold consecutive trading days 15 days      
Conversion price as percentage of average closing price 85.00%      
XML 48 R39.htm IDEA: XBRL DOCUMENT v3.5.0.2
COMMITMENTS AND CONTINGENCIES (Details) - USD ($)
$ in Millions
 6 Months Ended
Jun. 23, 2016
Feb. 25, 2016
Jun. 30, 2016
Jun. 30, 2015
Dec. 31, 2015
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]          
Future minimum payments due, remainder of 2016     $ 0.4    
Future minimum payments due, 2017     0.7    
Future minimum payments due, 2018     0.7    
Future minimum payments due, 2019     0.7    
Future minimum payments due, 2020     0.7    
Future minimum payments, due thereafter     0.4    
Rent expense     0.1 $ 0.1  
Firm commitments to vendors     0.1    
UNMC | Threatened Litigation | Breach of contract          
Loss Contingencies [Line Items]          
Damages sought in a lawsuit   $ 0.7      
Accrual of possible loss in a lawsuit     0.7   $ 0.7
Mount Sinai | Threatened Litigation | Breach of contract          
Loss Contingencies [Line Items]          
Damages sought in a lawsuit $ 0.7        
Accrual of possible loss in a lawsuit     $ 0.7   $ 0.7
XML 49 R40.htm IDEA: XBRL DOCUMENT v3.5.0.2
INCOME TAXES (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Income Tax Disclosure [Abstract]        
Income tax expense (benefit) $ 0 $ (1) $ 0 $ (1)
XML 50 R41.htm IDEA: XBRL DOCUMENT v3.5.0.2
STOCKHOLDERS' EQUITY (Common Stock) (Details)
 1 Months Ended 3 Months Ended 6 Months Ended
Jun. 14, 2016
shares
Jun. 07, 2016
USD ($)
May 31, 2016
shares
Jan. 06, 2016
USD ($)
$ / shares
shares
Jul. 07, 2015
USD ($)
$ / shares
shares
Feb. 27, 2015
USD ($)
$ / shares
$ / unit
shares
Oct. 22, 2014
USD ($)
$ / shares
shares
Jan. 24, 2013
USD ($)
$ / shares
shares
Feb. 02, 2012
USD ($)
$ / shares
shares
May 31, 2016
shares
Dec. 31, 2011
USD ($)
Jun. 30, 2016
USD ($)
$ / shares
shares
Jun. 30, 2016
USD ($)
$ / shares
shares
Jun. 30, 2015
USD ($)
Dec. 31, 2015
$ / shares
shares
Jan. 20, 2015
USD ($)
Jan. 15, 2015
USD ($)
$ / shares
shares
Dec. 31, 2014
USD ($)
$ / shares
shares
Oct. 21, 2014
$ / shares
shares
Mar. 05, 2014
$ / shares
shares
Dec. 31, 2012
$ / shares
shares
Class of Stock [Line Items]                                          
Common stock, shares authorized (in shares)                       150,000,000 150,000,000   150,000,000            
Common stock, shares issued (in shares)                       23,103,875 23,103,875   13,915,691            
Private placement, net (in shares)       6,780,179 1,500,000                                
Share price (in dollars per share) | $ / shares         $ 1.42             $ 0.55 $ 0.55                
Issuance of common stock, net | $                         $ 68,000 $ 6,209,000              
Private placement, net | $                         $ 107,000                
Proceeds from issuance of common stock and warrants | $         $ 3,000,000                                
Preferred stock, shares issued (in shares)                       214,705 214,705   4,029,502            
Preferred stock, par value (in dollars per share) | $ / shares                       $ 0.01 $ 0.01   $ 0.01            
Preferred stock, shares outstanding (in shares)                       214,705 214,705   4,029,502            
Craig-Hallum Capital Group LLC                                          
Class of Stock [Line Items]                                          
Warrants term       5 years 5 years                                
Common stock warrant, exercise price (in dollars per share) | $ / shares       $ 1.21 $ 1.66                                
Payments of stock issuance costs | $       $ 140,000 $ 212,783                                
Payments of stock issuance costs, percentage of gross offering proceeds       7.00% 7.00%                                
Payments of stock issuance costs, warrant right to purchase common stock shares       107,527 107,033                                
Stock issuance costs, reimbursable expenses (not to exceed) | $       $ 50,000 $ 50,000                                
Proceeds from issuance of warrants | $       50                                  
Convertible notes payable                                          
Class of Stock [Line Items]                                          
Face amount | $                                   $ 750,000      
Third Security LLC and affiliates                                          
Class of Stock [Line Items]                                          
Common stock warrant, common stock called (in shares)               1,097,600                       1,212,665  
Common stock warrant, exercise price (in dollars per share) | $ / shares               $ 12.96                       $ 11.73  
Series A Warrants                                          
Class of Stock [Line Items]                                          
Warrants term         5 years 6 months                                
Warrants, period exercisable         6 months                                
Warrant exchange amount | $       $ 941,197                                  
Warrant exercise period not subject to cash payment       90 days                                  
Warrant exchange price threshold (in dollars per share) | $ / shares       $ 0.50                                  
Series A Warrants | Maximum                                          
Class of Stock [Line Items]                                          
Common stock warrant, common stock called (in shares)       1,161,972                                  
Series A Warrant, Cashless Exchange | Maximum                                          
Class of Stock [Line Items]                                          
Common stock warrant, common stock called (in shares)       1,882,395                                  
Series A-1 Warrant                                          
Class of Stock [Line Items]                                          
Common stock warrant, common stock called (in shares)       1,773,929                                  
Common stock warrant, exercise price (in dollars per share) | $ / shares       $ 1.21                                  
Warrants, period exercisable       5 years                                  
Warrant exchange amount | $       $ 1,436,882                                  
Warrant exercise period not subject to cash payment       90 days                                  
Warrant exchange price threshold (in dollars per share) | $ / shares       $ 0.50                                  
Series A-1 Warrant | Maximum                                          
Class of Stock [Line Items]                                          
Common stock warrant, common stock called (in shares)       2,873,765                                  
Series B Warrants                                          
Class of Stock [Line Items]                                          
Warrants term         5 years 6 months                                
Common stock warrant, exercise price (in dollars per share) | $ / shares         $ 0.01                                
Series B Warrants | Maximum                                          
Class of Stock [Line Items]                                          
Common stock warrant, common stock called (in shares)         700,000.0                                
Warrants                                          
Class of Stock [Line Items]                                          
Common stock warrant, exercise price (in dollars per share) | $ / shares         $ 1.66                                
Warrants | Maximum                                          
Class of Stock [Line Items]                                          
Common stock warrant, common stock called (in shares)         1,200,000.0                                
Private Placement                                          
Class of Stock [Line Items]                                          
Proceeds from issuance of common stock and convertible notes | $                 $ 22,000,000   $ 3,000,000                    
Common stock, shares issued (in shares)                 1,583,333                        
Common stock, sale price per share (in dollars per share) | $ / shares                 $ 12                        
Warrants term                 5 years                        
Common stock warrant, common stock called (in shares)       3,239,827 2,188,177 1,881,396 1,309,785 1,097,600 823,333     3,262,088 3,262,088       1,483,161 1,387,685 1,212,665   948,333
Common stock warrant, exercise price (in dollars per share) | $ / shares       $ 4.39 $ 6.50 $ 7.56 $ 10.86 $ 12.96 $ 15.00     $ 4.36 $ 4.36       $ 9.59 $ 10.25 $ 11.73   $ 15.00
Payments of stock issuance costs | $                 $ 1,330,000                        
Payments of stock issuance costs, percentage of gross offering proceeds                 7.00%                        
Payments of stock issuance costs, warrant right to purchase common stock shares                 31,666                        
Payments of stock issuance costs, warrant right to purchase common stock shares, percentage of shares in offering                 2.00%                        
Stock issuance costs, reimbursable expenses (not to exceed) | $                 $ 125,000                        
Payments of stock issuance costs, reduction to equity | $                 $ 1,500,000                        
Private placement, net | $                         $ 543,000                
Private Placement | Third Security LLC and affiliates                                          
Class of Stock [Line Items]                                          
Convertible notes, common stock callable (in shares)                 250,000                        
Convertible notes, warrants callable (in shares)                 125,000                        
At the Market Offering [Member]                                          
Class of Stock [Line Items]                                          
Issuance of common stock, net | $                       $ 100,000 $ 100,000                
Offering                                          
Class of Stock [Line Items]                                          
Common stock warrant, common stock called (in shares)               691,655                          
Private placement, net (in shares)               1,383,333                          
Share price (in dollars per share) | $ / shares               $ 6.00                          
Private placement, net | $               $ 8,300,000                          
Class of warrant or right, number of securities called by warrants or rights, price per share (in dollars per share) | $ / shares               $ 9.00                          
Offering | Affiliates of Third Security, LLC; January 2018                                          
Class of Stock [Line Items]                                          
Common stock warrant, common stock called (in shares)               250,000                          
Private placement, net (in shares)               500,000                          
2014 Private Placement                                          
Class of Stock [Line Items]                                          
Common stock warrant, common stock called (in shares)             365,388                            
Common stock warrant, exercise price (in dollars per share) | $ / shares             $ 4.00                            
Private placement, net (in shares)             730,776                            
Share price (in dollars per share) | $ / shares             $ 3.25                            
Private placement, net | $             $ 2,400,000                            
2014 Private Placement | Advisor                                          
Class of Stock [Line Items]                                          
Common stock warrant, common stock called (in shares)             9,230                            
Additional Note Private Placement | Convertible notes payable                                          
Class of Stock [Line Items]                                          
Face amount | $                               $ 925,000          
Additional Note Private Placement | Convertible notes payable | Craig-Hallum Capital Group LLC                                          
Class of Stock [Line Items]                                          
Face amount | $                                 $ 46,250        
Face amount as percentage of proceeds from debt issuance                                 5.00%        
2015 Offering | Craig-Hallum Capital Group LLC                                          
Class of Stock [Line Items]                                          
Common stock warrant, common stock called (in shares)           714,780                              
Common stock warrant, exercise price (in dollars per share) | $ / shares           $ 2.24                              
Private placement, net (in shares)           3,573,899                              
Class of warrant or right, number of securities called by each warrant or right (in shares)           0.20                              
Class of warrant or right, purchase price per share, public (in dollars per share) | $ / unit           1.95                              
Class of warrant or right, purchase price per share, underwriter (in dollars per share) | $ / unit           1.8135                              
Proceeds from issuance of common stock and warrants, net | $           $ 6,200,000                              
Class of warrant or right, expiration period           5 years                              
Series A-1 Convertible Preferred Stock and Warrants                                          
Class of Stock [Line Items]                                          
Proceeds from issuance of convertible preferred stock | $       $ 2,200,000                                  
Price per share of shares issued (in dollars per share) | $ / shares       $ 0.93                                  
Series A-1 Convertible Preferred Stock                                          
Class of Stock [Line Items]                                          
Preferred stock, shares issued (in shares)       2,365,243                                  
Voting rights, number of shares per one vote       1.075269                                  
Number of shares converted                   2,150,538                      
Preferred stock, shares outstanding (in shares)                       214,705 214,705                
Common Stock                                          
Class of Stock [Line Items]                                          
Shares issued upon conversion of preferred stock (in shares)                   2,150,538                      
Series A Preferred Stock                                          
Class of Stock [Line Items]                                          
Dividend conversion rate per share | $ / shares       $ 1.00                                  
Preferred stock, par value (in dollars per share) | $ / shares       $ 0.01                                  
Preferred stock, shares outstanding (in shares)       0                     2,586,205            
Pro Forma | Series A Warrants                                          
Class of Stock [Line Items]                                          
Share price (in dollars per share) | $ / shares       $ 0.25                                  
Payments for Repurchase of Warrants | $       $ 470,599                                  
Warrant exchange amount | $       $ 941,197                                  
Pro Forma | Series A Warrant, Cashless Exchange | Maximum                                          
Class of Stock [Line Items]                                          
Common stock warrant, common stock called (in shares)       1,882,395                                  
Pro Forma | Series A-1 Warrant                                          
Class of Stock [Line Items]                                          
Share price (in dollars per share) | $ / shares       $ 0.25                                  
Payments for Repurchase of Warrants | $       $ 718,441                                  
Warrant exchange amount | $       $ 1,436,882                                  
Pro Forma | Series A-1 Warrant | Maximum                                          
Class of Stock [Line Items]                                          
Common stock warrant, common stock called (in shares)       2,873,765                                  
Common Stock                                          
Class of Stock [Line Items]                                          
Private placement, net (in shares)                         257,467                
Private placement, net | $                         $ 2,000                
Shares issued upon conversion of preferred stock (in shares)                         8,930,717                
Stock issued during period for services (in shares) 64,153   78,000                                    
Stock issued during period for services | $                       $ 89,000                  
Common Stock | At the Market Offering [Member]                                          
Class of Stock [Line Items]                                          
Private placement, net (in shares)                       115,314 115,314                
Aggregate authorized amount under At the Market Offering Agreement | $   $ 3,500,000                                      
Common Stock | At the Market Offering [Member] | Craig-Hallum Capital Group LLC                                          
Class of Stock [Line Items]                                          
Payments of stock issuance costs, percentage of gross offering proceeds   3.25%                                      
Common Stock | At the Market Offering [Member] | Weighted Average                                          
Class of Stock [Line Items]                                          
Share price (in dollars per share) | $ / shares                       $ 0.67 $ 0.67                
XML 51 R42.htm IDEA: XBRL DOCUMENT v3.5.0.2
STOCKHOLDERS' EQUITY (Common Stock Warrants) (Details) - $ / shares
 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jan. 06, 2016
Jul. 07, 2015
Feb. 27, 2015
Jan. 15, 2015
Dec. 31, 2014
Oct. 22, 2014
Oct. 21, 2014
Jan. 24, 2013
Dec. 31, 2012
Feb. 02, 2012
Class of Stock [Line Items]                        
Common stock warrants issued (in shares) 2,933,106 1,208,491                    
Underlying Shares 8,876,166                      
Various Institutional Holders; February 2017                        
Class of Stock [Line Items]                        
Underlying Shares 2,832,069                      
Exercise Price (in dollars per share) $ 4.36                      
Affiliates of Third Security, LLC; February 2017                        
Class of Stock [Line Items]                        
Underlying Shares 430,019                      
Exercise Price (in dollars per share) $ 4.36                      
Various Institutional Holders; January 2018                        
Class of Stock [Line Items]                        
Underlying Shares 441,655                      
Exercise Price (in dollars per share) $ 9                      
Affiliates of Third Security, LLC; January 2018                        
Class of Stock [Line Items]                        
Underlying Shares 250,000                      
Exercise Price (in dollars per share) $ 9                      
Various Institutional Holders; April 2020                        
Class of Stock [Line Items]                        
Underlying Shares 374,618                      
Exercise Price (in dollars per share) $ 4.00                      
Various Institutional Holders; February 2020                        
Class of Stock [Line Items]                        
Underlying Shares 714,780                      
Exercise Price (in dollars per share) $ 2.24                      
Various Institutional Holders; December 2020                        
Class of Stock [Line Items]                        
Underlying Shares 122,433                      
Exercise Price (in dollars per share) $ 1.66                      
Various Institutional Holders; December 2020                        
Class of Stock [Line Items]                        
Underlying Shares 667,164                      
Exercise Price (in dollars per share) $ 0.01                      
Various Institutional Holders; January 2021                        
Class of Stock [Line Items]                        
Underlying Shares 1,161,972                      
Exercise Price (in dollars per share) $ 1.21                      
Affiliates of Third Security, LLC; January 2021                        
Class of Stock [Line Items]                        
Underlying Shares 161,026                      
Exercise Price (in dollars per share) $ 1.21                      
Various Institutional Holders; January 2021                        
Class of Stock [Line Items]                        
Underlying Shares 1,720,430                      
Exercise Price (in dollars per share) $ 1.21                      
Private Placement                        
Class of Stock [Line Items]                        
Common stock warrants issued (in shares) 1,073,911 493,711                    
Exercise Price (in dollars per share) $ 4.36   $ 4.39 $ 6.50 $ 7.56 $ 9.59 $ 10.25 $ 10.86 $ 11.73 $ 12.96 $ 15.00 $ 15.00
Offering                        
Class of Stock [Line Items]                        
Common stock warrants issued (in shares) 1,881,456 714,780                    
XML 52 R43.htm IDEA: XBRL DOCUMENT v3.5.0.2
STOCKHOLDERS' EQUITY (Issuance of Series B Preferred Stock) (Details)
$ / shares in Units, $ in Thousands
 6 Months Ended
Jan. 06, 2016
shares
Jul. 07, 2015
$ / shares
shares
Mar. 05, 2014
USD ($)
$ / shares
shares
Jun. 30, 2016
USD ($)
$ / shares
Dec. 31, 2015
$ / shares
Jan. 24, 2013
$ / shares
shares
Class of Stock [Line Items]            
Private placement, net (in shares) | shares 6,780,179 1,500,000        
Preferred stock, par value (in dollars per share)       $ 0.01 $ 0.01  
Share price (in dollars per share)   $ 1.42   $ 0.55    
Private placement, net | $       $ 107    
Series B preferred stock            
Class of Stock [Line Items]            
Conversion ratio 1          
Third Security LLC and affiliates            
Class of Stock [Line Items]            
Common stock warrant, exercise price (in dollars per share)     $ 11.73     $ 12.96
Common stock warrant, common stock called (in shares) | shares     1,212,665     1,097,600
Third Security LLC and affiliates | Preferred stock | Series B preferred stock            
Class of Stock [Line Items]            
Private placement, net (in shares) | shares     1,443,297      
Preferred stock, par value (in dollars per share)     $ 0.01      
Share price (in dollars per share)     $ 4.85      
Private placement, net | $     $ 7,000      
Conversion ratio     1      
XML 53 R44.htm IDEA: XBRL DOCUMENT v3.5.0.2
STOCKHOLDERS' EQUITY (Conversion of Preferred Stock) (Details)
 6 Months Ended
Jan. 06, 2016
USD ($)
$ / shares
shares
Jul. 07, 2015
shares
Jun. 30, 2016
$ / shares
shares
Dec. 31, 2015
$ / shares
shares
Conversion of Stock [Line Items]        
Preferred stock, par value (in dollars per share) | $ / shares     $ 0.01 $ 0.01
Preferred stock, shares outstanding (in shares)     214,705 4,029,502
Number of shares of common stock dividends 4,474,825      
Private placement, net (in shares) 6,780,179 1,500,000    
Series A Preferred Stock        
Conversion of Stock [Line Items]        
Conversion ratio 0.3333      
Preferred stock, par value (in dollars per share) | $ / shares $ 0.01      
Dividend conversion rate per share | $ / shares $ 1.00      
Preferred stock, shares outstanding (in shares) 0     2,586,205
Number of common stock converted into 862,057      
Amount of preferred dividends in arrears | $ $ 3,681,591.90      
Number of shares of common stock dividends 3,681,590      
Series B preferred stock        
Conversion of Stock [Line Items]        
Conversion ratio 1      
Preferred stock, shares outstanding (in shares) 0     1,443,297
Number of common stock converted into 1,443,297      
Amount of preferred dividends in arrears | $ $ 793,236.17      
Number of shares of common stock dividends 793,235      
Series A-1 Convertible Preferred Stock and Warrants        
Conversion of Stock [Line Items]        
Conversion ratio 1      
Common Stock        
Conversion of Stock [Line Items]        
Number of common stock converted into 2,305,354      
Private placement, net (in shares)     257,467  
XML 54 R45.htm IDEA: XBRL DOCUMENT v3.5.0.2
STOCKHOLDERS' EQUITY (Preferred Stock Dividends) (Details) - USD ($)
Jun. 30, 2016
Dec. 31, 2015
Stockholders' Equity Note [Abstract]    
Cumulative undeclared dividends, preferred stock $ 0 $ 4,400,000
XML 55 R46.htm IDEA: XBRL DOCUMENT v3.5.0.2
FAIR VALUE (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 44 Months Ended
Sep. 30, 2015
Jan. 31, 2016
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Sep. 29, 2015
Jul. 07, 2015
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]                
Common stock warrants issued (in shares)         2,933,106 1,208,491    
Share price (in dollars per share)     $ 0.55   $ 0.55     $ 1.42
Percentage of simulated equity values below the down-round financing cut-off point         100.00%      
2012 Warrant Liability                
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]                
Common stock warrants issued (in shares) 3,300,000           1,200,000  
Stock options, fair value assumptions, expected life         7 months 8 days      
Volatility (as a percent)         67.00%      
Risk-free interest rate (as a percent)         0.42%      
Fair value assumptions, expected term         1 year      
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]                
Beginning balance   $ 350 $ 20 $ 290 $ 350 $ 145    
Total (gains) or losses:                
Recognized in earnings     (20) 270 (350) 415    
Balance at end of period     0 $ 560 $ 0 $ 560    
2016 Warrant Liability                
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]                
Common stock warrants issued (in shares)   1,800,000            
Volatility (as a percent)         135.00%      
Risk-free interest rate (as a percent)         1.21%      
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]                
Beginning balance   $ 0 1,446   $ 0      
Additions         1,437      
Total (gains) or losses:                
Recognized in earnings     (4)   5      
Balance at end of period     $ 1,442   $ 1,442      
XML 56 R47.htm IDEA: XBRL DOCUMENT v3.5.0.2
STOCK OPTIONS (Stock Options) (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2016
Jun. 30, 2015
Number of Options      
Granted (in shares) 0 14,000 608,910
Outstanding at end of period (in shares) 1,000,654 1,000,654  
Weighted-Average Exercise Price      
Stock options, expected to vest, outstanding (in shares) 980,388 980,388  
Stock options, expected to vest, outstanding, aggregate intrinsic value $ 0 $ 0  
Equity Incentive Plan 2006      
Number of Options      
Granted (in shares)   14,000  
Weighted-Average Exercise Price      
Granted (in dollars per share)   $ 1.07  
Employee Stock Option      
Number of Options      
Outstanding at beginning of period (in shares)   1,107,794  
Granted (in shares)   14,000  
Forfeited (in shares)   (121,140)  
Exercisable at end of period (in shares) 648,246 648,246  
Weighted-Average Exercise Price      
Outstanding at beginning of period (in dollars per share)   $ 3.45  
Granted (in dollars per share)   1.07  
Forfeited (in dollars per share)   3.69  
Outstanding at end of period (in dollars per share) $ 3.39 3.39  
Exercisable at end of period (in dollars per share) $ 4.01 $ 4.01  
XML 57 R48.htm IDEA: XBRL DOCUMENT v3.5.0.2
STOCK OPTIONS (Stock Appreciation Rights) (Details) - SARs - USD ($)
Jun. 30, 2016
Dec. 31, 2015
Number of SARs    
Outstanding (in shares) 98,333 98,333
Exercisable (in shares) 84,445  
Weighted-Average Exercise Price    
Outstanding (in dollars per share) $ 4.14 $ 4.14
Exercisable (in dollars per share) $ 4.21  
Stock appreciation rights, nonvested (in shares) 98,333  
Stock appreciation rights, aggregate intrinsic value, outstanding $ 0  
EXCEL 58 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 59 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 60 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 62 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 227 297 1 false 76 0 false 7 false false R1.htm 0001000 - Document - DOCUMENT AND ENTITY INFORMATION Sheet http://www.transgenomic.com/role/DocumentAndEntityInformation DOCUMENT AND ENTITY INFORMATION Cover 1 false false R2.htm 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.transgenomic.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1001001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICALS) Sheet http://www.transgenomic.com/role/CondensedConsolidatedBalanceSheetsParentheticals CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICALS) Statements 3 false false R4.htm 1002000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.transgenomic.com/role/UnauditedCondensedConsolidatedStatementsOfOperations UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 1003000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Sheet http://www.transgenomic.com/role/UnauditedCondensedConsolidatedStatementsOfComprehensiveLoss UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Statements 5 false false R6.htm 1004000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://www.transgenomic.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquity UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 6 false false R7.htm 1005000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.transgenomic.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 2101100 - Disclosure - BUSINESS DESCRIPTION Sheet http://www.transgenomic.com/role/BusinessDescription BUSINESS DESCRIPTION Notes 8 false false R9.htm 2102100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.transgenomic.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 2105100 - Disclosure - DISCONTINUED OPERATIONS Sheet http://www.transgenomic.com/role/DiscontinuedOperations DISCONTINUED OPERATIONS Notes 10 false false R11.htm 2106100 - Disclosure - INTANGIBLES AND OTHER ASSETS Sheet http://www.transgenomic.com/role/IntangiblesAndOtherAssets INTANGIBLES AND OTHER ASSETS Notes 11 false false R12.htm 2107100 - Disclosure - DEBT Sheet http://www.transgenomic.com/role/Debt DEBT Notes 12 false false R13.htm 2108100 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.transgenomic.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 13 false false R14.htm 2109100 - Disclosure - INCOME TAXES Sheet http://www.transgenomic.com/role/IncomeTaxes INCOME TAXES Notes 14 false false R15.htm 2110100 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.transgenomic.com/role/StockholdersEquity STOCKHOLDERS' EQUITY Notes 15 false false R16.htm 2111100 - Disclosure - FAIR VALUE Sheet http://www.transgenomic.com/role/FairValue FAIR VALUE Notes 16 false false R17.htm 2112100 - Disclosure - STOCK OPTIONS Sheet http://www.transgenomic.com/role/StockOptions STOCK OPTIONS Notes 17 false false R18.htm 2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 18 false false R19.htm 2302302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.transgenomic.com/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 2305301 - Disclosure - DISCONTINUED OPERATIONS (Tables) Sheet http://www.transgenomic.com/role/DiscontinuedOperationsTables DISCONTINUED OPERATIONS (Tables) Tables http://www.transgenomic.com/role/DiscontinuedOperations 20 false false R21.htm 2306301 - Disclosure - INTANGIBLES AND OTHER ASSETS (Tables) Sheet http://www.transgenomic.com/role/IntangiblesAndOtherAssetsTables INTANGIBLES AND OTHER ASSETS (Tables) Tables http://www.transgenomic.com/role/IntangiblesAndOtherAssets 21 false false R22.htm 2307301 - Disclosure - DEBT (Tables) Sheet http://www.transgenomic.com/role/DebtTables DEBT (Tables) Tables http://www.transgenomic.com/role/Debt 22 false false R23.htm 2310301 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.transgenomic.com/role/StockholdersEquityTables STOCKHOLDERS' EQUITY (Tables) Tables http://www.transgenomic.com/role/StockholdersEquity 23 false false R24.htm 2311301 - Disclosure - FAIR VALUE (Tables) Sheet http://www.transgenomic.com/role/FairValueTables FAIR VALUE (Tables) Tables http://www.transgenomic.com/role/FairValue 24 false false R25.htm 2312301 - Disclosure - STOCK OPTIONS (Tables) Sheet http://www.transgenomic.com/role/StockOptionsTables STOCK OPTIONS (Tables) Tables http://www.transgenomic.com/role/StockOptions 25 false false R26.htm 2401401 - Disclosure - BUSINESS DESCRIPTION (Details) Sheet http://www.transgenomic.com/role/BusinessDescriptionDetails BUSINESS DESCRIPTION (Details) Details http://www.transgenomic.com/role/BusinessDescription 26 false false R27.htm 2402403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narratives) (Details) Sheet http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesNarrativesDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narratives) (Details) Details http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesTables 27 false false R28.htm 2402404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Accounts Receivable) (Details) Sheet http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Accounts Receivable) (Details) Details http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesTables 28 false false R29.htm 2402405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Inventories) (Details) Sheet http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesInventoriesDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Inventories) (Details) Details http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesTables 29 false false R30.htm 2402406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Property, Plant and Equipment) (Details) Sheet http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Property, Plant and Equipment) (Details) Details http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesTables 30 false false R31.htm 2405402 - Disclosure - DISCONTINUED OPERATIONS (Narratives) (Details) Sheet http://www.transgenomic.com/role/DiscontinuedOperationsNarrativesDetails DISCONTINUED OPERATIONS (Narratives) (Details) Details http://www.transgenomic.com/role/DiscontinuedOperationsTables 31 false false R32.htm 2405403 - Disclosure - DISCONTINUED OPERATIONS (Revenues and Net Income (Loss)) (Details) Sheet http://www.transgenomic.com/role/DiscontinuedOperationsRevenuesAndNetIncomeLossDetails DISCONTINUED OPERATIONS (Revenues and Net Income (Loss)) (Details) Details http://www.transgenomic.com/role/DiscontinuedOperationsTables 32 false false R33.htm 2405404 - Disclosure - DISCONTINUED OPERATIONS (Assets and Liabilities Held for Sale) (Details) Sheet http://www.transgenomic.com/role/DiscontinuedOperationsAssetsAndLiabilitiesHeldForSaleDetails DISCONTINUED OPERATIONS (Assets and Liabilities Held for Sale) (Details) Details http://www.transgenomic.com/role/DiscontinuedOperationsTables 33 false false R34.htm 2405405 - Disclosure - DISCONTINUED OPERATIONS (Allowance for Doubtful Accounts) (Details) Sheet http://www.transgenomic.com/role/DiscontinuedOperationsAllowanceForDoubtfulAccountsDetails DISCONTINUED OPERATIONS (Allowance for Doubtful Accounts) (Details) Details http://www.transgenomic.com/role/DiscontinuedOperationsTables 34 false false R35.htm 2406402 - Disclosure - INTANGIBLES AND OTHER ASSETS (Details) Sheet http://www.transgenomic.com/role/IntangiblesAndOtherAssetsDetails INTANGIBLES AND OTHER ASSETS (Details) Details http://www.transgenomic.com/role/IntangiblesAndOtherAssetsTables 35 false false R36.htm 2407402 - Disclosure - DEBT (Schedule of Debt) (Details) Sheet http://www.transgenomic.com/role/DebtScheduleOfDebtDetails DEBT (Schedule of Debt) (Details) Details http://www.transgenomic.com/role/DebtTables 36 false false R37.htm 2407403 - Disclosure - DEBT (Revolving Line and Term Loan) (Details) Sheet http://www.transgenomic.com/role/DebtRevolvingLineAndTermLoanDetails DEBT (Revolving Line and Term Loan) (Details) Details http://www.transgenomic.com/role/DebtTables 37 false false R38.htm 2407404 - Disclosure - DEBT (Convertible Promissory Notes) (Details) Notes http://www.transgenomic.com/role/DebtConvertiblePromissoryNotesDetails DEBT (Convertible Promissory Notes) (Details) Details http://www.transgenomic.com/role/DebtTables 38 false false R39.htm 2408401 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.transgenomic.com/role/CommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://www.transgenomic.com/role/CommitmentsAndContingencies 39 false false R40.htm 2409401 - Disclosure - INCOME TAXES (Details) Sheet http://www.transgenomic.com/role/IncomeTaxesDetails INCOME TAXES (Details) Details http://www.transgenomic.com/role/IncomeTaxes 40 false false R41.htm 2410402 - Disclosure - STOCKHOLDERS' EQUITY (Common Stock) (Details) Sheet http://www.transgenomic.com/role/StockholdersEquityCommonStockDetails STOCKHOLDERS' EQUITY (Common Stock) (Details) Details http://www.transgenomic.com/role/StockholdersEquityTables 41 false false R42.htm 2410403 - Disclosure - STOCKHOLDERS' EQUITY (Common Stock Warrants) (Details) Sheet http://www.transgenomic.com/role/StockholdersEquityCommonStockWarrantsDetails STOCKHOLDERS' EQUITY (Common Stock Warrants) (Details) Details http://www.transgenomic.com/role/StockholdersEquityTables 42 false false R43.htm 2410404 - Disclosure - STOCKHOLDERS' EQUITY (Issuance of Series B Preferred Stock) (Details) Sheet http://www.transgenomic.com/role/StockholdersEquityIssuanceOfSeriesBPreferredStockDetails STOCKHOLDERS' EQUITY (Issuance of Series B Preferred Stock) (Details) Details http://www.transgenomic.com/role/StockholdersEquityTables 43 false false R44.htm 2410405 - Disclosure - STOCKHOLDERS' EQUITY (Conversion of Preferred Stock) (Details) Sheet http://www.transgenomic.com/role/StockholdersEquityConversionOfPreferredStockDetails STOCKHOLDERS' EQUITY (Conversion of Preferred Stock) (Details) Details http://www.transgenomic.com/role/StockholdersEquityTables 44 false false R45.htm 2410406 - Disclosure - STOCKHOLDERS' EQUITY (Preferred Stock Dividends) (Details) Sheet http://www.transgenomic.com/role/StockholdersEquityPreferredStockDividendsDetails STOCKHOLDERS' EQUITY (Preferred Stock Dividends) (Details) Details http://www.transgenomic.com/role/StockholdersEquityTables 45 false false R46.htm 2411402 - Disclosure - FAIR VALUE (Details) Sheet http://www.transgenomic.com/role/FairValueDetails FAIR VALUE (Details) Details http://www.transgenomic.com/role/FairValueTables 46 false false R47.htm 2412402 - Disclosure - STOCK OPTIONS (Stock Options) (Details) Sheet http://www.transgenomic.com/role/StockOptionsStockOptionsDetails STOCK OPTIONS (Stock Options) (Details) Details http://www.transgenomic.com/role/StockOptionsTables 47 false false R48.htm 2412403 - Disclosure - STOCK OPTIONS (Stock Appreciation Rights) (Details) Sheet http://www.transgenomic.com/role/StockOptionsStockAppreciationRightsDetails STOCK OPTIONS (Stock Appreciation Rights) (Details) Details http://www.transgenomic.com/role/StockOptionsTables 48 false false All Reports Book All Reports tbio-20160630.xml tbio-20160630.xsd tbio-20160630_cal.xml tbio-20160630_def.xml tbio-20160630_lab.xml tbio-20160630_pre.xml true true ZIP 64 0001043961-16-000034-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001043961-16-000034-xbrl.zip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